{"370d59bf7f643eb4a7f419b7cf31b3b67c6e0b13": [["IntroductionHuman rhinoviruses (HRV) are the causative agents of common cold and are the most frequent cause of acute respiratory tract infection both in children and in adults (Arden et al., 2006; Johnston et al., 1995; Nicholson et al., 1993) .", [["respiratory tract", "ANATOMY", 118, 135], ["respiratory tract infection", "DISEASE", 118, 145], ["IntroductionHuman rhinoviruses", "ORGANISM", 0, 30], ["respiratory tract", "ORGANISM_SUBDIVISION", 118, 135], ["children", "ORGANISM", 154, 162], ["rhinoviruses", "SPECIES", 18, 30], ["children", "SPECIES", 154, 162], ["HRV", "SPECIES", 32, 35], ["IntroductionHuman rhinoviruses", "PROBLEM", 0, 30], ["common cold", "PROBLEM", 65, 76], ["acute respiratory tract infection", "PROBLEM", 112, 145], ["acute", "OBSERVATION_MODIFIER", 112, 117], ["respiratory tract", "ANATOMY", 118, 135], ["infection", "OBSERVATION", 136, 145]]], ["HRV have a tremendous diversity and 160 subtypes have been recognized so far.", [["HRV", "PROBLEM", 0, 3], ["a tremendous diversity", "PROBLEM", 9, 31], ["tremendous", "OBSERVATION_MODIFIER", 11, 21], ["diversity", "OBSERVATION", 22, 31], ["160 subtypes", "OBSERVATION_MODIFIER", 36, 48]]], ["Historically, HRV were classified into 100 serotypes based on cross-reactivity in neutralization tests (Hamparian et al., 1987) .", [["neutralization tests", "TEST", 82, 102]]], ["These serotypes were categorized in a variety of ways such as receptor usage into major or minor group (Uncapher et al., 1991) , or according to the sensitivity to antiviral agents into group A or B (Andries et al., 1990) .", [["B", "CELL", 197, 198], ["These serotypes", "PROBLEM", 0, 15], ["antiviral agents", "TREATMENT", 164, 180]]], ["Based on the full-length or partial (VP2/VP4 and VP1) coding sequences they were initially classified into A and B genotypes (Ledford et al., 2004; Savolainen et al., 2002) .", [["VP2", "GENE_OR_GENE_PRODUCT", 37, 40], ["VP4", "GENE_OR_GENE_PRODUCT", 41, 44], ["VP1", "GENE_OR_GENE_PRODUCT", 49, 52], ["full-length or partial (VP2/VP4 and VP1) coding sequences", "DNA", 13, 70], ["partial (VP2/VP4 and VP1) coding sequences", "TEST", 28, 70]]], ["HRV-C are not emerging viruses but had been circulating unnoticed due to the inability to culture them.", [["HRV-C", "GENE_OR_GENE_PRODUCT", 0, 5], ["HRV", "TEST", 0, 3], ["emerging viruses", "PROBLEM", 14, 30], ["the inability to culture them", "PROBLEM", 73, 102], ["viruses", "OBSERVATION", 23, 30]]], ["Sequencing of the complete genomes of A, B and available C types confirmed their assignment into three distinct phylogenetic taxa (Palmenberg et al., 2009) .IntroductionHRV are associated with a broad range of clinical disease including the common cold, bronchiolitis, pneumonia, wheezing and asthma exacerbation especially in children Briese et al., 2008; Miller et al., 2009) .", [["bronchiolitis", "DISEASE", 254, 267], ["pneumonia", "DISEASE", 269, 278], ["wheezing", "DISEASE", 280, 288], ["asthma", "DISEASE", 293, 299], ["B", "GENE_OR_GENE_PRODUCT", 41, 42], ["children", "SPECIES", 327, 335], ["clinical disease", "PROBLEM", 210, 226], ["the common cold", "PROBLEM", 237, 252], ["bronchiolitis", "PROBLEM", 254, 267], ["pneumonia", "PROBLEM", 269, 278], ["wheezing", "PROBLEM", 280, 288], ["asthma exacerbation", "PROBLEM", 293, 312], ["common cold", "ANATOMY", 241, 252], ["bronchiolitis", "OBSERVATION", 254, 267], ["pneumonia", "OBSERVATION", 269, 278], ["wheezing", "OBSERVATION", 280, 288], ["asthma", "OBSERVATION", 293, 299]]], ["There is some evidence that HRV-C may be more virulent than other species (Kaida et al., 2011; Mak et al., 2011) .", [["HRV-C", "GENE_OR_GENE_PRODUCT", 28, 33]]], ["For example, HRV-C may be more likely than HRV-B to cause more severe illnesses in infancy (Lee et al., 2012) , and HRV-C may be more likely than other species to cause acute exacerbations of asthma (Bizzintino et al., 2011; Fry et al., 2011) .", [["asthma", "DISEASE", 192, 198], ["HRV-C", "GENE_OR_GENE_PRODUCT", 13, 18], ["HRV-B", "ORGANISM", 43, 48], ["HRV-C", "GENE_OR_GENE_PRODUCT", 116, 121], ["HRV", "TEST", 13, 16], ["HRV", "PROBLEM", 43, 46], ["more severe illnesses in infancy", "PROBLEM", 58, 90], ["HRV", "TEST", 116, 119], ["acute exacerbations", "PROBLEM", 169, 188], ["asthma", "PROBLEM", 192, 198], ["may be more likely", "UNCERTAINTY", 19, 37], ["severe", "OBSERVATION_MODIFIER", 63, 69], ["illnesses", "OBSERVATION", 70, 79], ["may be more likely", "UNCERTAINTY", 122, 140], ["acute", "OBSERVATION_MODIFIER", 169, 174], ["exacerbations", "OBSERVATION", 175, 188], ["asthma", "OBSERVATION", 192, 198]]], ["These findings, along with distinct genetic features and use of alternative cell surface receptor(s) (Bochkov et al., 2011) , suggest that there may be important differences in the replication cycle of HRV-C viruses compared to other HRV.IntroductionIn fact, unlike HRV-A and HRV-B species, HRV-C could not be propagated in standard cell culture.", [["cell surface", "ANATOMY", 76, 88], ["cell culture", "ANATOMY", 333, 345], ["cell surface receptor", "GENE_OR_GENE_PRODUCT", 76, 97], ["HRV-C viruses", "ORGANISM", 202, 215], ["HRV-A", "ORGANISM", 266, 271], ["HRV-B species", "ORGANISM", 276, 289], ["HRV-C", "CELL", 291, 296], ["cell", "CELL", 333, 337], ["alternative cell surface receptor", "PROTEIN", 64, 97], ["standard cell culture", "CELL_LINE", 324, 345], ["HRV-C viruses", "SPECIES", 202, 215], ["distinct genetic features", "PROBLEM", 27, 52], ["HRV", "PROBLEM", 202, 205], ["C viruses", "PROBLEM", 206, 215], ["HRV", "TEST", 266, 269], ["HRV", "TEST", 276, 279], ["B species", "PROBLEM", 280, 289], ["HRV", "TEST", 291, 294], ["standard cell culture", "TEST", 324, 345], ["may be", "UNCERTAINTY", 145, 151]]], ["We previously reported growth of an HRV-C isolate (HRV-C15) in organ cultures of human sinus epithelium (HSEC) obtained as a byproduct of human sinus surgeries (Bochkov et al., 2011) .", [["organ cultures", "ANATOMY", 63, 77], ["sinus epithelium", "ANATOMY", 87, 103], ["HSEC", "ANATOMY", 105, 109], ["sinus", "ANATOMY", 144, 149], ["HRV-C", "ORGANISM", 36, 41], ["HRV-C15", "CELL", 51, 58], ["organ cultures", "CELL", 63, 77], ["human", "ORGANISM", 81, 86], ["sinus epithelium", "TISSUE", 87, 103], ["HSEC", "CELL", 105, 109], ["human", "ORGANISM", 138, 143], ["sinus", "MULTI-TISSUE_STRUCTURE", 144, 149], ["human", "SPECIES", 81, 86], ["human", "SPECIES", 138, 143], ["human", "SPECIES", 81, 86], ["human", "SPECIES", 138, 143], ["an HRV", "TEST", 33, 39], ["C isolate", "PROBLEM", 40, 49], ["HRV", "TEST", 51, 54], ["organ cultures", "TEST", 63, 77], ["human sinus surgeries", "TREATMENT", 138, 159], ["growth", "OBSERVATION_MODIFIER", 23, 29], ["organ", "ANATOMY", 63, 68], ["human sinus", "ANATOMY", 81, 92], ["sinus", "ANATOMY", 144, 149]]], ["This system provided an important tool for HRV-C research, however, tissue samples obtained from patients are limited in amount and are difficult to standardize for quantitative research.IntroductionTo overcome these limitations, we developed a system for growing HRV-C in an air-liquid interface of differentiated human sinus epithelium (HSEC) that has pseudostratified morphology, cilia and goblet cells, and used it to study some of the basic biological properties of HRV-C.", [["tissue samples", "ANATOMY", 68, 82], ["sinus epithelium", "ANATOMY", 321, 337], ["HSEC", "ANATOMY", 339, 343], ["cilia", "ANATOMY", 383, 388], ["goblet cells", "ANATOMY", 393, 405], ["tissue samples", "CANCER", 68, 82], ["patients", "ORGANISM", 97, 105], ["HRV-C", "CELL", 264, 269], ["human", "ORGANISM", 315, 320], ["sinus epithelium", "TISSUE", 321, 337], ["HSEC", "CELL", 339, 343], ["cilia", "CELL", 383, 388], ["goblet cells", "CELL", 393, 405], ["HRV-C.", "ORGANISM", 471, 477], ["goblet cells", "CELL_TYPE", 393, 405], ["patients", "SPECIES", 97, 105], ["human", "SPECIES", 315, 320], ["human", "SPECIES", 315, 320], ["HRV", "TEST", 43, 46], ["tissue samples", "TEST", 68, 82], ["growing HRV", "PROBLEM", 256, 267], ["cilia and goblet cells", "PROBLEM", 383, 405], ["sinus epithelium", "ANATOMY", 321, 337], ["cilia", "ANATOMY_MODIFIER", 383, 388], ["goblet cells", "OBSERVATION", 393, 405]]], ["Two characteristics that distinguish HRV from human enteroviruses are their instability at low pH and their optimal growth at 33-34 1C (Dimmock and Tyrrell, 1964; Taylor-Robinson and Tyrrell, 1962; Turner, 2007) .", [["enteroviruses", "DISEASE", 52, 65], ["human", "ORGANISM", 46, 51], ["human", "SPECIES", 46, 51], ["human", "SPECIES", 46, 51], ["HRV", "PROBLEM", 37, 40], ["human enteroviruses", "PROBLEM", 46, 65], ["their instability at low pH", "PROBLEM", 70, 97], ["enteroviruses", "OBSERVATION", 52, 65], ["low pH", "OBSERVATION_MODIFIER", 91, 97]]], ["We used the HSEC ALI system to study the effects of low pH treatment and to determine effects of temperature on replication of two different HRV-C types.ResultsReplication of HRV-C15 in different culture systems for sinus epithelium Following inoculation of sinus organ cultures with purified HRV-C15 virions, the mean quantity of cell-associated HRV RNA 48-72 h post-inoculation (PI) increased by 1-1.5 log units (P\u00bc0.078; Fig. 2A ).", [["sinus epithelium", "ANATOMY", 216, 232], ["sinus organ cultures", "ANATOMY", 258, 278], ["cell", "ANATOMY", 331, 335], ["sinus epithelium", "TISSUE", 216, 232], ["sinus organ cultures", "CELL", 258, 278], ["HRV-C15 virions", "ORGANISM", 293, 308], ["cell", "CELL", 331, 335], ["the HSEC ALI system", "TREATMENT", 8, 27], ["low pH treatment", "TREATMENT", 52, 68], ["replication", "TREATMENT", 112, 123], ["HRV", "TEST", 175, 178], ["different culture systems", "TEST", 186, 211], ["sinus epithelium", "PROBLEM", 216, 232], ["sinus organ cultures", "TEST", 258, 278], ["HRV", "TEST", 293, 296], ["HRV RNA", "TEST", 347, 354], ["sinus epithelium", "ANATOMY", 216, 232], ["sinus organ", "ANATOMY", 258, 269]]], ["However, when these cells were grown in undifferentiated monolayers, viral attachment was lower and remained low over the next 48 h (P\u00bc0.244; Fig. 2B ).", [["cells", "ANATOMY", 20, 25], ["monolayers", "ANATOMY", 57, 67], ["cells", "CELL", 20, 25], ["monolayers", "CELL", 57, 67], ["these cells", "PROBLEM", 14, 25], ["undifferentiated monolayers", "PROBLEM", 40, 67], ["viral attachment", "TEST", 69, 85], ["undifferentiated monolayers", "OBSERVATION", 40, 67]]], ["Next, we tested HRV-C15 replication in epithelial cells from human sinus epithelium (HSEC) differentiated under ALI conditions.", [["epithelial cells", "ANATOMY", 39, 55], ["sinus epithelium", "ANATOMY", 67, 83], ["HSEC", "ANATOMY", 85, 89], ["ALI", "DISEASE", 112, 115], ["epithelial cells", "CELL", 39, 55], ["human", "ORGANISM", 61, 66], ["sinus epithelium", "TISSUE", 67, 83], ["HSEC", "CELL", 85, 89], ["epithelial cells", "CELL_TYPE", 39, 55], ["human", "SPECIES", 61, 66], ["human", "SPECIES", 61, 66], ["HRV", "TEST", 16, 19], ["epithelial cells", "OBSERVATION", 39, 55], ["sinus epithelium", "ANATOMY", 67, 83], ["ALI conditions", "OBSERVATION", 112, 126]]], ["Approximately two-thirds supported HRV-C15 replication (0.5-2 logs increase in HRV RNA, Po0.05; Fig. 2C ).", [["HRV RNA", "RNA", 79, 86], ["HRV-C15 replication", "TREATMENT", 35, 54], ["HRV RNA", "TEST", 79, 86]]], ["HRV-C15 infection did not cause notable cytopathic effects or changes to ciliary beating (data not shown).Comparison of HRV-C15 and HRV-A16 growth in ALI culturesFollowing inoculation with HRV-C15 virions (2.0 \u00c2 10 8 RNA copies), 4.7 \u00c2 10 5 HRV RNA copies were cell-associated, and 24 h later the RNA had increased to 2.1 \u00c2 10 7 RNA copies (P\u00bc0.002; Fig.3 ) with slightly less viral RNA after 48 h.", [["ciliary", "ANATOMY", 73, 80], ["cell", "ANATOMY", 261, 265], ["infection", "DISEASE", 8, 17], ["ALI", "DISEASE", 150, 153], ["HRV-A16", "ORGANISM", 132, 139], ["cell", "CELL", 261, 265], ["ALI cultures", "CELL_LINE", 150, 162], ["2.0 \u00c2 10 8 RNA copies", "RNA", 206, 227], ["HRV RNA copies", "RNA", 241, 255], ["2.1 \u00c2 10 7 RNA copies", "RNA", 318, 339], ["viral RNA", "RNA", 377, 386], ["HRV-A16", "SPECIES", 132, 139], ["HRV", "TEST", 0, 3], ["C15 infection", "PROBLEM", 4, 17], ["notable cytopathic effects", "PROBLEM", 32, 58], ["ciliary beating", "TEST", 73, 88], ["HRV", "TEST", 120, 123], ["C15", "TEST", 124, 127], ["HRV", "TEST", 132, 135], ["ALI cultures", "TEST", 150, 162], ["inoculation", "TEST", 172, 183], ["HRV", "TEST", 189, 192], ["virions", "TEST", 197, 204], ["RNA copies", "TEST", 217, 227], ["HRV RNA copies", "TEST", 241, 255], ["cell", "TEST", 261, 265], ["the RNA", "TEST", 293, 300], ["RNA copies", "TEST", 329, 339], ["Fig.3", "TEST", 350, 355], ["slightly less viral RNA", "PROBLEM", 363, 386], ["C15", "ANATOMY", 4, 7], ["infection", "OBSERVATION", 8, 17], ["notable", "OBSERVATION_MODIFIER", 32, 39], ["cytopathic", "OBSERVATION", 40, 50]]], ["After inoculation with the same dose of purified HRV-A16 virions, RNA concentration was greater just after inoculation (1.1 \u00c2 10 7 RNA copies) and also 24 h later (3.9 \u00c2 10 8 RNA copies, P\u00bc0.002).", [["HRV-A16 virions", "ORGANISM", 49, 64], ["HRV-A16", "SPECIES", 49, 56], ["inoculation", "TREATMENT", 6, 17], ["purified HRV", "TEST", 40, 52], ["RNA concentration", "TEST", 66, 83], ["inoculation", "TEST", 107, 118], ["RNA copies", "TEST", 131, 141], ["RNA copies", "TEST", 175, 185], ["P", "TEST", 187, 188], ["greater", "OBSERVATION_MODIFIER", 88, 95]]], ["The growth kinetics of infection and net increase in RNA (HRV-C15 1.6 log increase, HRV-A16 1.5 log increase) among the two viruses were similar.Comparison of HRV-C15 and HRV-A16 growth in ALI culturesIn order to compare dose-related effects on virus replication, HSEC ALI cultures were incubated with 10 3 -10 8 RNA copies of either HRV-C15 or HRV-A16 virions.", [["HSEC ALI cultures", "ANATOMY", 264, 281], ["infection", "DISEASE", 23, 32], ["ALI", "DISEASE", 189, 192], ["ALI", "DISEASE", 269, 272], ["HRV-A16", "ORGANISM", 171, 178], ["HSEC ALI cultures", "CELL", 264, 281], ["HRV-C15", "ORGANISM", 334, 341], ["HRV-A16 virions", "ORGANISM", 345, 360], ["ALI cultures", "CELL_LINE", 189, 201], ["HSEC ALI cultures", "CELL_LINE", 264, 281], ["HRV-A16", "SPECIES", 171, 178], ["HSEC", "SPECIES", 264, 268], ["HRV-A16", "SPECIES", 345, 352], ["infection", "PROBLEM", 23, 32], ["net increase", "PROBLEM", 37, 49], ["RNA", "TEST", 53, 56], ["HRV", "TEST", 58, 61], ["C15", "TEST", 62, 65], ["HRV", "TEST", 84, 87], ["the two viruses", "PROBLEM", 116, 131], ["HRV", "TEST", 159, 162], ["C15", "TEST", 163, 166], ["HRV", "TEST", 171, 174], ["ALI cultures", "TEST", 189, 201], ["virus replication", "TREATMENT", 245, 262], ["HSEC ALI cultures", "TEST", 264, 281], ["RNA copies", "TEST", 313, 323], ["HRV", "TEST", 334, 337], ["HRV", "TEST", 345, 348], ["growth", "OBSERVATION_MODIFIER", 4, 10], ["kinetics", "OBSERVATION_MODIFIER", 11, 19], ["infection", "OBSERVATION", 23, 32], ["net", "OBSERVATION_MODIFIER", 37, 40], ["increase", "OBSERVATION_MODIFIER", 41, 49], ["RNA", "OBSERVATION_MODIFIER", 53, 56], ["viruses", "OBSERVATION", 124, 131], ["similar", "OBSERVATION_MODIFIER", 137, 144], ["C15", "ANATOMY", 338, 341], ["A16 virions", "OBSERVATION", 349, 360]]], ["For both viruses, there was a 1-2 logs increase in cell-associated HRV RNA over a broad range of inoculating doses (Po0.05; Fig. 4A and B).", [["cell", "ANATOMY", 51, 55], ["cell", "CELL", 51, 55], ["B", "GENE_OR_GENE_PRODUCT", 136, 137], ["HRV RNA", "RNA", 67, 74], ["both viruses", "PROBLEM", 4, 16], ["HRV RNA", "PROBLEM", 67, 74], ["a broad range of inoculating doses", "TREATMENT", 80, 114], ["viruses", "OBSERVATION", 9, 16], ["increase", "OBSERVATION_MODIFIER", 39, 47]]], ["The peak amplification occurred at the doses of 10 4 -10 6 RNA copies per culture (Fig. 4C ).", [["The peak amplification", "PROBLEM", 0, 22], ["culture", "TEST", 74, 81], ["peak", "OBSERVATION_MODIFIER", 4, 8]]], ["When normalized for the amount of viral binding, the amounts of output HRV RNA 24 h PI were quite similar (Fig. 4D ).Optimization of ALI cultures conditions for the amplification of HRV-C15HRV-C15 replication was not altered by changing the concentration of sodium bicarbonate (0.05%-0.235%), MgCl 2 (0.7-30 mM), or altering pH (7.0-7.58).", [["ALI", "DISEASE", 133, 136], ["sodium bicarbonate", "CHEMICAL", 258, 276], ["MgCl", "CHEMICAL", 293, 297], ["sodium bicarbonate", "CHEMICAL", 258, 276], ["MgCl 2", "CHEMICAL", 293, 299], ["HRV-C15HRV-C15", "ORGANISM", 182, 196], ["sodium bicarbonate", "SIMPLE_CHEMICAL", 258, 276], ["MgCl 2", "SIMPLE_CHEMICAL", 293, 299], ["viral binding", "PROBLEM", 34, 47], ["output HRV RNA", "TEST", 64, 78], ["PI", "TEST", 84, 86], ["ALI cultures conditions", "TEST", 133, 156], ["HRV", "TEST", 182, 185], ["C15HRV", "TEST", 186, 192], ["C15 replication", "TREATMENT", 193, 208], ["sodium bicarbonate", "TREATMENT", 258, 276], ["MgCl", "TEST", 293, 297], ["altering pH", "TEST", 316, 327], ["viral binding", "OBSERVATION", 34, 47]]], ["We varied epithelial growth factor (EGF) concentrations (0.8-40 nM) to optimize HSEC cell differentiation and virus propagation.", [["HSEC cell", "ANATOMY", 80, 89], ["epithelial growth factor", "GENE_OR_GENE_PRODUCT", 10, 34], ["EGF", "GENE_OR_GENE_PRODUCT", 36, 39], ["HSEC cell", "CELL", 80, 89], ["epithelial growth factor", "PROTEIN", 10, 34], ["EGF", "PROTEIN", 36, 39], ["HSEC cell differentiation", "TREATMENT", 80, 105], ["virus propagation", "PROBLEM", 110, 127], ["epithelial", "OBSERVATION_MODIFIER", 10, 20], ["growth", "OBSERVATION_MODIFIER", 21, 27], ["cell differentiation", "OBSERVATION", 85, 105], ["virus propagation", "OBSERVATION", 110, 127]]], ["HSEC ALI cultures failed to grow and differentiate in 0.8 nM and 10 nM EGF and 40 nM was the optimal EGF concentration for optimal growth of the HSEC ALI cultures.", [["HSEC ALI cultures", "ANATOMY", 145, 162], ["ALI", "DISEASE", 5, 8], ["ALI", "DISEASE", 150, 153], ["EGF", "GENE_OR_GENE_PRODUCT", 71, 74], ["EGF", "GENE_OR_GENE_PRODUCT", 101, 104], ["HSEC ALI cultures", "CELL", 145, 162], ["HSEC ALI cultures", "CELL_LINE", 0, 17], ["EGF", "PROTEIN", 101, 104], ["HSEC ALI cultures", "CELL_LINE", 145, 162], ["HSEC", "SPECIES", 145, 149], ["HSEC ALI cultures", "TEST", 0, 17], ["the optimal EGF concentration", "TREATMENT", 89, 118], ["the HSEC ALI cultures", "TEST", 141, 162]]], ["HRV-C15 replication was similar for EGF concentrations of 20 vs. 40 nM.", [["EGF", "CHEMICAL", 36, 39], ["EGF", "GENE_OR_GENE_PRODUCT", 36, 39], ["EGF", "PROTEIN", 36, 39], ["HRV", "TEST", 0, 3], ["C15 replication", "TREATMENT", 4, 19], ["EGF concentrations", "TEST", 36, 54]]], ["Adsorption times of 1-4 h produced similar HRV-C15 binding and replication (data not shown).Optimization of ALI cultures conditions for the amplification of HRV-C15To test the effects of duration of differentiation on HRV-C15 replication, we cultured HSEC at ALI for 1 month or 2 months and then inoculated them with HRV-C15.", [["HSEC", "ANATOMY", 251, 255], ["ALI", "DISEASE", 259, 262], ["HRV-C15To", "ORGANISM", 157, 166], ["HRV-C15", "CELL", 218, 225], ["HSEC", "CELL", 251, 255], ["C15To", "DNA", 161, 166], ["ALI cultures conditions", "TEST", 108, 131], ["HRV", "TEST", 157, 160], ["HRV", "TEST", 218, 221], ["C15 replication", "TREATMENT", 222, 237], ["HRV", "TEST", 317, 320]]], ["Both RNA binding and replication were significantly higher in 2 month ALI cultures compared to those infected after 1 month differentiation (Po0.001, Fig. 5) .", [["ALI", "DISEASE", 70, 73], ["Both RNA binding", "PROBLEM", 0, 16], ["ALI cultures", "TEST", 70, 82], ["RNA binding", "OBSERVATION", 5, 16]]], ["TER values between 1 and 2 month old cultures were similar (data not shown).Effects of low pHTo determine if HRV-C15 infectivity is neutralized by low pH as are other HRV, we treated the HRV-C15 with pH 4.5 and assayed viral RNA replication in sinus organ cultures and in Fig. 4 .", [["sinus organ cultures", "ANATOMY", 244, 264], ["HRV-C15", "ORGANISM", 109, 116], ["sinus organ cultures", "CELL", 244, 264], ["TER values", "TEST", 0, 10], ["old cultures", "TEST", 33, 45], ["low pHTo", "PROBLEM", 87, 95], ["HRV", "TEST", 109, 112], ["C15 infectivity", "PROBLEM", 113, 128], ["low pH", "PROBLEM", 147, 153], ["the HRV", "TEST", 183, 190], ["pH", "TEST", 200, 202], ["viral RNA replication", "TREATMENT", 219, 240], ["sinus organ cultures", "TEST", 244, 264], ["low pHTo", "OBSERVATION_MODIFIER", 87, 95], ["sinus organ", "ANATOMY", 244, 255]]], ["Dose response curve of HRV in differentiated HSEC.", [["HSEC", "ANATOMY", 45, 49], ["HSEC", "CANCER", 45, 49], ["HSEC", "CELL_TYPE", 45, 49], ["Dose response curve", "TEST", 0, 19], ["HRV", "TEST", 23, 26]]], ["Differentiated HSEC cultures (n\u00bc3) were infected with HRV-C15 or HRV-A16 virions serially diluted (5 \u00c2 10 8 -5 \u00c2 10 3 RNA copies per well), and cell-associated viral RNA was quantitated immediately post-inoculation (PI) and 24 h later.", [["HSEC cultures", "ANATOMY", 15, 28], ["cell", "ANATOMY", 144, 148], ["HSEC cultures", "CELL", 15, 28], ["HRV-C15", "ORGANISM", 54, 61], ["HRV-A16", "ORGANISM", 65, 72], ["cell", "CELL", 144, 148], ["HSEC cultures", "CELL_LINE", 15, 28], ["viral RNA", "RNA", 160, 169], ["HRV-A16", "SPECIES", 65, 72], ["Differentiated HSEC cultures", "TEST", 0, 28], ["HRV", "TEST", 54, 57], ["HRV", "TEST", 65, 68], ["cell", "TEST", 144, 148], ["viral RNA", "PROBLEM", 160, 169], ["viral RNA", "OBSERVATION", 160, 169]]], ["Panels (A) and (B) illustrate the relationship between input virus, viral binding, and viral yield after 24 h for HRV-C15 and HRV-A16 respectively.", [["HRV-A16", "ORGANISM", 126, 133], ["HRV-A16", "SPECIES", 126, 133], ["Panels", "TEST", 0, 6], ["input virus", "PROBLEM", 55, 66], ["viral binding", "PROBLEM", 68, 81], ["HRV", "TEST", 114, 117], ["HRV", "TEST", 126, 129]]], ["These same data were replotted to illustrate the relationship between inoculum dose and net increase in viral RNA (C), and the relationship between viral binding and viral yield for the two viruses (D).", [["viral RNA", "RNA", 104, 113], ["inoculum dose", "TREATMENT", 70, 83], ["net increase in viral RNA (C)", "PROBLEM", 88, 117], ["viral binding", "PROBLEM", 148, 161], ["increase", "OBSERVATION_MODIFIER", 92, 100], ["viral RNA", "OBSERVATION", 104, 113], ["viral binding", "OBSERVATION", 148, 161]]], ["P o0.001.", [["P o0.001", "DNA", 0, 8]]], ["Optimum temperature for HRV-C15 growth HRV-C15 replication over 24 h was tested at temperatures ranging from 33 to 37 1C.", [["Optimum temperature", "TEST", 0, 19], ["HRV", "TEST", 24, 27], ["HRV", "TEST", 39, 42]]], ["HRV-C15 RNA increased by 1.5 logs after 24 h at all temperatures tested (Fig. 7A) .", [["HRV-C15 RNA", "RNA", 0, 11], ["HRV", "TEST", 0, 3]]], ["We repeated the experiments using two different HRV-C (purified C15 and C41 from cell lysates), and found that replication of both viruses was similar at 34 1C and 37 1C (Fig. 7B and C) .DiscussionHRV-C types are of great interest because of their association with childhood pneumonia, wheezing illnesses and the common cold, but not much is known about their biology because of difficulties in culturing these viruses.", [["cell lysates", "ANATOMY", 81, 93], ["pneumonia", "DISEASE", 275, 284], ["wheezing illnesses", "DISEASE", 286, 304], ["HRV-C", "CELL", 48, 53], ["C15", "CELL", 64, 67], ["C41", "CELL", 72, 75], ["cell lysates", "CELL", 81, 93], ["two different HRV", "TEST", 34, 51], ["cell lysates", "TEST", 81, 93], ["replication of both viruses", "PROBLEM", 111, 138], ["1C", "TEST", 167, 169], ["Fig. 7B", "TEST", 171, 178], ["childhood pneumonia", "PROBLEM", 265, 284], ["wheezing illnesses", "PROBLEM", 286, 304], ["the common cold", "PROBLEM", 309, 324], ["difficulties in culturing these viruses", "PROBLEM", 379, 418], ["viruses", "OBSERVATION", 131, 138], ["pneumonia", "OBSERVATION", 275, 284]]], ["HRV-C can be cultured in human sinus organ culture, but quantitative research is difficult with this technique.", [["sinus organ culture", "ANATOMY", 31, 50], ["HRV-C", "CELL", 0, 5], ["human", "ORGANISM", 25, 30], ["human", "SPECIES", 25, 30], ["human", "SPECIES", 25, 30], ["HRV", "TEST", 0, 3], ["human sinus organ culture", "TEST", 25, 50], ["this technique", "TREATMENT", 96, 110], ["sinus organ", "ANATOMY", 31, 42]]], ["Hence, in this study we developed a system for differentiating sinus epithelium cells in ALI that supported efficient HRV-C replication.", [["sinus epithelium cells", "ANATOMY", 63, 85], ["ALI", "DISEASE", 89, 92], ["sinus epithelium cells", "CELL", 63, 85], ["HRV-C", "GENE_OR_GENE_PRODUCT", 118, 123], ["differentiating sinus epithelium cells", "CELL_TYPE", 47, 85], ["this study", "TEST", 10, 20], ["sinus epithelium cells", "PROBLEM", 63, 85], ["ALI", "PROBLEM", 89, 92], ["C replication", "TREATMENT", 122, 135], ["sinus", "ANATOMY", 63, 68], ["epithelium cells", "OBSERVATION", 69, 85]]], ["Using this system, we demonstrated that HRV-C, like other HRV, is neutralized by low pH, but that HRV-C15 and C41 differ from most HRV-A and HRV-B types in replicating equally well at 33-34 1C and 37 1C.DiscussionHRV-C15 grows well in organ culture and in cells differentiated at ALI, but not in sinus epithelial cells grown in a monolayer.", [["organ culture", "ANATOMY", 235, 248], ["cells", "ANATOMY", 256, 261], ["sinus epithelial cells", "ANATOMY", 296, 318], ["monolayer", "ANATOMY", 330, 339], ["DiscussionHRV-C15", "CHEMICAL", 203, 220], ["ALI", "DISEASE", 280, 283], ["HRV-C", "SIMPLE_CHEMICAL", 40, 45], ["HRV-C15", "ORGANISM", 98, 105], ["C41", "GENE_OR_GENE_PRODUCT", 110, 113], ["HRV-A", "ORGANISM", 131, 136], ["HRV-B", "CELL", 141, 146], ["organ culture", "CELL", 235, 248], ["cells", "CELL", 256, 261], ["sinus epithelial cells", "CELL", 296, 318], ["monolayer", "CELL", 330, 339], ["sinus epithelial cells", "CELL_TYPE", 296, 318], ["HRV", "TEST", 40, 43], ["low pH", "PROBLEM", 81, 87], ["HRV", "TEST", 98, 101], ["C41", "TEST", 110, 113], ["HRV", "TEST", 131, 134], ["HRV", "TEST", 141, 144], ["organ culture", "TEST", 235, 248], ["sinus epithelial cells", "PROBLEM", 296, 318], ["organ", "ANATOMY", 235, 240], ["sinus", "ANATOMY", 296, 301], ["epithelial cells", "OBSERVATION", 302, 318]]], ["The paucity of cell-associated RNA immediately after inoculation indicates that the virus does not bind well to the undifferentiated epithelial cells in the monolayer.", [["cell", "ANATOMY", 15, 19], ["epithelial cells", "ANATOMY", 133, 149], ["monolayer", "ANATOMY", 157, 166], ["cell", "CELL", 15, 19], ["epithelial cells", "CELL", 133, 149], ["monolayer", "CELL", 157, 166], ["undifferentiated epithelial cells", "CELL_TYPE", 116, 149], ["cell-associated RNA", "PROBLEM", 15, 34], ["inoculation", "PROBLEM", 53, 64], ["the virus", "PROBLEM", 80, 89], ["paucity", "OBSERVATION_MODIFIER", 4, 11], ["cell", "OBSERVATION", 15, 19], ["virus", "OBSERVATION", 84, 89], ["undifferentiated epithelial cells", "OBSERVATION", 116, 149], ["monolayer", "OBSERVATION_MODIFIER", 157, 166]]], ["This finding indicates that the either the receptor is absent, or else the cells are lacking a cofactor that promotes cellular binding.", [["cells", "ANATOMY", 75, 80], ["cellular", "ANATOMY", 118, 126], ["cells", "CELL", 75, 80], ["cellular", "CELL", 118, 126], ["a cofactor", "PROBLEM", 93, 103], ["absent", "OBSERVATION", 55, 61], ["cellular binding", "OBSERVATION", 118, 134]]], ["When the cultures are re-differentiated, both binding and replication are restored, possibly due to re-expression of the receptor.DiscussionIn the differentiated cells, both HRV-C15 and HRV-A16 replicated well over a broad range of doses (10 4 RNA copies-10 7 RNA copies).", [["cultures", "ANATOMY", 9, 17], ["cells", "ANATOMY", 162, 167], ["cultures", "CELL", 9, 17], ["cells", "CELL", 162, 167], ["HRV-C15", "CELL", 174, 181], ["HRV-A16", "ORGANISM", 186, 193], ["differentiated cells", "CELL_TYPE", 147, 167], ["HRV-A16", "SPECIES", 186, 193], ["the cultures", "TEST", 5, 17], ["HRV", "TEST", 174, 177], ["HRV", "TEST", 186, 189], ["a broad range of doses", "TREATMENT", 215, 237], ["RNA copies", "TEST", 244, 254], ["possibly due to", "UNCERTAINTY", 84, 99]]], ["Peak viral replication was achieved with inoculum size between 10 4 and 10 6 RNA copies per sample.", [["Peak viral replication", "TREATMENT", 0, 22], ["inoculum size", "TEST", 41, 54], ["viral replication", "OBSERVATION", 5, 22]]], ["These findings suggest that relatively low-dose inoculation produces the best signal for studies of virus replication.", [["relatively low-dose inoculation", "PROBLEM", 28, 59], ["virus replication", "TREATMENT", 100, 117], ["relatively", "OBSERVATION_MODIFIER", 28, 38], ["low", "OBSERVATION_MODIFIER", 39, 42]]], ["If the goal is maximum yield, such as production of viral stocks, more input virus would be desirable.DiscussionFor any given concentration of input virus, binding of HRV-A16 was greater than that of HRV-C15.", [["HRV-A16", "ORGANISM", 167, 174], ["HRV-C15", "GENE_OR_GENE_PRODUCT", 200, 207], ["HRV-A16", "SPECIES", 167, 174], ["viral stocks", "TREATMENT", 52, 64], ["more input virus", "PROBLEM", 66, 82], ["input virus", "PROBLEM", 143, 154], ["HRV", "TEST", 167, 170], ["HRV", "TEST", 200, 203], ["viral stocks", "OBSERVATION", 52, 64]]], ["This could be due to increased expression of the receptor for HRV-A16 (i.e. ICAM-1), or perhaps a higher affinity of the HRV-A16 to its receptors as compared to HRV-C15.", [["HRV-A16", "GENE_OR_GENE_PRODUCT", 62, 69], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 76, 82], ["HRV-A16", "GENE_OR_GENE_PRODUCT", 121, 128], ["HRV-C15", "ORGANISM", 161, 168], ["ICAM", "PROTEIN", 76, 80], ["HRV", "TEST", 62, 65], ["ICAM", "TEST", 76, 80], ["the HRV", "TEST", 117, 124], ["HRV", "TEST", 161, 164], ["could be due to", "UNCERTAINTY", 5, 20], ["increased", "OBSERVATION_MODIFIER", 21, 30], ["higher affinity", "OBSERVATION", 98, 113]]], ["Molecular modeling studies of HRV-C15 have predicted a loss of mass at the 5-fold axis of symmetry, analogous to an area associated with receptor binding in HRV-A and HRV-B (Palmenberg et al., 2009 ).", [["HRV-C15", "CHEMICAL", 30, 37], ["HRV-C15", "GENE_OR_GENE_PRODUCT", 30, 37], ["HRV-A", "GENE_OR_GENE_PRODUCT", 157, 162], ["HRV-B", "CELL", 167, 172], ["Molecular modeling studies", "TEST", 0, 26], ["HRV", "TEST", 30, 33], ["a loss of mass", "PROBLEM", 53, 67], ["receptor binding", "PROBLEM", 137, 153], ["HRV", "TEST", 157, 160], ["HRV", "TEST", 167, 170], ["loss", "OBSERVATION_MODIFIER", 55, 59], ["mass", "OBSERVATION", 63, 67], ["5-fold axis", "OBSERVATION_MODIFIER", 75, 86]]], ["Sensitivity of HRV-C15 to low pH.", [["Sensitivity", "TEST", 0, 11], ["HRV", "TEST", 15, 18], ["low pH", "PROBLEM", 26, 32], ["low pH", "OBSERVATION_MODIFIER", 26, 32]]], ["HRV-C15 was diluted 1:10 in citrate phosphate buffer (pH \u00bc4.5) or left untreated (pH 7.5), and was then used to infect (A) sinus organ cultures (n \u00bc3) (B) differentiated cultures of HSEC (n\u00bc 3).", [["sinus organ cultures", "ANATOMY", 123, 143], ["cultures", "ANATOMY", 170, 178], ["HSEC", "ANATOMY", 182, 186], ["citrate phosphate", "CHEMICAL", 28, 45], ["citrate phosphate", "CHEMICAL", 28, 45], ["citrate phosphate buffer", "SIMPLE_CHEMICAL", 28, 52], ["B", "CELL", 152, 153], ["HSEC", "CELL", 182, 186], ["n\u00bc 3", "CELL", 188, 192], ["HRV", "TEST", 0, 3], ["citrate phosphate buffer", "TREATMENT", 28, 52], ["pH \u00bc", "TEST", 54, 58], ["pH", "TEST", 82, 84], ["A) sinus organ cultures", "TEST", 120, 143], ["HSEC", "TEST", 182, 186], ["left", "ANATOMY_MODIFIER", 66, 70], ["sinus organ", "ANATOMY", 123, 134]]], ["Similar experiments were conducted with HRV-A16 (C).", [["C", "CELL", 49, 50], ["HRV-A16", "SPECIES", 40, 47], ["HRV", "TEST", 40, 43]]], ["Virus titers were determined 24 h after inoculation. *P o0.05, **P o0.004 by t-test.", [["Virus", "ORGANISM", 0, 5], ["P o0.05", "DNA", 54, 61], ["**P o0.004", "DNA", 63, 73], ["Virus titers", "TEST", 0, 12], ["t-test", "TEST", 77, 83]]], ["(1 \u00c2 10 8 RNA copies), and viral RNA was measured immediately post-inoculation and again after incubation at 33-37 1C for 24, 48 and 72 h.", [["1 \u00c2 10 8 RNA copies", "RNA", 1, 20], ["viral RNA", "RNA", 27, 36], ["RNA copies", "TEST", 10, 20], ["viral RNA", "PROBLEM", 27, 36], ["incubation", "TEST", 95, 105], ["viral RNA", "OBSERVATION", 27, 36]]], ["In separate experiments, differentiated HSEC were inoculated with either HRV-C15 (2 \u00c2 10 8 RNA copies, n\u00bc5, panel B) or HRV-C41 (2 \u00c2 10 7 RNA copies, n\u00bc 7, panel C) and viral RNA was determined after incubation at either 34 1C or 37 1C for 24 h PI. differences in characteristics of HRV-C15 binding to epithelial cells.", [["HSEC", "ANATOMY", 40, 44], ["epithelial cells", "ANATOMY", 302, 318], ["HSEC", "CELL", 40, 44], ["HRV-C41", "CELL", 120, 127], ["HRV-C15", "GENE_OR_GENE_PRODUCT", 283, 290], ["epithelial cells", "CELL", 302, 318], ["HSEC", "CELL_TYPE", 40, 44], ["n\u00bc5", "DNA", 103, 106], ["HRV-C41", "DNA", 120, 127], ["viral RNA", "RNA", 169, 178], ["epithelial cells", "CELL_TYPE", 302, 318], ["HRV", "TEST", 73, 76], ["C15", "TEST", 77, 80], ["RNA copies", "TEST", 91, 101], ["n\u00bc5", "TEST", 103, 106], ["panel B", "TEST", 108, 115], ["HRV", "TEST", 120, 123], ["C41", "TEST", 124, 127], ["RNA copies", "TEST", 138, 148], ["n\u00bc", "TEST", 150, 152], ["panel C", "TEST", 156, 163], ["viral RNA", "TEST", 169, 178], ["HRV", "TEST", 283, 286], ["epithelial cells", "OBSERVATION", 302, 318]]], ["Notably, replication of the two different strains was nearly identical once the data were normalized for virus binding, suggesting that replication processes distal to binding are similar.DiscussionThe HSEC-ALI system for HRV-C replication has several advantages over the organ culture.", [["organ culture", "ANATOMY", 272, 285], ["HSEC", "GENE_OR_GENE_PRODUCT", 202, 206], ["HRV-C", "CELL", 222, 227], ["organ", "ORGAN", 272, 277], ["the two different strains", "PROBLEM", 24, 49], ["the data", "TEST", 76, 84], ["virus binding", "PROBLEM", 105, 118], ["replication processes distal to binding", "PROBLEM", 136, 175], ["HRV", "PROBLEM", 222, 225], ["C replication", "TREATMENT", 226, 239], ["the organ culture", "TEST", 268, 285], ["replication", "OBSERVATION", 136, 147], ["similar", "OBSERVATION_MODIFIER", 180, 187]]], ["First, it allows for expansion of HSEC before differentiation, thus providing more cells from the same donor for testing of multiple conditions.", [["HSEC", "ANATOMY", 34, 38], ["cells", "ANATOMY", 83, 88], ["HSEC", "CANCER", 34, 38], ["cells", "CELL", 83, 88], ["HSEC", "CELL_TYPE", 34, 38], ["expansion of HSEC", "TEST", 21, 38]]], ["Notably, stocks of undifferentiated cells can be cryopreserved for use on multiple days.", [["cells", "ANATOMY", 36, 41], ["cells", "CELL", 36, 41], ["undifferentiated cells", "CELL_TYPE", 19, 41], ["undifferentiated cells", "PROBLEM", 19, 41], ["undifferentiated cells", "OBSERVATION", 19, 41]]], ["In addition, the number of cells per well is uniform, and the cultures consist almost entirely of epithelial cells which provides a more uniform substrate for viral replication.", [["cells", "ANATOMY", 27, 32], ["cultures", "ANATOMY", 62, 70], ["epithelial cells", "ANATOMY", 98, 114], ["cells", "CELL", 27, 32], ["epithelial cells", "CELL", 98, 114], ["epithelial cells", "CELL_TYPE", 98, 114], ["the cultures", "TEST", 58, 70], ["epithelial cells", "PROBLEM", 98, 114], ["viral replication", "TREATMENT", 159, 176], ["cells", "OBSERVATION", 27, 32], ["uniform", "OBSERVATION_MODIFIER", 45, 52], ["epithelial cells", "OBSERVATION", 98, 114], ["viral replication", "OBSERVATION", 159, 176]]], ["Another group published the growth of HRV-C15 in ALI system that agrees with our findings (Hao et al., in press ).", [["ALI", "DISEASE", 49, 52], ["HRV-C15", "CELL", 38, 45], ["HRV", "TEST", 38, 41]]], ["These studies together demonstrate that the HSEC-ALI system is advantageous for quantitative studies of HRV-C biology, pathogenic mechanisms, and preclinical tests of anti-viral drugs.DiscussionGrowth of HRV-C15 in HSEC ALI cultures also enabled studies of basic characteristics of the HRV-C types.", [["HSEC ALI cultures", "ANATOMY", 215, 232], ["ALI", "DISEASE", 49, 52], ["ALI", "DISEASE", 220, 223], ["HSEC", "GENE_OR_GENE_PRODUCT", 44, 48], ["HRV-C", "GENE_OR_GENE_PRODUCT", 104, 109], ["HRV-C15", "SIMPLE_CHEMICAL", 204, 211], ["HSEC ALI cultures", "CELL", 215, 232], ["HSEC ALI cultures", "CELL_LINE", 215, 232], ["These studies", "TEST", 0, 13], ["the HSEC", "TEST", 40, 48], ["quantitative studies", "TEST", 80, 100], ["HRV", "TEST", 104, 107], ["preclinical tests", "TEST", 146, 163], ["anti-viral drugs", "TREATMENT", 167, 183], ["HRV", "TEST", 204, 207], ["HSEC ALI cultures", "TEST", 215, 232], ["C15", "ANATOMY", 208, 211]]], ["HRVs are rendered noninfectious by low pH, which causes a conformational change in virus capsid resulting in a loss of VP4 and uncoating of the virus (Giranda et al., 1992) .", [["HRVs", "SIMPLE_CHEMICAL", 0, 4], ["VP4", "GENE_OR_GENE_PRODUCT", 119, 122], ["VP4", "PROTEIN", 119, 122], ["noninfectious", "PROBLEM", 18, 31], ["low pH", "PROBLEM", 35, 41], ["a conformational change in virus capsid", "PROBLEM", 56, 95], ["a loss of VP4", "PROBLEM", 109, 122], ["the virus", "PROBLEM", 140, 149], ["noninfectious", "OBSERVATION", 18, 31], ["low pH", "OBSERVATION_MODIFIER", 35, 41], ["virus", "OBSERVATION", 83, 88]]], ["This is a defining property that distinguishes HRVs from the closely related enteroviruses.", [["enteroviruses", "DISEASE", 77, 90], ["HRVs", "CANCER", 47, 51], ["enteroviruses", "ORGANISM", 77, 90], ["HRVs", "PROBLEM", 47, 51], ["the closely related enteroviruses", "PROBLEM", 57, 90], ["enteroviruses", "OBSERVATION", 77, 90]]], ["Our results demonstrate that HRV-C strains, like HRV-A and HRV-B, are sensitive to low pH.DiscussionOne other notable characteristic is that most HRV grow optimally at 33-34 1C and have reduced replication at 37 1C (Schroth et al., 1999; Taylor-Robinson and Tyrrell, 1962; Tyrrell and Parsons, 1960; Papadopoulos et al., 1999) .", [["HRV-C strains", "ORGANISM", 29, 42], ["HRV-A", "ORGANISM", 49, 54], ["HRV-B", "CELL", 59, 64], ["HRV-A", "SPECIES", 49, 54], ["HRV", "TEST", 29, 32], ["C strains", "PROBLEM", 33, 42], ["HRV", "TEST", 49, 52], ["HRV", "TEST", 59, 62], ["low pH", "PROBLEM", 83, 89], ["low pH", "OBSERVATION_MODIFIER", 83, 89]]], ["Although the mechanism of temperature sensitivity is not completely understood, there has been a speculation that the lower GC content of HRV compared to other enteroviruses is an adaptation for replication at lower temperatures (McIntyre et al., 2010) .", [["enteroviruses", "DISEASE", 160, 173], ["temperature sensitivity", "PROBLEM", 26, 49], ["the lower GC content", "PROBLEM", 114, 134], ["HRV", "PROBLEM", 138, 141], ["other enteroviruses", "PROBLEM", 154, 173]]], ["Overall, HRV-C genomes have a higher G \u00feC content (43%) than HRV-A and HRV-B (37% and 38%) and are closer to HEV (ranging from 42 to 48%) (Linsuwanon et al., 2011) ; this has led to speculation that HRV-C might grow well at core body temperature.", [["body", "ANATOMY", 229, 233], ["HRV-C", "GENE_OR_GENE_PRODUCT", 9, 14], ["G \u00feC", "GENE_OR_GENE_PRODUCT", 37, 41], ["HRV-A", "GENE_OR_GENE_PRODUCT", 61, 66], ["HRV-B", "GENE_OR_GENE_PRODUCT", 71, 76], ["HEV", "ORGANISM", 109, 112], ["HRV-C", "GENE_OR_GENE_PRODUCT", 199, 204], ["body", "ORGANISM_SUBDIVISION", 229, 233], ["HRV-C genomes", "DNA", 9, 22], ["HRV-A", "SPECIES", 61, 66], ["HRV-B", "SPECIES", 71, 76], ["HEV", "SPECIES", 109, 112], ["HRV", "TEST", 9, 12], ["a higher G \u00feC content", "PROBLEM", 28, 49], ["HRV", "TEST", 61, 64], ["HRV", "TEST", 71, 74], ["HEV", "TEST", 109, 112]]], ["Our results support this theory, since both HRV-C15 and another clinical isolate (HRV-C41) grew equally well at 34 1C vs 37 1C.", [["HRV-C15", "ORGANISM", 44, 51], ["HRV-C41", "CELL", 82, 89], ["HRV", "TEST", 44, 47], ["HRV", "TEST", 82, 85]]], ["Additional isolates of HRV-C and other species need to be tested in the future to determine if the ability to grow well at 37 1C is a general and distinct property of the C species.DiscussionThis culture system has some advantages and some limitations that should be considered.", [["HRV-C", "ORGANISM", 23, 28], ["C species", "SIMPLE_CHEMICAL", 171, 180], ["HRV", "TEST", 23, 26], ["other species", "PROBLEM", 33, 46], ["the C species", "PROBLEM", 167, 180], ["This culture system", "TEST", 191, 210]]], ["The ALI culture system yields polarized cell layers that are morphologically similar to airway epithelium in vivo.", [["cell layers", "ANATOMY", 40, 51], ["airway epithelium", "ANATOMY", 88, 105], ["ALI", "DISEASE", 4, 7], ["cell layers", "CELL", 40, 51], ["airway epithelium", "TISSUE", 88, 105], ["The ALI culture system", "TEST", 0, 22], ["polarized cell layers", "PROBLEM", 30, 51], ["ALI", "ANATOMY", 4, 7], ["polarized cell layers", "OBSERVATION", 30, 51], ["airway epithelium", "OBSERVATION", 88, 105]]], ["This system, unlike cell lines (e.g. MRC-5, HeLa and WI-38) that are often used for HRV culture, supported the growth of all three species of HRV, and could therefore enable studies of comparative biology.", [["cell lines", "ANATOMY", 20, 30], ["MRC-5", "ANATOMY", 37, 42], ["HeLa", "ANATOMY", 44, 48], ["cell lines", "CELL", 20, 30], ["MRC-5", "CELL", 37, 42], ["HeLa", "CELL", 44, 48], ["WI-38", "CELL", 53, 58], ["cell lines", "CELL_LINE", 20, 30], ["MRC-5", "CELL_LINE", 37, 42], ["HeLa", "CELL_LINE", 44, 48], ["WI-38", "CELL_LINE", 53, 58], ["MRC", "TEST", 37, 40], ["HeLa", "TEST", 44, 48], ["WI", "TEST", 53, 55], ["HRV culture", "TEST", 84, 95], ["HRV", "PROBLEM", 142, 145], ["cell lines", "OBSERVATION", 20, 30]]], ["One limitation of our studies is that viral titer is inferred from the quantity of viral RNA and not by the progeny virus particles produced since plaque assays for HRV-C strains await development.", [["plaque", "ANATOMY", 147, 153], ["HRV-C strains", "ORGANISM", 165, 178], ["viral RNA", "RNA", 83, 92], ["our studies", "TEST", 18, 29], ["viral titer", "PROBLEM", 38, 49], ["viral RNA", "PROBLEM", 83, 92], ["the progeny virus particles", "PROBLEM", 104, 131], ["plaque assays", "TEST", 147, 160], ["HRV", "TEST", 165, 168], ["C strains", "PROBLEM", 169, 178], ["viral RNA", "OBSERVATION", 83, 92]]], ["Previous studies have demonstrated excellent correlation between HRV measured by plaque assay and by qPCR (Mosser et al., 2005) .", [["plaque", "ANATOMY", 81, 87], ["Previous studies", "TEST", 0, 16], ["HRV", "TEST", 65, 68], ["plaque assay", "TEST", 81, 93], ["qPCR", "TEST", 101, 105], ["excellent", "OBSERVATION_MODIFIER", 35, 44], ["plaque", "OBSERVATION", 81, 87]]], ["Addition of retinoic acid and steroids in the ALI medium is essential for development and differentiation of the HSEC epithelium.", [["HSEC epithelium", "ANATOMY", 113, 128], ["retinoic acid", "CHEMICAL", 12, 25], ["steroids", "CHEMICAL", 30, 38], ["ALI", "DISEASE", 46, 49], ["retinoic acid", "CHEMICAL", 12, 25], ["steroids", "CHEMICAL", 30, 38], ["retinoic acid", "SIMPLE_CHEMICAL", 12, 25], ["steroids", "SIMPLE_CHEMICAL", 30, 38], ["HSEC epithelium", "TISSUE", 113, 128], ["retinoic acid", "TREATMENT", 12, 25], ["steroids in the ALI medium", "TREATMENT", 30, 56], ["the HSEC epithelium", "PROBLEM", 109, 128], ["retinoic acid", "OBSERVATION", 12, 25], ["ALI", "ANATOMY", 46, 49]]], ["However, presence of steroids in the culture medium could affect antiviral responses and in turn virus replication.", [["steroids", "CHEMICAL", 21, 29], ["steroids", "CHEMICAL", 21, 29], ["steroids", "SIMPLE_CHEMICAL", 21, 29], ["steroids", "TREATMENT", 21, 29], ["the culture medium", "TEST", 33, 51], ["antiviral responses", "TREATMENT", 65, 84], ["turn virus replication", "TREATMENT", 92, 114], ["steroids", "OBSERVATION", 21, 29]]], ["Further studies are needed to decipher the role of such hormones and growth factors on HRV replication in differentiated HSEC.DiscussionTo summarize, we developed a culture system in which clinical HRV-C strains can be grown and tested.", [["HSEC", "ANATOMY", 121, 125], ["HSEC", "CELL", 121, 125], ["growth factors", "PROTEIN", 69, 83], ["HSEC", "CELL_TYPE", 121, 125], ["Further studies", "TEST", 0, 15], ["such hormones", "PROBLEM", 51, 64], ["growth factors", "PROBLEM", 69, 83], ["HRV replication", "TREATMENT", 87, 102], ["a culture system", "TEST", 163, 179], ["clinical HRV", "TEST", 189, 201], ["C strains", "PROBLEM", 202, 211]]], ["This model system serves as an important tool for studying HRV-C infections and provides useful insights into the biological properties of HRV-C strains.", [["HRV-C infections", "DISEASE", 59, 75], ["HRV-C", "ORGANISM", 59, 64], ["HRV-C strains", "ORGANISM", 139, 152], ["C infections", "PROBLEM", 63, 75], ["C strains", "PROBLEM", 143, 152]]], ["Ability to grow at a higher temperature may have clinical implications, and could contribute to a greater propensity for some HRV-C strains to cause lower airway syndromes such as wheezing illnesses and exacerbations of asthma.Materials and methodsViruses HRV-A16 and HRV-C15 were clinical isolates that were cloned and viruses were produced by transfecting viral RNA into Hela cells as previously described (Bochkov et al., 2011) .", [["lower airway", "ANATOMY", 149, 161], ["Hela cells", "ANATOMY", 373, 383], ["airway syndromes", "DISEASE", 155, 171], ["wheezing illnesses", "DISEASE", 180, 198], ["asthma", "DISEASE", 220, 226], ["HRV-C", "GENE_OR_GENE_PRODUCT", 126, 131], ["airway", "MULTI-TISSUE_STRUCTURE", 155, 161], ["methodsViruses HRV-A16", "ORGANISM", 241, 263], ["HRV-C15", "ORGANISM", 268, 275], ["Hela cells", "CELL", 373, 383], ["viral RNA", "RNA", 358, 367], ["Hela cells", "CELL_LINE", 373, 383], ["HRV-A16", "SPECIES", 256, 263], ["a higher temperature", "PROBLEM", 19, 39], ["some HRV", "PROBLEM", 121, 129], ["C strains", "PROBLEM", 130, 139], ["lower airway syndromes", "PROBLEM", 149, 171], ["wheezing illnesses", "PROBLEM", 180, 198], ["exacerbations", "PROBLEM", 203, 216], ["asthma", "PROBLEM", 220, 226], ["Materials", "TEST", 227, 236], ["methodsViruses", "TEST", 241, 255], ["HRV", "TEST", 256, 259], ["HRV", "TEST", 268, 271], ["clinical isolates", "PROBLEM", 281, 298], ["viruses", "PROBLEM", 320, 327], ["transfecting viral RNA into Hela cells", "PROBLEM", 345, 383], ["lower", "ANATOMY_MODIFIER", 149, 154], ["airway", "ANATOMY", 155, 161], ["syndromes", "OBSERVATION", 162, 171], ["asthma", "OBSERVATION", 220, 226], ["Hela cells", "OBSERVATION", 373, 383]]], ["After three freezes, thaw cycles the cell lysate was treated with RNaseA (10 mg/ml) for 10 min at room temperature to get rid of free RNA that is present outside the virions.", [["cell lysate", "ANATOMY", 37, 48], ["virions", "ANATOMY", 166, 173], ["RNaseA", "CHEMICAL", 66, 72], ["RNaseA", "CHEMICAL", 66, 72], ["cell lysate", "CELL", 37, 48], ["RNaseA", "SIMPLE_CHEMICAL", 66, 72], ["free RNA", "RNA", 129, 137], ["thaw cycles the cell lysate", "TREATMENT", 21, 48], ["RNaseA", "TREATMENT", 66, 72], ["free RNA", "PROBLEM", 129, 137], ["free RNA", "OBSERVATION", 129, 137], ["virions", "ANATOMY", 166, 173]]], ["This procedure was included so that viral RNA measurements would reflect the quantity of viruses and not unpackaged viral RNA.", [["viral RNA", "RNA", 36, 45], ["unpackaged viral RNA", "RNA", 105, 125], ["This procedure", "TREATMENT", 0, 14], ["viral RNA measurements", "TEST", 36, 58], ["viruses", "PROBLEM", 89, 96], ["unpackaged viral RNA", "PROBLEM", 105, 125], ["viruses", "OBSERVATION", 89, 96], ["viral RNA", "OBSERVATION", 116, 125]]], ["The viruses were purified by pelleting through a 30% sucrose cushion in a Beckman SW 41 rotor (40,000 rpm, 16 1C, 130 min) (Lee et al., 1995; Wang et al., 1998) .", [["sucrose", "CHEMICAL", 53, 60], ["sucrose", "CHEMICAL", 53, 60], ["The viruses", "PROBLEM", 0, 11], ["a 30% sucrose cushion", "TREATMENT", 47, 68], ["viruses", "OBSERVATION", 4, 11]]], ["Pelleted virus was resuspended in PBS with 0.01% BSA and stored at \u00c0 70 1C.", [["BSA", "SIMPLE_CHEMICAL", 49, 52], ["Pelleted virus", "PROBLEM", 0, 14], ["virus", "OBSERVATION", 9, 14]]], ["HRV-C41 was a clinical isolate produced by inoculating nasal secretions into sinus organ culture as previously described (Bochkov et al., 2011) .", [["nasal secretions", "ANATOMY", 55, 71], ["sinus organ culture", "ANATOMY", 77, 96], ["nasal secretions", "ORGANISM_SUBSTANCE", 55, 71], ["HRV", "TEST", 0, 3], ["a clinical isolate", "PROBLEM", 12, 30], ["inoculating nasal secretions", "PROBLEM", 43, 71], ["sinus organ culture", "TEST", 77, 96], ["sinus organ", "ANATOMY", 77, 88]]], ["The cultures were frozen and thawed thrice to release the virions and centrifuged at low speed to get rid of the cellular debris and frozen at \u00c070 1C till used.RNA extraction and quantitative (q) RT-PCRTotal RNA was extracted from sinus tissue or ALI cultures using the RNeasy Mini kit (Qiagen).", [["cultures", "ANATOMY", 4, 12], ["virions", "ANATOMY", 58, 65], ["cellular debris", "ANATOMY", 113, 128], ["sinus tissue", "ANATOMY", 231, 243], ["cellular", "CELL", 113, 121], ["sinus tissue", "TISSUE", 231, 243], ["PCRTotal RNA", "RNA", 199, 211], ["The cultures", "TEST", 0, 12], ["the virions", "PROBLEM", 54, 65], ["the cellular debris", "PROBLEM", 109, 128], ["RNA extraction", "TEST", 160, 174], ["quantitative (q) RT-PCRTotal RNA", "TREATMENT", 179, 211], ["sinus tissue", "PROBLEM", 231, 243], ["ALI cultures", "TEST", 247, 259], ["the RNeasy Mini kit", "TREATMENT", 266, 285], ["cellular", "ANATOMY", 113, 121], ["debris", "OBSERVATION", 122, 128], ["sinus tissue", "ANATOMY", 231, 243]]], ["HRV RNA concentrations were determined by qRT-PCR as previously described (Bochkov et al., 2011) .Sinus organ culturesSinus tissue was obtained from residual surgical specimens from individuals undergoing sinus surgery (Bochkov et al., 2011) and the protocol was approved by the University of Wisconsin-Madison Human Subjects Committee.", [["Sinus organ cultures", "ANATOMY", 98, 118], ["Sinus tissue", "ANATOMY", 118, 130], ["specimens", "ANATOMY", 167, 176], ["sinus", "ANATOMY", 205, 210], ["Sinus tissue", "TISSUE", 118, 130], ["sinus", "MULTI-TISSUE_STRUCTURE", 205, 210], ["Human", "ORGANISM", 311, 316], ["HRV RNA", "RNA", 0, 7], ["Sinus organ cultures", "CELL_LINE", 98, 118], ["Human", "SPECIES", 311, 316], ["HRV RNA concentrations", "TEST", 0, 22], ["PCR", "TEST", 46, 49], ["Sinus organ cultures", "TEST", 98, 118], ["Sinus tissue", "PROBLEM", 118, 130], ["residual surgical specimens", "PROBLEM", 149, 176], ["sinus surgery", "TREATMENT", 205, 218], ["organ", "ANATOMY", 104, 109], ["residual", "OBSERVATION_MODIFIER", 149, 157], ["surgical specimens", "OBSERVATION", 158, 176], ["sinus", "ANATOMY", 205, 210]]], ["All samples were washed thrice with PBS, cut in 4 \u00c2 4 mm 2 pieces and then tested for HRV, adenovirus, influenza, parainfluenza, enterovirus, respiratory syncytial virus, metapneumovirus, coronavirus and bocavirus by multiplex PCR (Lee et al., 2007) before proceeding with experiments.Cultures of human sinus epitheliumTo obtain sinus epithelial cells, the tissue was washed with PBS and digested by pronase (Roche, Basel, Switzerland) and DNase (Sigma-Aldrich, St.Louis, MO) (Schroth et al., 1999) .", [["samples", "ANATOMY", 4, 11], ["sinus epithelium", "ANATOMY", 303, 319], ["sinus epithelial cells", "ANATOMY", 329, 351], ["tissue", "ANATOMY", 357, 363], ["influenza, parainfluenza, enterovirus, respiratory syncytial virus, metapneumovirus, coronavirus and bocavirus", "DISEASE", 103, 213], ["adenovirus", "ORGANISM", 91, 101], ["parainfluenza", "ORGANISM", 114, 127], ["enterovirus", "ORGANISM", 129, 140], ["respiratory syncytial virus", "ORGANISM", 142, 169], ["metapneumovirus", "ORGANISM", 171, 186], ["coronavirus", "ORGANISM", 188, 199], ["human", "ORGANISM", 297, 302], ["sinus epithelium", "TISSUE", 303, 319], ["sinus epithelial cells", "CELL", 329, 351], ["tissue", "TISSUE", 357, 363], ["pronase", "SIMPLE_CHEMICAL", 400, 407], ["DNase", "GENE_OR_GENE_PRODUCT", 440, 445], ["St.Louis", "ORGANISM", 462, 470], ["sinus epithelial cells", "CELL_TYPE", 329, 351], ["DNase", "PROTEIN", 440, 445], ["parainfluenza", "SPECIES", 114, 127], ["respiratory syncytial virus", "SPECIES", 142, 169], [", metapneumovirus", "SPECIES", 169, 186], ["coronavirus", "SPECIES", 188, 199], ["human", "SPECIES", 297, 302], ["HRV", "SPECIES", 86, 89], ["adenovirus", "SPECIES", 91, 101], ["respiratory syncytial virus", "SPECIES", 142, 169], ["human", "SPECIES", 297, 302], ["All samples", "TEST", 0, 11], ["PBS", "TREATMENT", 36, 39], ["HRV", "PROBLEM", 86, 89], ["adenovirus", "PROBLEM", 91, 101], ["influenza", "PROBLEM", 103, 112], ["parainfluenza", "PROBLEM", 114, 127], ["enterovirus", "PROBLEM", 129, 140], ["respiratory syncytial virus", "PROBLEM", 142, 169], ["metapneumovirus", "PROBLEM", 171, 186], ["coronavirus", "PROBLEM", 188, 199], ["bocavirus", "PROBLEM", 204, 213], ["multiplex PCR", "TEST", 217, 230], ["Cultures", "TEST", 285, 293], ["human sinus epithelium", "PROBLEM", 297, 319], ["sinus epithelial cells", "PROBLEM", 329, 351], ["PBS", "TREATMENT", 380, 383], ["respiratory syncytial", "ANATOMY", 142, 163], ["human sinus", "ANATOMY", 297, 308], ["epithelium", "ANATOMY_MODIFIER", 309, 319], ["sinus", "ANATOMY", 329, 334], ["epithelial cells", "OBSERVATION", 335, 351]]], ["Epithelial cells were seeded in 75 cm 2 CellBind s flasks (Costar; Corning Inc., Corning, NY) and cultured in Bronchial Epithelial Growth Medium (BEGM, Lonza, Walkersville, MD).", [["Epithelial cells", "ANATOMY", 0, 16], ["Epithelial cells", "CELL", 0, 16], ["Epithelial cells", "CELL_TYPE", 0, 16], ["Epithelial cells", "PROBLEM", 0, 16], ["75 cm", "OBSERVATION_MODIFIER", 32, 37], ["Bronchial Epithelial", "ANATOMY", 110, 130]]], ["At 90% confluence, the cells were dissociated with trypsin and seeded either as monolayer cultures or for differentiation at ALI.", [["cells", "ANATOMY", 23, 28], ["monolayer cultures", "ANATOMY", 80, 98], ["ALI", "DISEASE", 125, 128], ["cells", "CELL", 23, 28], ["trypsin", "GENE_OR_GENE_PRODUCT", 51, 58], ["monolayer cultures", "CELL", 80, 98], ["trypsin", "PROTEIN", 51, 58], ["monolayer cultures", "CELL_LINE", 80, 98], ["the cells", "PROBLEM", 19, 28], ["trypsin", "TREATMENT", 51, 58], ["monolayer cultures", "TEST", 80, 98], ["differentiation at ALI", "PROBLEM", 106, 128], ["confluence", "OBSERVATION_MODIFIER", 7, 17]]], ["The cells obtained at P-0 and P-1 were frozen in liquid nitrogen for future use.", [["cells", "ANATOMY", 4, 9], ["nitrogen", "CHEMICAL", 56, 64], ["cells", "CELL", 4, 9], ["P-0 and P-1", "DNA", 22, 33], ["The cells", "TEST", 0, 9], ["P", "TEST", 22, 23], ["P", "TEST", 30, 31], ["liquid nitrogen", "TREATMENT", 49, 64]]], ["For monolayers, cells were seeded into 12-well tissue culture plates at a density of 1 \u00c2 10 5 cells/ml.", [["monolayers", "ANATOMY", 4, 14], ["cells", "ANATOMY", 16, 21], ["tissue", "ANATOMY", 47, 53], ["cells", "ANATOMY", 94, 99], ["monolayers", "CELL", 4, 14], ["cells", "CELL", 16, 21], ["tissue", "TISSUE", 47, 53], ["cells", "CELL", 94, 99]]], ["For differentiated cultures, cells were seeded at a density of 1.5 \u00c2 10 5 cells/cm 2 in BEGM (Lonza, Walkersville, MD) onto the apical surface of 1.13 cm 2 Transwell polycarbonate inserts (Costar 0.4 mm pore size, 10 mm membrane thickness; Corning Inc., Corning, NY) coated with human placental collagen Type VI (Sigma-Aldrich, St.Louis, MO) in a 12-well plate.", [["cultures", "ANATOMY", 19, 27], ["cells", "ANATOMY", 29, 34], ["cells", "ANATOMY", 74, 79], ["apical surface", "ANATOMY", 128, 142], ["pore", "ANATOMY", 203, 207], ["membrane", "ANATOMY", 220, 228], ["polycarbonate", "CHEMICAL", 166, 179], ["cultures", "CELL", 19, 27], ["cells", "CELL", 29, 34], ["human", "ORGANISM", 279, 284], ["collagen Type VI", "GENE_OR_GENE_PRODUCT", 295, 311], ["St.Louis", "ORGANISM", 328, 336], ["MO", "ORGANISM", 338, 340], ["differentiated cultures", "CELL_LINE", 4, 27], ["human", "SPECIES", 279, 284], ["human", "SPECIES", 279, 284], ["differentiated cultures", "TEST", 4, 27], ["cells", "TEST", 29, 34], ["a density", "TEST", 50, 59], ["Transwell polycarbonate inserts (Costar 0.4 mm pore size", "TREATMENT", 156, 212], ["apical", "ANATOMY_MODIFIER", 128, 134], ["surface", "ANATOMY_MODIFIER", 135, 142], ["1.13 cm", "OBSERVATION_MODIFIER", 146, 153]]], ["The cells were fed basally with BEGM and incubated at 37 1C for first 24 h.", [["cells", "ANATOMY", 4, 9], ["BEGM", "CHEMICAL", 32, 36], ["cells", "CELL", 4, 9]]], ["Media was removed from the apical surface and the basal medium was changed to BEGM and Dulbecco's modified Eagle's medium (DMEM) in a 1:1 ratio supplemented with the following additives: insulin, 2.5 mg/ml; transferrin, 5 mg/ml; recombinant epithelial growth factor, 0.25 ng/ml; hydrocortisone, 0.25 mg/ml; epinephrine, 0.25 mg/ml; triiodothyronine, 3.25 ng/ml; retinoic acid, 0.05 ng/ml; bovine pituitary extract, 1% (v/v); gentamycin, 50 mg/ml (''ALI'' medium) (Gray et al., 1996) .", [["apical surface", "ANATOMY", 27, 41], ["pituitary extract", "ANATOMY", 396, 413], ["insulin", "CHEMICAL", 187, 194], ["hydrocortisone", "CHEMICAL", 279, 293], ["epinephrine", "CHEMICAL", 307, 318], ["triiodothyronine", "CHEMICAL", 332, 348], ["retinoic acid", "CHEMICAL", 362, 375], ["gentamycin", "CHEMICAL", 425, 435], ["hydrocortisone", "CHEMICAL", 279, 293], ["epinephrine", "CHEMICAL", 307, 318], ["triiodothyronine", "CHEMICAL", 332, 348], ["retinoic acid", "CHEMICAL", 362, 375], ["gentamycin", "CHEMICAL", 425, 435], ["apical surface", "CELLULAR_COMPONENT", 27, 41], ["insulin", "GENE_OR_GENE_PRODUCT", 187, 194], ["transferrin", "GENE_OR_GENE_PRODUCT", 207, 218], ["recombinant epithelial growth factor", "GENE_OR_GENE_PRODUCT", 229, 265], ["hydrocortisone", "SIMPLE_CHEMICAL", 279, 293], ["epinephrine", "SIMPLE_CHEMICAL", 307, 318], ["triiodothyronine", "SIMPLE_CHEMICAL", 332, 348], ["retinoic acid", "SIMPLE_CHEMICAL", 362, 375], ["bovine", "ORGANISM", 389, 395], ["pituitary", "ORGAN", 396, 405], ["gentamycin", "SIMPLE_CHEMICAL", 425, 435], ["transferrin", "PROTEIN", 207, 218], ["recombinant epithelial growth factor", "PROTEIN", 229, 265], ["bovine", "SPECIES", 389, 395], ["the basal medium", "TREATMENT", 46, 62], ["BEGM", "TEST", 78, 82], ["Dulbecco's modified Eagle's medium (DMEM", "TREATMENT", 87, 127], ["a 1:1 ratio", "TREATMENT", 132, 143], ["insulin", "TREATMENT", 187, 194], ["transferrin", "TREATMENT", 207, 218], ["recombinant epithelial growth factor", "TREATMENT", 229, 265], ["hydrocortisone", "TREATMENT", 279, 293], ["epinephrine", "TREATMENT", 307, 318], ["triiodothyronine", "TREATMENT", 332, 348], ["retinoic acid", "TREATMENT", 362, 375], ["bovine pituitary extract", "TREATMENT", 389, 413], ["gentamycin", "TREATMENT", 425, 435], ["apical", "ANATOMY_MODIFIER", 27, 33], ["surface", "ANATOMY_MODIFIER", 34, 41], ["basal", "ANATOMY_MODIFIER", 50, 55]]], ["The medium was replaced daily for the first seven days and every other day thereafter.", [["medium", "OBSERVATION_MODIFIER", 4, 10]]], ["The cultures were allowed to mature for at least 21 days until ciliary movement was visualized.", [["cultures", "ANATOMY", 4, 12], ["ciliary", "ANATOMY", 63, 70], ["ciliary", "MULTI-TISSUE_STRUCTURE", 63, 70], ["The cultures", "TEST", 0, 12]]], ["The cultures exhibited trans-epithelial resistance (TER) values from 800-1200 O/cm 2 at 21 days consistent with formation of tight junctions.", [["cultures", "ANATOMY", 4, 12], ["epithelial", "ANATOMY", 29, 39], ["tight junctions", "ANATOMY", 125, 140], ["epithelial", "TISSUE", 29, 39], ["tight junctions", "CELLULAR_COMPONENT", 125, 140], ["The cultures", "TEST", 0, 12], ["epithelial resistance", "OBSERVATION", 29, 50], ["consistent with", "UNCERTAINTY", 96, 111], ["tight junctions", "OBSERVATION", 125, 140]]], ["The cultures on average contained 1 \u00c2 10 6 cells/well at 30 days of age and formed a pseudo-stratified epithelium (Fig. 1) .", [["cultures", "ANATOMY", 4, 12], ["cells", "ANATOMY", 43, 48], ["epithelium", "ANATOMY", 103, 113], ["cells", "CELL", 43, 48], ["epithelium", "TISSUE", 103, 113], ["The cultures", "TEST", 0, 12], ["a pseudo-stratified epithelium", "PROBLEM", 83, 113]]], ["Tissues from a total of 13 donors were tested, and all except one differentiated in the ALI conditions.HRV inoculationOnce the epithelial cells had differentiated, the medium was removed and cells were washed thrice with PBS.", [["Tissues", "ANATOMY", 0, 7], ["epithelial cells", "ANATOMY", 127, 143], ["cells", "ANATOMY", 191, 196], ["ALI", "DISEASE", 88, 91], ["Tissues", "CANCER", 0, 7], ["donors", "ORGANISM", 27, 33], ["epithelial cells", "CELL", 127, 143], ["cells", "CELL", 191, 196], ["epithelial cells", "CELL_TYPE", 127, 143], ["HRV inoculationOnce the epithelial cells", "PROBLEM", 103, 143], ["PBS", "TREATMENT", 221, 224], ["ALI conditions", "OBSERVATION", 88, 102], ["epithelial cells", "OBSERVATION", 127, 143], ["medium", "OBSERVATION_MODIFIER", 168, 174]]], ["Aliquots of HRV-C15, HRV-C41 or HRV-A16 were diluted in BEGM/0.01% BSA to a desired concentration and a 100 ml inoculum was added either to the apical surface of the ALI culture, to the monolayer or to the dissociated cells in suspension.", [["Aliquots", "ANATOMY", 0, 8], ["apical surface", "ANATOMY", 144, 158], ["monolayer", "ANATOMY", 186, 195], ["cells", "ANATOMY", 218, 223], ["BEGM", "CHEMICAL", 56, 60], ["BSA", "CHEMICAL", 67, 70], ["ALI", "DISEASE", 166, 169], ["HRV-C15", "CELL", 12, 19], ["HRV-C41", "ORGANISM", 21, 28], ["HRV-A16", "ORGANISM", 32, 39], ["BEGM", "SIMPLE_CHEMICAL", 56, 60], ["BSA", "SIMPLE_CHEMICAL", 67, 70], ["monolayer", "CELL", 186, 195], ["cells", "CELL", 218, 223], ["ALI culture", "CELL_LINE", 166, 177], ["dissociated cells", "CELL_LINE", 206, 223], ["HRV-A16", "SPECIES", 32, 39], ["Aliquots", "TEST", 0, 8], ["HRV", "TEST", 12, 15], ["HRV", "TEST", 21, 24], ["C41", "TEST", 25, 28], ["HRV", "TEST", 32, 35], ["A16", "PROBLEM", 36, 39], ["a 100 ml inoculum", "TREATMENT", 102, 119], ["the ALI culture", "TEST", 162, 177], ["apical", "ANATOMY_MODIFIER", 144, 150], ["ALI", "ANATOMY", 166, 169], ["dissociated cells", "OBSERVATION", 206, 223]]], ["The cultures were gently shaken (15 min, RT) and then incubated with virus at 34 1C for 1-4 h.", [["cultures", "ANATOMY", 4, 12], ["The cultures", "TEST", 0, 12], ["virus", "TREATMENT", 69, 74]]], ["The cultures were washed at the apical surface thrice with PBS (Ca and Mg free) and samples to assess cell-associated virus were collected in 350 ml RLT buffer (Qiagen).", [["cultures", "ANATOMY", 4, 12], ["apical surface", "ANATOMY", 32, 46], ["samples", "ANATOMY", 84, 91], ["cell", "ANATOMY", 102, 106], ["Ca", "CHEMICAL", 64, 66], ["Mg", "CHEMICAL", 71, 73], ["Ca", "CHEMICAL", 64, 66], ["Mg", "CHEMICAL", 71, 73], ["Ca", "SIMPLE_CHEMICAL", 64, 66], ["cell", "CELL", 102, 106], ["The cultures", "TEST", 0, 12], ["PBS", "TEST", 59, 62], ["Ca", "TEST", 64, 66], ["samples", "TEST", 84, 91], ["cell-associated virus", "PROBLEM", 102, 123], ["apical", "ANATOMY_MODIFIER", 32, 38]]], ["The remaining samples were fed basally with 1 ml of ALI medium while dissociated cells were plated in a 12-well plate and incubated (34-37 1C) for 24-72 h.", [["samples", "ANATOMY", 14, 21], ["cells", "ANATOMY", 81, 86], ["cells", "CELL", 81, 86], ["The remaining samples", "TEST", 0, 21], ["ALI medium", "TREATMENT", 52, 62], ["dissociated cells", "PROBLEM", 69, 86]]], ["After aspirating the medium, cells were collected in 350 ml of RLT buffer (Qiagen) for RNA extraction and qRT-PCR analysis.Acid lability of HRV-C15Purified HRV-C15 and HRV-A16 were diluted 1:10 in 0.15 M citrate buffer (pH\u00bc 4.5) for 15 min at room temperature.", [["cells", "ANATOMY", 29, 34], ["citrate", "CHEMICAL", 204, 211], ["citrate", "CHEMICAL", 204, 211], ["cells", "CELL", 29, 34], ["Acid", "SIMPLE_CHEMICAL", 123, 127], ["C15", "SIMPLE_CHEMICAL", 160, 163], ["HRV-A16", "ORGANISM", 168, 175], ["citrate", "SIMPLE_CHEMICAL", 204, 211], ["HRV-A16", "SPECIES", 168, 175], ["aspirating the medium, cells", "PROBLEM", 6, 34], ["RLT buffer", "TREATMENT", 63, 73], ["RNA extraction", "TREATMENT", 87, 101], ["qRT-PCR analysis", "TEST", 106, 122], ["Acid lability", "TEST", 123, 136], ["HRV", "TEST", 140, 143], ["HRV", "TEST", 156, 159], ["HRV", "TEST", 168, 171], ["citrate buffer", "TREATMENT", 204, 218], ["pH\u00bc", "TEST", 220, 223]]], ["The pH treated and untreated viruses (1 \u00c2 10 8 RNA copies) were used to infect different pieces of sinus organ cultures or ALI cultures.Statistical analysisStudent's t-test was used to analyze viral replication between two groups (in the Figs.", [["sinus organ cultures", "ANATOMY", 99, 119], ["ALI", "DISEASE", 123, 126], ["sinus organ cultures", "CELL", 99, 119], ["sinus organ cultures", "CELL_LINE", 99, 119], ["ALI cultures", "CELL_LINE", 123, 135], ["The pH", "TEST", 0, 6], ["untreated viruses", "PROBLEM", 19, 36], ["RNA copies", "TEST", 47, 57], ["sinus organ cultures", "TEST", 99, 119], ["ALI cultures", "TEST", 123, 135], ["Statistical analysisStudent's t-test", "TEST", 136, 172], ["viral replication", "TREATMENT", 193, 210], ["sinus organ", "ANATOMY", 99, 110]]], ["1-7) using SigmaPlot 11.0 (Systat Inc., San Jose, CA), and Po0.05 was considered significant.", [["SigmaPlot", "TEST", 11, 20]]]], "PMC7151928": [["Types ::: Overview of Hematopoietic stem cell transplantationHematopoietic stem cell transplantation is classified as autologous, allogeneic, or syngeneic.", [["Hematopoietic stem cell", "ANATOMY", 22, 45], ["Hematopoietic stem cell", "ANATOMY", 61, 84], ["Hematopoietic stem cell", "CELL", 22, 45], ["Hematopoietic stem cell", "CELL", 61, 84], ["syngeneic", "CANCER", 145, 154], ["Hematopoietic stem cell transplantation", "TREATMENT", 22, 61], ["Hematopoietic stem cell transplantation", "TREATMENT", 61, 100], ["autologous, allogeneic", "TREATMENT", 118, 140], ["syngeneic", "PROBLEM", 145, 154], ["Hematopoietic stem cell transplantation", "OBSERVATION", 22, 61], ["Hematopoietic", "OBSERVATION", 61, 74], ["stem cell transplantation", "OBSERVATION", 75, 100]]], ["In autologous HSCT, patients receive their own hematopoietic stem cells.", [["hematopoietic stem cells", "ANATOMY", 47, 71], ["patients", "ORGANISM", 20, 28], ["hematopoietic stem cells", "CELL", 47, 71], ["hematopoietic stem cells", "CELL_TYPE", 47, 71], ["patients", "SPECIES", 20, 28], ["their own hematopoietic stem cells", "TREATMENT", 37, 71], ["autologous HSCT", "OBSERVATION", 3, 18], ["hematopoietic stem cells", "OBSERVATION", 47, 71]]], ["In allogeneic HSCT, patients receive hematopoietic stem cells from a nonidentical sibling or unrelated matched donor.", [["hematopoietic stem cells", "ANATOMY", 37, 61], ["patients", "ORGANISM", 20, 28], ["hematopoietic stem cells", "CELL", 37, 61], ["hematopoietic stem cells", "CELL_TYPE", 37, 61], ["patients", "SPECIES", 20, 28], ["allogeneic HSCT", "TREATMENT", 3, 18], ["hematopoietic stem cells", "TREATMENT", 37, 61], ["unrelated matched donor", "PROBLEM", 93, 116], ["allogeneic HSCT", "OBSERVATION", 3, 18], ["hematopoietic stem cells", "OBSERVATION", 37, 61]]], ["In syngeneic HSCT, patients receive hematopoietic stem cells from a genetically identical twin.", [["hematopoietic stem cells", "ANATOMY", 36, 60], ["patients", "ORGANISM", 19, 27], ["hematopoietic stem cells", "CELL", 36, 60], ["hematopoietic stem cells", "CELL_TYPE", 36, 60], ["patients", "SPECIES", 19, 27], ["hematopoietic stem cells", "TREATMENT", 36, 60], ["syngeneic HSCT", "OBSERVATION", 3, 17], ["hematopoietic stem cells", "OBSERVATION", 36, 60]]], ["The source of the donor hematopoietic stem cells can be bone marrow, peripheral blood, or umbilical cord blood.", [["hematopoietic stem cells", "ANATOMY", 24, 48], ["bone marrow", "ANATOMY", 56, 67], ["peripheral blood", "ANATOMY", 69, 85], ["umbilical cord blood", "ANATOMY", 90, 110], ["hematopoietic stem cells", "CELL", 24, 48], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 56, 67], ["peripheral blood", "ORGANISM_SUBSTANCE", 69, 85], ["cord blood", "ORGANISM_SUBSTANCE", 100, 110], ["donor hematopoietic stem cells", "CELL_TYPE", 18, 48], ["the donor hematopoietic stem cells", "PROBLEM", 14, 48], ["bone marrow", "PROBLEM", 56, 67], ["peripheral blood, or umbilical cord blood", "PROBLEM", 69, 110], ["donor hematopoietic stem cells", "OBSERVATION", 18, 48], ["bone marrow", "OBSERVATION", 56, 67], ["peripheral", "ANATOMY_MODIFIER", 69, 79], ["blood", "ANATOMY", 80, 85], ["umbilical cord", "ANATOMY", 90, 104]]], ["Because autologous and syngeneic transplants involve stem cells that are immunologically identical to the recipient, reactions between graft and host are avoided.", [["stem cells", "ANATOMY", 53, 63], ["graft", "ANATOMY", 135, 140], ["stem cells", "CELL", 53, 63], ["graft", "TISSUE", 135, 140], ["stem cells", "CELL_TYPE", 53, 63], ["autologous and syngeneic transplants", "TREATMENT", 8, 44], ["stem cells", "PROBLEM", 53, 63], ["graft", "TREATMENT", 135, 140], ["syngeneic transplants", "OBSERVATION", 23, 44], ["stem cells", "OBSERVATION", 53, 63], ["graft", "OBSERVATION", 135, 140]]], ["In allogeneic transplants, mismatch between donor and recipient human leukocyte antigens (HLAs) mediate graft-versus-host disease (GVHD), which may lead to allograft rejection.Types ::: Overview of Hematopoietic stem cell transplantationFactors that determine the type of transplant to be performed include the nature and stage of the underlying disease, the availability of a suitable donor, and the medical condition of the recipient.", [["graft", "ANATOMY", 104, 109], ["allograft", "ANATOMY", 156, 165], ["Hematopoietic stem cell", "ANATOMY", 198, 221], ["graft-versus-host disease", "DISEASE", 104, 129], ["GVHD", "DISEASE", 131, 135], ["human", "ORGANISM", 64, 69], ["leukocyte antigens", "GENE_OR_GENE_PRODUCT", 70, 88], ["HLAs", "GENE_OR_GENE_PRODUCT", 90, 94], ["graft", "TISSUE", 104, 109], ["allograft", "TISSUE", 156, 165], ["Hematopoietic stem cell", "CELL", 198, 221], ["recipient human leukocyte antigens", "PROTEIN", 54, 88], ["HLAs", "PROTEIN", 90, 94], ["human", "SPECIES", 64, 69], ["human", "SPECIES", 64, 69], ["allogeneic transplants", "TREATMENT", 3, 25], ["mismatch between donor and recipient human leukocyte antigens", "PROBLEM", 27, 88], ["host disease", "PROBLEM", 117, 129], ["GVHD", "PROBLEM", 131, 135], ["allograft rejection", "PROBLEM", 156, 175], ["Hematopoietic stem cell transplantation", "TREATMENT", 198, 237], ["transplant", "TREATMENT", 272, 282], ["the underlying disease", "PROBLEM", 331, 353], ["a suitable donor", "TREATMENT", 375, 391], ["the recipient", "TREATMENT", 422, 435], ["allogeneic transplants", "OBSERVATION", 3, 25], ["mismatch", "OBSERVATION", 27, 35], ["human leukocyte", "OBSERVATION", 64, 79], ["graft", "OBSERVATION", 104, 109], ["host disease", "OBSERVATION", 117, 129], ["GVHD", "OBSERVATION", 131, 135], ["may lead to", "UNCERTAINTY", 144, 155], ["allograft rejection", "OBSERVATION", 156, 175], ["Hematopoietic stem cell transplantation", "OBSERVATION", 198, 237], ["disease", "OBSERVATION", 346, 353]]], ["The advantages of allogeneic transplantation over autologous transplantation include a higher likelihood that the stem cell product is free of tumor contamination and graft-versus-host activity.Indications ::: Overview of Hematopoietic stem cell transplantationA survey from several countries found that the most common indications for HSCT are lymphoproliferative disorders (55%), leukemias (34%), solid tumors (6%), and nonmalignant disorders (5%).", [["stem cell", "ANATOMY", 114, 123], ["tumor", "ANATOMY", 143, 148], ["graft", "ANATOMY", 167, 172], ["Hematopoietic stem cell", "ANATOMY", 222, 245], ["leukemias", "ANATOMY", 382, 391], ["solid tumors", "ANATOMY", 399, 411], ["nonmalignant", "ANATOMY", 422, 434], ["tumor", "DISEASE", 143, 148], ["lymphoproliferative disorders", "DISEASE", 345, 374], ["leukemias", "DISEASE", 382, 391], ["solid tumors", "DISEASE", 399, 411], ["nonmalignant disorders", "DISEASE", 422, 444], ["stem cell", "CELL", 114, 123], ["tumor", "CANCER", 143, 148], ["graft", "TISSUE", 167, 172], ["Hematopoietic stem cell", "CELL", 222, 245], ["leukemias", "CANCER", 382, 391], ["solid tumors", "CANCER", 399, 411], ["nonmalignant disorders", "CANCER", 422, 444], ["allogeneic transplantation", "TREATMENT", 18, 44], ["autologous transplantation", "TREATMENT", 50, 76], ["the stem cell product", "PROBLEM", 110, 131], ["tumor contamination", "PROBLEM", 143, 162], ["graft", "TREATMENT", 167, 172], ["HSCT", "TEST", 336, 340], ["lymphoproliferative disorders", "PROBLEM", 345, 374], ["leukemias", "PROBLEM", 382, 391], ["solid tumors", "PROBLEM", 399, 411], ["nonmalignant disorders", "PROBLEM", 422, 444], ["allogeneic transplantation", "OBSERVATION", 18, 44], ["stem cell", "OBSERVATION", 114, 123], ["tumor", "OBSERVATION", 143, 148], ["graft", "OBSERVATION", 167, 172], ["Hematopoietic stem cell", "OBSERVATION", 222, 245], ["lymphoproliferative", "OBSERVATION", 345, 364], ["leukemias", "OBSERVATION", 382, 391], ["solid", "OBSERVATION_MODIFIER", 399, 404], ["tumors", "OBSERVATION", 405, 411], ["nonmalignant", "OBSERVATION_MODIFIER", 422, 434]]], ["The lymphoproliferative disorders included plasma cell disorder, Hodgkin disease, and non-Hodgkin lymphoma.", [["plasma cell", "ANATOMY", 43, 54], ["Hodgkin", "ANATOMY", 65, 72], ["non-Hodgkin lymphoma", "ANATOMY", 86, 106], ["lymphoproliferative disorders", "DISEASE", 4, 33], ["plasma cell disorder", "DISEASE", 43, 63], ["Hodgkin disease", "DISEASE", 65, 80], ["non-Hodgkin lymphoma", "DISEASE", 86, 106], ["plasma cell", "CELL", 43, 54], ["Hodgkin disease", "CANCER", 65, 80], ["non-Hodgkin lymphoma", "CANCER", 86, 106], ["The lymphoproliferative disorders", "PROBLEM", 0, 33], ["plasma cell disorder", "PROBLEM", 43, 63], ["Hodgkin disease", "PROBLEM", 65, 80], ["non-Hodgkin lymphoma", "PROBLEM", 86, 106], ["lymphoproliferative disorders", "OBSERVATION", 4, 33], ["plasma cell disorder", "OBSERVATION", 43, 63], ["Hodgkin disease", "OBSERVATION", 65, 80], ["non-Hodgkin lymphoma", "OBSERVATION", 86, 106]]], ["Autologous HSCT was slightly more common than allogeneic HSCT.", [["Autologous HSCT", "TEST", 0, 15], ["allogeneic HSCT", "TREATMENT", 46, 61], ["slightly", "OBSERVATION_MODIFIER", 20, 28], ["more common", "OBSERVATION_MODIFIER", 29, 40]]], ["For allogeneic HSCT, the most frequent malignant disease was acute myeloid leukemia (33%) and the most common nonmalignant disease, bone marrow failure syndrome (6%).", [["malignant disease", "ANATOMY", 39, 56], ["acute myeloid leukemia", "ANATOMY", 61, 83], ["nonmalignant", "ANATOMY", 110, 122], ["bone marrow", "ANATOMY", 132, 143], ["acute myeloid leukemia", "DISEASE", 61, 83], ["bone marrow failure syndrome", "DISEASE", 132, 160], ["malignant disease", "CANCER", 39, 56], ["acute myeloid leukemia", "CANCER", 61, 83], ["nonmalignant disease", "CANCER", 110, 130], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 132, 143], ["allogeneic HSCT", "TREATMENT", 4, 19], ["the most frequent malignant disease", "PROBLEM", 21, 56], ["acute myeloid leukemia", "PROBLEM", 61, 83], ["the most common nonmalignant disease", "PROBLEM", 94, 130], ["bone marrow failure syndrome", "PROBLEM", 132, 160], ["most frequent", "OBSERVATION_MODIFIER", 25, 38], ["malignant", "OBSERVATION_MODIFIER", 39, 48], ["disease", "OBSERVATION", 49, 56], ["acute", "OBSERVATION_MODIFIER", 61, 66], ["myeloid leukemia", "OBSERVATION", 67, 83], ["most common", "OBSERVATION_MODIFIER", 98, 109], ["nonmalignant", "OBSERVATION_MODIFIER", 110, 122], ["disease", "OBSERVATION", 123, 130], ["bone", "ANATOMY", 132, 136], ["marrow failure", "OBSERVATION", 137, 151]]], ["For autologous HSCT, the most frequent indication was for a plasma cell disorder (41%); the most common nonmalignant indications included bone marrow failure, hemoglobinopathies, immune deficiencies, inherited diseases of metabolism, and autoimmune disorders.Conditioning Regimens ::: Overview of Hematopoietic stem cell transplantationBefore undergoing HSCT, patients receive a conditioning regimen with the goals of reducing the tumor burden (with malignancy), ablating the bone marrow, and suppressing the recipient's immune system, thereby allowing engraftment of stem cells.", [["plasma cell", "ANATOMY", 60, 71], ["nonmalignant", "ANATOMY", 104, 116], ["bone marrow", "ANATOMY", 138, 149], ["Hematopoietic stem cell", "ANATOMY", 297, 320], ["tumor", "ANATOMY", 431, 436], ["bone marrow", "ANATOMY", 476, 487], ["immune system", "ANATOMY", 521, 534], ["stem cells", "ANATOMY", 568, 578], ["plasma cell disorder", "DISEASE", 60, 80], ["bone marrow failure", "DISEASE", 138, 157], ["hemoglobinopathies", "DISEASE", 159, 177], ["immune deficiencies", "DISEASE", 179, 198], ["inherited diseases of metabolism", "DISEASE", 200, 232], ["autoimmune disorders", "DISEASE", 238, 258], ["tumor", "DISEASE", 431, 436], ["malignancy", "DISEASE", 450, 460], ["plasma cell", "CELL", 60, 71], ["nonmalignant", "CANCER", 104, 116], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 138, 149], ["Hematopoietic stem cell", "CELL", 297, 320], ["patients", "ORGANISM", 360, 368], ["tumor", "CANCER", 431, 436], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 476, 487], ["immune system", "ANATOMICAL_SYSTEM", 521, 534], ["stem cells", "CELL", 568, 578], ["stem cells", "CELL_TYPE", 568, 578], ["patients", "SPECIES", 360, 368], ["autologous HSCT", "TREATMENT", 4, 19], ["a plasma cell disorder", "PROBLEM", 58, 80], ["bone marrow failure", "PROBLEM", 138, 157], ["hemoglobinopathies", "PROBLEM", 159, 177], ["immune deficiencies", "PROBLEM", 179, 198], ["inherited diseases of metabolism", "PROBLEM", 200, 232], ["autoimmune disorders", "PROBLEM", 238, 258], ["Hematopoietic stem cell transplantation", "TREATMENT", 297, 336], ["HSCT", "TREATMENT", 354, 358], ["a conditioning regimen", "TREATMENT", 377, 399], ["the tumor burden", "PROBLEM", 427, 443], ["malignancy", "PROBLEM", 450, 460], ["engraftment of stem cells", "TREATMENT", 553, 578], ["bone", "ANATOMY", 138, 142], ["marrow failure", "OBSERVATION", 143, 157], ["immune deficiencies", "OBSERVATION", 179, 198], ["autoimmune disorders", "OBSERVATION", 238, 258], ["Hematopoietic stem cell transplantation", "OBSERVATION", 297, 336], ["tumor", "OBSERVATION", 431, 436], ["bone marrow", "ANATOMY", 476, 487], ["stem cells", "OBSERVATION", 568, 578]]], ["The three regimen types are myeloablative conditioning, reduced-intensity conditioning, and nonmyeloablative conditioning.", [["The three regimen types", "TREATMENT", 0, 23], ["myeloablative conditioning", "TREATMENT", 28, 54], ["reduced-intensity conditioning", "TREATMENT", 56, 86], ["nonmyeloablative conditioning", "TREATMENT", 92, 121], ["myeloablative conditioning", "OBSERVATION", 28, 54], ["nonmyeloablative conditioning", "OBSERVATION", 92, 121]]], ["This classification is based on the duration of cytopenia and the requirement for stem cell support.", [["stem cell", "ANATOMY", 82, 91], ["cytopenia", "DISEASE", 48, 57], ["stem cell", "CELL", 82, 91], ["cytopenia", "PROBLEM", 48, 57], ["stem cell support", "TREATMENT", 82, 99], ["cytopenia", "OBSERVATION", 48, 57], ["stem cell support", "OBSERVATION", 82, 99]]], ["Myeloablative conditioning causes irreversible cytopenia, for which stem cell support is always necessary, whereas nonmyeloablative conditioning causes minimal cytopenia, for which stem cell support may not be needed.", [["stem cell", "ANATOMY", 68, 77], ["stem cell", "ANATOMY", 181, 190], ["cytopenia", "DISEASE", 47, 56], ["cytopenia", "DISEASE", 160, 169], ["stem cell", "CELL", 68, 77], ["stem cell", "CELL", 181, 190], ["Myeloablative conditioning", "TREATMENT", 0, 26], ["irreversible cytopenia", "PROBLEM", 34, 56], ["stem cell support", "TREATMENT", 68, 85], ["nonmyeloablative conditioning", "TREATMENT", 115, 144], ["minimal cytopenia", "PROBLEM", 152, 169], ["stem cell support", "TREATMENT", 181, 198], ["irreversible", "OBSERVATION_MODIFIER", 34, 46], ["cytopenia", "OBSERVATION", 47, 56], ["minimal", "OBSERVATION_MODIFIER", 152, 159], ["cytopenia", "OBSERVATION", 160, 169]]], ["Reduced-intensity conditioning causes cytopenia of variable duration, and stem cell support should be given.Conditioning Regimens ::: Overview of Hematopoietic stem cell transplantationConventional myeloablative conditioning regimens include cyclophosphamide and total-body irradiation (TBI) or busulfan.", [["stem cell", "ANATOMY", 74, 83], ["Hematopoietic stem cell", "ANATOMY", 146, 169], ["body", "ANATOMY", 269, 273], ["cytopenia", "DISEASE", 38, 47], ["cyclophosphamide", "CHEMICAL", 242, 258], ["TBI", "DISEASE", 287, 290], ["busulfan", "CHEMICAL", 295, 303], ["cyclophosphamide", "CHEMICAL", 242, 258], ["busulfan", "CHEMICAL", 295, 303], ["stem cell", "CELL", 74, 83], ["Hematopoietic stem cell", "CELL", 146, 169], ["cyclophosphamide", "SIMPLE_CHEMICAL", 242, 258], ["busulfan", "SIMPLE_CHEMICAL", 295, 303], ["Reduced-intensity conditioning", "PROBLEM", 0, 30], ["cytopenia of variable duration", "PROBLEM", 38, 68], ["stem cell support", "TREATMENT", 74, 91], ["Hematopoietic stem cell transplantation", "TREATMENT", 146, 185], ["Conventional myeloablative conditioning regimens", "TREATMENT", 185, 233], ["cyclophosphamide", "TREATMENT", 242, 258], ["total-body irradiation (TBI)", "TREATMENT", 263, 291], ["busulfan", "TREATMENT", 295, 303], ["-intensity", "OBSERVATION_MODIFIER", 7, 17], ["cytopenia", "OBSERVATION", 38, 47], ["variable duration", "OBSERVATION_MODIFIER", 51, 68], ["stem cell support", "OBSERVATION", 74, 91], ["Hematopoietic stem cell transplantation", "OBSERVATION", 146, 185]]], ["The more recent nonmyeloablative or reduced-intensity conditioning regimens have used fludarabine and reduced-dose alkylating agents or TBI.", [["fludarabine", "CHEMICAL", 86, 97], ["alkylating agents", "CHEMICAL", 115, 132], ["TBI", "DISEASE", 136, 139], ["fludarabine", "CHEMICAL", 86, 97], ["fludarabine", "SIMPLE_CHEMICAL", 86, 97], ["reduced-intensity conditioning regimens", "TREATMENT", 36, 75], ["fludarabine", "TREATMENT", 86, 97], ["reduced-dose alkylating agents", "TREATMENT", 102, 132], ["TBI", "PROBLEM", 136, 139], ["nonmyeloablative", "OBSERVATION", 16, 32], ["reduced", "OBSERVATION_MODIFIER", 36, 43], ["-intensity", "OBSERVATION_MODIFIER", 43, 53]]], ["Although these less intensive regimens do not provide a strong cytoreductive effect, they allow engraftment of the donor stem cells with a subsequent potentially beneficial graft-versus-malignancy effect.", [["stem cells", "ANATOMY", 121, 131], ["graft", "ANATOMY", 173, 178], ["malignancy", "DISEASE", 186, 196], ["donor stem cells", "CELL", 115, 131], ["graft", "TISSUE", 173, 178], ["donor stem cells", "CELL_TYPE", 115, 131], ["these less intensive regimens", "TREATMENT", 9, 38], ["a strong cytoreductive effect", "TREATMENT", 54, 83], ["the donor stem cells", "TREATMENT", 111, 131], ["beneficial graft", "TREATMENT", 162, 178], ["malignancy effect", "PROBLEM", 186, 203], ["donor stem cells", "OBSERVATION", 115, 131], ["beneficial", "OBSERVATION_MODIFIER", 162, 172], ["graft", "OBSERVATION", 173, 178], ["malignancy", "OBSERVATION", 186, 196]]], ["The nonmyeloablative or reduced-intensity conditioning regimens are associated with reduced transplant-associated morbidity and lower incidence of pulmonary complications after transplantation.Conditioning Regimens ::: Overview of Hematopoietic stem cell transplantationProphylaxis after allogeneic transplant to prevent GVHD usually involves methotrexate, cyclosporin, corticosteroids, or in vitro T cell depletion of the graft before infusion.Risk Factors for Pulmonary Disease ::: Posttransplant Pulmonary ComplicationsRelapse status at transplant and donor-recipient HLA mismatching or nonidentity are risk factors for pulmonary complications and mortality after HSCT (Box 77-1).", [["pulmonary", "ANATOMY", 147, 156], ["Hematopoietic stem cell", "ANATOMY", 231, 254], ["T cell", "ANATOMY", 399, 405], ["graft", "ANATOMY", 423, 428], ["Pulmonary", "ANATOMY", 462, 471], ["Pulmonary", "ANATOMY", 499, 508], ["pulmonary", "ANATOMY", 623, 632], ["pulmonary complications", "DISEASE", 147, 170], ["GVHD", "DISEASE", 321, 325], ["methotrexate", "CHEMICAL", 343, 355], ["cyclosporin", "CHEMICAL", 357, 368], ["Pulmonary Disease", "DISEASE", 462, 479], ["pulmonary complications", "DISEASE", 623, 646], ["methotrexate", "CHEMICAL", 343, 355], ["cyclosporin", "CHEMICAL", 357, 368], ["corticosteroids", "CHEMICAL", 370, 385], ["pulmonary", "ORGAN", 147, 156], ["Hematopoietic stem cell", "CELL", 231, 254], ["methotrexate", "SIMPLE_CHEMICAL", 343, 355], ["cyclosporin", "SIMPLE_CHEMICAL", 357, 368], ["corticosteroids", "SIMPLE_CHEMICAL", 370, 385], ["T cell", "CELL", 399, 405], ["graft", "TISSUE", 423, 428], ["Pulmonary", "ORGAN", 462, 471], ["pulmonary", "ORGAN", 623, 632], ["The nonmyeloablative", "TREATMENT", 0, 20], ["reduced-intensity conditioning regimens", "TREATMENT", 24, 63], ["reduced transplant-associated morbidity", "PROBLEM", 84, 123], ["pulmonary complications", "PROBLEM", 147, 170], ["transplantation", "TREATMENT", 177, 192], ["Hematopoietic stem cell transplantationProphylaxis", "TREATMENT", 231, 281], ["allogeneic transplant", "TREATMENT", 288, 309], ["GVHD", "PROBLEM", 321, 325], ["methotrexate", "TREATMENT", 343, 355], ["cyclosporin", "TREATMENT", 357, 368], ["corticosteroids", "TREATMENT", 370, 385], ["vitro T cell depletion of the graft", "TREATMENT", 393, 428], ["infusion", "TREATMENT", 436, 444], ["Pulmonary Disease", "PROBLEM", 462, 479], ["Posttransplant Pulmonary Complications", "PROBLEM", 484, 522], ["transplant", "TREATMENT", 540, 550], ["donor-recipient HLA mismatching", "TREATMENT", 555, 586], ["risk factors", "PROBLEM", 606, 618], ["pulmonary complications", "PROBLEM", 623, 646], ["HSCT (Box", "TEST", 667, 676], ["nonmyeloablative", "OBSERVATION", 4, 20], ["reduced", "OBSERVATION_MODIFIER", 24, 31], ["-intensity", "OBSERVATION_MODIFIER", 31, 41], ["reduced", "OBSERVATION_MODIFIER", 84, 91], ["transplant", "OBSERVATION", 92, 102], ["morbidity", "OBSERVATION", 114, 123], ["lower", "OBSERVATION_MODIFIER", 128, 133], ["pulmonary", "ANATOMY", 147, 156], ["complications", "OBSERVATION", 157, 170], ["Hematopoietic stem cell transplantation", "OBSERVATION", 231, 270], ["GVHD", "OBSERVATION", 321, 325], ["cell depletion", "OBSERVATION", 401, 415], ["graft", "OBSERVATION", 423, 428], ["Pulmonary", "ANATOMY", 462, 471], ["Disease", "OBSERVATION", 472, 479], ["Pulmonary", "ANATOMY", 499, 508], ["Complications", "OBSERVATION", 509, 522], ["pulmonary", "ANATOMY", 623, 632], ["complications", "OBSERVATION", 633, 646]]], ["Active phase of malignancy, age over 21 years, and receipt of HLA-nonidentical donor marrow are risk factors for respiratory failure after HSCT.Box 77-1Risk Factors for Pulmonary Complications After Hematopoietic Stem Cell Transplantation (HSCT)Donor-recipient human leukocyte antigen mismatchRelapse statusActive phase of malignancyAge over 21 yearsPretransplant pulmonary function abnormalitiesReduced diffusion capacityIncreased alveolar-arterial oxygen gradientRestrictive lung diseaseFEV1 <80% predictedElevated pretransplant cytokine levels (TGF-\u03b2, TGF-\u03b1, GM-CSF)Allogeneic transplantationGraft-versus-host disease and type of GVHD prophylaxisRenal disease", [["marrow", "ANATOMY", 85, 91], ["respiratory", "ANATOMY", 113, 124], ["Pulmonary", "ANATOMY", 169, 178], ["Hematopoietic Stem Cell", "ANATOMY", 199, 222], ["malignancy", "ANATOMY", 323, 333], ["pulmonary", "ANATOMY", 364, 373], ["alveolar", "ANATOMY", 432, 440], ["arterial", "ANATOMY", 441, 449], ["lung", "ANATOMY", 477, 481], ["Graft", "ANATOMY", 595, 600], ["Renal", "ANATOMY", 649, 654], ["malignancy", "DISEASE", 16, 26], ["respiratory failure", "DISEASE", 113, 132], ["malignancy", "DISEASE", 323, 333], ["pulmonary function abnormalities", "DISEASE", 364, 396], ["oxygen", "CHEMICAL", 450, 456], ["Graft-versus-host disease", "DISEASE", 595, 620], ["GVHD", "DISEASE", 633, 637], ["Renal disease", "DISEASE", 649, 662], ["oxygen", "CHEMICAL", 450, 456], ["donor marrow", "MULTI-TISSUE_STRUCTURE", 79, 91], ["human", "ORGANISM", 261, 266], ["leukocyte antigen", "GENE_OR_GENE_PRODUCT", 267, 284], ["pulmonary", "ORGAN", 364, 373], ["alveolar", "MULTI-TISSUE_STRUCTURE", 432, 440], ["arterial", "MULTI-TISSUE_STRUCTURE", 441, 449], ["oxygen", "SIMPLE_CHEMICAL", 450, 456], ["lung", "ORGAN", 477, 481], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 548, 553], ["TGF-\u03b1", "GENE_OR_GENE_PRODUCT", 555, 560], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 562, 568], ["Renal", "ORGAN", 649, 654], ["cytokine", "PROTEIN", 531, 539], ["TGF-\u03b2", "PROTEIN", 548, 553], ["TGF", "PROTEIN", 555, 558], ["human", "SPECIES", 261, 266], ["human", "SPECIES", 261, 266], ["malignancy", "PROBLEM", 16, 26], ["HLA-nonidentical donor marrow", "TREATMENT", 62, 91], ["risk factors", "PROBLEM", 96, 108], ["respiratory failure", "PROBLEM", 113, 132], ["Box", "TEST", 144, 147], ["Pulmonary Complications", "PROBLEM", 169, 192], ["Hematopoietic Stem Cell Transplantation", "TREATMENT", 199, 238], ["Donor-recipient human leukocyte antigen mismatch", "TREATMENT", 245, 293], ["malignancy", "PROBLEM", 323, 333], ["Pretransplant pulmonary function abnormalities", "PROBLEM", 350, 396], ["Reduced diffusion capacity", "PROBLEM", 396, 422], ["Increased alveolar-arterial oxygen gradient", "PROBLEM", 422, 465], ["Restrictive lung diseaseFEV1", "PROBLEM", 465, 493], ["Elevated pretransplant cytokine levels", "PROBLEM", 508, 546], ["TGF", "TEST", 548, 551], ["\u03b2", "TEST", 552, 553], ["TGF", "TEST", 555, 558], ["\u03b1", "TEST", 559, 560], ["GM", "TEST", 562, 564], ["Allogeneic transplantation", "TREATMENT", 569, 595], ["Graft-versus-host disease", "PROBLEM", 595, 620], ["GVHD prophylaxis", "TREATMENT", 633, 649], ["Renal disease", "PROBLEM", 649, 662], ["phase", "OBSERVATION_MODIFIER", 7, 12], ["malignancy", "OBSERVATION", 16, 26], ["donor marrow", "OBSERVATION", 79, 91], ["failure", "OBSERVATION", 125, 132], ["Pulmonary", "ANATOMY", 169, 178], ["Complications", "OBSERVATION", 179, 192], ["Hematopoietic Stem Cell Transplantation", "OBSERVATION", 199, 238], ["malignancy", "OBSERVATION", 323, 333], ["pulmonary", "ANATOMY", 364, 373], ["diffusion capacity", "OBSERVATION", 404, 422], ["alveolar", "ANATOMY_MODIFIER", 432, 440], ["arterial", "ANATOMY_MODIFIER", 441, 449], ["oxygen gradient", "OBSERVATION", 450, 465], ["lung", "ANATOMY", 477, 481], ["diseaseFEV1", "OBSERVATION", 482, 493], ["CSF", "ANATOMY", 565, 568], ["Allogeneic transplantation", "OBSERVATION", 569, 595], ["host disease", "OBSERVATION", 608, 620], ["GVHD prophylaxis", "OBSERVATION", 633, 649], ["disease", "OBSERVATION", 655, 662]]]], "PMC7467203": [["Coronavirus disease (COVID-19)A cluster of pneumonia of unknown etiology was reported in Wuhan City, China, on December 31, 2019.", [["Coronavirus disease", "DISEASE", 0, 19], ["pneumonia", "DISEASE", 43, 52], ["Coronavirus disease", "PROBLEM", 0, 19], ["COVID", "TEST", 21, 26], ["pneumonia", "PROBLEM", 43, 52], ["pneumonia", "OBSERVATION", 43, 52]]], ["On 7 January, the Chinese authorities identified a new CoV as a cause of pneumonia outbreak.", [["pneumonia", "DISEASE", 73, 82], ["CoV", "ORGANISM", 55, 58], ["a new CoV", "PROBLEM", 49, 58], ["pneumonia outbreak", "PROBLEM", 73, 91], ["pneumonia", "OBSERVATION", 73, 82]]], ["The new strain was named SARS-CoV-2 or the novel coronavirus and the disease as COVID-19.", [["SARS-CoV-2", "ORGANISM", 25, 35], ["coronavirus", "ORGANISM", 49, 60], ["coronavirus", "SPECIES", 49, 60], ["SARS-CoV", "SPECIES", 25, 33], ["The new strain", "PROBLEM", 0, 14], ["CoV", "TEST", 30, 33], ["the novel coronavirus", "PROBLEM", 39, 60], ["the disease", "PROBLEM", 65, 76], ["COVID", "TEST", 80, 85], ["new", "OBSERVATION_MODIFIER", 4, 7], ["coronavirus", "OBSERVATION", 49, 60], ["disease", "OBSERVATION", 69, 76]]], ["The most common symptoms of COVID-19 are fever, tiredness, and dry cough.", [["COVID", "DISEASE", 28, 33], ["fever", "DISEASE", 41, 46], ["tiredness", "DISEASE", 48, 57], ["dry cough", "DISEASE", 63, 72], ["COVID", "TEST", 28, 33], ["fever", "PROBLEM", 41, 46], ["tiredness", "PROBLEM", 48, 57], ["dry cough", "PROBLEM", 63, 72], ["fever", "OBSERVATION", 41, 46], ["dry", "OBSERVATION_MODIFIER", 63, 66], ["cough", "OBSERVATION", 67, 72]]], ["Some patients may have aches and pains, nasal congestion, runny nose, sore throat, or diarrhea.", [["nasal", "ANATOMY", 40, 45], ["pains", "DISEASE", 33, 38], ["nasal congestion", "DISEASE", 40, 56], ["runny nose", "DISEASE", 58, 68], ["sore throat", "DISEASE", 70, 81], ["diarrhea", "DISEASE", 86, 94], ["patients", "ORGANISM", 5, 13], ["aches", "ORGANISM_SUBDIVISION", 23, 28], ["nasal", "ORGANISM_SUBDIVISION", 40, 45], ["nose", "ORGANISM_SUBDIVISION", 64, 68], ["patients", "SPECIES", 5, 13], ["aches", "PROBLEM", 23, 28], ["pains", "PROBLEM", 33, 38], ["nasal congestion", "PROBLEM", 40, 56], ["runny nose", "PROBLEM", 58, 68], ["sore throat", "PROBLEM", 70, 81], ["diarrhea", "PROBLEM", 86, 94], ["nasal", "ANATOMY", 40, 45], ["congestion", "OBSERVATION", 46, 56], ["runny nose", "ANATOMY", 58, 68], ["sore throat", "ANATOMY", 70, 81], ["diarrhea", "OBSERVATION", 86, 94]]], ["These symptoms are usually mild and begin gradually.[6] Some people become infected but do not develop any symptoms and do not feel unwell.[6] Most people (about 80%) recover from the disease without needing special treatment.", [["people", "ORGANISM", 61, 67], ["people", "ORGANISM", 148, 154], ["people", "SPECIES", 61, 67], ["people", "SPECIES", 148, 154], ["These symptoms", "PROBLEM", 0, 14], ["infected", "PROBLEM", 75, 83], ["any symptoms", "PROBLEM", 103, 115], ["unwell", "PROBLEM", 132, 138], ["the disease", "PROBLEM", 180, 191], ["special treatment", "TREATMENT", 208, 225], ["mild", "OBSERVATION_MODIFIER", 27, 31], ["infected", "OBSERVATION", 75, 83], ["disease", "OBSERVATION", 184, 191]]], ["Around 1 out of every 6 people who gets COVID-19 becomes seriously ill and develops difficulty in breathing.[6]Coronavirus disease (COVID-19)As per the Revised Guidelines on Clinical Management of COVID-19 by the Ministry of Health and Family Welfare (MoHFW), Government of India, COVID-19 may present with mild, moderate, or severe illness; the latter includes severe pneumonia, acute respiratory distress syndrome, sepsis, and septic shock.[7] Early recognition of suspected patients and early identification of severe cases allows for timely initiation of infection prevention control and provision for optimal supportive care treatments and rapid admission to intensive care unit, respectively.[7] The whole population is deemed susceptible to this virus and infection depends mainly on contact with COVID-19-infected patients or other individuals with asymptomatic infections.", [["respiratory", "ANATOMY", 386, 397], ["illness", "DISEASE", 333, 340], ["pneumonia", "DISEASE", 369, 378], ["acute respiratory distress syndrome", "DISEASE", 380, 415], ["sepsis", "DISEASE", 417, 423], ["septic shock", "DISEASE", 429, 441], ["infection", "DISEASE", 559, 568], ["infection", "DISEASE", 763, 772], ["COVID-19-infected", "DISEASE", 804, 821], ["infections", "DISEASE", 870, 880], ["people", "ORGANISM", 24, 30], ["patients", "ORGANISM", 477, 485], ["COVID-19", "ORGANISM", 804, 812], ["patients", "ORGANISM", 822, 830], ["people", "SPECIES", 24, 30], ["patients", "SPECIES", 477, 485], ["patients", "SPECIES", 822, 830], ["seriously ill", "PROBLEM", 57, 70], ["difficulty in breathing", "PROBLEM", 84, 107], ["Coronavirus disease", "PROBLEM", 111, 130], ["COVID", "TEST", 197, 202], ["mild, moderate, or severe illness", "PROBLEM", 307, 340], ["severe pneumonia", "PROBLEM", 362, 378], ["acute respiratory distress syndrome", "PROBLEM", 380, 415], ["sepsis", "PROBLEM", 417, 423], ["septic shock", "PROBLEM", 429, 441], ["severe cases", "PROBLEM", 514, 526], ["infection prevention control", "TREATMENT", 559, 587], ["optimal supportive care treatments", "TREATMENT", 606, 640], ["this virus", "PROBLEM", 748, 758], ["infection", "PROBLEM", 763, 772], ["COVID", "TEST", 804, 809], ["asymptomatic infections", "PROBLEM", 857, 880], ["Coronavirus disease", "OBSERVATION", 111, 130], ["mild", "OBSERVATION_MODIFIER", 307, 311], ["moderate", "OBSERVATION_MODIFIER", 313, 321], ["severe", "OBSERVATION_MODIFIER", 326, 332], ["illness", "OBSERVATION", 333, 340], ["severe", "OBSERVATION_MODIFIER", 362, 368], ["pneumonia", "OBSERVATION", 369, 378], ["acute", "OBSERVATION_MODIFIER", 380, 385], ["respiratory distress syndrome", "OBSERVATION", 386, 415], ["sepsis", "OBSERVATION", 417, 423], ["septic shock", "OBSERVATION", 429, 441], ["infection", "OBSERVATION", 559, 568], ["infection", "OBSERVATION", 763, 772], ["asymptomatic", "OBSERVATION_MODIFIER", 857, 869], ["infections", "OBSERVATION", 870, 880]]], ["Individuals older than 60 years of age and people with medical problems such as high blood pressure, heart problems, respiratory disease/asthma, cancer, or diabetes are at higher risk for developing serious complications.[8]Coronavirus disease (COVID-19)The incubation period of COVID-19 ranges from 1 to 14 days[89] with majority presenting between 3 to 7 days.[9] COVID-19 probably emerged from an animal source, but is now spreading from person to person.[10] The virus spreads mainly between people who are in close contact with one another (within about 6 feet) through respiratory droplets produced when an infected person coughs or sneezes.[10] It also may be possible that a person can get COVID-19 by touching a surface or object that has the virus on it and then touching their own mouth, nose, or possibly their eyes.[10] Research exploring the possibility of airborne transmission of SARS-CoV-2 is ongoing.", [["blood", "ANATOMY", 85, 90], ["heart", "ANATOMY", 101, 106], ["respiratory", "ANATOMY", 117, 128], ["cancer", "ANATOMY", 145, 151], ["respiratory droplets", "ANATOMY", 575, 595], ["surface", "ANATOMY", 721, 728], ["mouth", "ANATOMY", 792, 797], ["nose", "ANATOMY", 799, 803], ["eyes", "ANATOMY", 823, 827], ["high blood pressure", "DISEASE", 80, 99], ["heart problems", "DISEASE", 101, 115], ["respiratory disease", "DISEASE", 117, 136], ["asthma", "DISEASE", 137, 143], ["cancer", "DISEASE", 145, 151], ["diabetes", "DISEASE", 156, 164], ["[9] COVID-19", "CHEMICAL", 362, 374], ["SARS", "DISEASE", 896, 900], ["COVID-19", "CHEMICAL", 698, 706], ["people", "ORGANISM", 43, 49], ["blood", "ORGANISM_SUBSTANCE", 85, 90], ["heart", "ORGAN", 101, 106], ["cancer", "CANCER", 145, 151], ["people", "ORGANISM", 496, 502], ["feet", "ORGANISM_SUBDIVISION", 561, 565], ["surface", "CELLULAR_COMPONENT", 721, 728], ["mouth", "ORGANISM_SUBDIVISION", 792, 797], ["nose", "ORGANISM_SUBDIVISION", 799, 803], ["eyes", "ORGAN", 823, 827], ["people", "SPECIES", 43, 49], ["person", "SPECIES", 441, 447], ["person", "SPECIES", 451, 457], ["people", "SPECIES", 496, 502], ["person", "SPECIES", 622, 628], ["person", "SPECIES", 683, 689], ["SARS-CoV", "SPECIES", 896, 904], ["medical problems", "PROBLEM", 55, 71], ["high blood pressure", "PROBLEM", 80, 99], ["heart problems", "PROBLEM", 101, 115], ["respiratory disease", "PROBLEM", 117, 136], ["asthma", "PROBLEM", 137, 143], ["cancer", "PROBLEM", 145, 151], ["diabetes", "PROBLEM", 156, 164], ["developing serious complications", "PROBLEM", 188, 220], ["Coronavirus disease", "PROBLEM", 224, 243], ["COVID", "TEST", 245, 250], ["COVID", "TEST", 279, 284], ["COVID", "TEST", 366, 371], ["The virus spreads", "PROBLEM", 463, 480], ["respiratory droplets", "PROBLEM", 575, 595], ["an infected person coughs", "PROBLEM", 610, 635], ["sneezes", "PROBLEM", 639, 646], ["COVID", "TREATMENT", 698, 703], ["the virus", "PROBLEM", 748, 757], ["SARS", "PROBLEM", 896, 900], ["heart", "ANATOMY", 101, 106], ["respiratory disease", "OBSERVATION", 117, 136], ["asthma", "OBSERVATION", 137, 143], ["cancer", "OBSERVATION", 145, 151], ["serious", "OBSERVATION_MODIFIER", 199, 206], ["complications", "OBSERVATION", 207, 220], ["Coronavirus disease", "OBSERVATION", 224, 243], ["infected", "OBSERVATION", 613, 621], ["may be possible", "UNCERTAINTY", 660, 675], ["virus", "OBSERVATION", 752, 757], ["nose", "ANATOMY", 799, 803]]], ["In a study, viral RNA was found to be present in aerosols in isolation rooms of SARS-CoV-2 patients.[11] Another study found the stability of the SARS-CoV-2 in aerosols, generated under experimental conditions, to be three hours.[12] According to the National Academies of Sciences, Engineering, and Medicine, USA, available research indicates that viral particles are found in bioaerosols generated through normal breathing of infected people.", [["SARS", "DISEASE", 80, 84], ["SARS", "DISEASE", 146, 150], ["SARS-CoV-2", "ORGANISM", 80, 90], ["patients", "ORGANISM", 91, 99], ["people", "ORGANISM", 437, 443], ["viral RNA", "RNA", 12, 21], ["patients", "SPECIES", 91, 99], ["people", "SPECIES", 437, 443], ["SARS-CoV", "SPECIES", 80, 88], ["a study", "TEST", 3, 10], ["viral RNA", "PROBLEM", 12, 21], ["Another study", "TEST", 105, 118], ["the SARS", "PROBLEM", 142, 150], ["CoV", "TEST", 151, 154], ["viral particles", "PROBLEM", 349, 364], ["stability", "OBSERVATION_MODIFIER", 129, 138], ["SARS", "OBSERVATION", 146, 150], ["viral particles", "OBSERVATION", 349, 364]]], ["However, more SARS-CoV-2-specific research is needed regarding the infectivity of such viral particles in bioaerosols.", [["SARS", "DISEASE", 14, 18], ["CoV-2", "ORGANISM", 19, 24], ["bioaerosols", "SIMPLE_CHEMICAL", 106, 117], ["CoV", "TEST", 19, 22], ["the infectivity", "PROBLEM", 63, 78], ["such viral particles", "PROBLEM", 82, 102], ["viral particles", "OBSERVATION", 87, 102]]], ["As SARS-CoV-2 is a newly identified pathogen, there is no known preexisting immunity in humans.[13] We do not know the duration of the protective immune response against SARS-CoV-2.Coronavirus disease (COVID-19)A few emerging studies have explored the effect of temperature and humidity on the transmission of novel CoV; however, data remain inconclusive.", [["Coronavirus disease", "DISEASE", 181, 200], ["SARS-CoV-2", "ORGANISM", 3, 13], ["humans", "ORGANISM", 88, 94], ["SARS-CoV-2", "ORGANISM", 170, 180], ["CoV", "ORGANISM", 316, 319], ["humans", "SPECIES", 88, 94], ["SARS-CoV", "SPECIES", 3, 11], ["humans", "SPECIES", 88, 94], ["SARS-CoV", "SPECIES", 170, 178], ["a newly identified pathogen", "PROBLEM", 17, 44], ["known preexisting immunity in humans", "PROBLEM", 58, 94], ["SARS", "PROBLEM", 170, 174], ["CoV", "TEST", 175, 178], ["Coronavirus disease", "PROBLEM", 181, 200], ["COVID", "TEST", 202, 207], ["novel CoV", "TEST", 310, 319], ["pathogen", "OBSERVATION", 36, 44], ["no known", "UNCERTAINTY", 55, 63], ["preexisting", "OBSERVATION_MODIFIER", 64, 75], ["immunity", "OBSERVATION", 76, 84]]], ["The effect of temperature on survival and transmission of SARS-CoV-2 is yet to be known.[14]Coronavirus disease (COVID-19)A report of the World Health Organization (WHO)-China Joint Mission on Coronavirus Disease 2019 (COVID-19) gives a case fatality ratio (CFR) of 3.8% in China.[13] The CFR was also reported to be higher among males compared to females (4.7% vs. 2.8%).", [["SARS", "DISEASE", 58, 62], ["Coronavirus Disease", "DISEASE", 193, 212], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 58, 68], ["SARS-CoV", "SPECIES", 58, 66], ["survival", "TREATMENT", 29, 37], ["SARS", "PROBLEM", 58, 62], ["Coronavirus disease", "PROBLEM", 92, 111], ["Coronavirus Disease", "PROBLEM", 193, 212], ["COVID", "TEST", 219, 224], ["CFR", "TEST", 258, 261], ["The CFR", "TEST", 285, 292], ["Coronavirus disease", "OBSERVATION", 92, 111], ["Joint", "ANATOMY", 176, 181]]], ["A higher mortality was also reported more in patients with comorbid conditions (CFR of 13.2% for those with cardiovascular disease, 9.2% for diabetes, 8.4% for hypertension, 8.0% for chronic respiratory disease, and 7.6% for cancer) compared to patients without comorbid conditions (CFR of 1.4%).[13] It also reported an increase in mortality with increasing age, with the highest mortality among people over 80 years of age (CFR 21.9%).", [["cardiovascular", "ANATOMY", 108, 122], ["respiratory", "ANATOMY", 191, 202], ["cancer", "ANATOMY", 225, 231], ["cardiovascular disease", "DISEASE", 108, 130], ["diabetes", "DISEASE", 141, 149], ["hypertension", "DISEASE", 160, 172], ["chronic respiratory disease", "DISEASE", 183, 210], ["cancer", "DISEASE", 225, 231], ["patients", "ORGANISM", 45, 53], ["cancer", "CANCER", 225, 231], ["patients", "ORGANISM", 245, 253], ["people", "ORGANISM", 397, 403], ["patients", "SPECIES", 45, 53], ["patients", "SPECIES", 245, 253], ["people", "SPECIES", 397, 403], ["A higher mortality", "PROBLEM", 0, 18], ["comorbid conditions", "PROBLEM", 59, 78], ["CFR", "TEST", 80, 83], ["cardiovascular disease", "PROBLEM", 108, 130], ["diabetes", "PROBLEM", 141, 149], ["hypertension", "PROBLEM", 160, 172], ["chronic respiratory disease", "PROBLEM", 183, 210], ["cancer", "PROBLEM", 225, 231], ["comorbid conditions", "PROBLEM", 262, 281], ["CFR", "TEST", 283, 286], ["CFR", "TEST", 426, 429], ["higher", "OBSERVATION_MODIFIER", 2, 8], ["mortality", "OBSERVATION", 9, 18], ["respiratory disease", "OBSERVATION", 191, 210], ["increase", "OBSERVATION_MODIFIER", 321, 329]]], ["Although elderly is affected more, the severity of disease in younger age groups should not be discounted.", [["disease", "PROBLEM", 51, 58], ["disease", "OBSERVATION", 51, 58]]], ["20% of deaths from South Korea were reported in people under 60 years of age.", [["deaths", "DISEASE", 7, 13], ["people", "ORGANISM", 48, 54], ["people", "SPECIES", 48, 54]]], ["15% of cases requiring intensive care treatment in Italy were among individuals 50 years and younger.[15] India, with a median age of 26.4 years, has a younger population than most countries.", [["intensive care treatment", "TREATMENT", 23, 47]]], ["The effect of demographic distribution of the country on the severity of disease is yet to be ascertained.Global situationA total of 3,018,952 confirmed cases of COVID-19 were reported globally by World Health Organization (WHO) as on 29 April 2020, affecting a total of 212 countries, areas or territories(16).", [["disease", "PROBLEM", 73, 80], ["Global situationA", "TEST", 106, 123], ["COVID", "TEST", 162, 167], ["disease", "OBSERVATION", 73, 80]]], ["The European Region and the USA are contributing to the maximum number of cases across the world [Table 1].[16]Control measures adopted by countries across the globeCountries across the globe have adopted various prevention and control measures ranging from social distancing and isolation to shutting down nonessential services and countrywide lockdowns.", [["Control measures", "TREATMENT", 111, 127], ["various prevention", "TREATMENT", 205, 223], ["control measures", "TREATMENT", 228, 244], ["globe", "ANATOMY", 186, 191]]], ["The testing strategies are also varied with some countries employing selective testing, while others have attempted more widespread testing.Control measures adopted by countries across the globePrevious experience from SARS-CoV outbreak shows that isolation of cases and infection control were effective measures to contain the outbreak.[17] The WHO-China Joint Commission report talks extensively of the efficacy of nonpharmaceutical measures, including isolation/quarantine and community engagement, in controlling the outbreak in China.[13] Further, modeling studies show that effective social distancing measures are useful in preventing subsequent waves of the infection, irrespective of variations between countries in implementing these measures.[18]Control measures adopted by countries across the globeProper hand-washing has been shown to inactivate/remove various microorganisms.", [["hand", "ANATOMY", 818, 822], ["SARS", "DISEASE", 219, 223], ["infection", "DISEASE", 271, 280], ["infection", "DISEASE", 666, 675], ["SARS-CoV", "ORGANISM", 219, 227], ["SARS-CoV", "SPECIES", 219, 227], ["selective testing", "TEST", 69, 86], ["widespread testing", "TEST", 121, 139], ["SARS", "PROBLEM", 219, 223], ["CoV outbreak", "PROBLEM", 224, 236], ["isolation of cases", "TREATMENT", 248, 266], ["infection control", "TREATMENT", 271, 288], ["nonpharmaceutical measures", "TREATMENT", 417, 443], ["isolation/quarantine", "TREATMENT", 455, 475], ["Further, modeling studies", "TEST", 544, 569], ["the infection", "PROBLEM", 662, 675], ["these measures", "TREATMENT", 738, 752], ["Control measures", "TREATMENT", 757, 773], ["washing", "TREATMENT", 823, 830], ["various microorganisms", "PROBLEM", 867, 889], ["globe", "ANATOMY", 189, 194], ["infection", "OBSERVATION", 271, 280], ["Joint", "ANATOMY", 356, 361], ["infection", "OBSERVATION", 666, 675]]], ["The use of soap and water or alcohol-based handrub has proven efficacy over various viruses.[19] The Centers for Disease Control and Prevention (CDC) recommends hand-washing as an effective measure for reducing Covid-19 infections in community settings.Control measures adopted by countries across the globeThere have been reports of both asymptomatic[2021] and presymptomatic[22] transmission of Covid-19.", [["hand", "ANATOMY", 161, 165], ["alcohol", "CHEMICAL", 29, 36], ["handrub", "CHEMICAL", 43, 50], ["infections", "DISEASE", 220, 230], ["alcohol", "CHEMICAL", 29, 36], ["water", "SIMPLE_CHEMICAL", 20, 25], ["alcohol", "SIMPLE_CHEMICAL", 29, 36], ["handrub", "SIMPLE_CHEMICAL", 43, 50], ["Covid-19", "SPECIES", 211, 219], ["soap and water", "TREATMENT", 11, 25], ["Disease Control", "TREATMENT", 113, 128], ["hand-washing", "TREATMENT", 161, 173], ["Covid", "TEST", 397, 402], ["globe", "ANATOMY", 302, 307]]], ["Further, viral load was found to be similar in symptomatic and asymptomatic cases.[23] As has already been discussed, there is a plausibility of airborne transmission.", [["[23] As", "CHEMICAL", 82, 89], ["Further, viral load", "TEST", 0, 19], ["viral load", "OBSERVATION", 9, 19], ["symptomatic", "OBSERVATION_MODIFIER", 47, 58], ["airborne transmission", "OBSERVATION", 145, 166]]], ["Considering these factors, it might be prudent to assume that the use of masks might be beneficial in reducing transmission.", [["masks", "TREATMENT", 73, 78]]], ["The CDC has recommended the use of simple cloth masks or homemade masks in public settings.[24]IndiaIndia reported its first positive case of novel coronavirus on January 30, 2020, in Kerala, in a student, who returned from Wuhan University [Table 2].[40] Three positive cases were reported in Kerala till 7 February.", [["coronavirus", "DISEASE", 148, 159], ["coronavirus", "ORGANISM", 148, 159], ["simple cloth masks", "TREATMENT", 35, 53], ["homemade masks", "TREATMENT", 57, 71], ["novel coronavirus", "PROBLEM", 142, 159]]], ["By 16 March, there were 114 confirmed cases of COVID-19 in the country.", [["COVID", "TEST", 47, 52]]], ["As on 19 April, India had reported 17,264 total COVID-19 cases: 14,175 active cases, 2546 cured/discharged, and 543 deaths.[41]IndiaIndia has adopted various public health measures to combat the spread of the disease.", [["deaths", "DISEASE", 116, 122], ["total COVID", "TEST", 42, 53], ["the disease", "PROBLEM", 205, 216], ["disease", "OBSERVATION", 209, 216]]], ["There is a policy intervention at the highest level and the Prime Minister has highlighted the government's large-scale efforts.", [["a policy intervention", "TREATMENT", 9, 30]]], ["These groups aid in planning and implementation of COVID-19-related activities.[42]Screening and surveillance activitiesMoHFW-Government of India issued its first advisory on January 17, 2020, instructing screening of international travelers from China at three airports, namely, Delhi, Mumbai, and Kolkata.", [["COVID", "TEST", 51, 56], ["Screening", "TEST", 83, 92]]], ["Screening at all international sea ports was also conducted.", [["Screening", "TEST", 0, 9], ["all international sea ports", "TREATMENT", 13, 40]]], ["Entry screening was extended to flights from Japan, South Korea, Vietnam, Nepal, Indonesia, and Malaysia from 23 February.", [["Entry screening", "TEST", 0, 15]]], ["On 3 March, the Government of India suspended visas of Italy, Iran, South Korea, and Japan and universal screening for all passengers since 4 March came into effect.", [["universal screening", "TEST", 95, 114]]], ["No passenger (Indian or Foreign) was allowed to disembark on Indian soil after March 23, 2020.", [["passenger", "OBSERVATION", 3, 12]]], ["By 30 March, 1,524,266 passengers had been screened at airports.[41]Screening and surveillance activitiesEarly identification of suspects should be followed by quarantine wherever applicable and they should be subjected to appropriate testing.", [["Screening", "TEST", 68, 77], ["surveillance activities", "TEST", 82, 105], ["appropriate testing", "TEST", 223, 242]]], ["Those testing positive should be isolated at the designated isolation facilities.", [["Those testing", "TEST", 0, 13]]], ["Quarantine, testing, and isolation are mainstays in the contained of COVID-19.", [["Quarantine", "CHEMICAL", 0, 10], ["COVID-19", "CHEMICAL", 69, 77], ["testing", "TEST", 12, 19], ["isolation", "TREATMENT", 25, 34], ["COVID", "TEST", 69, 74]]], ["For early identification of cases in community, the surveillance of severe acute respiratory illness is strengthened in states under the Integrated Disease Surveillance Program; all cases are identified and contacts of suspected/confirmed cases are followed up regularly.[43] In addition, cluster containment strategy for control of local clustering of cases and geographical containment strategy for large outbreaks with single or multiple foci of transmission have been laid out.", [["respiratory", "ANATOMY", 81, 92], ["acute respiratory illness", "DISEASE", 75, 100], ["severe acute respiratory illness", "PROBLEM", 68, 100], ["cluster containment strategy", "TREATMENT", 289, 317], ["geographical containment strategy", "TREATMENT", 363, 396], ["large outbreaks", "PROBLEM", 401, 416], ["severe", "OBSERVATION_MODIFIER", 68, 74], ["acute", "OBSERVATION_MODIFIER", 75, 80], ["respiratory illness", "OBSERVATION", 81, 100], ["large", "OBSERVATION_MODIFIER", 401, 406], ["outbreaks", "OBSERVATION", 407, 416], ["multiple", "OBSERVATION_MODIFIER", 432, 440], ["foci", "OBSERVATION", 441, 445]]], ["The strategy in cluster containment includes (a) extensive contact tracing and active search for cases in containment zone, (b) testing all suspect cases and high-risk contacts, (c) isolating all suspect/confirmed cases and providing medical care, (d) quarantining contacts, (e) implementing social distancing measures, and (f) intensive risk communication.", [["extensive contact tracing", "TEST", 49, 74], ["cluster", "OBSERVATION_MODIFIER", 16, 23], ["containment", "OBSERVATION_MODIFIER", 24, 35]]], ["The area for geographical quarantine is divided into a containment zone containing the cluster of cases, surrounded by a buffer zone consisting of adjoining blocks of affected district or rural districts of affected city.", [["geographical quarantine", "TREATMENT", 13, 36], ["a buffer zone", "PROBLEM", 119, 132], ["affected district", "PROBLEM", 167, 184], ["area", "OBSERVATION_MODIFIER", 4, 8], ["geographical", "OBSERVATION_MODIFIER", 13, 25], ["quarantine", "OBSERVATION", 26, 36], ["cluster", "OBSERVATION_MODIFIER", 87, 94]]], ["It implies almost complete interruption of movement to and from the containment area.", [["almost", "OBSERVATION_MODIFIER", 11, 17], ["complete", "OBSERVATION_MODIFIER", 18, 26], ["interruption", "OBSERVATION", 27, 39], ["movement", "OBSERVATION_MODIFIER", 43, 51], ["containment", "OBSERVATION_MODIFIER", 68, 79], ["area", "OBSERVATION_MODIFIER", 80, 84]]], ["The strategy includes; (a) detailed outbreak mapping, (b) active surveillance for cases and contacts in the geographic area and enhanced passive surveillance of influenza-like illness and severe acute respiratory illness cases in surrounding districts, (c) expanding laboratory network, (d) three-tier management plan for designated COVID19 hospitals to deal with mild, moderate, to severe and critical cases, respectively, (e) enhancing surge capacity of hospitals, (f) strict perimeter control and thermal screening at entry and exit points, and (g) providing chemoprophylaxis for all asymptomatic healthcare workers and asymptomatic contacts of laboratory-confirmed cases.[44]Laboratory networkThe National Institute of Virology, Pune, is the designated nodal laboratory and tasked with coordinating the testing of samples for COVID-19 in the country.", [["samples", "ANATOMY", 818, 825], ["influenza-like illness", "DISEASE", 161, 183], ["acute respiratory illness", "DISEASE", 195, 220], ["influenza", "PROBLEM", 161, 170], ["severe acute respiratory illness cases", "PROBLEM", 188, 226], ["mild, moderate, to severe and critical cases", "PROBLEM", 364, 408], ["strict perimeter control", "TREATMENT", 471, 495], ["thermal screening", "TEST", 500, 517], ["chemoprophylaxis", "TREATMENT", 562, 578], ["COVID", "TEST", 830, 835], ["influenza", "OBSERVATION", 161, 170], ["severe", "OBSERVATION_MODIFIER", 188, 194], ["acute", "OBSERVATION_MODIFIER", 195, 200], ["respiratory illness", "OBSERVATION", 201, 220], ["mild", "OBSERVATION_MODIFIER", 364, 368], ["moderate", "OBSERVATION_MODIFIER", 370, 378], ["severe", "OBSERVATION_MODIFIER", 383, 389]]], ["As on 29 April, a total of 292 government laboratories are operational.[45] To augment the testing capacity of the country, additionally 97 accredited private laboratories have also been made functional across the country.[46] As on 30 April, a total of 830,201 samples have been tested in India.[47]Laboratory networkThe current guidelines for COVID-19 testing strategy in India include testing of all symptomatic individuals who have undertaken international travel in the last 14 days, all symptomatic contacts of laboratory confirmed cases, all symptomatic health-care workers, and all patients with severe acute respiratory illness (fever AND cough and/or shortness of breath).[48] Asymptomatic direct and high-risk contacts of a confirmed case should be tested once between day 5 and day 14 of coming in his/her contact.[48] Guidelines for hotspots/cluster and in large migration gatherings/evacuees centers require all symptomatic influenza-like illness (fever, cough, sore throat, and runny nose) to be tested (a) within 7 days of illness \u2013 rRT-PCR and (b) after 7 days of illness \u2013 antibody test (if negative, confirmed by rRT-PCR).[48] ICMR has issued guidance on the use of Truenat\u2122 beta CoV as a screening test on April 14, 2020.[49]Laboratory networkTo meet the health-care challenges posed by COVID-19, the government has forged collaborations with the private sector.", [["samples", "ANATOMY", 262, 269], ["respiratory", "ANATOMY", 617, 628], ["acute respiratory illness", "DISEASE", 611, 636], ["fever", "DISEASE", 638, 643], ["cough", "DISEASE", 648, 653], ["shortness of breath", "DISEASE", 661, 680], ["influenza-like illness", "DISEASE", 938, 960], ["fever", "DISEASE", 962, 967], ["cough", "DISEASE", 969, 974], ["sore throat", "DISEASE", 976, 987], ["[46] As", "CHEMICAL", 222, 229], ["samples", "CANCER", 262, 269], ["patients", "ORGANISM", 590, 598], ["nose", "ORGANISM_SUBDIVISION", 999, 1003], ["Truenat\u2122 beta CoV", "GENE_OR_GENE_PRODUCT", 1185, 1202], ["Truenat\u2122 beta CoV", "PROTEIN", 1185, 1202], ["patients", "SPECIES", 590, 598], ["Truenat\u2122 beta CoV", "SPECIES", 1185, 1202], ["the testing capacity", "TEST", 87, 107], ["COVID", "TEST", 345, 350], ["severe acute respiratory illness", "PROBLEM", 604, 636], ["fever", "PROBLEM", 638, 643], ["cough", "PROBLEM", 648, 653], ["shortness of breath", "PROBLEM", 661, 680], ["hotspots/cluster", "PROBLEM", 846, 862], ["all symptomatic influenza", "PROBLEM", 922, 947], ["illness", "PROBLEM", 953, 960], ["fever", "PROBLEM", 962, 967], ["cough", "PROBLEM", 969, 974], ["sore throat", "PROBLEM", 976, 987], ["runny nose", "PROBLEM", 993, 1003], ["illness", "PROBLEM", 1039, 1046], ["rRT-PCR", "TEST", 1049, 1056], ["illness", "PROBLEM", 1081, 1088], ["antibody test", "TEST", 1091, 1104], ["rRT", "TEST", 1132, 1135], ["PCR", "TEST", 1136, 1139], ["a screening test", "TEST", 1206, 1222], ["severe", "OBSERVATION_MODIFIER", 604, 610], ["acute", "OBSERVATION_MODIFIER", 611, 616], ["respiratory", "ANATOMY", 617, 628], ["illness", "OBSERVATION", 629, 636], ["symptomatic", "OBSERVATION_MODIFIER", 926, 937], ["influenza", "OBSERVATION", 938, 947]]], ["Secretary has also informed of setting up a manufacturing facility for indigenous development of ventilators, testing kits, imaging equipment, ultrasound, and high and radiology equipment in Vishakhapatnam where manufacturing is started in the 1st week of April.", [["ventilators", "TREATMENT", 97, 108], ["testing kits", "TEST", 110, 122], ["imaging equipment", "TEST", 124, 141], ["ultrasound", "TEST", 143, 153]]], ["Director General, Council of Scientific and Industrial Research, has informed of a five-pronged strategy to find science and technology solutions, comprising (1) surveillance using digital and molecular methods which includes genome sequencing of the virus strains across the country; (2) cheaper, fast, and accurate diagnosis methods; (3) intervention strategies comprising repurposing drugs and developing new drugs; (4) R and D in hospital assistive equipment; and (5) development of supply chain logistics models for items required for Covid-19 mitigation.Laboratory networkThe current production capacity of indigenous Personal protection equipment (PPE) kits and N-95 masks as per Press Information Bureau of Ministry of Textiles was more than 1 lakh per day as on 26 April, 2020.[50] By 23 April a total of 2,033 dedicated COVID facilities with 190,000 isolation beds and 24,000 ICU beds with more than 12,000 ventilators were available.[51]Public health measuresOn 16 March, social distancing was proposed as a measure of nonpharmaceutical infection prevention and control.", [["infection", "DISEASE", 1048, 1057], ["digital and molecular methods", "TEST", 181, 210], ["the virus strains", "PROBLEM", 247, 264], ["intervention strategies", "TREATMENT", 340, 363], ["repurposing drugs", "TREATMENT", 375, 392], ["assistive equipment", "TREATMENT", 443, 462], ["Covid", "TEST", 540, 545], ["190,000 isolation beds", "TREATMENT", 852, 874], ["ventilators", "TREATMENT", 917, 928], ["nonpharmaceutical infection prevention", "TREATMENT", 1030, 1068], ["infection", "OBSERVATION", 1048, 1057]]], ["Offices, both government and private sector, were advised to discourage entry of visitors, meetings with large number of people, and use digital communication to the maximum extent.Public health measuresAll educational establishments, gyms, museums, cultural and social centers, swimming pools, and theaters were closed and children were advised to stay at home.", [["people", "ORGANISM", 121, 127], ["children", "ORGANISM", 324, 332], ["people", "SPECIES", 121, 127], ["children", "SPECIES", 324, 332], ["Public health measures", "TREATMENT", 181, 203]]], ["Local authorities were advised to have meetings with religious leaders to regulate mass gatherings and ensure physical distancing measures.", [["physical distancing measures", "TREATMENT", 110, 138]]], ["Special advice to high-risk groups (including individuals 65 years and above and children below 10 years of age) to stay at home and avoid large gatherings.", [["children", "ORGANISM", 81, 89], ["children", "SPECIES", 81, 89]]], ["On 19 March, all health establishments were advised to avoid nonurgent hospitalization and minimize elective surgeries.Public health measuresTo effectively tackle the rapid spread of the coronavirus, experts across the globe expressed the need to observe stricter social distancing measures.", [["coronavirus", "DISEASE", 187, 198], ["coronavirus", "ORGANISM", 187, 198], ["nonurgent hospitalization", "TREATMENT", 61, 86], ["elective surgeries", "TREATMENT", 100, 118], ["Public health measures", "TREATMENT", 119, 141], ["the coronavirus", "PROBLEM", 183, 198], ["rapid", "OBSERVATION_MODIFIER", 167, 172], ["spread", "OBSERVATION_MODIFIER", 173, 179], ["globe", "ANATOMY", 219, 224]]], ["On 22 March, the Prime Minister engaged all individuals and a nationwide voluntary curfew \u201cJanata Curfew\u201d was observed by the people which extended to all public transport services, including railways and metros.", [["people", "ORGANISM", 126, 132], ["people", "SPECIES", 126, 132]]], ["On 24 March, a nationwide lockdown came into force and a total ban was imposed on people for stepping out of their homes for a period of 21 days.", [["people", "ORGANISM", 82, 88], ["people", "SPECIES", 82, 88], ["a total ban", "TREATMENT", 55, 66]]], ["On 14 April, the lockdown was extended for additional 19 days.", [["the lockdown", "TREATMENT", 13, 25]]], ["All districts in the country have been evaluated on the risk of spread of disease and demarcated as red, orange, or green zones; as on 17th April, 170 districts are under red zone/hotspot (reporting more than 80% case load of COVID-19 in India or in a state, and/or with doubling rate <4 days) and 353 districts which are placed in green zone (reporting no new confirmed cases in last 28 days).", [["disease", "PROBLEM", 74, 81], ["COVID", "TEST", 226, 231], ["disease", "OBSERVATION", 74, 81]]], ["In addition, 207 districts have been identified as potential hotspots/orange zones.", [["orange zones", "OBSERVATION", 70, 82]]], ["Conditional permissions are granted for selective and cautious reopening of selected activities in areas with lower risk of spread of disease.[52]Information, education, and communicationThe union government, state governments, Panchayati Raj institutions, community-based organizations, non-governmental organizations, civil society representatives, and other voluntary organizations are engaged in spreading the message about COVID-19.", [["disease", "PROBLEM", 134, 141], ["COVID", "TEST", 428, 433], ["lower risk", "OBSERVATION_MODIFIER", 110, 120], ["spread", "OBSERVATION", 124, 130], ["disease", "OBSERVATION", 134, 141]]], ["Messaging around awareness in the community on signs and symptoms of disease, self-reporting of travel history, and basic public health measures (social distancing measures, proper usage of masks, hand-washing techniques, avoiding unnecessary travel, and maintaining hygiene of common infected surfaces) have been circulated extensively.Information, education, and communicationA round-the-clock National CDC (NCDC) control room was made operational and a national helpline number and helpline email id is provided to individuals for any queries related to COVID-19.", [["hand", "ANATOMY", 197, 201], ["symptoms", "PROBLEM", 57, 65], ["disease", "PROBLEM", 69, 76], ["social distancing measures", "TREATMENT", 146, 172], ["masks", "TREATMENT", 190, 195], ["hand-washing techniques", "TREATMENT", 197, 220], ["common infected surfaces", "TREATMENT", 278, 302], ["COVID", "TEST", 557, 562]]], ["The MoHFW website cohesively collates and displays information, advisories, and guidelines on COVID-19.", [["COVID", "TEST", 94, 99]]], ["Additional resources can also be accessed on NCDC website.Way forwardBoth primary and secondary prevention are important in disease control.", [["disease control", "TREATMENT", 124, 139], ["secondary prevention", "OBSERVATION", 86, 106]]], ["We present the way forward by identifying specific actions under enhancing preparedness and response, enabling care for patients, and broadening community and stakeholder engagement.", [["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 120, 128]]], ["The following no-regret moves can be considered.", [["The following no-regret moves", "TREATMENT", 0, 29]]], ["These moves complement the government's efforts and its response to the disease.Enhancing preparedness and responseThe national government must continue to take the leadership role and providing the policy direction to the control efforts.", [["the disease", "PROBLEM", 68, 79], ["disease", "OBSERVATION", 72, 79]]], ["It should issue regular updated guidance on implementation and action to be undertaken at the various levels of the health systemThe state governments must align with the overall country efforts and ensure adherence to the guidelines and augment containment efforts.", [["the guidelines", "TREATMENT", 219, 233], ["augment containment efforts", "TREATMENT", 238, 265]]], ["State should assume the lead in ensuring continuity of clinical and testing supplies as well as PPEs at the facility level within the stateThe national government must design an intensive strategy for \u201chot\u201d districts with active disease clusters/those which reported several cases.", [["clinical and testing supplies", "TREATMENT", 55, 84], ["an intensive strategy", "TREATMENT", 175, 196], ["active disease clusters", "PROBLEM", 222, 245], ["active", "OBSERVATION_MODIFIER", 222, 228], ["disease", "OBSERVATION", 229, 236]]], ["The district administration across the country will have to lead the disease control efforts within respective districts and prepare a district plan for handling the situation within the district.", [["The district administration", "TREATMENT", 0, 27], ["the disease control efforts", "TREATMENT", 65, 92]]], ["Proactive and strategic approach at the district level leadership will be the key to halting the spread of the disease and reversing the trend in casesDistrict administration must expand efforts for tracing all the contacts/suspects and testing for the disease wherever indicated by current testing protocols.", [["strategic approach", "TREATMENT", 14, 32], ["the disease", "PROBLEM", 107, 118], ["District administration", "TREATMENT", 151, 174], ["tracing", "TEST", 199, 206], ["the disease", "PROBLEM", 249, 260], ["current testing protocols", "TEST", 283, 308], ["disease", "OBSERVATION", 111, 118]]], ["At the district level, the health department along with the civic bodies such as the municipal corporations should actively and promptly undertake contact tracing.", [["the civic bodies", "TREATMENT", 56, 72]]], ["An early telephonic call should emphasize on immediate home precautions and should be followed by a home visit to emphasize important issues and mitigate anxietyMaintain strict surveillance of suspect cases and contacts of confirmed cases.", [["anxiety", "DISEASE", 154, 161], ["immediate home precautions", "TREATMENT", 45, 71], ["anxiety", "PROBLEM", 154, 161]]], ["In urban areas, residents welfare associations/housing societies will have to assume greater responsibilityResearch in the epidemiology, clinical management of cases, and control measures must be promptly designed, implemented, and published.", [["control measures", "TREATMENT", 171, 187]]], ["We need a detailed assessment of the natural history of the disease in the Indian population and the seroprevalence of COVID-19 within the population.", [["a detailed assessment", "TEST", 8, 29], ["the disease", "PROBLEM", 56, 67], ["COVID", "TREATMENT", 119, 124], ["disease", "OBSERVATION", 60, 67]]], ["Research to document the efficacy of treatment modalities and various drugs must be prioritized.", [["treatment modalities", "TREATMENT", 37, 57], ["various drugs", "TREATMENT", 62, 75]]]], "PMC7126621": [["IntroductionAstroviruses are small single-stranded positive sense RNA viruses of approximately 28\u201330 nm in diameter belonging to the family Astroviridae (Fauquet et al., 2005).", [["IntroductionAstroviruses", "TEST", 0, 24], ["small single-stranded positive sense RNA viruses", "PROBLEM", 29, 77], ["small", "OBSERVATION_MODIFIER", 29, 34], ["positive sense RNA viruses", "OBSERVATION", 51, 77]]], ["These round star-shaped viruses have been detected in many species of birds (genus Avastrovirus) and mammals (genus Mamastrovirus), including humans.", [["birds", "ORGANISM", 70, 75], ["genus Avastrovirus", "ORGANISM", 77, 95], ["humans", "ORGANISM", 142, 148], ["humans", "SPECIES", 142, 148], ["humans", "SPECIES", 142, 148], ["These round star-shaped viruses", "PROBLEM", 0, 31], ["mammals (genus Mamastrovirus", "PROBLEM", 101, 129], ["round", "OBSERVATION_MODIFIER", 6, 11], ["star", "OBSERVATION_MODIFIER", 12, 16], ["shaped", "OBSERVATION_MODIFIER", 17, 23], ["viruses", "OBSERVATION", 24, 31], ["many", "OBSERVATION_MODIFIER", 54, 58], ["species", "OBSERVATION_MODIFIER", 59, 66], ["genus Mamastrovirus", "OBSERVATION", 110, 129]]], ["Generally, astrovirus infections in animals are associated with enteric diseases, with mild to severe signs such as diarrhoea, vomiting, abdominal pain, sometimes associated with fever and immunodepression (Moser and Schultz-Cherry, 2005).", [["abdominal", "ANATOMY", 137, 146], ["astrovirus infections", "DISEASE", 11, 32], ["enteric diseases", "DISEASE", 64, 80], ["diarrhoea", "DISEASE", 116, 125], ["vomiting", "DISEASE", 127, 135], ["abdominal pain", "DISEASE", 137, 151], ["fever", "DISEASE", 179, 184], ["immunodepression", "DISEASE", 189, 205], ["astrovirus", "ORGANISM", 11, 21], ["abdominal", "ORGANISM_SUBDIVISION", 137, 146], ["astrovirus infections in animals", "PROBLEM", 11, 43], ["enteric diseases", "PROBLEM", 64, 80], ["mild to severe signs", "PROBLEM", 87, 107], ["diarrhoea", "PROBLEM", 116, 125], ["vomiting", "PROBLEM", 127, 135], ["abdominal pain", "PROBLEM", 137, 151], ["fever", "PROBLEM", 179, 184], ["immunodepression", "PROBLEM", 189, 205], ["astrovirus infections", "OBSERVATION", 11, 32], ["enteric", "ANATOMY", 64, 71], ["diseases", "OBSERVATION", 72, 80], ["mild", "OBSERVATION_MODIFIER", 87, 91], ["severe", "OBSERVATION_MODIFIER", 95, 101], ["diarrhoea", "OBSERVATION", 116, 125], ["abdominal", "ANATOMY", 137, 146], ["pain", "OBSERVATION", 147, 151], ["fever", "OBSERVATION", 179, 184], ["immunodepression", "OBSERVATION", 189, 205]]], ["In some cases, astroviruses can cause extra-enteric infections, as is the case of the avian nephritis virus (AVN), known to cause interstitial nephritis and growth retardation of young chickens (Imada et al., 2000) and the duck astrovirus (DAstV), that cause severe hepatitis and mortality rates up to 50% in ducklings (Gough et al., 1984).", [["interstitial", "ANATOMY", 130, 142], ["astroviruses", "DISEASE", 15, 27], ["extra-enteric infections", "DISEASE", 38, 62], ["avian nephritis", "DISEASE", 86, 101], ["AVN", "DISEASE", 109, 112], ["interstitial nephritis", "DISEASE", 130, 152], ["growth retardation", "DISEASE", 157, 175], ["duck astrovirus", "DISEASE", 223, 238], ["hepatitis", "DISEASE", 266, 275], ["avian nephritis virus", "ORGANISM", 86, 107], ["AVN", "CANCER", 109, 112], ["chickens", "ORGANISM", 185, 193], ["duck astrovirus", "ORGANISM", 223, 238], ["DAstV", "ORGANISM", 240, 245], ["ducklings", "ORGANISM", 309, 318], ["avian nephritis virus", "SPECIES", 86, 107], ["chickens", "SPECIES", 185, 193], ["duck astrovirus", "SPECIES", 223, 238], ["ducklings", "SPECIES", 309, 318], ["avian nephritis virus", "SPECIES", 86, 107], ["chickens", "SPECIES", 185, 193], ["duck astrovirus", "SPECIES", 223, 238], ["DAstV", "SPECIES", 240, 245], ["astroviruses", "PROBLEM", 15, 27], ["extra-enteric infections", "PROBLEM", 38, 62], ["the avian nephritis virus (AVN)", "PROBLEM", 82, 113], ["interstitial nephritis", "PROBLEM", 130, 152], ["growth retardation", "PROBLEM", 157, 175], ["young chickens", "PROBLEM", 179, 193], ["the duck astrovirus", "PROBLEM", 219, 238], ["severe hepatitis", "PROBLEM", 259, 275], ["mortality rates", "TEST", 280, 295], ["infections", "OBSERVATION", 52, 62], ["nephritis", "OBSERVATION", 92, 101], ["interstitial", "ANATOMY_MODIFIER", 130, 142], ["nephritis", "OBSERVATION", 143, 152], ["growth", "OBSERVATION_MODIFIER", 157, 163], ["retardation", "OBSERVATION_MODIFIER", 164, 175], ["severe", "OBSERVATION_MODIFIER", 259, 265], ["hepatitis", "OBSERVATION", 266, 275]]], ["Some astroviruses do not cause a detectable disease: the bovine astrovirus (BAstV) is asymptomatic or induces only slight changes in faeces of experimentally infected calves (Bridger et al., 1984) and the feline astrovirus (FAstV) cause disease only occasionally (Marshall et al., 1984b).", [["feline astrovirus", "DISEASE", 205, 222], ["bovine astrovirus", "ORGANISM", 57, 74], ["BAstV", "ORGANISM", 76, 81], ["faeces", "ORGANISM_SUBDIVISION", 133, 139], ["calves", "ORGANISM", 167, 173], ["feline astrovirus", "ORGANISM", 205, 222], ["FAstV", "ORGANISM", 224, 229], ["bovine", "SPECIES", 57, 63], ["calves", "SPECIES", 167, 173], ["feline astrovirus", "SPECIES", 205, 222], ["bovine astrovirus", "SPECIES", 57, 74], ["BAstV", "SPECIES", 76, 81], ["feline astrovirus", "SPECIES", 205, 222], ["FAstV", "SPECIES", 224, 229], ["Some astroviruses", "PROBLEM", 0, 17], ["a detectable disease", "PROBLEM", 31, 51], ["the bovine astrovirus", "PROBLEM", 53, 74], ["asymptomatic", "PROBLEM", 86, 98], ["slight changes in faeces", "PROBLEM", 115, 139], ["experimentally infected calves", "PROBLEM", 143, 173], ["the feline astrovirus", "PROBLEM", 201, 222], ["disease", "PROBLEM", 237, 244], ["astroviruses", "OBSERVATION", 5, 17], ["do not cause", "UNCERTAINTY", 18, 30], ["detectable", "OBSERVATION_MODIFIER", 33, 43], ["disease", "OBSERVATION", 44, 51], ["slight", "OBSERVATION_MODIFIER", 115, 121], ["experimentally", "OBSERVATION_MODIFIER", 143, 157], ["infected", "OBSERVATION", 158, 166], ["feline astrovirus", "OBSERVATION", 205, 222]]], ["In other instances, the association of astroviruses with diseases is simply unknown, as the case of the recently discovered astroviruses in insectivorous bats (Chu et al., 2008).", [["astroviruses", "DISEASE", 39, 51], ["astroviruses", "DISEASE", 124, 136], ["astroviruses", "GENE_OR_GENE_PRODUCT", 39, 51], ["astroviruses", "PROBLEM", 39, 51], ["diseases", "PROBLEM", 57, 65], ["astroviruses", "OBSERVATION", 39, 51], ["astroviruses", "OBSERVATION", 124, 136]]], ["The most well characterized astroviruses are those that infect humans (HAstVs).", [["astroviruses", "CANCER", 28, 40], ["humans", "ORGANISM", 63, 69], ["HAstVs", "GENE_OR_GENE_PRODUCT", 71, 77], ["humans", "SPECIES", 63, 69], ["humans", "SPECIES", 63, 69], ["astroviruses", "PROBLEM", 28, 40], ["most well characterized", "OBSERVATION_MODIFIER", 4, 27], ["astroviruses", "OBSERVATION", 28, 40]]], ["They are classified in eight different serotypes, HAstV-1 to HAstV-8 (Walter and Mitchell, 2003) and HAstV-1 appears to be the most common, in particular among children, elderly and immunocompromised persons (Moser and Schultz-Cherry, 2005, Walter and Mitchell, 2003).IntroductionTo date, astrovirus-like particles have been reported only three times in dogs (Marshall et al., 1984a, Vieler and Herbst, 1995, Williams, 1980).", [["HAstV-1", "ORGANISM", 50, 57], ["HAstV-8", "ORGANISM", 61, 68], ["HAstV-1", "GENE_OR_GENE_PRODUCT", 101, 108], ["children", "ORGANISM", 160, 168], ["persons", "ORGANISM", 200, 207], ["astrovirus", "ORGANISM", 289, 299], ["dogs", "ORGANISM", 354, 358], ["children", "SPECIES", 160, 168], ["persons", "SPECIES", 200, 207], ["dogs", "SPECIES", 354, 358], ["HAstV-1", "SPECIES", 101, 108], ["astrovirus", "PROBLEM", 289, 299]]], ["However, the previous studies observations were based on electron microscopy only and their presence in canine faeces had never been confirmed by genetic or antigenic analysis.", [["faeces", "ANATOMY", 111, 117], ["canine", "ORGANISM", 104, 110], ["faeces", "ORGANISM_SUBDIVISION", 111, 117], ["canine", "SPECIES", 104, 110], ["canine", "SPECIES", 104, 110], ["the previous studies observations", "TEST", 9, 42], ["electron microscopy", "TEST", 57, 76], ["genetic or antigenic analysis", "TEST", 146, 175]]], ["It is noteworthy that electron microscopy often leads to wrong classification of small viral particles since they share similar morphological and physiochemical features (Guy et al., 2004).", [["electron microscopy", "TEST", 22, 41], ["small viral particles", "PROBLEM", 81, 102], ["small", "OBSERVATION_MODIFIER", 81, 86], ["viral particles", "OBSERVATION", 87, 102]]], ["In the above-mentioned reports, astroviruses were detected in symptomatic puppies, associated with other enteric viruses such as parvoviruses, rotaviruses and coronaviruses.IntroductionIn this paper we report the first case of confirmatory PCR and genetic characterization of canine astrovirus particles identified by EM from ill puppies.Sample collection ::: Materials and methodsFaecal samples were collected individually in sterile tubes from one group of 11 diarrhoeic puppies and immediately submitted to the Istituto Zooprofilattico Sperimentale delle Venezie (IZSVe, Italy) for suspected viral enteritis.", [["Faecal samples", "ANATOMY", 381, 395], ["rotaviruses and coronaviruses", "DISEASE", 143, 172], ["viral enteritis", "DISEASE", 595, 610], ["astroviruses", "GENE_OR_GENE_PRODUCT", 32, 44], ["puppies", "ORGANISM_SUBDIVISION", 74, 81], ["coronaviruses", "ORGANISM", 159, 172], ["canine", "ORGANISM", 276, 282], ["astrovirus", "ORGANISM", 283, 293], ["Faecal samples", "CANCER", 381, 395], ["puppies", "ORGANISM", 473, 480], ["canine", "SPECIES", 276, 282], ["canine astrovirus", "SPECIES", 276, 293], ["astroviruses", "PROBLEM", 32, 44], ["symptomatic puppies", "PROBLEM", 62, 81], ["other enteric viruses", "PROBLEM", 99, 120], ["parvoviruses", "PROBLEM", 129, 141], ["rotaviruses", "PROBLEM", 143, 154], ["coronaviruses", "PROBLEM", 159, 172], ["confirmatory PCR", "TEST", 227, 243], ["genetic characterization", "TEST", 248, 272], ["canine astrovirus particles", "PROBLEM", 276, 303], ["methodsFaecal samples", "TEST", 374, 395], ["sterile tubes", "TREATMENT", 427, 440], ["suspected viral enteritis", "PROBLEM", 585, 610], ["symptomatic", "OBSERVATION_MODIFIER", 62, 73], ["puppies", "OBSERVATION", 74, 81], ["viruses", "OBSERVATION", 113, 120], ["viral enteritis", "OBSERVATION", 595, 610]]], ["In addition, to exclude the presence of other pathogens, bacteriological and parasitological tests were requested and performed according to standard procedures (Capelli et al., 2006, Quinn et al., 1994).Electron microscopy ::: Materials and methodsFaeces were 10-fold diluted in phosphate buffered saline (PBS), repeatedly frozen and thawed and clarified by a two-step centrifugation (2500 \u00d7g at 8 \u00b0C for 30 min and 7000 \u00d7g at 8 \u00b0C for 30 min).", [["phosphate", "CHEMICAL", 280, 289], ["phosphate", "CHEMICAL", 280, 289], ["phosphate buffered saline", "SIMPLE_CHEMICAL", 280, 305], ["other pathogens", "PROBLEM", 40, 55], ["parasitological tests", "TEST", 77, 98], ["Electron microscopy", "TEST", 204, 223], ["methodsFaeces", "TREATMENT", 242, 255], ["phosphate buffered saline (PBS", "TREATMENT", 280, 310], ["a two-step centrifugation", "TREATMENT", 359, 384]]], ["An aliquot of 85 \u03bcL of the supernatant was ultracentrifuged for 15 min in a Beckman Airfuge, using an A-100 rotor, at 20 psi (125,000 \u00d7g).", [["supernatant", "ANATOMY", 27, 38], ["the supernatant", "TREATMENT", 23, 38]]], ["The grids were stained using a 2% sodium phosphotungstate solution in distilled water (pH 6.8) for at least 3 min.", [["sodium phosphotungstate", "CHEMICAL", 34, 57], ["sodium phosphotungstate", "CHEMICAL", 34, 57], ["sodium phosphotungstate", "SIMPLE_CHEMICAL", 34, 57], ["a 2% sodium phosphotungstate solution", "TREATMENT", 29, 66], ["pH", "TEST", 87, 89]]], ["The dried grids were observed using a TEM Philips operating at 80 kV, at a magnification of 19,000\u201345,000.", [["The dried grids", "PROBLEM", 0, 15], ["a TEM Philips", "TREATMENT", 36, 49]]], ["Morphometric measurements were performed on astrovirus-like positive samples.", [["samples", "ANATOMY", 69, 76], ["astrovirus", "ORGANISM", 44, 54], ["Morphometric measurements", "TEST", 0, 25], ["astrovirus", "TEST", 44, 54]]], ["A minimum of 20 viral particles were measured at a magnification of 36,000 and statistically analysed with Soft-imaging software analySIS 2.1 (GmbH\u00a9 1996).Virus isolation ::: Materials and methodsVirus isolation was attempted for all the samples submitted in MDCK and VERO cells.", [["samples", "ANATOMY", 238, 245], ["MDCK", "ANATOMY", 259, 263], ["VERO cells", "ANATOMY", 268, 278], ["Virus", "ORGANISM", 155, 160], ["Virus", "ORGANISM", 196, 201], ["MDCK", "CELL", 259, 263], ["VERO cells", "CELL", 268, 278], ["MDCK", "CELL_LINE", 259, 263], ["VERO cells", "CELL_LINE", 268, 278], ["A minimum of 20 viral particles", "TEST", 0, 31], ["Soft-imaging software analySIS", "TEST", 107, 137], ["Virus isolation", "TREATMENT", 196, 211], ["the samples", "TEST", 234, 245], ["VERO cells", "OBSERVATION", 268, 278]]], ["Samples were diluted 1:10 in PBS solution with antibiotics (10,000 U/mL penycillin, 10 mg/mL streptomycin, 0.25 mg/mL gentamycin and 5000 U/mL mycostatin), then clarified by centrifugation and filtered (0.22 \u03bcm disposable filter).", [["Samples", "ANATOMY", 0, 7], ["penycillin", "CHEMICAL", 72, 82], ["streptomycin", "CHEMICAL", 93, 105], ["gentamycin", "CHEMICAL", 118, 128], ["mycostatin", "CHEMICAL", 143, 153], ["penycillin", "CHEMICAL", 72, 82], ["streptomycin", "CHEMICAL", 93, 105], ["gentamycin", "CHEMICAL", 118, 128], ["mycostatin", "CHEMICAL", 143, 153], ["penycillin", "SIMPLE_CHEMICAL", 72, 82], ["streptomycin", "SIMPLE_CHEMICAL", 93, 105], ["gentamycin", "SIMPLE_CHEMICAL", 118, 128], ["mycostatin", "SIMPLE_CHEMICAL", 143, 153], ["Samples", "TEST", 0, 7], ["antibiotics", "TREATMENT", 47, 58], ["penycillin", "TREATMENT", 72, 82], ["streptomycin", "TREATMENT", 93, 105], ["gentamycin", "TREATMENT", 118, 128], ["mycostatin", "TREATMENT", 143, 153], ["filtered (0.22 \u03bcm disposable filter", "TREATMENT", 193, 228]]], ["Samples were inoculated into confluent cell monolayers with and without trypsin 20 \u03bcg/mL (Trypsin Invitrogen, cat. no. 15090.046) (Lee and Kurtz, 1981).", [["Samples", "ANATOMY", 0, 7], ["cell monolayers", "ANATOMY", 39, 54], ["cell monolayers", "CELL", 39, 54], ["trypsin", "GENE_OR_GENE_PRODUCT", 72, 79], ["confluent cell monolayers", "CELL_LINE", 29, 54], ["trypsin", "PROTEIN", 72, 79], ["Samples", "TEST", 0, 7], ["confluent cell monolayers", "TEST", 29, 54], ["trypsin", "TREATMENT", 72, 79], ["confluent", "OBSERVATION_MODIFIER", 29, 38], ["cell monolayers", "OBSERVATION", 39, 54]]], ["The inoculum was adsorbed for 1 h at 37 \u00b0C, then removed and Eagle's Minimum Essential Medium was added.", [["The inoculum", "TREATMENT", 0, 12], ["inoculum", "OBSERVATION", 4, 12], ["Medium", "OBSERVATION_MODIFIER", 87, 93]]], ["Cell cultures were observed daily for cytopathic effect (CPE).", [["Cell cultures", "ANATOMY", 0, 13], ["Cell cultures", "CELL", 0, 13], ["Cell cultures", "TEST", 0, 13], ["cytopathic effect (CPE", "PROBLEM", 38, 60]]], ["Up to five blind passages were performed for cell cultures being considered negative.", [["cell cultures", "ANATOMY", 45, 58], ["cell cultures", "CELL", 45, 58], ["blind passages", "TEST", 11, 25], ["cell cultures", "TEST", 45, 58]]], ["Presence of virus particles in cell supernatants at the end of each passage was assessed by EM.Virus isolation ::: Materials and methodsHuman astrovirus serotype 8 was propagated in CaCo-2 cells and used as positive control for subsequent RT-PCR assays.RT-PCR design, sequencing and phylogenetic analysis ::: Materials and methodsRNA from the faecal samples was isolated with NucliSens\u00ae easyMAG\u2122 (BioM\u00e9rieux) according to the manufacturer's instructions.RT-PCR design, sequencing and phylogenetic analysis ::: Materials and methodsSince several astroviruses contain a very conserved RNA motif, called stem-loop-2-like motif (s2m), in the 3\u2032 non-coding region (Jonassen et al., 1998), RT-PCR was performed using a forward primer located within s2m towards a reverse primer mostly targeting the viral poly-(A) tail AV12 (5\u2032-TTT TTT TTT TTT TTT TTT GC-3\u2032), which amplifies the 3\u2032-end of the genome if s2m is part of it, about 40\u2013200 nt (Jonassen, 2008, Jonassen et al., 2001). cDNA synthesis was performed using SuperScript III Rnase H\u2212 Reverse Transcriptase (Invitrogen) according to the manufacturer's protocol, with 0.125 \u03bcM AV12 primer.", [["cell supernatants", "ANATOMY", 31, 48], ["CaCo-2 cells", "ANATOMY", 182, 194], ["faecal samples", "ANATOMY", 343, 357], ["cell", "CELL", 31, 35], ["Virus", "ORGANISM", 95, 100], ["Human", "ORGANISM", 136, 141], ["astrovirus serotype 8", "ORGANISM", 142, 163], ["CaCo-2 cells", "CELL", 182, 194], ["faecal samples", "ORGANISM_SUBSTANCE", 343, 357], ["astroviruses", "CANCER", 545, 557], ["stem-loop-2", "GENE_OR_GENE_PRODUCT", 601, 612], ["s2m", "GENE_OR_GENE_PRODUCT", 743, 746], ["s2m", "GENE_OR_GENE_PRODUCT", 898, 901], ["CaCo-2 cells", "CELL_LINE", 182, 194], ["RNA motif", "RNA", 583, 592], ["stem-loop-2-like motif", "DNA", 601, 623], ["3\u2032 non-coding region", "DNA", 638, 658], ["RT-PCR", "DNA", 684, 690], ["forward primer", "DNA", 713, 727], ["s2m", "DNA", 743, 746], ["reverse primer", "DNA", 757, 771], ["viral poly-(A) tail AV12", "DNA", 793, 817], ["5\u2032-TTT TTT", "DNA", 819, 829], ["3\u2032-end", "DNA", 874, 880], ["s2m", "DNA", 898, 901], ["cDNA", "DNA", 974, 978], ["SuperScript III Rnase H\u2212 Reverse Transcriptase", "PROTEIN", 1009, 1055], ["Human", "SPECIES", 136, 141], ["astrovirus serotype", "SPECIES", 142, 161], ["Human astrovirus serotype 8", "SPECIES", 136, 163], ["virus particles in cell supernatants", "PROBLEM", 12, 48], ["Materials", "TREATMENT", 115, 124], ["methodsHuman astrovirus serotype", "TREATMENT", 129, 161], ["CaCo-2 cells", "TREATMENT", 182, 194], ["subsequent RT-PCR assays", "TEST", 228, 252], ["RT-PCR design", "TEST", 253, 266], ["phylogenetic analysis", "TEST", 283, 304], ["methodsRNA", "TEST", 323, 333], ["the faecal samples", "TEST", 339, 357], ["NucliSens\u00ae easyMAG\u2122 (BioM\u00e9rieux)", "TREATMENT", 376, 408], ["RT-PCR design", "TEST", 454, 467], ["phylogenetic analysis", "TEST", 484, 505], ["several astroviruses", "PROBLEM", 537, 557], ["RT-PCR", "TEST", 684, 690], ["a forward primer", "TREATMENT", 711, 727], ["the viral poly", "TEST", 789, 803], ["AV12", "TEST", 813, 817], ["TTT", "TEST", 822, 825], ["TTT", "TEST", 826, 829], ["TTT", "TEST", 830, 833], ["TTT", "TEST", 834, 837], ["TTT", "TEST", 838, 841], ["TTT", "TEST", 842, 845], ["GC", "TEST", 846, 848], ["cDNA synthesis", "TEST", 974, 988], ["SuperScript III Rnase", "TREATMENT", 1009, 1030], ["Reverse Transcriptase (Invitrogen)", "TREATMENT", 1034, 1068], ["the manufacturer's protocol", "TREATMENT", 1082, 1109], ["virus particles", "OBSERVATION", 12, 27], ["cell supernatants", "OBSERVATION", 31, 48], ["end", "OBSERVATION_MODIFIER", 56, 59], ["passage", "OBSERVATION_MODIFIER", 68, 75], ["viral poly", "OBSERVATION", 793, 803]]], ["The RT reaction was performed in a thermocycler (MJ Research) at 50 \u00b0C for 30 min, followed by an inactivation step at 70 \u00b0C for 15 min.", [["The RT reaction", "PROBLEM", 0, 15], ["a thermocycler (MJ Research", "TREATMENT", 33, 60], ["an inactivation step", "TREATMENT", 95, 115]]], ["2,5 \u03bcL cDNA were used in a 25 \u03bcL PCR reaction and amplified by using HotStar Taq DNA polymerase (Qiagen).", [["DNA", "CELLULAR_COMPONENT", 81, 84], ["2,5 \u03bcL cDNA", "DNA", 0, 11], ["HotStar Taq DNA polymerase", "PROTEIN", 69, 95], ["a 25 \u03bcL PCR reaction", "TREATMENT", 25, 45], ["HotStar Taq DNA polymerase", "TREATMENT", 69, 95]]], ["The primers used were s2m-core (0.5 \u03bcM): 5\u2032-CCG AGT A(C/G)G ATC AGG G-3\u2032 and AV12 (0.5 \u03bcM).", [["5\u2032-CCG", "SIMPLE_CHEMICAL", 41, 47], ["G-3\u2032", "SIMPLE_CHEMICAL", 68, 72], ["AV12", "SIMPLE_CHEMICAL", 77, 81], ["s2m-core", "DNA", 22, 30], ["The primers", "TREATMENT", 0, 11], ["A(C/G)", "TREATMENT", 52, 58], ["AGG", "TEST", 64, 67], ["G", "TEST", 68, 69], ["AV12", "TEST", 77, 81]]], ["The concentration of Mg2+ in the reaction was 1.5 mM.", [["Mg2", "CHEMICAL", 21, 24], ["Mg2+", "CHEMICAL", 21, 25], ["Mg2+", "SIMPLE_CHEMICAL", 21, 25], ["The concentration of Mg2", "TREATMENT", 0, 24], ["concentration", "OBSERVATION_MODIFIER", 4, 17]]], ["A final elongation step at 72 \u00b0C for 5 min was performed, followed by chilling to 8 \u00b0C. RNA isolated from human astrovirus serotype 8 was used as a positive control in the RT-PCR set-up.", [["human", "ORGANISM", 106, 111], ["astrovirus serotype 8", "ORGANISM", 112, 133], ["RNA", "RNA", 88, 91], ["human", "SPECIES", 106, 111], ["astrovirus serotype", "SPECIES", 112, 131], ["human astrovirus", "SPECIES", 106, 122], ["A final elongation step", "TEST", 0, 23], ["RNA", "TEST", 88, 91], ["human astrovirus serotype", "TREATMENT", 106, 131], ["the RT", "TEST", 168, 174], ["PCR set", "TEST", 175, 182], ["elongation", "OBSERVATION_MODIFIER", 8, 18]]], ["Negative controls consisted of RNase/DNase-free water.RT-PCR design, sequencing and phylogenetic analysis ::: Materials and methodsAll PCR products were purified by using ExoSAP-IT\u00ae (GE Healthcare Bio-Sciences) according to the manufacturer's instructions.", [["RNase", "GENE_OR_GENE_PRODUCT", 31, 36], ["DNase", "GENE_OR_GENE_PRODUCT", 37, 42], ["ExoSAP", "SIMPLE_CHEMICAL", 171, 177], ["RNase", "PROTEIN", 31, 36], ["DNase", "PROTEIN", 37, 42], ["RNase/DNase", "TREATMENT", 31, 42], ["RT-PCR design", "TEST", 54, 67], ["phylogenetic analysis", "TEST", 84, 105], ["All PCR products", "TREATMENT", 131, 147]]], ["Sequencing was performed by using the ABI PRISM BigDye Terminator Cycle Sequencing Ready Reaction kit v1.1 (Applied Biosystems) according to manufacturer's instructions, and analysed on an ABI PRISM 3130xl Genetic Analyzer (Applied Biosystems).RT-PCR design, sequencing and phylogenetic analysis ::: Materials and methodsThe sequences obtained from the samples that contained s2m, were most similar to human astroviruses, and new RT and PCR were therefore performed with a forward consensus primer designed in the YGDD-motif of the polymerase gene of astrovirus, Astro-YGDD (5\u2032-TTA TGG AGA TGA (C/T)(A/C)G GCT-3\u2032), towards a reverse primer s2m-rev (5\u2032-CCC TCG ATC CTA CTC GG-3\u2032).", [["samples", "ANATOMY", 353, 360], ["s2m", "GENE_OR_GENE_PRODUCT", 376, 379], ["human", "ORGANISM", 402, 407], ["astroviruses", "CANCER", 408, 420], ["astrovirus", "ORGANISM", 551, 561], ["forward consensus primer", "DNA", 473, 497], ["YGDD-motif", "DNA", 514, 524], ["polymerase gene", "DNA", 532, 547], ["reverse primer s2m", "DNA", 625, 643], ["rev", "DNA", 644, 647], ["CCC", "DNA", 652, 655], ["human", "SPECIES", 402, 407], ["human", "SPECIES", 402, 407], ["the ABI PRISM BigDye Terminator Cycle", "TREATMENT", 34, 71], ["kit v", "TEST", 98, 103], ["an ABI PRISM", "TEST", 186, 198], ["Genetic Analyzer", "TEST", 206, 222], ["RT-PCR design", "TEST", 244, 257], ["phylogenetic analysis", "TEST", 274, 295], ["The sequences", "TEST", 321, 334], ["human astroviruses", "PROBLEM", 402, 420], ["new RT and PCR", "TEST", 426, 440], ["a forward consensus primer", "PROBLEM", 471, 497], ["astrovirus", "PROBLEM", 551, 561], ["AGA TGA", "TEST", 586, 593], ["A/C", "TEST", 600, 603], ["GCT", "TEST", 606, 609], ["CTA", "TEST", 664, 667], ["GG", "TEST", 672, 674]]], ["The expected size of the PCR products was about 2800 nt. cDNA synthesis was performed using 0.125 \u03bcM of a specific primer designed partially in the poly(A)-tail (5\u2032-TTT TTT TTT TTG CCT AAA CTA-3\u2032), and performed as described above with some modifications to allow for long-range cDNA synthesis: the amount of SuperScript\u2122 III RT enzyme was raised to 400 U/reaction, and the RT reaction was performed at 55 \u00b0C for 60 min, followed by an inactivation step at 70 \u00b0C for 15 min.", [["SuperScript\u2122 III", "GENE_OR_GENE_PRODUCT", 309, 325], ["PCR products", "DNA", 25, 37], ["cDNA", "DNA", 57, 61], ["poly(A)-tail (5\u2032-TTT TTT TTT TTG CCT AAA CTA-3\u2032", "DNA", 148, 195], ["SuperScript\u2122 III RT enzyme", "PROTEIN", 309, 335], ["the PCR products", "TREATMENT", 21, 37], ["cDNA synthesis", "TEST", 57, 71], ["a specific primer", "TREATMENT", 104, 121], ["TTT", "TEST", 165, 168], ["TTT", "TEST", 169, 172], ["TTT TTG CCT AAA CTA", "TEST", 173, 192], ["long-range cDNA synthesis", "TREATMENT", 268, 293], ["SuperScript\u2122 III RT enzyme", "TEST", 309, 335], ["reaction", "PROBLEM", 356, 364], ["the RT reaction", "PROBLEM", 370, 385], ["an inactivation step", "TREATMENT", 433, 453], ["size", "OBSERVATION_MODIFIER", 13, 17], ["PCR products", "OBSERVATION", 25, 37], ["tail", "ANATOMY", 156, 160]]], ["2.5 \u03bcL cDNA was used in a 25 \u03bcL PCR reaction and amplified by using BD Advantage 2 Polymerase (BD Biosciences Clontech).", [["2.5 \u03bcL cDNA", "DNA", 0, 11], ["BD Advantage 2 Polymerase", "PROTEIN", 68, 93], ["BD Biosciences Clontech", "PROTEIN", 95, 118], ["a 25 \u03bcL PCR reaction", "TREATMENT", 24, 44], ["BD Advantage 2 Polymerase", "TREATMENT", 68, 93]]], ["The primers used were Astro-YGDD (1.0 \u03bcM) and s2m-rev (0.5 \u03bcM).", [["Astro-YGDD", "SIMPLE_CHEMICAL", 22, 32], ["s2m-rev", "GENE_OR_GENE_PRODUCT", 46, 53], ["s2m-rev", "DNA", 46, 53], ["The primers", "TREATMENT", 0, 11], ["Astro-YGDD", "TREATMENT", 22, 32]]], ["A final elongation step at 68 \u00b0C for 5 min was performed, followed by chilling to 8 \u00b0C. The PCR products obtained from this amplification were sequenced and, based on these preliminary results, new canine astrovirus specific forward primer could be designed about 60 nt downstream the YGDD-motif, HundAstroF2800 (5\u2032-GAT GTT TTT GGA ATG TGG GT-3\u2032), to allow for a more specific amplification.", [["canine", "ORGANISM", 198, 204], ["astrovirus", "ORGANISM", 205, 215], ["PCR products", "DNA", 92, 104], ["canine astrovirus specific forward primer", "DNA", 198, 239], ["60 nt downstream", "DNA", 264, 280], ["YGDD-motif", "DNA", 285, 295], ["HundAstroF2800", "DNA", 297, 311], ["canine", "SPECIES", 198, 204], ["A final elongation step", "TEST", 0, 23], ["The PCR products", "TREATMENT", 88, 104], ["this amplification", "TREATMENT", 119, 137], ["new canine astrovirus specific forward primer", "PROBLEM", 194, 239], ["GAT GTT TTT GGA ATG TGG GT", "TREATMENT", 316, 342], ["elongation", "OBSERVATION_MODIFIER", 8, 18]]], ["A new dog long-range cDNA was then successfully amplified using this primer (0.5 \u03bcM) as a forward primer towards s2m-rev in a similar amplification as described above using BD Advantage 2 Poymerase, but the annealing temperature was decreased to 55 \u00b0C. The new-amplified PCR products were then sequenced, and new primers were designed and used for sequencing of this PCR product in a primer-walking strategy.RT-PCR design, sequencing and phylogenetic analysis ::: Materials and methodsSoftware used for sequence analysis and phylogeny were Sequencher version 4.1.4 (Gene Codes Corporation; http://www.genecodes.com), FASTA similarity search and CLUSTALW Multiple Sequence Alignment Program (http://www.ebi.ac.uk), and MEGA version 3.1 (Kumar et al., 2004, http://megasoftware.net).", [["dog", "ORGANISM", 6, 9], ["s2m", "GENE_OR_GENE_PRODUCT", 113, 116], ["dog long-range cDNA", "DNA", 6, 25], ["forward primer", "DNA", 90, 104], ["s2m", "DNA", 113, 116], ["rev", "DNA", 117, 120], ["PCR products", "DNA", 271, 283], ["A new dog long-range cDNA", "TREATMENT", 0, 25], ["this primer", "TREATMENT", 64, 75], ["a forward primer", "TREATMENT", 88, 104], ["a similar amplification", "TREATMENT", 124, 147], ["BD Advantage 2 Poymerase", "TREATMENT", 173, 197], ["the annealing temperature", "TEST", 203, 228], ["The new-amplified PCR products", "TREATMENT", 253, 283], ["this PCR product", "TREATMENT", 362, 378], ["a primer-walking strategy", "TREATMENT", 382, 407], ["RT-PCR design", "TEST", 408, 421], ["phylogenetic analysis", "TEST", 438, 459], ["sequence analysis", "TEST", 503, 520], ["Sequencher version", "TEST", 540, 558], ["FASTA similarity search", "TEST", 617, 640], ["new", "OBSERVATION_MODIFIER", 2, 5], ["new", "OBSERVATION_MODIFIER", 257, 260]]], ["Topology of the phylogenetic trees obtained was then compared to the topology of the trees generated with Bayesian methods.", [["Bayesian methods", "TREATMENT", 106, 122]]], ["3.1.1 were applied to generate the dendrograms and to assess statistical supports for the branches.", [["the dendrograms", "TEST", 31, 46], ["branches", "ANATOMY_MODIFIER", 90, 98]]], ["ORF analyses, and protein domain predictions were performed using JustBio (http://www.justbio.com), PSORT II prediction (http://psort.nibb.ac.jp/form2.html), TMHMM server version 2 (http://www.cbs.dtu.dk/services/TMHMM/) and HMMTOP (http://www.enzim.hu/hmmtop/index.html).Case history and laboratory results ::: ResultsIn June 2005 eleven 2\u20133-month-old puppies were imported to Italy from an East European country for commercial purposes.", [["puppies", "ORGANISM", 353, 360], ["ORF", "DNA", 0, 3], ["ORF analyses", "TEST", 0, 12], ["protein domain predictions", "TEST", 18, 44], ["JustBio", "TEST", 66, 73]]], ["In the country of origin, the puppies underwent antibiotic (spyramicin for 8 days), antihelminthic (levamisole) and multi-vitamin treatment.", [["spyramicin", "CHEMICAL", 60, 70], ["levamisole", "CHEMICAL", 100, 110], ["multi-vitamin", "CHEMICAL", 116, 129], ["spyramicin", "CHEMICAL", 60, 70], ["levamisole", "CHEMICAL", 100, 110], ["multi-vitamin", "CHEMICAL", 116, 129], ["puppies", "ORGANISM_SUBDIVISION", 30, 37], ["spyramicin", "SIMPLE_CHEMICAL", 60, 70], ["levamisole", "SIMPLE_CHEMICAL", 100, 110], ["multi-vitamin", "SIMPLE_CHEMICAL", 116, 129], ["antibiotic (spyramicin", "TREATMENT", 48, 70], ["antihelminthic (levamisole)", "TREATMENT", 84, 111], ["multi-vitamin treatment", "TREATMENT", 116, 139], ["origin", "ANATOMY_MODIFIER", 18, 24]]], ["Few days after the end of the quarantine period they started to show depression, decreased feed consumption and diarrhoea.", [["depression", "DISEASE", 69, 79], ["diarrhoea", "DISEASE", 112, 121], ["depression", "PROBLEM", 69, 79], ["decreased feed consumption", "PROBLEM", 81, 107], ["diarrhoea", "PROBLEM", 112, 121], ["depression", "OBSERVATION", 69, 79]]], ["A viral enteritis was suspected and samples were collected singularly and submitted for laboratory examinations.", [["samples", "ANATOMY", 36, 43], ["viral enteritis", "DISEASE", 2, 17], ["A viral enteritis", "PROBLEM", 0, 17], ["laboratory examinations", "TEST", 88, 111], ["viral", "OBSERVATION_MODIFIER", 2, 7], ["enteritis", "OBSERVATION", 8, 17]]], ["All puppies recovered spontaneously after 5\u20137 days of illness.Case history and laboratory results ::: ResultsFour (ID nos.", [["puppies", "ORGANISM", 4, 11], ["illness", "PROBLEM", 54, 61], ["puppies", "OBSERVATION", 4, 11]]], ["3, 6, 8 and 11) out of 11 samples collected and analysed by EM revealed the presence of astrovirus-like particles.", [["samples", "ANATOMY", 26, 33], ["astrovirus", "ORGANISM", 88, 98], ["astrovirus", "PROBLEM", 88, 98], ["astrovirus", "OBSERVATION", 88, 98]]], ["In one sample, parvovirus-like particles were also observed (Table 1).", [["sample", "ANATOMY", 7, 13], ["parvovirus", "ORGANISM", 15, 25], ["parvovirus-like particles", "PROBLEM", 15, 40], ["parvovirus", "OBSERVATION", 15, 25], ["like particles", "OBSERVATION_MODIFIER", 26, 40]]], ["Astrovirus-like particles appeared as small round, non-enveloped viruses of 27\u201330 nm in diameter with distinctive features due to small surface projections with a five to six point star-like appearance.", [["surface", "ANATOMY", 136, 143], ["Astrovirus", "ORGANISM", 0, 10], ["Astrovirus", "TEST", 0, 10], ["small round, non-enveloped viruses", "PROBLEM", 38, 72], ["distinctive features", "PROBLEM", 102, 122], ["small surface projections", "PROBLEM", 130, 155], ["small", "OBSERVATION_MODIFIER", 38, 43], ["round", "OBSERVATION_MODIFIER", 44, 49], ["non-enveloped", "OBSERVATION_MODIFIER", 51, 64], ["viruses", "OBSERVATION", 65, 72], ["27\u201330 nm", "OBSERVATION_MODIFIER", 76, 84], ["diameter", "OBSERVATION_MODIFIER", 88, 96], ["small", "OBSERVATION_MODIFIER", 130, 135], ["surface", "OBSERVATION_MODIFIER", 136, 143], ["five to six point", "OBSERVATION_MODIFIER", 163, 180], ["star", "OBSERVATION", 181, 185]]], ["Aggregation of viral particles was a common finding in the samples examined.", [["samples", "ANATOMY", 59, 66], ["samples", "CANCER", 59, 66], ["Aggregation of viral particles", "PROBLEM", 0, 30], ["the samples", "TEST", 55, 66], ["viral particles", "OBSERVATION", 15, 30]]], ["The difference in size (27\u201330 nm vs. 18\u201320 nm) permitted to easily discriminate between astrovirus and parvovirus (Fig. 1).", [["astrovirus and parvovirus", "DISEASE", 88, 113], ["astrovirus", "ORGANISM", 88, 98], ["parvovirus", "ORGANISM", 103, 113], ["The difference in size", "PROBLEM", 0, 22], ["astrovirus", "PROBLEM", 88, 98], ["parvovirus", "PROBLEM", 103, 113], ["difference", "OBSERVATION_MODIFIER", 4, 14], ["size", "OBSERVATION_MODIFIER", 18, 22], ["astrovirus", "OBSERVATION", 88, 98], ["parvovirus", "OBSERVATION", 103, 113]]], ["In 6/7 of the remaining samples, no virus particles were revealed by EM.", [["samples", "ANATOMY", 24, 31], ["samples", "CANCER", 24, 31], ["virus particles", "PROBLEM", 36, 51], ["no", "UNCERTAINTY", 33, 35]]], ["In one sample, parvovirus-like and coronavirus-like particles were detected.Case history and laboratory results ::: ResultsAstrovirus-positive samples by EM were submitted for virus isolation.", [["sample", "ANATOMY", 7, 13], ["samples", "ANATOMY", 143, 150], ["parvovirus-like", "ORGANISM", 15, 30], ["coronavirus", "ORGANISM", 35, 46], ["coronavirus", "SPECIES", 35, 46], ["one sample", "TEST", 3, 13], ["parvovirus", "TEST", 15, 25], ["coronavirus-like particles", "PROBLEM", 35, 61], ["ResultsAstrovirus", "TEST", 116, 133], ["virus isolation", "TREATMENT", 176, 191], ["parvovirus", "OBSERVATION", 15, 25], ["coronavirus", "OBSERVATION", 35, 46]]], ["Growth of astrovirus-like particles was not detected by EM in the cell cultures used in this study.", [["cell cultures", "ANATOMY", 66, 79], ["astrovirus", "ORGANISM", 10, 20], ["cell cultures", "CELL", 66, 79], ["cell cultures", "CELL_LINE", 66, 79], ["astrovirus", "PROBLEM", 10, 20], ["the cell cultures", "TEST", 62, 79], ["this study", "TEST", 88, 98], ["astrovirus", "OBSERVATION", 10, 20]]], ["In one sample (no. 8) rotavirus was isolated and identified by EM after two passages in cell cultures displaying CPE (Table 1).Case history and laboratory results ::: ResultsBacteriological cultures were not conclusive and analysis yielded negative results specifically for Salmonella spp., Yersinia spp. and Campylobacter spp.", [["sample", "ANATOMY", 7, 13], ["cell cultures", "ANATOMY", 88, 101], ["Campylobacter spp", "DISEASE", 309, 326], ["rotavirus", "ORGANISM", 22, 31], ["cell cultures", "CELL", 88, 101], ["Salmonella spp.", "ORGANISM", 274, 289], ["Yersinia spp.", "ORGANISM", 291, 304], ["Campylobacter spp", "ORGANISM", 309, 326], ["cell cultures", "CELL_LINE", 88, 101], ["Salmonella spp.", "SPECIES", 274, 289], ["Yersinia spp.", "SPECIES", 291, 304], ["rotavirus", "SPECIES", 22, 31], ["Salmonella spp.", "SPECIES", 274, 289], ["Yersinia spp.", "SPECIES", 291, 304], ["rotavirus", "PROBLEM", 22, 31], ["cell cultures", "TEST", 88, 101], ["CPE", "PROBLEM", 113, 116], ["Bacteriological cultures", "TEST", 174, 198], ["analysis", "TEST", 223, 231], ["Salmonella spp.", "PROBLEM", 274, 289], ["Yersinia spp.", "PROBLEM", 291, 304], ["Campylobacter spp", "PROBLEM", 309, 326], ["Campylobacter spp", "OBSERVATION", 309, 326]]], ["Parasitological examination revealed infestation by Toxocara canis in sample no. 11.RT-PCR and sequencing ::: ResultsAmplification products using s2m-AV12 primers were obtained only for the four samples found positive for astrovirus-like particles by EM and their identity was confirmed by sequencing.", [["samples", "ANATOMY", 195, 202], ["infestation by Toxocara canis", "DISEASE", 37, 66], ["Toxocara canis", "ORGANISM", 52, 66], ["s2m-AV12", "GENE_OR_GENE_PRODUCT", 146, 154], ["astrovirus", "ORGANISM", 222, 232], ["s2m-AV12 primers", "DNA", 146, 162], ["Toxocara canis", "SPECIES", 52, 66], ["Toxocara canis", "SPECIES", 52, 66], ["Parasitological examination", "TEST", 0, 27], ["infestation", "PROBLEM", 37, 48], ["Toxocara canis", "TEST", 52, 66], ["RT-PCR", "TEST", 84, 90], ["s2m-AV12 primers", "TREATMENT", 146, 162], ["the four samples", "TEST", 186, 202], ["astrovirus", "PROBLEM", 222, 232], ["infestation", "OBSERVATION", 37, 48], ["Toxocara canis", "OBSERVATION", 52, 66]]], ["Long-range RT-PCR products were sequenced as well and, by the adoption of the primer-walking strategy, sequences encompassing the C-terminal part of the viral polymerase as well as the entire capsid gene were generated for 2 out of 4 samples (namely, sample nos.", [["samples", "ANATOMY", 234, 241], ["C", "CHEMICAL", 130, 131], ["Long-range RT-PCR products", "DNA", 0, 26], ["C-terminal part", "DNA", 130, 145], ["viral polymerase", "PROTEIN", 153, 169], ["capsid gene", "DNA", 192, 203], ["Long-range RT-PCR products", "TREATMENT", 0, 26], ["viral polymerase", "OBSERVATION", 153, 169]]], ["3 and 8), and sequence encompassing almost the entire capsid gene (2487 nt) was generated for an additional sample (no. 6).", [["capsid gene", "DNA", 54, 65], ["2487 nt", "DNA", 67, 74], ["an additional sample", "TEST", 94, 114]]], ["Sequences have been deposited in GenBank database with accession numbers from FM213330 to FM213332.", [["FM213332", "CHEMICAL", 90, 98]]], ["The phylogenetic dendrograms for the partial ORF 2 (Fig. 2) and for ORF 1b were obtained through the alignment of 2443 and 346 nt, respectively.", [["ORF 1b", "GENE_OR_GENE_PRODUCT", 68, 74], ["partial ORF 2", "DNA", 37, 50], ["ORF 1b", "DNA", 68, 74], ["The phylogenetic dendrograms", "TEST", 0, 28], ["the partial ORF", "TEST", 33, 48], ["ORF 1b", "TEST", 68, 74], ["the alignment", "TEST", 97, 110]]], ["Based on the capsid gene sequences, similarity of 94.4% at nucleotide level was revealed among the astrovirus sequences in sample 3 and 8.", [["nucleotide", "CHEMICAL", 59, 69], ["nucleotide", "CHEMICAL", 59, 69], ["capsid gene sequences", "DNA", 13, 34], ["astrovirus sequences", "DNA", 99, 119], ["the capsid gene sequences", "TEST", 9, 34], ["similarity", "TEST", 36, 46], ["nucleotide level", "TEST", 59, 75], ["the astrovirus sequences", "TEST", 95, 119]]], ["Higher similarity (98.3%) was detected for the partial sequence related to ORF 1b.", [["ORF 1b", "GENE_OR_GENE_PRODUCT", 75, 81], ["ORF 1b", "DNA", 75, 81], ["the partial sequence", "PROBLEM", 43, 63]]], ["Sequences clustered in the clade of the Mamastroviruses, including viruses isolated or sequenced from mammalian hosts, but clearly grouped in a lineage separated from the astroviruses previously sequenced from feline, porcine, ovine, bat, mink and human hosts (Fig. 2).", [["Mamastroviruses", "GENE_OR_GENE_PRODUCT", 40, 55], ["feline", "ORGANISM", 210, 216], ["porcine", "ORGANISM", 218, 225], ["ovine", "ORGANISM", 227, 232], ["bat", "ORGANISM", 234, 237], ["mink", "ORGANISM", 239, 243], ["human", "ORGANISM", 248, 253], ["Mamastroviruses", "DNA", 40, 55], ["feline", "SPECIES", 210, 216], ["porcine", "SPECIES", 218, 225], ["ovine", "SPECIES", 227, 232], ["mink", "SPECIES", 239, 243], ["human", "SPECIES", 248, 253], ["ovine", "SPECIES", 227, 232], ["mink", "SPECIES", 239, 243], ["human", "SPECIES", 248, 253], ["Sequences", "TEST", 0, 9], ["viruses", "PROBLEM", 67, 74], ["the astroviruses", "PROBLEM", 167, 183], ["astroviruses", "OBSERVATION", 171, 183]]], ["Among the available sequences, the closest similarity for the capsid gene was found with HAstV7 (22%).", [["capsid gene", "DNA", 62, 73], ["HAstV7", "TEST", 89, 95]]], ["Similar findings and tree topology (data not shown) were observed for the analysis of the partial ORF1b sequences, with a closest similarity found with HAstV1 (59.4%).", [["ORF1b", "GENE_OR_GENE_PRODUCT", 98, 103], ["ORF1b sequences", "DNA", 98, 113], ["the analysis", "TEST", 70, 82], ["the partial ORF1b sequences", "TEST", 86, 113], ["a closest similarity", "TEST", 120, 140], ["HAstV1", "TEST", 152, 158], ["tree", "OBSERVATION_MODIFIER", 21, 25]]], ["However no sequence information is available for the feline or porcine astroviruses in the part of the polymerase sequenced for the present work.RT-PCR and sequencing ::: ResultsThe dog astrovirus was found to have an in-frame start codon for capsid precursor protein 180 nt upstream of the start codon homologous to other Mamastrovirus genomes.", [["feline", "ORGANISM", 53, 59], ["dog", "ORGANISM", 182, 185], ["astrovirus", "ORGANISM", 186, 196], ["in-frame start codon", "DNA", 218, 238], ["capsid precursor protein", "PROTEIN", 243, 267], ["start codon", "DNA", 291, 302], ["Mamastrovirus genomes", "DNA", 323, 344], ["dog", "SPECIES", 182, 185], ["dog astrovirus", "SPECIES", 182, 196], ["sequence information", "TEST", 11, 31], ["porcine astroviruses", "PROBLEM", 63, 83], ["the polymerase", "TEST", 99, 113], ["RT-PCR", "TEST", 145, 151], ["The dog astrovirus", "PROBLEM", 178, 196], ["codon", "TREATMENT", 233, 238], ["capsid precursor protein", "TREATMENT", 243, 267], ["codon homologous", "TREATMENT", 297, 313]]], ["This leads to an overlapping reading frame for the C-terminal part of the polymerase and the N-part of the capsid precursor of 62 amino acids (Fig. 3).", [["amino acids", "CHEMICAL", 130, 141], ["C", "CHEMICAL", 51, 52], ["amino acids", "CHEMICAL", 130, 141], ["amino acids", "AMINO_ACID", 130, 141], ["overlapping reading frame", "DNA", 17, 42], ["C-terminal part", "PROTEIN", 51, 66], ["polymerase", "PROTEIN", 74, 84], ["N-part", "PROTEIN", 93, 99], ["capsid precursor", "PROTEIN", 107, 123], ["amino acids", "TEST", 130, 141]]], ["Amino acid sequence analysis of this N-terminal additional peptide predicted a transmembrane domain (data not shown).RT-PCR and sequencing ::: ResultsThe s2m feature of the canine astrovirus was somewhat different from all other described s2m, having a longer stem-part, but all conserved residues involved in the structure of this motif were still conserved (Robertson et al., 2005).Discussion and conclusionsDescription of virus particles resembling astroviruses in canine faeces is sporadic and consisting only in three reports from Australia, Germany and USA (Marshall et al., 1984a, Vieler and Herbst, 1995, Williams, 1980).", [["transmembrane", "ANATOMY", 79, 92], ["faeces", "ANATOMY", 475, 481], ["Amino acid", "CHEMICAL", 0, 10], ["astroviruses", "DISEASE", 452, 464], ["Amino acid", "CHEMICAL", 0, 10], ["N", "CHEMICAL", 37, 38], ["Amino acid", "AMINO_ACID", 0, 10], ["s2m", "GENE_OR_GENE_PRODUCT", 154, 157], ["canine", "ORGANISM", 173, 179], ["astrovirus", "ORGANISM", 180, 190], ["s2m", "GENE_OR_GENE_PRODUCT", 239, 242], ["astroviruses", "CANCER", 452, 464], ["canine", "ORGANISM", 468, 474], ["transmembrane domain", "PROTEIN", 79, 99], ["canine", "SPECIES", 173, 179], ["canine", "SPECIES", 468, 474], ["canine astrovirus", "SPECIES", 173, 190], ["canine", "SPECIES", 468, 474], ["Amino acid sequence analysis", "TEST", 0, 28], ["this N", "TEST", 32, 38], ["terminal additional peptide", "PROBLEM", 39, 66], ["a transmembrane domain", "TEST", 77, 99], ["RT-PCR", "TEST", 117, 123], ["the canine astrovirus", "PROBLEM", 169, 190], ["virus particles", "PROBLEM", 425, 440], ["astroviruses in canine faeces", "PROBLEM", 452, 481], ["s2m", "OBSERVATION_MODIFIER", 154, 157], ["canine astrovirus", "OBSERVATION", 173, 190], ["residues", "OBSERVATION", 289, 297], ["virus particles", "OBSERVATION", 425, 440], ["astroviruses", "OBSERVATION", 452, 464]]], ["Astroviruses have been previously observed in dogs with diarrhoea, but Marshall et al., 1984a, Marshall et al., 1984b reported astrovirus-like particles also in asymptomatic puppies.", [["diarrhoea", "DISEASE", 56, 65], ["Astroviruses", "GENE_OR_GENE_PRODUCT", 0, 12], ["dogs", "ORGANISM", 46, 50], ["astrovirus", "ORGANISM", 127, 137], ["puppies", "ORGANISM_SUBDIVISION", 174, 181], ["dogs", "SPECIES", 46, 50], ["Astroviruses", "PROBLEM", 0, 12], ["diarrhoea", "PROBLEM", 56, 65], ["astrovirus", "PROBLEM", 127, 137], ["asymptomatic puppies", "PROBLEM", 161, 181], ["asymptomatic", "OBSERVATION_MODIFIER", 161, 173], ["puppies", "OBSERVATION", 174, 181]]], ["Based on the anamnestic records (i.e. previous antibiotic and anti-helminthic treatments) and laboratory results (i.e. presence of co-infections with parvovirus, rotavirus and T. canis) presented in this paper, it was not possible to associate the presence of astroviruses with the enteric disease.", [["co-infections", "DISEASE", 131, 144], ["parvovirus, rotavirus and T. canis", "DISEASE", 150, 184], ["astroviruses", "DISEASE", 260, 272], ["enteric disease", "DISEASE", 282, 297], ["parvovirus", "ORGANISM", 150, 160], ["rotavirus", "ORGANISM", 162, 171], ["T. canis", "ORGANISM", 176, 184], ["astroviruses", "CANCER", 260, 272], ["T. canis", "SPECIES", 176, 184], ["rotavirus", "SPECIES", 162, 171], ["T. canis", "SPECIES", 176, 184], ["previous antibiotic", "TREATMENT", 38, 57], ["anti-helminthic treatments", "TREATMENT", 62, 88], ["laboratory results", "TEST", 94, 112], ["co-infections", "PROBLEM", 131, 144], ["parvovirus", "PROBLEM", 150, 160], ["rotavirus", "PROBLEM", 162, 171], ["T. canis", "PROBLEM", 176, 184], ["astroviruses", "PROBLEM", 260, 272], ["the enteric disease", "PROBLEM", 278, 297], ["astroviruses", "OBSERVATION", 260, 272], ["enteric", "ANATOMY", 282, 289], ["disease", "OBSERVATION", 290, 297]]], ["However, based on the results presented herein, their role in the aetiology of canine enteric diseases should be considered and investigate further.Discussion and conclusionsUnfortunately, the isolation attempts in continuous cell lines failed, confirming the difficulties to in vitro replicate astroviruses reported in the literature (Chu et al., 2008, Moser and Schultz-Cherry, 2005).", [["cell lines", "ANATOMY", 226, 236], ["enteric diseases", "DISEASE", 86, 102], ["astroviruses", "DISEASE", 295, 307], ["canine", "ORGANISM", 79, 85], ["cell lines", "CELL", 226, 236], ["continuous cell lines", "CELL_LINE", 215, 236], ["canine", "SPECIES", 79, 85], ["canine enteric diseases", "PROBLEM", 79, 102], ["the isolation attempts", "TREATMENT", 189, 211], ["continuous cell lines", "TREATMENT", 215, 236], ["the difficulties to in vitro replicate astroviruses", "PROBLEM", 256, 307], ["cell lines", "OBSERVATION", 226, 236], ["astroviruses", "OBSERVATION", 295, 307]]], ["However, RT-PCR and sequencing could confirm the EM identification in 4/4 cases, allowing the correct identification and the genetic characterization of astroviruses in dogs.Discussion and conclusionsIn some mammalian species, the detection of astroviruses in clinical samples, such as faeces, is considered a common finding.", [["samples", "ANATOMY", 269, 276], ["faeces", "ANATOMY", 286, 292], ["astroviruses", "DISEASE", 153, 165], ["astroviruses", "CANCER", 153, 165], ["dogs", "ORGANISM", 169, 173], ["astroviruses", "GENE_OR_GENE_PRODUCT", 244, 256], ["samples", "CANCER", 269, 276], ["faeces", "ORGANISM_SUBDIVISION", 286, 292], ["dogs", "SPECIES", 169, 173], ["RT-PCR", "TEST", 9, 15], ["the EM identification", "TEST", 45, 66], ["the correct identification", "TEST", 90, 116], ["the genetic characterization", "TEST", 121, 149], ["astroviruses in dogs", "PROBLEM", 153, 173], ["astroviruses", "PROBLEM", 244, 256], ["clinical samples", "TEST", 260, 276], ["astroviruses", "OBSERVATION", 153, 165], ["mammalian species", "OBSERVATION", 208, 225], ["astroviruses", "OBSERVATION", 244, 256]]], ["In humans, these viruses are considered one of the most common causes of diarrhoea in children (Walter and Mitchell, 2003).", [["diarrhoea", "DISEASE", 73, 82], ["humans", "ORGANISM", 3, 9], ["children", "ORGANISM", 86, 94], ["humans", "SPECIES", 3, 9], ["children", "SPECIES", 86, 94], ["humans", "SPECIES", 3, 9], ["diarrhoea", "PROBLEM", 73, 82], ["viruses", "OBSERVATION", 17, 24], ["most common", "OBSERVATION_MODIFIER", 51, 62], ["diarrhoea", "OBSERVATION", 73, 82]]], ["Very recently, astrovirus detection rates up to 100% have been reported in insectivorous bats in Hong Kong (Chu et al., 2008).", [["astrovirus", "ORGANISM", 15, 25], ["astrovirus detection rates", "PROBLEM", 15, 41]]], ["On the contrary, in other species such as dogs or cats, their detection appears very sporadic.", [["dogs", "ORGANISM", 42, 46], ["cats", "ORGANISM", 50, 54], ["dogs", "SPECIES", 42, 46], ["cats", "SPECIES", 50, 54], ["very sporadic", "PROBLEM", 80, 93], ["very", "OBSERVATION_MODIFIER", 80, 84], ["sporadic", "OBSERVATION", 85, 93]]], ["Whether this is due to a true lower prevalence or to the fact that they are simply under-detected remains questionable and further analysis should be conducted to increase our understanding of the epidemiology of this infection in domestic carnivores.Discussion and conclusionsThe canine astrovirus displayed some unique genomic features, including a possible upstream start for the capsid precursor protein.", [["infection", "DISEASE", 218, 227], ["astrovirus", "DISEASE", 288, 298], ["canine astrovirus", "ORGANISM", 281, 298], ["upstream start", "DNA", 360, 374], ["capsid precursor protein", "PROTEIN", 383, 407], ["canine", "SPECIES", 281, 287], ["canine astrovirus", "SPECIES", 281, 298], ["a true lower prevalence", "PROBLEM", 23, 46], ["further analysis", "TEST", 123, 139], ["this infection", "PROBLEM", 213, 227], ["The canine astrovirus", "PROBLEM", 277, 298], ["the capsid precursor protein", "PROBLEM", 379, 407], ["infection", "OBSERVATION", 218, 227], ["astrovirus", "OBSERVATION", 288, 298]]], ["None of the possible start codons for the capsid precursor were in an optimal context for translation initiation as proposed by Kozak (1989), as they both lack a purine at position-3, but the most upstream codon did have a context most resembling the consensus vertebrate sequence around start codons GCCRCCAUGG (Kozak, 1989).", [["purine", "CHEMICAL", 162, 168], ["purine", "CHEMICAL", 162, 168], ["purine", "SIMPLE_CHEMICAL", 162, 168], ["position-3", "GENE_OR_GENE_PRODUCT", 172, 182], ["start codons", "DNA", 21, 33], ["capsid precursor", "PROTEIN", 42, 58], ["position-3", "DNA", 172, 182], ["upstream codon", "DNA", 197, 211], ["consensus vertebrate sequence", "DNA", 251, 280], ["start codons", "DNA", 288, 300], ["the capsid precursor", "PROBLEM", 38, 58]]], ["The canine astrovirus genome, however, displayed the very conserved region right upstream of the Mamastrovirus-homologous start codon, that could be involved in subgenomic RNA transcription (Jonassen et al., 2003), and it is therefore not clear if a subgenomic RNA spanning the first initiation codon is synthesised.", [["canine astrovirus", "ORGANISM", 4, 21], ["Mamastrovirus", "GENE_OR_GENE_PRODUCT", 97, 110], ["canine astrovirus genome", "DNA", 4, 28], ["Mamastrovirus-homologous start codon", "DNA", 97, 133], ["subgenomic RNA", "RNA", 161, 175], ["subgenomic RNA", "RNA", 250, 264], ["first initiation codon", "DNA", 278, 300], ["canine", "SPECIES", 4, 10], ["canine astrovirus", "SPECIES", 4, 21], ["The canine astrovirus genome", "PROBLEM", 0, 28], ["a subgenomic RNA", "PROBLEM", 248, 264], ["astrovirus genome", "OBSERVATION", 11, 28], ["region", "ANATOMY_MODIFIER", 68, 74], ["right", "ANATOMY_MODIFIER", 75, 80]]], ["However, the fact that a functional domain could be predicted for the additional N-terminal peptide could suggest that longer transcripts actually are translated.", [["N", "CHEMICAL", 81, 82], ["a functional domain", "PROBLEM", 23, 42], ["the additional N-terminal peptide", "TREATMENT", 66, 99]]], ["The role of the transmembrane domain and membrane localisation of the resulting protein would still need to be elucidated.Discussion and conclusionsThe phylogenetic analysis clearly clustered canine astroviruses in the genus Mamastrovirus, in a well defined and distinct branch of the phylogenetic tree.", [["transmembrane", "ANATOMY", 16, 29], ["membrane", "ANATOMY", 41, 49], ["transmembrane", "CELLULAR_COMPONENT", 16, 29], ["membrane", "CELLULAR_COMPONENT", 41, 49], ["canine", "ORGANISM", 192, 198], ["transmembrane domain", "PROTEIN", 16, 36], ["the transmembrane domain", "TEST", 12, 36], ["the resulting protein", "PROBLEM", 66, 87], ["The phylogenetic analysis", "TEST", 148, 173], ["clustered canine astroviruses in the genus Mamastrovirus", "PROBLEM", 182, 238], ["clustered", "OBSERVATION_MODIFIER", 182, 191], ["canine astroviruses", "OBSERVATION", 192, 211], ["genus Mamastrovirus", "ANATOMY", 219, 238], ["well defined", "OBSERVATION_MODIFIER", 245, 257], ["distinct", "OBSERVATION_MODIFIER", 262, 270], ["branch", "ANATOMY_MODIFIER", 271, 277], ["phylogenetic tree", "OBSERVATION", 285, 302]]], ["The relatively closest similarities were revealed with a cluster comprising human, porcine and feline astroviruses, based on the ORF2 sequences available.Discussion and conclusionsBased on the species definition for astroviruses (Fauquet et al., 2005) and on the data obtained in this study, we suggest a new species of astrovirus (canine astrovirus, CaAstV) to be included in the genus Mamastrovirus.", [["astroviruses", "ANATOMY", 102, 114], ["astrovirus", "DISEASE", 320, 330], ["human", "ORGANISM", 76, 81], ["porcine", "ORGANISM", 83, 90], ["feline", "ORGANISM", 95, 101], ["astroviruses", "CANCER", 102, 114], ["astrovirus", "ORGANISM", 320, 330], ["canine astrovirus", "ORGANISM", 332, 349], ["CaAstV", "GENE_OR_GENE_PRODUCT", 351, 357], ["ORF2 sequences", "DNA", 129, 143], ["human", "SPECIES", 76, 81], ["porcine", "SPECIES", 83, 90], ["feline", "SPECIES", 95, 101], ["canine astrovirus", "SPECIES", 332, 349], ["human", "SPECIES", 76, 81], ["canine astrovirus", "SPECIES", 332, 349], ["a cluster comprising human, porcine and feline astroviruses", "PROBLEM", 55, 114], ["the ORF2 sequences", "TEST", 125, 143], ["astroviruses", "PROBLEM", 216, 228], ["this study", "TEST", 280, 290], ["astrovirus (canine astrovirus", "PROBLEM", 320, 349], ["feline astroviruses", "OBSERVATION", 95, 114], ["genus Mamastrovirus", "ANATOMY", 381, 400]]]], "6049f1c151fa95bc40deaf050225dd7a00880171": [["IntroductionInfluenza A virus (IAV), a member of the genus Orthomyxovirus, causes a highly contagious respiratory disease in avian species and mammals [1] .", [["respiratory", "ANATOMY", 102, 113], ["Influenza A virus", "DISEASE", 12, 29], ["respiratory disease", "DISEASE", 102, 121], ["Influenza A virus", "ORGANISM", 12, 29], ["IAV", "ORGANISM", 31, 34], ["Influenza A virus", "SPECIES", 12, 29], ["Influenza A virus", "SPECIES", 12, 29], ["IAV", "SPECIES", 31, 34], ["IntroductionInfluenza A virus", "PROBLEM", 0, 29], ["a highly contagious respiratory disease", "PROBLEM", 82, 121], ["highly", "OBSERVATION_MODIFIER", 84, 90], ["contagious", "OBSERVATION_MODIFIER", 91, 101], ["respiratory disease", "OBSERVATION", 102, 121]]], ["Except for influenza H17 and H18 viruses that originated from bats, the waterfowl are known as a primordial reservoir for all subtypes of IAV [1, 2] .", [["influenza H17", "ORGANISM", 11, 24], ["H18 viruses", "ORGANISM", 29, 40], ["influenza H17", "PROBLEM", 11, 24], ["H18 viruses", "PROBLEM", 29, 40], ["a primordial reservoir", "TREATMENT", 95, 117], ["influenza", "OBSERVATION", 11, 20]]], ["Unlike human influenza viruses, avian influenza (AI) viruses are classified into two pathotypes-low pathogenic avian influenza (LPAI) and HPAI-based on the pathogenicity in chickens and molecular determinants of the multibasic cleavage site motif in the hemagglutinin (HA) protein [3, 4] .", [["influenza viruses", "DISEASE", 13, 30], ["avian influenza (AI) viruses", "DISEASE", 32, 60], ["avian influenza", "DISEASE", 111, 126], ["LPAI", "DISEASE", 128, 132], ["HPAI", "DISEASE", 138, 142], ["human influenza viruses", "ORGANISM", 7, 30], ["avian influenza (AI) viruses", "ORGANISM", 32, 60], ["avian influenza", "ORGANISM", 111, 126], ["LPAI", "ORGANISM", 128, 132], ["chickens", "ORGANISM", 173, 181], ["hemagglutinin (HA)", "GENE_OR_GENE_PRODUCT", 254, 272], ["multibasic cleavage site motif", "DNA", 216, 246], ["hemagglutinin (HA) protein", "PROTEIN", 254, 280], ["human", "SPECIES", 7, 12], ["avian influenza", "SPECIES", 32, 47], ["avian influenza", "SPECIES", 111, 126], ["chickens", "SPECIES", 173, 181], ["human influenza viruses", "SPECIES", 7, 30], ["LPAI", "SPECIES", 128, 132], ["chickens", "SPECIES", 173, 181], ["human influenza viruses", "PROBLEM", 7, 30], ["avian influenza (AI) viruses", "PROBLEM", 32, 60], ["low pathogenic avian influenza (LPAI)", "PROBLEM", 96, 133], ["HPAI", "PROBLEM", 138, 142], ["the pathogenicity in chickens", "PROBLEM", 152, 181], ["the multibasic cleavage site", "PROBLEM", 212, 240], ["the hemagglutinin (HA) protein", "TEST", 250, 280], ["influenza viruses", "OBSERVATION", 13, 30]]], ["During the circulation of HPAI virus subtypes H5Nx and H7Nx in poultry, they proved to be highly pathogenic with mortality of up to 100%.", [["HPAI virus subtypes H5Nx", "ORGANISM", 26, 50], ["HPAI virus", "SPECIES", 26, 36], ["H7Nx", "SPECIES", 55, 59], ["poultry", "SPECIES", 63, 70], ["HPAI virus subtypes H5Nx", "PROBLEM", 26, 50]]], ["Sporadically, the H5N1 HPAI viruses cross the species barrier into humans.", [["H5N1 HPAI viruses", "ORGANISM", 18, 35], ["humans", "ORGANISM", 67, 73], ["H5N1 HPAI", "SPECIES", 18, 27], ["humans", "SPECIES", 67, 73], ["H5N1 HPAI viruses", "SPECIES", 18, 35], ["humans", "SPECIES", 67, 73], ["the H5N1 HPAI viruses", "PROBLEM", 14, 35], ["H5N1", "OBSERVATION", 18, 22]]], ["According to the WHO report [5] , different subtypes of H5 HPAI viruses pose a substantial threat to global health with high mortality rate and huge economic burden to poultry farms.IntroductionOutbreaks of H5Nx HPAI viruses in poultry are increasing, and numerous clades of H5Nx HPAI have been classified since the first detection of the goose/Guangdong (Gs/GD) H5N1 HPAI virus in China [6] .", [["HPAI viruses", "DISEASE", 59, 71], ["HPAI viruses", "DISEASE", 212, 224], ["HPAI", "DISEASE", 280, 284], ["H5N1 HPAI virus", "DISEASE", 363, 378], ["H5 HPAI viruses", "ORGANISM", 56, 71], ["H5Nx HPAI viruses", "ORGANISM", 207, 224], ["H5Nx HPAI", "ORGANISM", 275, 284], ["goose", "ORGANISM", 339, 344], ["Gs/GD) H5N1 HPAI virus", "ORGANISM", 356, 378], ["HPAI", "SPECIES", 280, 284], ["goose", "SPECIES", 339, 344], ["H5N1 HPAI virus", "SPECIES", 363, 378], ["H5 HPAI viruses", "SPECIES", 56, 71], ["goose/Guangdong (Gs/GD) H5N1 HPAI virus", "SPECIES", 339, 378], ["H5 HPAI viruses", "PROBLEM", 56, 71], ["high mortality rate", "PROBLEM", 120, 139], ["huge economic burden", "PROBLEM", 144, 164], ["H5Nx HPAI viruses", "PROBLEM", 207, 224], ["HPAI", "PROBLEM", 280, 284], ["H5N1 HPAI virus", "PROBLEM", 363, 378], ["huge", "OBSERVATION_MODIFIER", 144, 148], ["economic", "OBSERVATION_MODIFIER", 149, 157], ["burden", "OBSERVATION", 158, 164], ["HPAI viruses", "OBSERVATION", 212, 224], ["poultry", "OBSERVATION_MODIFIER", 228, 235], ["increasing", "OBSERVATION_MODIFIER", 240, 250], ["numerous", "OBSERVATION_MODIFIER", 256, 264], ["clades", "OBSERVATION_MODIFIER", 265, 271]]], ["However, the Gs/GD viruses and other IAVs have reassorted and diversified into 10 separate clades with more than 30 classified higher-order clades identified so far [7] .", [["Gs", "GENE_OR_GENE_PRODUCT", 13, 15], ["IAVs", "GENE_OR_GENE_PRODUCT", 37, 41], ["Gs", "PROTEIN", 13, 15], ["the Gs/GD viruses", "PROBLEM", 9, 26]]], ["In particular, among the reassortment of novel H5Nx HPAI viruses, 2.3.2.1 and 2.3.4.4 clades of H5 HPAI viruses have become endemic in poultry populations in Asian countries, such as China, Vietnam, and South Korea [8, 9] .", [["HPAI viruses", "DISEASE", 99, 111], ["H5Nx HPAI viruses", "ORGANISM", 47, 64], ["H5 HPAI viruses", "ORGANISM", 96, 111], ["H5 HPAI viruses", "SPECIES", 96, 111], ["H5Nx HPAI viruses", "SPECIES", 47, 64], ["H5 HPAI viruses", "SPECIES", 96, 111], ["novel H5Nx HPAI viruses", "PROBLEM", 41, 64], ["H5 HPAI viruses", "PROBLEM", 96, 111], ["HPAI viruses", "OBSERVATION", 99, 111], ["endemic", "OBSERVATION_MODIFIER", 124, 131]]], ["The novel H5Nx viruses have reassorted with different NA subtypes, such as H5N2, H5N5, H5N6, and H5N8, in poultry and migratory birds [10] .", [["H5N2, H5N5, H5N6, and H5N8", "DISEASE", 75, 101], ["H5Nx viruses", "ORGANISM", 10, 22], ["H5N2", "ORGANISM", 75, 79], ["H5N5", "SPECIES", 81, 85], ["H5N6", "SPECIES", 87, 91], ["H5N8", "SPECIES", 97, 101], ["The novel H5Nx viruses", "PROBLEM", 0, 22], ["different NA subtypes", "PROBLEM", 44, 65], ["H5N2", "PROBLEM", 75, 79], ["H5N5", "TREATMENT", 81, 85], ["H5N6", "TREATMENT", 87, 91], ["H5N8", "TREATMENT", 97, 101]]], ["The interaction between poultry and migratory wild birds and the complex overlapping flyways contribute to their long distance virus transmission [11] .", [["flyways", "CANCER", 85, 92]]], ["In addition, there was an outbreak of the H5 clade 2.3.4.4 virus around the East Asian-Australasian and American flyways in recent years [13] [14] [15] .", [["H5 clade 2.3.4.4 virus", "SPECIES", 42, 64], ["the H5 clade", "TREATMENT", 38, 50]]], ["Furthermore, these lineage viruses with different antigenic properties have been cocirculating.", [["these lineage viruses", "PROBLEM", 13, 34], ["lineage viruses", "OBSERVATION", 19, 34], ["different", "OBSERVATION_MODIFIER", 40, 49], ["antigenic properties", "OBSERVATION", 50, 70]]], ["Thus, rapid and highly accurate methods are necessary for the detection of H5 HPAI viruses and clade identification.IntroductionMolecular diagnostic methods are used as the first step in the identification and control of the IAV outbreaks.", [["H5 HPAI viruses", "ORGANISM", 75, 90], ["H5 HPAI viruses", "SPECIES", 75, 90], ["IAV", "SPECIES", 225, 228], ["the detection", "TEST", 58, 71], ["H5 HPAI viruses", "PROBLEM", 75, 90], ["the identification", "TEST", 187, 205], ["the IAV outbreaks", "PROBLEM", 221, 238], ["IAV", "OBSERVATION", 225, 228]]], ["Thus, a number of molecular methods, such as DNA microarrays [16] , loop-mediated isothermal amplification tests [17] , and restriction fragment mass analysis [18] , have been developed and applied for rapid HA subtyping of the IAV field isolates [19] .", [["DNA", "CELLULAR_COMPONENT", 45, 48], ["molecular methods", "TREATMENT", 18, 35], ["DNA microarrays", "TEST", 45, 60], ["loop-mediated isothermal amplification tests", "TEST", 68, 112], ["restriction fragment mass analysis", "TEST", 124, 158], ["rapid HA subtyping", "TREATMENT", 202, 220], ["fragment", "OBSERVATION_MODIFIER", 136, 144], ["mass", "OBSERVATION", 145, 149]]], ["Among these methods, RT-qPCR has been implemented in most reference diagnostics laboratories for the detection and characterization of IAVs.", [["IAVs", "DISEASE", 135, 139], ["IAVs", "CANCER", 135, 139], ["the detection", "TEST", 97, 110], ["IAVs", "PROBLEM", 135, 139], ["IAVs", "OBSERVATION", 135, 139]]], ["These diagnostic techniques were developed and used for subtyping or sequencing of novel viruses.", [["These diagnostic techniques", "TEST", 0, 27], ["novel viruses", "PROBLEM", 83, 96]]], ["However, due to the continuous circulation of H5Nx HPAI and other virus clades in avian species, it is very difficult to control viral transmission in poultry [3] .", [["HPAI", "DISEASE", 51, 55], ["H5Nx HPAI", "ORGANISM", 46, 55], ["HPAI", "PROBLEM", 51, 55], ["other virus clades in avian species", "PROBLEM", 60, 95]]], ["To effectively control and rapidly diagnose suspected infection on poultry farms, it is important to develop a rapid diagnostic assay for the simultaneous detection of different H5 HPAI viruses [20] .IntroductionIn this study, we tested our one-step multiplex method using clinical poultry samples to simultaneously detect pan-HPAI and two H5 clades.", [["samples", "ANATOMY", 290, 297], ["infection", "DISEASE", 54, 63], ["H5 HPAI", "ORGANISM", 178, 185], ["pan-HPAI", "PROTEIN", 323, 331], ["poultry", "SPECIES", 67, 74], ["H5 HPAI viruses", "SPECIES", 178, 193], ["infection on poultry farms", "PROBLEM", 54, 80], ["a rapid diagnostic assay", "TEST", 109, 133], ["the simultaneous detection", "TEST", 138, 164], ["different H5 HPAI viruses", "PROBLEM", 168, 193], ["this study", "TEST", 215, 225], ["pan-HPAI", "TREATMENT", 323, 331], ["infection", "OBSERVATION", 54, 63]]], ["Thus, our one-step multiplex RT-qPCR assay can be used for the screening of virus-infected field samples.Reference Viruses and Field Samples CollectionA total of 15 reference influenza virus samples were obtained from the Korea Research Institute of Bioscience and Biotechnology (KRIBB) and National Vietnam University of Agriculture.", [["samples", "ANATOMY", 97, 104], ["influenza virus", "SPECIES", 175, 190], ["qPCR assay", "TEST", 32, 42], ["the screening", "TEST", 59, 72], ["virus", "PROBLEM", 76, 81], ["infected field samples", "PROBLEM", 82, 104], ["Field Samples", "TEST", 127, 140], ["influenza virus samples", "TEST", 175, 198]]], ["Coronavirus-229E and parainfluenza virus 1 were purchased from the Korea Bank for Pathogenic Viruses.", [["Coronavirus-229E", "CHEMICAL", 0, 16], ["Pathogenic Viruses", "DISEASE", 82, 100], ["Coronavirus-229E", "ORGANISM", 0, 16], ["parainfluenza virus 1", "ORGANISM", 21, 42], ["parainfluenza virus 1", "SPECIES", 21, 42], ["Coronavirus-229E", "SPECIES", 0, 16], ["parainfluenza virus 1", "SPECIES", 21, 42], ["Coronavirus", "TEST", 0, 11], ["parainfluenza virus", "PROBLEM", 21, 40], ["Pathogenic Viruses", "PROBLEM", 82, 100], ["Pathogenic Viruses", "OBSERVATION", 82, 100]]], ["Newcastle disease virus (VN1) and Infectious bronchitis virus (VNUA3) were kindly supported by Dr. Le Van Phan (National Vietnam University of Agriculture).", [["Newcastle disease", "DISEASE", 0, 17], ["Infectious bronchitis virus", "DISEASE", 34, 61], ["Newcastle disease virus", "ORGANISM", 0, 23], ["VN1", "ORGANISM", 25, 28], ["Infectious bronchitis virus", "ORGANISM", 34, 61], ["Newcastle disease virus", "SPECIES", 0, 23], ["Infectious bronchitis virus", "SPECIES", 34, 61], ["Newcastle disease virus", "SPECIES", 0, 23], ["VN1", "SPECIES", 25, 28], ["Infectious bronchitis virus", "SPECIES", 34, 61], ["Newcastle disease virus (VN1)", "PROBLEM", 0, 29], ["Infectious bronchitis virus", "PROBLEM", 34, 61], ["disease", "OBSERVATION", 10, 17], ["Infectious", "OBSERVATION_MODIFIER", 34, 44], ["bronchitis", "OBSERVATION", 45, 55]]], ["All the reference influenza viruses were propagated in the allantoic fluid of 9-11 days old embryonated specific pathogen-free chicken eggs.", [["allantoic fluid", "ANATOMY", 59, 74], ["eggs", "ANATOMY", 135, 139], ["influenza viruses", "ORGANISM", 18, 35], ["allantoic fluid", "MULTI-TISSUE_STRUCTURE", 59, 74], ["chicken", "ORGANISM", 127, 134], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 135, 139], ["chicken", "SPECIES", 127, 134], ["chicken", "SPECIES", 127, 134], ["All the reference influenza viruses", "PROBLEM", 0, 35], ["the allantoic fluid", "TEST", 55, 74], ["embryonated specific pathogen", "PROBLEM", 92, 121], ["influenza viruses", "OBSERVATION", 18, 35]]], ["Field samples obtained from 12 farms in Vietnam were taken from domestic chickens with signs of respiratory illness in 2016 to 2018.", [["samples", "ANATOMY", 6, 13], ["respiratory", "ANATOMY", 96, 107], ["respiratory illness", "DISEASE", 96, 115], ["Field samples", "CANCER", 0, 13], ["chickens", "ORGANISM", 73, 81], ["chickens", "SPECIES", 73, 81], ["chickens", "SPECIES", 73, 81], ["Field samples", "TEST", 0, 13], ["respiratory illness", "PROBLEM", 96, 115], ["respiratory illness", "OBSERVATION", 96, 115]]], ["For the screening of influenza positive field samples, all filed samples were analyzed using M-gene-specific RT-qPCR according to the WHO manual on animal influenza diagnosis and surveillance [21] , and only M-gene positive field samples were used in the present study.Primer and Probe DesignTo detect the pan-H5 HPAI-specific and HPAI clade-specific probes, H5Nx HA gene sequences of 1018 low pathogenic and 4301 highly pathogenic avian influenza viruses from the GenBank database of the National Center for Biotechnology Information or Influenza Research Database (IRD, www.fludb.org) were analyzed, and complementary sequences were designed using ClustalW in BioEdit software (7.2 version) to identify conserved regions.", [["samples", "ANATOMY", 46, 53], ["samples", "ANATOMY", 65, 72], ["samples", "ANATOMY", 230, 237], ["avian influenza viruses", "DISEASE", 432, 455], ["samples", "CANCER", 65, 72], ["pan-H5", "GENE_OR_GENE_PRODUCT", 306, 312], ["H5Nx HA", "GENE_OR_GENE_PRODUCT", 359, 366], ["avian influenza viruses", "ORGANISM", 432, 455], ["Probe DesignTo", "DNA", 280, 294], ["pan-H5 HPAI-specific and HPAI clade-specific probes", "DNA", 306, 357], ["H5Nx HA gene sequences", "DNA", 359, 381], ["complementary sequences", "DNA", 606, 629], ["avian influenza viruses", "SPECIES", 432, 455], ["the screening", "TEST", 4, 17], ["influenza", "PROBLEM", 21, 30], ["all filed samples", "TEST", 55, 72], ["surveillance", "TEST", 179, 191], ["the present study", "TEST", 251, 268], ["the pan-H5 HPAI", "TEST", 302, 317], ["HPAI clade", "TEST", 331, 341], ["specific probes", "TEST", 342, 357], ["H5Nx HA gene sequences", "TEST", 359, 381], ["low pathogenic", "PROBLEM", 390, 404], ["highly pathogenic avian influenza viruses", "PROBLEM", 414, 455]]], ["The All amplicons obtained using one set of HA primers were 201 base pairs in length.Sensitivity Analyses of One-Step Multiplex RT-qPCR AnalysisTo assess the reaction efficiency and limit of detection of our multiplex qPCR assay, viral H5-HA gene was synthesized using the full-length H5-HA gene sequence from A/environment/Korea/W150/2006 for HPAI detection, A/Environment/Korea/W541/2016 for clade 2.3.4.4 detection, or A/wild bird/Jiangsu/H184/2015 for clade 2.3.2.1 detection and cloned using the Mighty TA cloning kit according to the manufacturer's recommendations.", [["HA", "GENE_OR_GENE_PRODUCT", 239, 241], ["HA primers", "DNA", 44, 54], ["viral H5-HA gene", "DNA", 230, 246], ["full-length H5-HA gene sequence", "DNA", 273, 304], ["HPAI", "SPECIES", 344, 348], ["A/Environment/Korea/W541/2016", "SPECIES", 360, 389], ["A/wild bird/Jiangsu/H184/2015", "SPECIES", 422, 451], ["The All amplicons", "TREATMENT", 0, 17], ["HA primers", "TREATMENT", 44, 54], ["Sensitivity Analyses", "TEST", 85, 105], ["One-Step Multiplex RT", "TEST", 109, 130], ["the reaction efficiency", "PROBLEM", 154, 177], ["our multiplex qPCR assay", "TEST", 204, 228], ["viral H5-HA gene", "PROBLEM", 230, 246], ["the full-length H5-HA gene sequence", "TREATMENT", 269, 304], ["HPAI detection", "TEST", 344, 358], ["clade", "TEST", 394, 399], ["the Mighty TA cloning kit", "TREATMENT", 497, 522], ["length", "OBSERVATION_MODIFIER", 78, 84]]], ["After cloning, each H5-HA gene plasmid insertion was confirmed by DNA sequencing analysis.", [["DNA", "CELLULAR_COMPONENT", 66, 69], ["H5-HA gene plasmid", "DNA", 20, 38], ["H5-HA gene plasmid insertion", "TREATMENT", 20, 48], ["DNA sequencing analysis", "TEST", 66, 89]]], ["For the determination of limit of detection, one-step multiplex qPCR assays were performed using a serial 10-fold dilution (5 \u00d7 10 8 to 5 \u00d7 10 0 copies of plasmid DNA/\u00b5L) of each plasmid; each qPCR assay was performed in triplicate.", [["plasmid", "ANATOMY", 155, 162], ["plasmid", "ANATOMY", 179, 186], ["DNA", "CELLULAR_COMPONENT", 163, 166], ["plasmid DNA", "DNA", 155, 166], ["\u00b5L", "DNA", 167, 169], ["step multiplex qPCR assays", "TEST", 49, 75], ["a serial 10-fold dilution", "TREATMENT", 97, 122], ["plasmid DNA/\u00b5L) of each plasmid", "TREATMENT", 155, 186], ["each qPCR assay", "TEST", 188, 203]]], ["The plasmid copy number was calculated using the URI Genomics & Sequencing Center program (http://cels.uri.edu/gsc/cndna.html).One-Step Multiplex RT-qPCR AnalysisFor the one-step multiplex RT-qPCR, viral RNA was extracted using the RNeasy Mini Kit (Hilden, Germany) following the manufacturer's instructions.", [["plasmid", "ANATOMY", 4, 11], ["viral RNA", "RNA", 198, 207], ["Multiplex RT-qPCR Analysis", "TEST", 136, 162], ["viral RNA", "PROBLEM", 198, 207], ["viral RNA", "OBSERVATION", 198, 207]]], ["The RT-qPCR assays were performed using the LightCycler 96 instrument and software (1.1 version).", [["The RT-qPCR assays", "TEST", 0, 18], ["the LightCycler", "TEST", 40, 55], ["software", "TEST", 74, 82]]], ["The one-step multiplex RT-qPCR reaction mixture contained 0.8 \u00b5L of enzyme mixture, 4 \u00b5L of 5\u00d7 reaction buffer, 0.8 \u00b5L of deoxynucleoside triphosphate (10 pmol) from a Qiagen (Hilden, Germany) one-step RT-qPCR kit, 1 \u00b5L of each primer (10 pmol), 1 \u00b5L of each probe (5 \u00b5M), 3 \u00b5L RNA template and RNase-free water so that the final reaction volume reached 20 \u00b5L.", [["deoxynucleoside triphosphate", "CHEMICAL", 122, 150], ["deoxynucleoside triphosphate", "CHEMICAL", 122, 150], ["deoxynucleoside triphosphate", "SIMPLE_CHEMICAL", 122, 150], ["RNase", "GENE_OR_GENE_PRODUCT", 295, 300], ["RNase", "PROTEIN", 295, 300], ["qPCR reaction mixture", "TEST", 26, 47], ["enzyme mixture", "TREATMENT", 68, 82], ["deoxynucleoside triphosphate", "TREATMENT", 122, 150], ["a Qiagen (Hilden", "TREATMENT", 166, 182], ["3 \u00b5L RNA template", "TREATMENT", 273, 290], ["RNase-free water", "TREATMENT", 295, 311], ["the final reaction volume", "TEST", 320, 345]]], ["The PCR thermocycling procedure was performed at 50 \u2022 C for 30 min and 94 \u2022 C for 10 min for the reverse transcription step; the next step was performed at 94 \u2022 C for 20 s, 56 \u2022 C for 20 s, and 72 \u2022 C for 30 s for 40 cycles.", [["The PCR thermocycling procedure", "TREATMENT", 0, 31]]], ["Fluorescence data were acquired during the annealing step to distinguish the positive and negative results.", [["Fluorescence data", "TEST", 0, 17], ["the annealing step", "TEST", 39, 57]]], ["The RT-qPCR positive reaction of ct value was set to 35 and RNase-free water was used as a negative control.Specificity Analyses of One-Step Multiplex RT-qPCR AnalysisSpecificity of our multiplex RT-qPCR system was evaluated with different influenza virus and other avian/human pathogens. total viral RNA samples from 1 human influenza virus (H1N1 subtype), 11 avian influenza viruses (H1N1, H3N3, H5N1, H5N2, H5N6, H5N8, H7N1, H9N2, and H10N1 subtype), 1 equine influenza virus (H3N8 subtype), 1 canine influenza virus (H3N2), 1 swine influenza virus (H3N2 subtype), avian infectious bronchitis virus, Newcastle disease virus, human Coronavirus-229E, and human Parainfluenza were assessed using one-step multiplex RT-qPCR described in this study.H5 HPAI Clade Assignment of Filed SamplesAll H5 HPAI-positive field samples were identified by conventional reverse transcription polymerase chain reaction (RT-PCR), and the HA gene was amplified using the following primer set: forward 5 -GCATTGGYTAYCATGCAAAYA-3 and reverse 5 -TTGCTRTGGTGRTAYCCATACA-3 .", [["samples", "ANATOMY", 305, 312], ["samples", "ANATOMY", 815, 822], ["influenza virus", "DISEASE", 326, 341], ["influenza viruses", "DISEASE", 367, 384], ["H1N1, H3N3, H5N1, H5N2, H5N6, H5N8, H7N1, H9N2, and H10N1 subtype", "DISEASE", 386, 451], ["influenza virus", "DISEASE", 463, 478], ["canine influenza virus", "DISEASE", 497, 519], ["influenza virus", "DISEASE", 536, 551], ["avian infectious bronchitis virus", "DISEASE", 568, 601], ["Newcastle disease", "DISEASE", 603, 620], ["RNase", "GENE_OR_GENE_PRODUCT", 60, 65], ["influenza virus", "ORGANISM", 240, 255], ["avian", "ORGANISM", 266, 271], ["human", "ORGANISM", 272, 277], ["human influenza virus", "ORGANISM", 320, 341], ["H1N1 subtype", "ORGANISM", 343, 355], ["avian", "ORGANISM", 361, 366], ["influenza viruses", "ORGANISM", 367, 384], ["H3N3, H5N1", "ORGANISM", 392, 402], ["H5N2", "ORGANISM", 404, 408], ["H5N6, H5N8, H7N1, H9N2", "ORGANISM", 410, 432], ["H10N1 subtype", "ORGANISM", 438, 451], ["1", "ORGANISM", 454, 455], ["equine influenza virus", "ORGANISM", 456, 478], ["H3N8 subtype", "ORGANISM", 480, 492], ["1", "ORGANISM", 495, 496], ["canine influenza virus (H3N2", "ORGANISM", 497, 525], ["1", "ORGANISM", 528, 529], ["swine influenza virus", "ORGANISM", 530, 551], ["H3N2 subtype", "ORGANISM", 553, 565], ["avian infectious bronchitis virus", "ORGANISM", 568, 601], ["Newcastle disease virus", "ORGANISM", 603, 626], ["human", "ORGANISM", 628, 633], ["Coronavirus-229E", "ORGANISM", 634, 650], ["human", "ORGANISM", 656, 661], ["Parainfluenza", "CANCER", 662, 675], ["H5 HPAI", "ORGANISM", 792, 799], ["HA", "GENE_OR_GENE_PRODUCT", 921, 923], ["RNase", "PROTEIN", 60, 65], ["HA gene", "DNA", 921, 928], ["forward 5 -GCATTGGYTAYCATGCAAAYA-3", "DNA", 975, 1009], ["reverse 5 -TTGCTRTGGTGRTAYCCATACA-3", "DNA", 1014, 1049], ["influenza virus", "SPECIES", 240, 255], ["avian", "SPECIES", 266, 271], ["human", "SPECIES", 272, 277], ["human influenza virus", "SPECIES", 320, 341], ["avian influenza viruses", "SPECIES", 361, 384], ["H5N1, H5N2", "SPECIES", 398, 408], ["equine influenza virus", "SPECIES", 456, 478], ["canine influenza virus", "SPECIES", 497, 519], ["(H3N2", "SPECIES", 520, 525], ["swine influenza virus", "SPECIES", 530, 551], ["(H3N2", "SPECIES", 552, 557], ["avian infectious bronchitis virus", "SPECIES", 568, 601], ["Newcastle disease virus", "SPECIES", 603, 626], ["human", "SPECIES", 628, 633], ["human", "SPECIES", 656, 661], ["influenza virus", "SPECIES", 240, 255], ["human", "SPECIES", 272, 277], ["human influenza virus", "SPECIES", 320, 341], ["H3N3", "SPECIES", 392, 396], ["H5N6", "SPECIES", 410, 414], ["H5N8", "SPECIES", 416, 420], ["H7N1", "SPECIES", 422, 426], ["H10N1", "SPECIES", 438, 443], ["equine influenza virus", "SPECIES", 456, 478], ["canine influenza virus", "SPECIES", 497, 519], ["swine influenza virus", "SPECIES", 530, 551], ["infectious bronchitis virus", "SPECIES", 574, 601], ["Newcastle disease virus", "SPECIES", 603, 626], ["human Coronavirus-229E", "SPECIES", 628, 650], ["human", "SPECIES", 656, 661], ["The RT-qPCR", "TEST", 0, 11], ["ct value", "TEST", 33, 41], ["RNase-free water", "TREATMENT", 60, 76], ["Specificity Analyses", "TEST", 108, 128], ["One-Step", "TEST", 132, 140], ["Multiplex RT", "TEST", 141, 153], ["our multiplex RT-qPCR system", "TEST", 182, 210], ["different influenza virus", "PROBLEM", 230, 255], ["other avian/human pathogens", "PROBLEM", 260, 287], ["total viral RNA samples", "TEST", 289, 312], ["1 human influenza virus", "PROBLEM", 318, 341], ["H1N1 subtype", "TEST", 343, 355], ["11 avian influenza viruses", "PROBLEM", 358, 384], ["H1N1", "PROBLEM", 386, 390], ["H3N3", "TEST", 392, 396], ["H5N1", "PROBLEM", 398, 402], ["H5N2", "TEST", 404, 408], ["H5N6", "TEST", 410, 414], ["H5N8", "TEST", 416, 420], ["H7N1", "TEST", 422, 426], ["H9N2", "TEST", 428, 432], ["1 equine influenza virus (H3N8 subtype)", "PROBLEM", 454, 493], ["1 canine influenza virus", "PROBLEM", 495, 519], ["H3N2", "PROBLEM", 521, 525], ["1 swine influenza virus (H3N2 subtype)", "PROBLEM", 528, 566], ["avian infectious bronchitis virus", "PROBLEM", 568, 601], ["Newcastle disease virus", "PROBLEM", 603, 626], ["human Coronavirus", "TEST", 628, 645], ["human Parainfluenza", "PROBLEM", 656, 675], ["this study", "TEST", 736, 746], ["Filed Samples", "TEST", 775, 788], ["All H5 HPAI", "TEST", 788, 799], ["RT-PCR", "TEST", 904, 910], ["the HA gene", "TREATMENT", 917, 928], ["-GCATTGGYTAYCATGCAAAYA", "TEST", 985, 1007], ["viral RNA", "OBSERVATION", 295, 304], ["infectious", "OBSERVATION_MODIFIER", 574, 584], ["bronchitis virus", "OBSERVATION", 585, 601]]], ["Specific amplicons were purified from 1.5% agarose gels using a QIAquick Gel Extraction Kit (Hilden, Germany) and sequenced using an ABI PRISM 3730 DNA Sequencer.", [["agarose", "SIMPLE_CHEMICAL", 43, 50], ["DNA", "CELLULAR_COMPONENT", 148, 151], ["Specific amplicons", "TREATMENT", 0, 18], ["1.5% agarose gels", "TREATMENT", 38, 55], ["a QIAquick Gel Extraction", "TREATMENT", 62, 87], ["an ABI PRISM", "TEST", 130, 142], ["DNA Sequencer", "TEST", 148, 161]]], ["Based on their sequences, all H5 HPAI-positive field viruses were classified as the H5 HPAI clade using Highly Pathogenic H5N1 Clade Classification Tool in the Influenza Research Database.Sensitivity of One-Step Multiplex RT-qPCR AssayTo develop the one-step multiplex RT-qPCR assay, a specific primer set and the probes for pan-H5 HPAI and two clades, 2.3.4.4 or 2.3.2.1, were designed.", [["H5 HPAI", "ORGANISM", 30, 37], ["H5 HPAI", "ORGANISM", 84, 91], ["pan-H5 HPAI", "SPECIES", 325, 336], ["their sequences", "TEST", 9, 24], ["all H5 HPAI", "TEST", 26, 37], ["positive field viruses", "PROBLEM", 38, 60], ["the H5 HPAI clade", "TREATMENT", 80, 97], ["Sensitivity", "TEST", 188, 199], ["One-Step Multiplex RT", "TEST", 203, 224], ["the probes", "TEST", 310, 320], ["pan-H5 HPAI", "TREATMENT", 325, 336]]], ["In order to enhance the simultaneous detection specificity of a target gene, the H5 HPAI HA gene sequences from different years and various clades of H5 HPAI strains were downloaded from the GenBank database; primers and probes for the most conserved regions of the HA gene ( Figure 1 ) were designed.", [["H5 HPAI", "ORGANISM", 81, 88], ["HA", "GENE_OR_GENE_PRODUCT", 89, 91], ["H5 HPAI", "ORGANISM", 150, 157], ["target gene", "DNA", 64, 75], ["H5 HPAI HA gene sequences", "DNA", 81, 106], ["HA gene", "DNA", 266, 273], ["H5 HPAI", "SPECIES", 150, 157], ["H5 HPAI", "SPECIES", 81, 88], ["H5 HPAI", "SPECIES", 150, 157], ["the H5 HPAI HA gene sequences", "TREATMENT", 77, 106], ["H5 HPAI strains", "PROBLEM", 150, 165], ["the GenBank database", "TEST", 187, 207]]], ["To optimize our one-step multiplex qPCR, three HA gene plasmids, containing the H5 HPAI HA genes of two clades, were amplified and used as a quantitative standard in our system.", [["HA gene plasmids", "DNA", 47, 63], ["H5 HPAI HA genes", "DNA", 80, 96], ["H5 HPAI", "SPECIES", 80, 87], ["our one-step multiplex qPCR", "TREATMENT", 12, 39], ["three HA gene plasmids", "TREATMENT", 41, 63], ["the H5 HPAI HA genes", "TREATMENT", 76, 96]]], ["Each plasmid was serially diluted (5 \u00d7 10 8 to 5 \u00d7 10 0 copies per microliter), and the sensitivity of our primer/probe set was determined using the singleplex and multiplex qPCR assays targeting pan-H5 HPAI, clade 2.3.4.4, or 2.3.2.1.", [["plasmid", "ANATOMY", 5, 12], ["pan-H5 HPAI", "ORGANISM", 196, 207], ["Each plasmid", "TREATMENT", 0, 12], ["our primer/probe set", "TEST", 103, 123], ["the singleplex", "TREATMENT", 145, 159], ["multiplex qPCR assays", "TEST", 164, 185], ["HPAI", "TEST", 203, 207], ["clade", "TEST", 209, 214]]], ["The standard curves, generated for these targets under both qPCR conditions, showed linearity (R 2 = 0.9918 to 0.9997, Figure 2 ).", [["both qPCR conditions", "TEST", 55, 75], ["linearity", "TEST", 84, 93]]], ["Also, we showed that the detection limit under both qPCR conditions was 5 \u00d7 10 1 copies per microliter ( Table 1 ).", [["the detection", "TEST", 21, 34]]], ["The cut-off for the cycle threshold of RT-qPCR was set to 35. forward 5\u2032-GCATTGGYTAYCATGCAAAYA-3\u2032 and reverse 5\u2032-TTGCTRTGGTGRTAYCCATACA-3\u2032.", [["reverse 5\u2032-TTGCTRTGGTGRTAYCCATACA-3\u2032", "DNA", 102, 138], ["RT-qPCR", "TEST", 39, 46], ["GCATTGGYTAYCATGCAAAYA", "TEST", 73, 94]]], ["Specific amplicons were purified from 1.5% agarose gels using a QIAquick Gel Extraction Kit (Hilden, Germany) and sequenced using an ABI PRISM 3730 DNA Sequencer.", [["agarose", "SIMPLE_CHEMICAL", 43, 50], ["DNA", "CELLULAR_COMPONENT", 148, 151], ["Specific amplicons", "TREATMENT", 0, 18], ["1.5% agarose gels", "TREATMENT", 38, 55], ["a QIAquick Gel Extraction", "TREATMENT", 62, 87], ["an ABI PRISM", "TEST", 130, 142], ["DNA Sequencer", "TEST", 148, 161]]], ["Based on their sequences, all H5 HPAI-positive field viruses were classified as the H5 HPAI clade using Highly Pathogenic H5N1 Clade Classification Tool in the Influenza Research Database.Sensitivity of One-Step Multiplex RT-qPCR AssayTo develop the one-step multiplex RT-qPCR assay, a specific primer set and the probes for pan-H5 HPAI and two clades, 2.3.4.4 or 2.3.2.1, were designed.", [["H5 HPAI", "ORGANISM", 30, 37], ["H5 HPAI", "ORGANISM", 84, 91], ["pan-H5 HPAI", "SPECIES", 325, 336], ["their sequences", "TEST", 9, 24], ["all H5 HPAI", "TEST", 26, 37], ["positive field viruses", "PROBLEM", 38, 60], ["the H5 HPAI clade", "TREATMENT", 80, 97], ["Sensitivity", "TEST", 188, 199], ["One-Step Multiplex RT", "TEST", 203, 224], ["the probes", "TEST", 310, 320], ["pan-H5 HPAI", "TREATMENT", 325, 336]]], ["In order to enhance the simultaneous detection specificity of a target gene, the H5 HPAI HA gene sequences from different years and various clades of H5 HPAI strains were downloaded from the GenBank database; primers and probes for the most conserved regions of the HA gene ( Figure 1 ) were designed.", [["H5 HPAI", "ORGANISM", 81, 88], ["HA", "GENE_OR_GENE_PRODUCT", 89, 91], ["H5 HPAI", "ORGANISM", 150, 157], ["target gene", "DNA", 64, 75], ["H5 HPAI HA gene sequences", "DNA", 81, 106], ["HA gene", "DNA", 266, 273], ["H5 HPAI", "SPECIES", 150, 157], ["H5 HPAI", "SPECIES", 81, 88], ["H5 HPAI", "SPECIES", 150, 157], ["the H5 HPAI HA gene sequences", "TREATMENT", 77, 106], ["H5 HPAI strains", "PROBLEM", 150, 165], ["the GenBank database", "TEST", 187, 207]]], ["To optimize our one-step multiplex qPCR, three HA gene plasmids, containing the H5 HPAI HA genes of two clades, were amplified and used as a quantitative standard in our system.", [["HA gene plasmids", "DNA", 47, 63], ["H5 HPAI HA genes", "DNA", 80, 96], ["H5 HPAI", "SPECIES", 80, 87], ["our one-step multiplex qPCR", "TREATMENT", 12, 39], ["three HA gene plasmids", "TREATMENT", 41, 63], ["the H5 HPAI HA genes", "TREATMENT", 76, 96]]], ["Each plasmid was serially diluted (5 \u00d7 10 8 to 5 \u00d7 10 0 copies per microliter), and the sensitivity of our primer/probe set was determined using the singleplex and multiplex qPCR assays targeting pan-H5 HPAI, clade 2.3.4.4, or 2.3.2.1.", [["plasmid", "ANATOMY", 5, 12], ["pan-H5 HPAI", "ORGANISM", 196, 207], ["Each plasmid", "TREATMENT", 0, 12], ["our primer/probe set", "TEST", 103, 123], ["the singleplex", "TREATMENT", 145, 159], ["multiplex qPCR assays", "TEST", 164, 185], ["HPAI", "TEST", 203, 207], ["clade", "TEST", 209, 214]]], ["The standard curves, generated for these targets under both qPCR conditions, showed linearity (R 2 = 0.9918 to 0.9997, Figure 2 ).", [["both qPCR conditions", "TEST", 55, 75], ["linearity", "TEST", 84, 93]]], ["Also, we showed that the detection limit under both qPCR conditions was 5 \u00d7 10 1 copies per microliter ( Table 1 ).", [["the detection", "TEST", 21, 34]]], ["The cut-off for the cycle threshold of RT-qPCR was set to 35.", [["RT-qPCR", "TEST", 39, 46]]], ["Each concentration had triple replicates and the mean and SD were conducted using GraphPad Prism software (version 5.1).Specificity of One-Step Multiplex RT-qPCR AssayTo assess analytical specificity of the one-step multiplex RT-qPCR assay, strains of different subtypes or clades of influenza A virus, as well as other avian or human origin viruses, infectious bronchitis virus, Newcastle disease virus, coronavirus-229E strain, and parainfluenza virus 1, were tested.", [["influenza A virus", "DISEASE", 284, 301], ["infectious bronchitis virus", "DISEASE", 351, 378], ["Newcastle disease", "DISEASE", 380, 397], ["influenza A virus", "ORGANISM", 284, 301], ["human origin viruses", "ORGANISM", 329, 349], ["infectious bronchitis virus", "ORGANISM", 351, 378], ["Newcastle disease virus", "ORGANISM", 380, 403], ["coronavirus-229E strain", "ORGANISM", 405, 428], ["parainfluenza virus 1", "ORGANISM", 434, 455], ["influenza A virus", "SPECIES", 284, 301], ["avian", "SPECIES", 320, 325], ["human", "SPECIES", 329, 334], ["infectious bronchitis virus", "SPECIES", 351, 378], ["Newcastle disease virus", "SPECIES", 380, 403], ["coronavirus-229E", "SPECIES", 405, 421], ["parainfluenza virus 1", "SPECIES", 434, 455], ["influenza A virus", "SPECIES", 284, 301], ["human origin viruses", "SPECIES", 329, 349], ["infectious bronchitis virus", "SPECIES", 351, 378], ["Newcastle disease virus", "SPECIES", 380, 403], ["coronavirus-229E strain", "SPECIES", 405, 428], ["parainfluenza virus 1", "SPECIES", 434, 455], ["triple replicates", "TREATMENT", 23, 40], ["version", "TEST", 107, 114], ["Specificity", "TEST", 120, 131], ["One-Step Multiplex RT-qPCR Assay", "TEST", 135, 167], ["qPCR assay", "TEST", 229, 239], ["different subtypes", "PROBLEM", 252, 270], ["influenza A virus", "PROBLEM", 284, 301], ["human origin viruses", "PROBLEM", 329, 349], ["infectious bronchitis virus", "PROBLEM", 351, 378], ["Newcastle disease virus", "PROBLEM", 380, 403], ["coronavirus", "PROBLEM", 405, 416], ["229E strain", "PROBLEM", 417, 428], ["parainfluenza virus", "PROBLEM", 434, 453], ["influenza", "OBSERVATION", 284, 293], ["infectious", "OBSERVATION_MODIFIER", 351, 361]]], ["As we expected, all H5 HPAI and two clade viruses were successfully detected, while the other influenza A virus subtypes and viruses of other origin were not amplified by our multiplex RT-qPCR (Table 2 ).", [["H5 HPAI", "ORGANISM", 20, 27], ["influenza A virus", "ORGANISM", 94, 111], ["influenza A virus", "SPECIES", 94, 111], ["H5 HPAI", "SPECIES", 20, 27], ["influenza A virus", "SPECIES", 94, 111], ["all H5 HPAI", "PROBLEM", 16, 27], ["two clade viruses", "TREATMENT", 32, 49], ["the other influenza A virus subtypes", "PROBLEM", 84, 120]]], ["In addition, the H5 LPAI subtype viruses were not detected using our specific H5 HPAI primer/probe set.", [["H5 LPAI", "ORGANISM", 17, 24], ["H5 HPAI primer", "DNA", 78, 92], ["H5 LPAI", "SPECIES", 17, 24], ["H5 HPAI", "SPECIES", 78, 85], ["the H5 LPAI subtype viruses", "PROBLEM", 13, 40], ["viruses", "OBSERVATION", 33, 40]]], ["Interestingly, although the H5N1 HPAI subtypes of A/environment/Korea/W150/2006 (clade 2.2) and A/duck/Vietnam/NCVD-1648/2012 (clade 2.3.2.1) are the same, our primer/probe set detected only clade 2.3.2.1.", [["HPAI", "DISEASE", 33, 37], ["H5N1 HPAI", "ORGANISM", 28, 37], ["A/duck", "ORGANISM", 96, 102], ["NCVD-1648/2012", "ORGANISM", 111, 125], ["H5N1", "SPECIES", 28, 32], ["duck", "SPECIES", 98, 102], ["A/duck/Vietnam/NCVD-1648/2012", "SPECIES", 96, 125], ["clade", "TEST", 81, 86], ["NCVD", "TEST", 111, 115], ["clade", "TEST", 127, 132], ["our primer/probe set", "TEST", 156, 176], ["H5N1", "OBSERVATION", 28, 32]]], ["These results show that our multiplex RT-qPCR assay is highly specific and exhibits no cross-reactivity for H5 HPAI and the other clades.Specificity of One-Step Multiplex RT-qPCR AssayTo assess analytical specificity of the one-step multiplex RT-qPCR assay, strains of different subtypes or clades of influenza A virus, as well as other avian or human origin viruses, infectious bronchitis virus, Newcastle disease virus, coronavirus-229E strain, and parainfluenza virus 1, were tested.", [["influenza A virus", "DISEASE", 301, 318], ["infectious bronchitis virus", "DISEASE", 368, 395], ["Newcastle disease", "DISEASE", 397, 414], ["H5 HPAI", "ORGANISM", 108, 115], ["influenza A virus", "ORGANISM", 301, 318], ["human origin viruses", "ORGANISM", 346, 366], ["infectious bronchitis virus", "ORGANISM", 368, 395], ["Newcastle disease virus", "ORGANISM", 397, 420], ["coronavirus-229E strain", "ORGANISM", 422, 445], ["parainfluenza virus 1", "ORGANISM", 451, 472], ["influenza A virus", "SPECIES", 301, 318], ["avian", "SPECIES", 337, 342], ["human", "SPECIES", 346, 351], ["infectious bronchitis virus", "SPECIES", 368, 395], ["Newcastle disease virus", "SPECIES", 397, 420], ["coronavirus-229E", "SPECIES", 422, 438], ["parainfluenza virus 1", "SPECIES", 451, 472], ["H5 HPAI", "SPECIES", 108, 115], ["influenza A virus", "SPECIES", 301, 318], ["human origin viruses", "SPECIES", 346, 366], ["infectious bronchitis virus", "SPECIES", 368, 395], ["Newcastle disease virus", "SPECIES", 397, 420], ["coronavirus-229E strain", "SPECIES", 422, 445], ["parainfluenza virus 1", "SPECIES", 451, 472], ["our multiplex RT-qPCR assay", "TEST", 24, 51], ["cross-reactivity", "PROBLEM", 87, 103], ["H5 HPAI", "TREATMENT", 108, 115], ["Specificity", "TEST", 137, 148], ["One-Step Multiplex RT-qPCR Assay", "TEST", 152, 184], ["qPCR assay", "TEST", 246, 256], ["different subtypes", "PROBLEM", 269, 287], ["influenza A virus", "PROBLEM", 301, 318], ["human origin viruses", "PROBLEM", 346, 366], ["infectious bronchitis virus", "PROBLEM", 368, 395], ["Newcastle disease virus", "PROBLEM", 397, 420], ["coronavirus", "PROBLEM", 422, 433], ["229E strain", "PROBLEM", 434, 445], ["parainfluenza virus", "PROBLEM", 451, 470], ["influenza", "OBSERVATION", 301, 310], ["infectious", "OBSERVATION_MODIFIER", 368, 378]]], ["As we expected, all H5 HPAI and two clade viruses were successfully detected, while the other influenza A virus subtypes and viruses of other origin were not amplified by our multiplex RT-qPCR ( Table 2 ).", [["H5 HPAI", "ORGANISM", 20, 27], ["influenza A virus", "ORGANISM", 94, 111], ["influenza A virus", "SPECIES", 94, 111], ["H5 HPAI", "SPECIES", 20, 27], ["influenza A virus", "SPECIES", 94, 111], ["all H5 HPAI", "PROBLEM", 16, 27], ["two clade viruses", "TREATMENT", 32, 49], ["the other influenza A virus subtypes", "PROBLEM", 84, 120]]], ["In addition, the H5 LPAI subtype viruses were not detected using our specific H5 HPAI primer/probe set.", [["H5 LPAI", "ORGANISM", 17, 24], ["H5 HPAI primer", "DNA", 78, 92], ["H5 LPAI", "SPECIES", 17, 24], ["H5 HPAI", "SPECIES", 78, 85], ["the H5 LPAI subtype viruses", "PROBLEM", 13, 40], ["viruses", "OBSERVATION", 33, 40]]], ["Interestingly, although the H5N1 HPAI subtypes of A/environment/Korea/W150/2006 (clade 2.2) and A/duck/Vietnam/NCVD-1648/2012 (clade 2.3.2.1) are the same, our primer/probe set detected only clade 2.3.2.1.", [["HPAI", "DISEASE", 33, 37], ["H5N1 HPAI", "ORGANISM", 28, 37], ["A/duck", "ORGANISM", 96, 102], ["NCVD-1648/2012", "ORGANISM", 111, 125], ["H5N1", "SPECIES", 28, 32], ["duck", "SPECIES", 98, 102], ["A/duck/Vietnam/NCVD-1648/2012", "SPECIES", 96, 125], ["clade", "TEST", 81, 86], ["NCVD", "TEST", 111, 115], ["clade", "TEST", 127, 132], ["our primer/probe set", "TEST", 156, 176], ["H5N1", "OBSERVATION", 28, 32]]], ["These results show that our multiplex RT-qPCR assay is highly specific and exhibits no cross-reactivity for H5 HPAI and the other clades.Application of One-Step Multiplex RT-qPCR Assay Using Clinical SamplesTo detect H5 HPAI in fecal samples using our one-step multiplex RT-qPCR assay, we obtained a total of 4350 fecal samples from domestic chickens with signs of respiratory illness in Vietnam, and viral RNA was isolated from these samples.", [["fecal samples", "ANATOMY", 228, 241], ["fecal samples", "ANATOMY", 314, 327], ["respiratory", "ANATOMY", 365, 376], ["samples", "ANATOMY", 435, 442], ["respiratory illness", "DISEASE", 365, 384], ["H5 HPAI", "ORGANISM", 108, 115], ["H5 HPAI", "ORGANISM", 217, 224], ["fecal samples", "ORGANISM_SUBSTANCE", 228, 241], ["fecal samples", "ORGANISM_SUBSTANCE", 314, 327], ["chickens", "ORGANISM", 342, 350], ["viral RNA", "RNA", 401, 410], ["chickens", "SPECIES", 342, 350], ["H5 HPAI", "SPECIES", 108, 115], ["H5 HPAI", "SPECIES", 217, 224], ["chickens", "SPECIES", 342, 350], ["our multiplex RT-qPCR assay", "TEST", 24, 51], ["cross-reactivity", "PROBLEM", 87, 103], ["H5 HPAI", "TREATMENT", 108, 115], ["One-Step Multiplex RT-qPCR Assay", "TREATMENT", 152, 184], ["Clinical SamplesTo", "TEST", 191, 209], ["HPAI", "PROBLEM", 220, 224], ["fecal samples", "TEST", 228, 241], ["domestic chickens", "TREATMENT", 333, 350], ["respiratory illness in Vietnam", "PROBLEM", 365, 395], ["viral RNA", "PROBLEM", 401, 410], ["these samples", "TEST", 429, 442], ["fecal", "ANATOMY", 228, 233], ["respiratory illness", "OBSERVATION", 365, 384], ["viral RNA", "OBSERVATION", 401, 410]]], ["A total of 68 samples were confirmed influenza positive by M-gene-specific RT-qPCR.", [["samples", "ANATOMY", 14, 21], ["samples", "CANCER", 14, 21], ["M-gene", "DNA", 59, 65], ["A total of 68 samples", "TEST", 0, 21], ["influenza", "PROBLEM", 37, 46]]], ["Among the IAV-positive clinical samples, 51 samples were H5 HPAI-positive, and each clade was successfully analyzed using our one-step multiplex RT-qPCR assay (Table 3 and Figure 3 ).", [["samples", "ANATOMY", 32, 39], ["samples", "ANATOMY", 44, 51], ["IAV", "ORGANISM", 10, 13], ["samples", "CANCER", 44, 51], ["H5 HPAI", "SPECIES", 57, 64], ["samples", "TEST", 44, 51], ["H5 HPAI", "TEST", 57, 64]]], ["Next, we confirmed the sequence of all H5 HPAI-positive samples using the universal HA sequencing primers, forward 5 -GCATTGGYTAYCATGCAAAYA-3 and reverse 5 -TTGCTRTGGTGRTAYCCATACA-3 , and classified each clade using the Influenza Research Database.", [["samples", "ANATOMY", 56, 63], ["H5 HPAI", "ORGANISM", 39, 46], ["HA sequencing primers", "DNA", 84, 105], ["forward 5 -GCATTGGYTAYCATGCAAAYA-3", "DNA", 107, 141], ["reverse 5 -TTGCTRTGGTGRTAYCCATACA-3", "DNA", 146, 181], ["H5 HPAI", "SPECIES", 39, 46], ["all H5 HPAI", "TEST", 35, 46], ["the universal HA sequencing primers", "TREATMENT", 70, 105], ["-GCATTGGYTAYCATGCAAAYA", "TEST", 117, 139]]], ["Interestingly, when we have compared with sequencing analysis and clade identification using each amplicon, the primers and probes for the pan-H5 HPAI-specific and two clade-specific multiplex RT-qPCR assays were well-matched ( Figure 3D ).", [["pan-H5 HPAI", "ORGANISM", 139, 150], ["sequencing analysis", "TEST", 42, 61], ["each amplicon", "TREATMENT", 93, 106], ["the primers", "TREATMENT", 108, 119], ["the pan-H5 HPAI", "TEST", 135, 150], ["qPCR assays", "TEST", 196, 207]]], ["These results show that our one-step multiplex RT-qPCR assay could be a promising technique for specific discrimination of multiple H5 HPAI viruses in field samples from infected avian species.Application of One-Step Multiplex RT-qPCR Assay Using Clinical SamplesTo detect H5 HPAI in fecal samples using our one-step multiplex RT-qPCR assay, we obtained a total of 4350 fecal samples from domestic chickens with signs of respiratory illness in Vietnam, and viral RNA was isolated from these samples.", [["samples", "ANATOMY", 157, 164], ["fecal samples", "ANATOMY", 284, 297], ["fecal samples", "ANATOMY", 370, 383], ["respiratory", "ANATOMY", 421, 432], ["samples", "ANATOMY", 491, 498], ["respiratory illness", "DISEASE", 421, 440], ["H5 HPAI viruses", "ORGANISM", 132, 147], ["avian", "ORGANISM", 179, 184], ["H5 HPAI", "ORGANISM", 273, 280], ["fecal samples", "ORGANISM_SUBSTANCE", 284, 297], ["fecal samples", "ORGANISM_SUBSTANCE", 370, 383], ["chickens", "ORGANISM", 398, 406], ["viral RNA", "RNA", 457, 466], ["chickens", "SPECIES", 398, 406], ["H5 HPAI viruses", "SPECIES", 132, 147], ["H5 HPAI", "SPECIES", 273, 280], ["chickens", "SPECIES", 398, 406], ["qPCR assay", "TEST", 50, 60], ["a promising technique", "TREATMENT", 70, 91], ["multiple H5 HPAI viruses", "PROBLEM", 123, 147], ["infected avian species", "PROBLEM", 170, 192], ["One-Step Multiplex RT-qPCR Assay", "TREATMENT", 208, 240], ["Clinical SamplesTo", "TEST", 247, 265], ["HPAI", "PROBLEM", 276, 280], ["fecal samples", "TEST", 284, 297], ["domestic chickens", "TREATMENT", 389, 406], ["respiratory illness in Vietnam", "PROBLEM", 421, 451], ["viral RNA", "PROBLEM", 457, 466], ["these samples", "TEST", 485, 498], ["multiple", "OBSERVATION_MODIFIER", 123, 131], ["H5", "OBSERVATION_MODIFIER", 132, 134], ["HPAI viruses", "OBSERVATION", 135, 147], ["infected avian species", "OBSERVATION", 170, 192], ["fecal", "ANATOMY", 284, 289], ["respiratory illness", "OBSERVATION", 421, 440], ["viral RNA", "OBSERVATION", 457, 466]]], ["A total of 68 samples were confirmed influenza positive by M-gene-specific RT-qPCR.", [["samples", "ANATOMY", 14, 21], ["samples", "CANCER", 14, 21], ["M-gene", "DNA", 59, 65], ["A total of 68 samples", "TEST", 0, 21], ["influenza", "PROBLEM", 37, 46]]], ["Among the IAV-positive clinical samples, 51 samples were H5 HPAIpositive, and each clade was successfully analyzed using our one-step multiplex RT-qPCR assay (Table 3 and Figure 3 ).", [["samples", "ANATOMY", 32, 39], ["samples", "ANATOMY", 44, 51], ["IAV", "ORGANISM", 10, 13], ["samples", "CANCER", 44, 51], ["H5", "SPECIES", 57, 59]]], ["Next, we confirmed the sequence of all H5 HPAI-positive samples using the universal HA sequencing primers, forward 5\u2032-GCATTGGYTAYCATGCAAAYA-3\u2032 and reverse 5\u2032-TTGCTRTGGTGRTAYCCATACA-3\u2032, and classified each clade using the Influenza Research Database.", [["samples", "ANATOMY", 56, 63], ["H5 HPAI", "ORGANISM", 39, 46], ["HA sequencing primers", "DNA", 84, 105], ["reverse 5\u2032-TTGCTRTGGTGRTAYCCATACA-3\u2032", "DNA", 147, 183], ["H5 HPAI", "SPECIES", 39, 46], ["all H5 HPAI", "PROBLEM", 35, 46], ["the universal HA sequencing primers", "TREATMENT", 70, 105], ["GCATTGGYTAYCATGCAAAYA", "TEST", 118, 139]]], ["Interestingly, when we have compared with sequencing analysis and clade identification using each amplicon, the primers and probes for the pan-H5 HPAI-specific and two clade-specific multiplex RT-qPCR assays were well-matched ( Figure 3D ).", [["pan-H5 HPAI", "ORGANISM", 139, 150], ["sequencing analysis", "TEST", 42, 61], ["each amplicon", "TREATMENT", 93, 106], ["the primers", "TREATMENT", 108, 119], ["the pan-H5 HPAI", "TEST", 135, 150], ["qPCR assays", "TEST", 196, 207]]], ["These results show that our one-step multiplex RT-qPCR assay could be a promising technique for specific discrimination of multiple H5 HPAI viruses in field samples from infected avian species.", [["samples", "ANATOMY", 157, 164], ["H5 HPAI viruses", "ORGANISM", 132, 147], ["avian", "ORGANISM", 179, 184], ["H5 HPAI viruses", "SPECIES", 132, 147], ["qPCR assay", "TEST", 50, 60], ["a promising technique", "TREATMENT", 70, 91], ["multiple H5 HPAI viruses", "PROBLEM", 123, 147], ["infected avian species", "PROBLEM", 170, 192], ["multiple", "OBSERVATION_MODIFIER", 123, 131], ["H5", "OBSERVATION_MODIFIER", 132, 134], ["HPAI viruses", "OBSERVATION", 135, 147], ["infected avian species", "OBSERVATION", 170, 192]]], ["ND: not detected; LPAI: low-pathogenic avian influenza. * Primers and probes set for M gene specific performed using the protocol from the WHO manual on animal influenza diagnosis and surveillance [21] . + Influenza positive sample. ** All sequences were confirmed from GenBank at the National Center for Biotechnology Information (NCBI) or the Influenza Research Database (IRD, www.fludb.org).", [["influenza", "DISEASE", 45, 54], ["avian", "ORGANISM", 39, 44], ["M gene", "DNA", 85, 91], ["avian", "SPECIES", 39, 44], ["ND", "PROBLEM", 0, 2], ["influenza", "PROBLEM", 45, 54], ["the protocol", "TREATMENT", 117, 129], ["animal influenza diagnosis", "TEST", 153, 179], ["surveillance", "TEST", 184, 196], ["Influenza positive sample", "PROBLEM", 206, 231], ["All sequences", "TEST", 236, 249]]], ["Each concentration had triple replicates.DiscussionSince H5N1 HPAI viruses was first identified in 1996, diverse subtypes of H5 HPAI were classified.", [["H5N1 HPAI viruses", "DISEASE", 57, 74], ["HPAI", "DISEASE", 128, 132], ["DiscussionSince H5N1 HPAI viruses", "ORGANISM", 41, 74], ["H5 HPAI", "ORGANISM", 125, 132], ["H5N1 HPAI", "SPECIES", 57, 66], ["H5 HPAI", "SPECIES", 125, 132], ["triple replicates", "TREATMENT", 23, 40], ["H5N1 HPAI viruses", "PROBLEM", 57, 74], ["H5 HPAI", "PROBLEM", 125, 132]]], ["Global and domestic spread of these virus caused huge losses to the poultry industry [18] .", [["Global and domestic spread", "PROBLEM", 0, 26], ["these virus", "PROBLEM", 30, 41], ["huge losses", "PROBLEM", 49, 60], ["domestic", "OBSERVATION_MODIFIER", 11, 19], ["spread", "OBSERVATION_MODIFIER", 20, 26], ["huge", "OBSERVATION_MODIFIER", 49, 53], ["losses", "OBSERVATION_MODIFIER", 54, 60]]], ["Novel H5Nx HPAI viruses appeared due to reassortment of the HA gene with different NA genes.", [["H5Nx HPAI viruses", "ORGANISM", 6, 23], ["HA", "GENE_OR_GENE_PRODUCT", 60, 62], ["HA gene", "DNA", 60, 67], ["NA genes", "DNA", 83, 91], ["Novel H5Nx HPAI viruses", "PROBLEM", 0, 23]]], ["According to the WHO report [22] , H5Nx [24] , Vietnam [25] , and Laos [26] between 2013 and 2016.DiscussionDespite many efforts to control the spread of H5 HPAI viruses [27] in poultry, such as development of a vaccine and diagnostic systems [28] , viruses evolved and infected wild birds and domestic poultry.", [["H5 HPAI viruses", "ORGANISM", 154, 169], ["H5 HPAI viruses", "SPECIES", 154, 169], ["H5 HPAI viruses", "SPECIES", 154, 169], ["H5 HPAI viruses", "PROBLEM", 154, 169], ["a vaccine", "TREATMENT", 210, 219], ["diagnostic systems", "TEST", 224, 242], ["viruses", "TREATMENT", 250, 257], ["infected", "OBSERVATION_MODIFIER", 270, 278], ["wild birds", "OBSERVATION", 279, 289], ["domestic poultry", "OBSERVATION", 294, 310]]], ["In particular, to effectively monitor and control H5Nx HPAI virus transmission, a number of diagnostic techniques, including virus isolation and conventional RT-qPCR, have been reported [29] .", [["H5Nx HPAI virus", "ORGANISM", 50, 65], ["H5Nx HPAI virus", "SPECIES", 50, 65], ["diagnostic techniques", "TEST", 92, 113], ["virus isolation", "TREATMENT", 125, 140], ["conventional RT-qPCR", "TEST", 145, 165]]], ["Virus isolation is the gold standard for influenza virus diagnosis, but it is time-consuming, expensive, and not suitable for discrimination of multiple HPAI viruses.", [["HPAI", "DISEASE", 153, 157], ["Virus", "ORGANISM", 0, 5], ["influenza virus", "ORGANISM", 41, 56], ["HPAI viruses", "ORGANISM", 153, 165], ["influenza virus", "SPECIES", 41, 56], ["HPAI viruses", "SPECIES", 153, 165], ["Virus isolation", "TREATMENT", 0, 15], ["influenza virus diagnosis", "PROBLEM", 41, 66], ["multiple HPAI viruses", "PROBLEM", 144, 165], ["multiple", "OBSERVATION_MODIFIER", 144, 152], ["HPAI viruses", "OBSERVATION", 153, 165]]], ["The conventional RT-qPCR assay is well-known and useful for molecular detection of influenza viruses such as influenza virus subtyping and positive detection using matrix gene detection [30] .", [["influenza viruses", "DISEASE", 83, 100], ["influenza viruses", "ORGANISM", 83, 100], ["influenza virus", "ORGANISM", 109, 124], ["matrix", "CELLULAR_COMPONENT", 164, 170], ["influenza virus", "SPECIES", 109, 124], ["influenza virus", "SPECIES", 109, 124], ["The conventional RT-qPCR assay", "TEST", 0, 30], ["molecular detection", "TEST", 60, 79], ["influenza viruses", "PROBLEM", 83, 100], ["influenza virus subtyping", "PROBLEM", 109, 134], ["matrix gene detection", "TEST", 164, 185], ["influenza viruses", "OBSERVATION", 83, 100]]], ["In particular, this method detects the fluorescence signal of a positive sample in real time due to using of the target-specific probe/primers, resulting in high sensitivity and specificity.", [["sample", "ANATOMY", 73, 79], ["this method", "TEST", 15, 26], ["a positive sample", "PROBLEM", 62, 79], ["specific probe/primers", "TREATMENT", 120, 142], ["high sensitivity", "PROBLEM", 157, 173]]], ["Therefore, the RT-qPCR assay could be widely used as molecular diagnostic technology in clinical fields.", [["the RT-qPCR assay", "TEST", 11, 28]]], ["To detect H5 HPAI virus and difference of H5 HPAI clade viruses in clinical samples, a multiplex RT-qPCR assay has been developed using several pairs of primers and probes [29, 31, 32] .", [["samples", "ANATOMY", 76, 83], ["H5 HPAI virus", "ORGANISM", 10, 23], ["H5 HPAI", "ORGANISM", 42, 49], ["H5 HPAI virus", "SPECIES", 10, 23], ["H5 HPAI virus", "SPECIES", 10, 23], ["H5 HPAI clade viruses", "SPECIES", 42, 63], ["H5 HPAI virus", "PROBLEM", 10, 23], ["H5 HPAI clade viruses", "PROBLEM", 42, 63], ["clinical samples", "TEST", 67, 83], ["a multiplex RT-qPCR assay", "TEST", 85, 110]]], ["However, some drawbacks are the reduced specificity and sensitivity of the target gene amplification due to the nonspecific interaction among primers and probes in the same reaction [32] .DiscussionIn this study, novel primers and probes were designed for the pan-H5 HPAI detection and the classification of two clades of H5 HPAI, 2.3.4.4 or 2.3.3.1, in field samples.", [["samples", "ANATOMY", 360, 367], ["H5 HPAI", "ORGANISM", 322, 329], ["H5 HPAI", "SPECIES", 322, 329], ["the target gene amplification", "TREATMENT", 71, 100], ["the nonspecific interaction among primers", "PROBLEM", 108, 149], ["this study", "TEST", 201, 211], ["the pan-H5 HPAI detection", "TEST", 256, 281], ["H5 HPAI", "TEST", 322, 329]]], ["Our one-step multiplex RT-qPCR assay was successfully employed to amplify viruses and IAV-positive field samples using novel primers/probes for the simultaneous detection of pan-H5 HPAI and two clades without cross-reactivity.", [["samples", "ANATOMY", 105, 112], ["HPAI", "DISEASE", 181, 185], ["IAV", "ORGANISM", 86, 89], ["pan-H5 HPAI", "ORGANISM", 174, 185], ["IAV", "SPECIES", 86, 89], ["qPCR assay", "TEST", 26, 36], ["viruses", "PROBLEM", 74, 81], ["IAV", "PROBLEM", 86, 89], ["novel primers/probes", "TREATMENT", 119, 139], ["the simultaneous detection", "TEST", 144, 170], ["pan-H5 HPAI", "TREATMENT", 174, 185]]], ["To enhance the specificity of target detection, we designed a new single primer set and each probe for the conserved sequences of H5 HPAI.", [["HPAI", "DISEASE", 133, 137], ["H5 HPAI", "ORGANISM", 130, 137], ["H5 HPAI", "SPECIES", 130, 137], ["a new single primer set and each probe", "TREATMENT", 60, 98], ["H5 HPAI", "PROBLEM", 130, 137]]], ["After testing the IAV-positive clinical field samples, 51 were H5 HPAI positive and the cycle threshold values of these positive samples ranged from around 20 to 24.", [["samples", "ANATOMY", 46, 53], ["samples", "ANATOMY", 129, 136], ["IAV", "ORGANISM", 18, 21], ["H5 HPAI", "SPECIES", 63, 70], ["the IAV", "TEST", 14, 21], ["clinical field samples", "TEST", 31, 53], ["H5 HPAI", "TEST", 63, 70], ["the cycle threshold values", "TEST", 84, 110], ["these positive samples", "TEST", 114, 136]]], ["Moreover, all H5 HPAI-positive samples were sequenced, and the results were verified by GenBank BLAST processing.", [["samples", "ANATOMY", 31, 38], ["H5 HPAI", "ORGANISM", 14, 21], ["all H5 HPAI", "TEST", 10, 21]]], ["Interestingly, the limit of detection of pan-H5 HPAI and clades in the singleplex and multiplex RT-qPCR assays was the same when our new single primer set and each probe combination was used.ConclusionsOur one-step multiplex RT-qPCR method ensures highly specific and sensitive simultaneous detection of pan-H5 HPAI and two clades of H5 HPAI.", [["HPAI", "DISEASE", 311, 315], ["HPAI", "DISEASE", 337, 341], ["pan-H5 HPAI", "ORGANISM", 41, 52], ["pan-H5 HPAI", "ORGANISM", 304, 315], ["H5 HPAI", "ORGANISM", 334, 341], ["H5 HPAI", "SPECIES", 334, 341], ["pan-H5 HPAI", "TREATMENT", 41, 52], ["the singleplex", "TEST", 67, 81], ["multiplex RT-qPCR assays", "TEST", 86, 110], ["ConclusionsOur", "TEST", 191, 205], ["pan-H5 HPAI", "PROBLEM", 304, 315], ["HPAI", "PROBLEM", 337, 341], ["H5 HPAI", "OBSERVATION", 334, 341]]], ["Our method development focused on pan-H5 HPAI and two clades of H5 HPAI virus, 2.", [["pan-H5 HPAI", "ORGANISM", 34, 45], ["H5 HPAI virus", "ORGANISM", 64, 77], ["H5 HPAI virus", "SPECIES", 64, 77], ["H5 HPAI virus", "SPECIES", 64, 77], ["pan-H5 HPAI", "TREATMENT", 34, 45], ["H5 HPAI virus", "PROBLEM", 64, 77]]]], "PMC7501147": [["Authors\u2019 contributionsDO, AE, LW and JM designed the study.", [["the study", "TEST", 49, 58]]]], "d21d5102b9e1e76889d79cd888fe79ca0de58c6a": [["BackgroundObesity, measured as body mass index (BMI), is reported to associate with increase the risk of developing severe pneumonia in COVID-19 [1] .", [["body", "ANATOMY", 31, 35], ["pneumonia", "DISEASE", 123, 132], ["body", "ORGANISM_SUBDIVISION", 31, 35], ["BackgroundObesity", "PROBLEM", 0, 17], ["body mass index", "PROBLEM", 31, 46], ["developing severe pneumonia", "PROBLEM", 105, 132], ["COVID", "TEST", 136, 141], ["body", "OBSERVATION_MODIFIER", 31, 35], ["mass", "OBSERVATION", 36, 40], ["severe", "OBSERVATION_MODIFIER", 116, 122], ["pneumonia", "OBSERVATION", 123, 132]]], ["Indeed, the risk correlated to obesity with COVID-19 severity is greater in metabolic associated fatty liver patients [2] .", [["fatty liver", "ANATOMY", 97, 108], ["obesity", "DISEASE", 31, 38], ["fatty liver", "DISEASE", 97, 108], ["COVID-19", "GENE_OR_GENE_PRODUCT", 44, 52], ["liver", "ORGAN", 103, 108], ["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 109, 117], ["obesity", "PROBLEM", 31, 38], ["COVID", "TEST", 44, 49], ["obesity", "OBSERVATION", 31, 38], ["greater", "OBSERVATION_MODIFIER", 65, 72], ["fatty liver", "OBSERVATION", 97, 108]]], ["At the basis, we found altered mechanism of inflammation and immune response typic of obesity and correlated with alteration in the levels of circulating cytokines [3] .", [["inflammation", "DISEASE", 44, 56], ["obesity", "DISEASE", 86, 93], ["circulating cytokines", "PROTEIN", 142, 163], ["inflammation", "PROBLEM", 44, 56], ["immune response", "PROBLEM", 61, 76], ["obesity", "PROBLEM", 86, 93], ["alteration in the levels of circulating cytokines", "PROBLEM", 114, 163], ["inflammation", "OBSERVATION", 44, 56], ["obesity", "OBSERVATION", 86, 93]]], ["In particular, obese patients have higher concentrations of TNF-alpha, MCP-1 and IL-6 which are produced by visceral and subcutaneous adipose tissue and implicated in innate immunity [4, 5] .BackgroundFurthermore, adipose tissue releases high levels of leptin, which creates an unfavorable inflammatory milieu that leads to dysregulation of the immune response [6] .BackgroundIn 2009, during H1N1 pandemia, in obese patients it was characterized changing of differentiation of B cells [7, 8] , predisposing to a greater risk of contracting influence, but also of being more contagious towards other people [9] .", [["visceral", "ANATOMY", 108, 116], ["subcutaneous adipose tissue", "ANATOMY", 121, 148], ["adipose tissue", "ANATOMY", 214, 228], ["B cells", "ANATOMY", 477, 484], ["H1N1 pandemia", "DISEASE", 392, 405], ["patients", "ORGANISM", 21, 29], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 60, 69], ["MCP-1", "GENE_OR_GENE_PRODUCT", 71, 76], ["IL-6", "GENE_OR_GENE_PRODUCT", 81, 85], ["visceral", "TISSUE", 108, 116], ["subcutaneous adipose tissue", "TISSUE", 121, 148], ["adipose tissue", "TISSUE", 214, 228], ["leptin", "GENE_OR_GENE_PRODUCT", 253, 259], ["patients", "ORGANISM", 416, 424], ["B cells", "CELL", 477, 484], ["people", "ORGANISM", 599, 605], ["TNF-alpha", "PROTEIN", 60, 69], ["MCP-1", "PROTEIN", 71, 76], ["IL-6", "PROTEIN", 81, 85], ["leptin", "PROTEIN", 253, 259], ["B cells", "CELL_TYPE", 477, 484], ["patients", "SPECIES", 21, 29], ["patients", "SPECIES", 416, 424], ["people", "SPECIES", 599, 605], ["TNF", "TEST", 60, 63], ["alpha", "TEST", 64, 69], ["MCP", "TEST", 71, 74], ["IL", "TEST", 81, 83], ["visceral and subcutaneous adipose tissue", "PROBLEM", 108, 148], ["high levels of leptin", "PROBLEM", 238, 259], ["an unfavorable inflammatory milieu", "PROBLEM", 275, 309], ["B cells", "PROBLEM", 477, 484], ["contracting influence", "PROBLEM", 528, 549], ["obese", "OBSERVATION", 15, 20], ["higher concentrations", "OBSERVATION_MODIFIER", 35, 56], ["TNF", "ANATOMY", 60, 63], ["alpha", "ANATOMY", 64, 69], ["visceral", "ANATOMY", 108, 116], ["subcutaneous adipose", "ANATOMY", 121, 141], ["adipose tissue", "OBSERVATION", 214, 228], ["high", "OBSERVATION_MODIFIER", 238, 242], ["unfavorable", "OBSERVATION_MODIFIER", 278, 289], ["inflammatory", "OBSERVATION", 290, 302], ["greater", "OBSERVATION_MODIFIER", 512, 519], ["contracting influence", "OBSERVATION", 528, 549]]], ["However, they have impaired memory T cell response and vaccination efficacy [10] .", [["T cell", "ANATOMY", 35, 41], ["memory T cell", "CELL", 28, 41], ["impaired", "OBSERVATION_MODIFIER", 19, 27], ["memory T cell", "OBSERVATION", 28, 41]]], ["Specifically, reduced response of virus-specific CD8 + lymphocytes and suboptimal macrophage functionality have been demonstrated, which could explain the low response to the vaccine stimulus [11] .BackgroundFor COVID-19, in Intensive Care Unit (ICU), it was observed that the highest percentage are patients affects by severe obesity, with BMI > 35 kg/m 2 [12] .BackgroundThe BMI does not reflect necessarily the fat mass (FM).", [["CD8 + lymphocytes", "ANATOMY", 49, 66], ["macrophage", "ANATOMY", 82, 92], ["fat mass", "ANATOMY", 414, 422], ["obesity", "DISEASE", 327, 334], ["CD8", "GENE_OR_GENE_PRODUCT", 49, 52], ["macrophage", "CELL", 82, 92], ["patients", "ORGANISM", 300, 308], ["fat", "TISSUE", 414, 417], ["CD8 + lymphocytes", "CELL_TYPE", 49, 66], ["patients", "SPECIES", 300, 308], ["virus", "PROBLEM", 34, 39], ["lymphocytes", "PROBLEM", 55, 66], ["suboptimal macrophage functionality", "PROBLEM", 71, 106], ["the vaccine stimulus", "TREATMENT", 171, 191], ["COVID", "TEST", 212, 217], ["severe obesity", "PROBLEM", 320, 334], ["BMI", "TEST", 341, 344], ["the fat mass", "PROBLEM", 410, 422], ["reduced", "OBSERVATION_MODIFIER", 14, 21], ["response", "OBSERVATION_MODIFIER", 22, 30], ["virus", "OBSERVATION_MODIFIER", 34, 39], ["lymphocytes", "ANATOMY", 55, 66], ["suboptimal", "OBSERVATION_MODIFIER", 71, 81], ["macrophage functionality", "OBSERVATION", 82, 106], ["low response", "OBSERVATION_MODIFIER", 155, 167], ["severe", "OBSERVATION_MODIFIER", 320, 326], ["obesity", "OBSERVATION", 327, 334], ["does not reflect necessarily", "UNCERTAINTY", 381, 409], ["fat", "ANATOMY", 414, 417], ["mass", "OBSERVATION", 418, 422]]], ["There are evidence that suggest how FM% rather than BMI, predicts inflammatory (TNF-alpha, MCP-1 and IL-6) and immune (leptin) response.", [["TNF-alpha", "GENE_OR_GENE_PRODUCT", 80, 89], ["MCP-1", "GENE_OR_GENE_PRODUCT", 91, 96], ["IL-6", "GENE_OR_GENE_PRODUCT", 101, 105], ["leptin", "GENE_OR_GENE_PRODUCT", 119, 125], ["TNF", "PROTEIN", 80, 83], ["MCP", "PROTEIN", 91, 94], ["IL-6", "PROTEIN", 101, 105], ["BMI", "TEST", 52, 55], ["inflammatory", "TEST", 66, 78], ["TNF", "TEST", 80, 83], ["alpha", "TEST", 84, 89], ["MCP", "TEST", 91, 94], ["IL", "TEST", 101, 103], ["inflammatory", "OBSERVATION_MODIFIER", 66, 78]]], ["These ultimate variables that relates with immune and inflammatory response in FM% [13] .BackgroundDespite the relationship between FM% and severity of progression inflammatory response in patients admitted to ICU for underlying infective disease, there are no available data on the relevance of FM% in COVID-19 patients treated in ICU.BackgroundMoreover, prognostic nutritional index (PNI) can be used to evaluate the nutritional status and survival for ICU patients [14] .BackgroundAim of this prospective observational study, in patients admitted to ICU for COVID-19, is to evaluate the relationship between FM% and immune-inflammatory response, after 10 days in ICU.BackgroundAlso, we want to investigate the metabolic associated fatty liver and PNI and the comparison between FM% and BMI.Subjects and methodsAfter IRB approval (Regional Ethic Committee, Section \"Area Sud\", 20th April, 2020) and having obtained the signed informed consent by the next of kin, clinical and anthropometric data of patients with COVID-19 pneumonia admitted to the ICU of the Hospital \"Bianchi Melacrino Morelli\" Reggio Calabria, Italy between 13 March and 6 April 2020, were recorded and analyzed.", [["fatty liver", "ANATOMY", 734, 745], ["infective disease", "DISEASE", 229, 246], ["fatty liver", "DISEASE", 734, 745], ["pneumonia", "DISEASE", 1024, 1033], ["FM", "MULTI-TISSUE_STRUCTURE", 132, 134], ["patients", "ORGANISM", 189, 197], ["patients", "ORGANISM", 312, 320], ["patients", "ORGANISM", 459, 467], ["patients", "ORGANISM", 532, 540], ["liver", "ORGAN", 740, 745], ["patients", "ORGANISM", 1001, 1009], ["patients", "SPECIES", 189, 197], ["patients", "SPECIES", 312, 320], ["patients", "SPECIES", 459, 467], ["patients", "SPECIES", 532, 540], ["patients", "SPECIES", 1001, 1009], ["immune and inflammatory response", "PROBLEM", 43, 75], ["progression inflammatory response", "PROBLEM", 152, 185], ["underlying infective disease", "PROBLEM", 218, 246], ["this prospective observational study", "TEST", 491, 527], ["COVID", "TEST", 561, 566], ["the metabolic associated fatty liver", "PROBLEM", 709, 745], ["PNI", "PROBLEM", 750, 753], ["BMI", "PROBLEM", 789, 792], ["COVID", "TEST", 1015, 1020], ["pneumonia", "PROBLEM", 1024, 1033], ["inflammatory", "OBSERVATION_MODIFIER", 54, 66], ["progression", "OBSERVATION_MODIFIER", 152, 163], ["inflammatory", "OBSERVATION_MODIFIER", 164, 176], ["infective", "OBSERVATION", 229, 238], ["inflammatory", "OBSERVATION", 626, 638], ["fatty", "OBSERVATION", 734, 739], ["liver", "ANATOMY", 740, 745], ["PNI", "OBSERVATION", 750, 753], ["pneumonia", "OBSERVATION", 1024, 1033]]], ["Standard therapeutic protocol included, for all patients: low molecular weight heparin (LMWH), azithromycin, hydroxychloroquine, lopinavir/ritonavir.", [["heparin", "CHEMICAL", 79, 86], ["LMWH", "CHEMICAL", 88, 92], ["azithromycin", "CHEMICAL", 95, 107], ["hydroxychloroquine", "CHEMICAL", 109, 127], ["lopinavir/ritonavir", "CHEMICAL", 129, 148], ["azithromycin", "CHEMICAL", 95, 107], ["hydroxychloroquine", "CHEMICAL", 109, 127], ["lopinavir", "CHEMICAL", 129, 138], ["ritonavir", "CHEMICAL", 139, 148], ["patients", "ORGANISM", 48, 56], ["low molecular weight heparin", "SIMPLE_CHEMICAL", 58, 86], ["LMWH", "SIMPLE_CHEMICAL", 88, 92], ["azithromycin", "SIMPLE_CHEMICAL", 95, 107], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 109, 127], ["lopinavir", "SIMPLE_CHEMICAL", 129, 138], ["ritonavir", "SIMPLE_CHEMICAL", 139, 148], ["patients", "SPECIES", 48, 56], ["Standard therapeutic protocol", "TREATMENT", 0, 29], ["low molecular weight heparin (LMWH)", "TREATMENT", 58, 93], ["azithromycin", "TREATMENT", 95, 107], ["hydroxychloroquine", "TREATMENT", 109, 127], ["lopinavir", "TREATMENT", 129, 138], ["ritonavir", "TREATMENT", 139, 148]]], ["Prospective observational study of 22 adult patients affected by COVID-19 pneumonia and admitted to the ICU.", [["pneumonia", "DISEASE", 74, 83], ["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["Prospective observational study", "TEST", 0, 31], ["COVID", "TEST", 65, 70], ["pneumonia", "PROBLEM", 74, 83], ["pneumonia", "OBSERVATION", 74, 83]]], ["Patients with a history of neutropenia, acquired immunodeficiency, who underwent transplants or who received previous immunosuppressive therapies were excluded.Subjects and methodsRather than considering only the BMI, patients recruited in this study were categorized in two sets: \"lean\" or \"obese\" according to FM% and age, based on criteria presented by De Lorenzo [15] .Subjects and methodsComputed tomography (CT) (GE Medical SYSTEMS, Gamma Optima, USA) without intravenous contrast was performed within 24 h of admission to the emergency department.Subjects and methodsHepatic steatosis was evaluated on CT images in 4 liver segments, independently, by 2 qualified operators (LR and CF) [16] .", [["intravenous", "ANATOMY", 466, 477], ["Hepatic", "ANATOMY", 574, 581], ["liver", "ANATOMY", 624, 629], ["neutropenia", "DISEASE", 27, 38], ["immunodeficiency", "DISEASE", 49, 65], ["steatosis", "DISEASE", 582, 591], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 218, 226], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 466, 477], ["Hepatic", "ORGAN", 574, 581], ["liver", "ORGAN", 624, 629], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 218, 226], ["neutropenia", "PROBLEM", 27, 38], ["acquired immunodeficiency", "PROBLEM", 40, 65], ["transplants", "TREATMENT", 81, 92], ["previous immunosuppressive therapies", "TREATMENT", 109, 145], ["the BMI", "PROBLEM", 209, 216], ["this study", "TEST", 240, 250], ["Computed tomography", "TEST", 393, 412], ["Hepatic steatosis", "PROBLEM", 574, 591], ["CT images", "TEST", 609, 618], ["neutropenia", "OBSERVATION", 27, 38], ["steatosis", "OBSERVATION", 582, 591], ["liver", "ANATOMY", 624, 629], ["segments", "ANATOMY_MODIFIER", 630, 638]]], ["Liver Spleen Ration (LRS) was calculated If reported difference between the measures were > 5%, a third operator was asked to repeat the evaluation of CT.", [["Liver Spleen", "ANATOMY", 0, 12], ["Liver Spleen", "MULTI-TISSUE_STRUCTURE", 0, 12], ["the evaluation", "TEST", 133, 147], ["CT", "TEST", 151, 153], ["Spleen", "ANATOMY", 6, 12]]], ["From CT chest image, waist circumference was measured at the last rib with distance measurement tools.", [["waist", "ANATOMY", 21, 26], ["waist", "ORGANISM_SUBDIVISION", 21, 26], ["rib", "ORGAN", 66, 69], ["CT chest image", "TEST", 5, 19], ["waist circumference", "TEST", 21, 40], ["distance measurement tools", "TEST", 75, 101], ["chest", "ANATOMY", 8, 13], ["rib", "ANATOMY", 66, 69]]], ["Where part of the abdomen was outside the field of the image, waist circumference was estimated with a continuous arc [16] .", [["abdomen", "ANATOMY", 18, 25], ["abdomen", "ORGAN", 18, 25], ["waist", "ORGANISM_SUBDIVISION", 62, 67], ["waist circumference", "TEST", 62, 81], ["a continuous arc", "TREATMENT", 101, 117], ["abdomen", "ANATOMY", 18, 25]]], ["To estimate the FM% we used the Siri Eq.", [["Siri Eq.", "SPECIES", 32, 40]]], ["The subcutaneous fat thickness was measured at CT, given the agreement between the CT and plicometry method [18] .", [["subcutaneous fat", "ANATOMY", 4, 20], ["subcutaneous fat", "TISSUE", 4, 20], ["The subcutaneous fat thickness", "TEST", 0, 30], ["CT", "TEST", 47, 49], ["the CT", "TEST", 79, 85], ["subcutaneous fat", "ANATOMY", 4, 20]]], ["Body density was obtained by the equation of Durnin, using two subcutaneous fat thicknesses of the chest, suprascapular and suprailiac and the correction factors according to age, sex and folds used [19] .", [["Body", "ANATOMY", 0, 4], ["subcutaneous fat", "ANATOMY", 63, 79], ["chest", "ANATOMY", 99, 104], ["suprascapular", "ANATOMY", 106, 119], ["suprailiac", "ANATOMY", 124, 134], ["Body", "TISSUE", 0, 4], ["fat", "TISSUE", 76, 79], ["chest", "ORGAN", 99, 104], ["suprascapular", "MULTI-TISSUE_STRUCTURE", 106, 119], ["Durnin", "TREATMENT", 45, 51], ["two subcutaneous fat thicknesses of the chest", "TREATMENT", 59, 104], ["density", "OBSERVATION", 5, 12], ["chest", "ANATOMY", 99, 104], ["suprascapular", "ANATOMY", 106, 119], ["suprailiac", "ANATOMY", 124, 134]]], ["All CTs were performed with patients in the supine position with arms folded and hands positioned under neck.", [["neck", "ANATOMY", 104, 108], ["patients", "ORGANISM", 28, 36], ["hands", "ORGANISM_SUBDIVISION", 81, 86], ["neck", "ORGANISM_SUBDIVISION", 104, 108], ["patients", "SPECIES", 28, 36], ["All CTs", "TEST", 0, 7], ["arms folded and hands positioned under neck", "PROBLEM", 65, 108], ["arms", "ANATOMY", 65, 69], ["hands", "ANATOMY", 81, 86], ["neck", "ANATOMY", 104, 108]]], ["The subscapular fat thickness was measured in cross section starting from the origin of the scapular spine on the posterior medial edge up to the skin.", [["subscapular fat", "ANATOMY", 4, 19], ["scapular spine", "ANATOMY", 92, 106], ["medial edge", "ANATOMY", 124, 135], ["skin", "ANATOMY", 146, 150], ["subscapular fat", "TISSUE", 4, 19], ["scapular spine", "MULTI-TISSUE_STRUCTURE", 92, 106], ["posterior medial edge", "MULTI-TISSUE_STRUCTURE", 114, 135], ["skin", "ORGAN", 146, 150], ["cross section", "TREATMENT", 46, 59], ["subscapular fat", "ANATOMY", 4, 19], ["thickness", "OBSERVATION_MODIFIER", 20, 29], ["origin", "ANATOMY_MODIFIER", 78, 84], ["scapular spine", "ANATOMY", 92, 106], ["posterior", "ANATOMY_MODIFIER", 114, 123], ["medial", "ANATOMY_MODIFIER", 124, 130], ["edge", "ANATOMY_MODIFIER", 131, 135], ["skin", "ANATOMY", 146, 150]]], ["The suprailiac fat thickness was measured in cross Sect.", [["suprailiac fat", "ANATOMY", 4, 18], ["suprailiac fat", "TISSUE", 4, 18], ["suprailiac fat", "ANATOMY", 4, 18], ["thickness", "OBSERVATION_MODIFIER", 19, 28], ["cross Sect", "OBSERVATION_MODIFIER", 45, 55]]], ["2 cm from the last rib on the middle axillary line up to the skin.", [["rib", "ANATOMY", 19, 22], ["axillary line", "ANATOMY", 37, 50], ["skin", "ANATOMY", 61, 65], ["rib", "ORGAN", 19, 22], ["skin", "ORGAN", 61, 65], ["rib", "ANATOMY", 19, 22], ["middle", "ANATOMY_MODIFIER", 30, 36], ["axillary", "ANATOMY", 37, 45], ["line", "OBSERVATION", 46, 50], ["skin", "ANATOMY", 61, 65]]], ["The subcutaneous fat thickness parameters were measured two times on CT.", [["subcutaneous fat", "ANATOMY", 4, 20], ["subcutaneous fat", "TISSUE", 4, 20], ["The subcutaneous fat thickness parameters", "TEST", 0, 41], ["CT", "TEST", 69, 71], ["subcutaneous fat", "ANATOMY", 4, 20]]], ["Only at baseline, CT was used to estimated FM% to stratificate the sample.", [["CT", "TEST", 18, 20], ["the sample", "TEST", 63, 73]]], ["The BMI was calculated as weight (kg) divided by height (m) squared and the patients were classified as follows: obese (OB) for BMI > 29.99 kg/ m 2 , pre obese (PO) for BMI between 25.00 kg/m 2 and 29.99 kg/m 2 , normal weight (NW) for BMI between 18.50 and 24.99 kg/m 2 .Subjects and methodsPrognostic nutritional index (PNI) was calculated for each patient as a serum albumin (g/dL) \u00d7 10 + total lymphocyte count (mm \u2212 3) \u00d7 0.005 [20] .Subjects and methodsThe following blood analysis were performed: C-reactive protein (mg/L), glycemia (mg/dL), creatinine (mg/ dL), albumin (g/dL), AST (U/L), ALT (U/L), indirect bilirubin (mg/dl), total bilirubin (mg/dl), direct bilirubin (mg/dl), Platelets (10 3 /\u03bcL), white blood cells (WBC) (10 3 / \u03bcL), neutrophils (10 3 /\u03bcL), Lymphocytes (10 3 /\u03bcL), PNI, fibrinogen (mg/dL), D-dimer (ng/mL).StatisticsCalculation of the sample size was based on a comparison between matched pairs, a power of 80%, a significance level of 5% (two-tails) and the detection of an effect size of 0.6 between the pairs.", [["serum", "ANATOMY", 364, 369], ["lymphocyte", "ANATOMY", 398, 408], ["blood", "ANATOMY", 472, 477], ["Platelets", "ANATOMY", 686, 695], ["white blood cells", "ANATOMY", 708, 725], ["WBC", "ANATOMY", 727, 730], ["neutrophils", "ANATOMY", 745, 756], ["Lymphocytes", "ANATOMY", 769, 780], ["creatinine", "CHEMICAL", 548, 558], ["bilirubin", "CHEMICAL", 616, 625], ["bilirubin", "CHEMICAL", 641, 650], ["bilirubin", "CHEMICAL", 667, 676], ["creatinine", "CHEMICAL", 548, 558], ["bilirubin", "CHEMICAL", 616, 625], ["bilirubin", "CHEMICAL", 641, 650], ["bilirubin", "CHEMICAL", 667, 676], ["patients", "ORGANISM", 76, 84], ["patient", "ORGANISM", 351, 358], ["serum", "ORGANISM_SUBSTANCE", 364, 369], ["albumin", "GENE_OR_GENE_PRODUCT", 370, 377], ["lymphocyte", "CELL", 398, 408], ["blood", "ORGANISM_SUBSTANCE", 472, 477], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 503, 521], ["creatinine", "SIMPLE_CHEMICAL", 548, 558], ["albumin", "GENE_OR_GENE_PRODUCT", 569, 576], ["AST", "SIMPLE_CHEMICAL", 585, 588], ["U/L", "GENE_OR_GENE_PRODUCT", 590, 593], ["ALT", "SIMPLE_CHEMICAL", 596, 599], ["U/L", "GENE_OR_GENE_PRODUCT", 601, 604], ["bilirubin", "GENE_OR_GENE_PRODUCT", 616, 625], ["bilirubin", "GENE_OR_GENE_PRODUCT", 641, 650], ["bilirubin", "GENE_OR_GENE_PRODUCT", 667, 676], ["Platelets", "CELL", 686, 695], ["white blood cells", "CELL", 708, 725], ["WBC", "CELL", 727, 730], ["neutrophils", "CELL", 745, 756], ["Lymphocytes", "CELL", 769, 780], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 798, 808], ["D-dimer", "SIMPLE_CHEMICAL", 818, 825], ["C-reactive protein", "PROTEIN", 503, 521], ["albumin", "PROTEIN", 569, 576], ["AST", "PROTEIN", 585, 588], ["ALT", "PROTEIN", 596, 599], ["Platelets", "CELL_TYPE", 686, 695], ["white blood cells", "CELL_TYPE", 708, 725], ["WBC", "CELL_TYPE", 727, 730], ["neutrophils", "CELL_TYPE", 745, 756], ["Lymphocytes", "CELL_TYPE", 769, 780], ["PNI", "PROTEIN", 793, 796], ["fibrinogen", "PROTEIN", 798, 808], ["D-dimer", "PROTEIN", 818, 825], ["patients", "SPECIES", 76, 84], ["patient", "SPECIES", 351, 358], ["The BMI", "TEST", 0, 7], ["BMI", "TEST", 128, 131], ["BMI", "TEST", 169, 172], ["BMI", "TEST", 236, 239], ["Prognostic nutritional index", "PROBLEM", 292, 320], ["a serum albumin", "TEST", 362, 377], ["total lymphocyte count", "TEST", 392, 414], ["The following blood analysis", "TEST", 458, 486], ["C", "TEST", 503, 504], ["reactive protein", "TEST", 505, 521], ["mg", "TEST", 523, 525], ["glycemia", "TEST", 530, 538], ["dL", "TEST", 543, 545], ["creatinine", "TEST", 548, 558], ["albumin", "TEST", 569, 576], ["dL", "TEST", 580, 582], ["AST", "TEST", 585, 588], ["U", "TEST", 590, 591], ["ALT", "TEST", 596, 599], ["U", "TEST", 601, 602], ["indirect bilirubin", "TEST", 607, 625], ["dl", "TEST", 630, 632], ["total bilirubin", "TEST", 635, 650], ["direct bilirubin", "TEST", 660, 676], ["dl", "TEST", 681, 683], ["Platelets", "TEST", 686, 695], ["white blood cells", "TEST", 708, 725], ["WBC", "TEST", 727, 730], ["neutrophils", "TEST", 745, 756], ["Lymphocytes", "TEST", 769, 780], ["PNI", "TEST", 793, 796], ["fibrinogen", "TEST", 798, 808], ["mg", "TEST", 810, 812], ["dL", "TEST", 813, 815], ["D-dimer", "TEST", 818, 825], ["the sample size", "TEST", 859, 874], ["the detection", "TEST", 983, 996], ["an effect size", "TEST", 1000, 1014], ["size", "OBSERVATION_MODIFIER", 870, 874], ["effect", "OBSERVATION_MODIFIER", 1003, 1009], ["size", "OBSERVATION_MODIFIER", 1010, 1014]]], ["According to the study setting, necessary calculated sample size is 20 patients and the G*Power software (Version 3.1.9.6, Germany) was used.", [["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["Power software", "TEST", 90, 104], ["Version", "TEST", 106, 113], ["size", "OBSERVATION_MODIFIER", 60, 64]]], ["[21] Since 20% of the sample may not have all the expected parameters, 24 subjects were enrolled.StatisticsAll statistical analyzes were conducted with SPSS 23 software (version 23.0, IBM, Armonk, NY, USA).", [["SPSS", "TEST", 152, 156]]], ["The data collected before statistical evaluations were analyzed for the presence of outliners and for non-normally distribution with the Kolmogorov-Smirnov Test.", [["The data", "TEST", 0, 8], ["statistical evaluations", "TEST", 26, 49], ["the Kolmogorov-Smirnov Test", "TEST", 133, 160]]], ["Before, the differences between lean and obese subjects were assessed at admission with the Mann Whitney test for independent samples.", [["obese", "OBSERVATION", 41, 46]]], ["Subsequently, the differences in lean and obese subjects were assessed between admission and 10th day with the Wilcox test for matched pairs.", [["lean", "ORGANISM_SUBDIVISION", 33, 37], ["the differences in lean and obese subjects", "PROBLEM", 14, 56], ["the Wilcox test", "TEST", 107, 122], ["obese", "OBSERVATION", 42, 47]]], ["Cohen's Kappa was used with binary data to measure the agreement between adiposity classification according to the FM% criterion and the BMI.", [["binary data", "TEST", 28, 39], ["the BMI", "PROBLEM", 133, 140]]], ["According to Landis and Koch [22] , Cohen's Kappa (\u03ba) values could indicate an agreement: poor (\u03ba < 0.00), light (0.00 \u2264 \u03ba \u2264 0.20), discrete (0.21 \u2264 \u03ba \u2264 0.40), moderate (0.41 \u2264 \u03ba \u2264 0.60), substantial (0.61 \u2264 \u03ba \u2264 0.80) or near-perfect (\u03ba > 0.80).", [["Cohen's Kappa", "TEST", 36, 49], ["light", "TEST", 107, 112], ["discrete", "TEST", 132, 140], ["moderate", "OBSERVATION_MODIFIER", 160, 168]]], ["Furthermore, the false-positive rate and false-negative rate were calculated for the different classification methods.StatisticsCorrelation analysis was conducted with Spearman's rho test.", [["the false", "TEST", 13, 22], ["Correlation analysis", "TEST", 128, 148], ["Spearman's rho test", "TEST", 168, 187], ["false", "OBSERVATION", 17, 22], ["positive rate", "OBSERVATION", 23, 36]]], ["All p values shown are two-tailed.ResultsA total of 27 patients were evaluated for this prospective analytical observational study, 5 subjects were excluded from the study because the following reasons: 1 because COVID-19 negative, 1 died before 10th day; 3 had incomplete data.", [["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["All p values", "TEST", 0, 12], ["this prospective analytical observational study", "TEST", 83, 130], ["the study", "TEST", 162, 171], ["COVID", "TEST", 213, 218]]], ["Finally, 22 patients were included in the study (Fig. 1 ).", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["the study", "TEST", 38, 47]]], ["Mean age of enrolled patients was 58 years (range 49-67), 45% were females and 55% males.", [["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29]]], ["Patients were divided into two groups according to FM% and age: 12 patients were \"obese\" and 10 were \"lean\" ( Table 1) .ResultsThe BMI-based classification, as compared to FM%, presents a discrete and significant Cohen \u03ba-value (\u03ba = 0.405 p < 0.000).", [["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 67, 75], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 67, 75], ["The BMI", "TEST", 127, 134], ["significant", "OBSERVATION_MODIFIER", 201, 212]]], ["According to the BMI, 36% of the patients were categorized differently, in detail, 9% of the patients that presented a BMI within normal values were detected to have a FM% criteria for being considered \"obese\" according to FM% and age based on criteria presented by De Lorenzo [15] and 27% of the patients classified PO were \"obese\".", [["patients", "ORGANISM", 33, 41], ["patients", "ORGANISM", 93, 101], ["patients", "ORGANISM", 297, 305], ["patients", "SPECIES", 33, 41], ["patients", "SPECIES", 93, 101], ["patients", "SPECIES", 297, 305], ["the BMI", "TEST", 13, 20], ["obese", "PROBLEM", 203, 208]]], ["The FM%-based categorization coincided to BMI-based categorization for the 10 patients considered \"lean\" according the FM% and for 4 patients considered \"obese\".", [["patients", "ORGANISM", 78, 86], ["patients", "ORGANISM", 133, 141], ["patients", "SPECIES", 78, 86], ["patients", "SPECIES", 133, 141], ["The FM%", "TREATMENT", 0, 7], ["BMI", "TEST", 42, 45], ["obese", "PROBLEM", 154, 159]]], ["Lastly, for this sample the frequency of false negatives was 36%, while there were no false positives.ResultsBaseline characteristics of \"lean\" vs. \"obese\" patients.", [["patients", "ORGANISM", 156, 164], ["patients", "SPECIES", 156, 164], ["false negatives", "TEST", 41, 56], ["false positives", "PROBLEM", 86, 101], ["no", "UNCERTAINTY", 83, 85], ["false positives", "OBSERVATION", 86, 101]]], ["No statistical differences were present for age and spleen attenuation between groups.", [["spleen", "ANATOMY", 52, 58], ["spleen", "ORGAN", 52, 58], ["statistical differences", "PROBLEM", 3, 26], ["spleen", "ANATOMY", 52, 58], ["attenuation", "OBSERVATION", 59, 70]]], ["Liver and LSR attenuation were lower in \"obese\" than in \"lean\" ( Table 1 ).", [["Liver", "ANATOMY", 0, 5], ["Liver", "ORGAN", 0, 5], ["LSR", "GENE_OR_GENE_PRODUCT", 10, 13], ["Liver and LSR attenuation", "TEST", 0, 25], ["LSR", "ANATOMY", 10, 13], ["attenuation", "OBSERVATION_MODIFIER", 14, 25], ["lower", "OBSERVATION_MODIFIER", 31, 36], ["obese", "OBSERVATION", 41, 46]]], ["The ALT and AST were significantly more elevated in \"obese\" than in \"lean\".", [["ALT", "SIMPLE_CHEMICAL", 4, 7], ["AST", "SIMPLE_CHEMICAL", 12, 15], ["ALT", "PROTEIN", 4, 7], ["AST", "PROTEIN", 12, 15], ["The ALT and AST", "TEST", 0, 15], ["ALT", "ANATOMY", 4, 7]]], ["No other statistical difference was found in blood chemistry parameters between the groups.", [["blood", "ANATOMY", 45, 50], ["blood", "ORGANISM_SUBSTANCE", 45, 50], ["blood chemistry parameters", "TEST", 45, 71], ["statistical", "OBSERVATION_MODIFIER", 9, 20], ["difference", "OBSERVATION", 21, 31]]], ["At day 10th, the C-reactive protein, direct bilirubin, fibrinogen concentrations were lower in were lower than in \"lean\" (respectively p = 0.005; p = 0.033; p = 0.028), the lymphocytes concentration was increased in \"lean\" (p = 0.038) and not changed was observed in \"obese\".", [["lymphocytes", "ANATOMY", 173, 184], ["bilirubin", "CHEMICAL", 44, 53], ["bilirubin", "CHEMICAL", 44, 53], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 17, 35], ["bilirubin", "GENE_OR_GENE_PRODUCT", 44, 53], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 55, 65], ["lymphocytes", "CELL", 173, 184], ["C-reactive protein", "PROTEIN", 17, 35], ["fibrinogen", "PROTEIN", 55, 65], ["lymphocytes", "CELL_TYPE", 173, 184], ["the C-reactive protein", "TEST", 13, 35], ["direct bilirubin", "TEST", 37, 53], ["fibrinogen concentrations", "TEST", 55, 80], ["p", "TEST", 146, 147], ["p", "TEST", 157, 158], ["the lymphocytes concentration", "TEST", 169, 198], ["reactive protein", "OBSERVATION", 19, 35], ["lymphocytes", "ANATOMY", 173, 184], ["increased", "OBSERVATION_MODIFIER", 203, 212]]], ["Comparison of baseline to day 10th, concentrations of albumin and PNI decreased in \"obese\" while remained unchanged in \"lean\" patients.", [["albumin", "GENE_OR_GENE_PRODUCT", 54, 61], ["patients", "ORGANISM", 126, 134], ["albumin", "PROTEIN", 54, 61], ["patients", "SPECIES", 126, 134], ["albumin", "TREATMENT", 54, 61], ["PNI", "PROBLEM", 66, 69], ["unchanged", "OBSERVATION_MODIFIER", 106, 115]]], ["No statistical difference was present in \"lean\" and \"obese\" groups between baseline and 10 days (Table 3) .ResultsFinally, an inversely proportional correlation was observed between FM% and liver attenuation (correlation coefficient = \u2212 0.702 and p = 0.002).DiscussionThe distinctive feature of this prospective observational study, in patients admitted to the ICU for COVID-19, is a persistent lymphocyte reaction at 10th day in FM%based \"obese\" patients that suggest a protract inflammatory reaction.", [["liver", "ANATOMY", 190, 195], ["lymphocyte", "ANATOMY", 395, 405], ["liver", "ORGAN", 190, 195], ["patients", "ORGANISM", 336, 344], ["lymphocyte", "CELL", 395, 405], ["patients", "ORGANISM", 447, 455], ["patients", "SPECIES", 336, 344], ["patients", "SPECIES", 447, 455], ["FM", "TEST", 182, 184], ["correlation coefficient", "TEST", 209, 232], ["this prospective observational study", "TEST", 295, 331], ["COVID", "TEST", 369, 374], ["a persistent lymphocyte reaction", "PROBLEM", 382, 414], ["a protract inflammatory reaction", "PROBLEM", 469, 501], ["statistical", "OBSERVATION_MODIFIER", 3, 14], ["difference", "OBSERVATION", 15, 25], ["liver", "ANATOMY", 190, 195], ["persistent", "OBSERVATION_MODIFIER", 384, 394], ["lymphocyte reaction", "OBSERVATION", 395, 414], ["inflammatory", "OBSERVATION_MODIFIER", 480, 492]]], ["In these patients, at the beginning of ICU treatment, the metabolic associated fatty liver, PNI and the immune-inflammatory response are severely compromised.", [["fatty liver", "ANATOMY", 79, 90], ["fatty liver", "DISEASE", 79, 90], ["PNI", "DISEASE", 92, 95], ["patients", "ORGANISM", 9, 17], ["liver", "ORGAN", 85, 90], ["patients", "SPECIES", 9, 17], ["ICU treatment", "TREATMENT", 39, 52], ["the metabolic associated fatty liver", "PROBLEM", 54, 90], ["PNI", "PROBLEM", 92, 95], ["severely compromised", "PROBLEM", 137, 157], ["fatty", "OBSERVATION", 79, 84], ["liver", "ANATOMY", 85, 90], ["PNI", "OBSERVATION", 92, 95], ["inflammatory response", "OBSERVATION", 111, 132], ["severely", "OBSERVATION_MODIFIER", 137, 145], ["compromised", "OBSERVATION", 146, 157]]], ["Furthermore, at baseline more patients evaluated according FM% result to be \"obese\" than using the BMI criteria.DiscussionIn COVID-19 patients it is crucial to find risk factors associated with worse clinical course to allocate appropriate resources.", [["patients", "ORGANISM", 30, 38], ["patients", "ORGANISM", 134, 142], ["patients", "SPECIES", 30, 38], ["patients", "SPECIES", 134, 142], ["obese", "PROBLEM", 77, 82]]], ["In Italy, COVID-19 mortality is strongly influenced by different comorbidities [23] and 52% of deaths are above 80 years of age, unlike China, for which only 20% are above the same age threshold [23] .DiscussionIn particular, pre-existing pathologies including obesity, cardiovascular co-morbidity, arterial hypertension and type 2 diabetes mellitus are established risk factors [24] [25] [26] .", [["cardiovascular", "ANATOMY", 270, 284], ["arterial", "ANATOMY", 299, 307], ["deaths", "DISEASE", 95, 101], ["obesity", "DISEASE", 261, 268], ["cardiovascular co-morbidity", "DISEASE", 270, 297], ["arterial hypertension", "DISEASE", 299, 320], ["type 2 diabetes mellitus", "DISEASE", 325, 349], ["arterial", "MULTI-TISSUE_STRUCTURE", 299, 307], ["[24] [25] [26]", "SIMPLE_CHEMICAL", 379, 393], ["COVID", "TEST", 10, 15], ["different comorbidities", "PROBLEM", 55, 78], ["pre-existing pathologies", "PROBLEM", 226, 250], ["obesity", "PROBLEM", 261, 268], ["cardiovascular co-morbidity", "PROBLEM", 270, 297], ["arterial hypertension", "PROBLEM", 299, 320], ["type 2 diabetes mellitus", "PROBLEM", 325, 349], ["risk factors", "PROBLEM", 366, 378], ["obesity", "OBSERVATION", 261, 268], ["arterial", "ANATOMY", 299, 307], ["hypertension", "OBSERVATION", 308, 320]]], ["Obesity also can be associated to insulin-resistance, that alters immune response [27] .", [["Obesity", "DISEASE", 0, 7], ["insulin", "GENE_OR_GENE_PRODUCT", 34, 41], ["Obesity", "PROBLEM", 0, 7]]], ["Obese patients have greater infectivity correlated with exhalation, since they have higher ventilator volumes, due to a lower expansion capacity of the thoracic cavity, which consequently limits the lung expansion [28] .", [["thoracic cavity", "ANATOMY", 152, 167], ["lung", "ANATOMY", 199, 203], ["Obese", "DISEASE", 0, 5], ["patients", "ORGANISM", 6, 14], ["thoracic cavity", "ORGAN", 152, 167], ["lung", "ORGAN", 199, 203], ["patients", "SPECIES", 6, 14], ["greater infectivity", "PROBLEM", 20, 39], ["higher ventilator volumes", "PROBLEM", 84, 109], ["a lower expansion capacity of the thoracic cavity", "PROBLEM", 118, 167], ["the lung expansion", "PROBLEM", 195, 213], ["greater", "OBSERVATION_MODIFIER", 20, 27], ["infectivity", "OBSERVATION", 28, 39], ["higher", "OBSERVATION_MODIFIER", 84, 90], ["ventilator volumes", "OBSERVATION", 91, 109], ["lower", "OBSERVATION_MODIFIER", 120, 125], ["expansion", "OBSERVATION_MODIFIER", 126, 135], ["capacity", "OBSERVATION_MODIFIER", 136, 144], ["thoracic cavity", "ANATOMY", 152, 167], ["lung", "ANATOMY", 199, 203], ["expansion", "OBSERVATION_MODIFIER", 204, 213]]], ["This also results in increased aerosol production [28] .", [["increased aerosol production", "PROBLEM", 21, 49], ["increased", "OBSERVATION_MODIFIER", 21, 30], ["aerosol production", "OBSERVATION", 31, 49]]], ["In particularly, Maier et al. [29] showed that obese patients have a longer viral interaction.DiscussionIn the case of COVID-19, it has been observed that the infectious charge has an average duration of 20 days, but it can last up to 37 days after the infection Table 1 Descriptive and compared between group at baseline Differences among groups at baseline.", [["infection", "DISEASE", 253, 262], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["a longer viral interaction", "PROBLEM", 67, 93], ["COVID", "TEST", 119, 124], ["the infectious charge", "PROBLEM", 155, 176], ["the infection Table", "PROBLEM", 249, 268], ["obese", "OBSERVATION", 47, 52], ["infectious", "OBSERVATION", 159, 169]]], ["All parameters are presented as median (interquartile range) and were compared by Mann Whitney test Statistical significance was attributed as p < 0.05 IQR Interquartile Range, LSR Liver Spleen Ratio AST Aspartate Aminotransferase, ALT Alanine Aminotransferase, WBC White Blood Cell, PNI Prognostic Nutritional IndexMedian (IQR) Median (IQR) Median (IQR)Anthropometrics and body parameters [30] .", [["Liver", "ANATOMY", 181, 186], ["Blood Cell", "ANATOMY", 272, 282], ["body", "ANATOMY", 374, 378], ["Alanine", "CHEMICAL", 236, 243], ["Aspartate", "CHEMICAL", 204, 213], ["Alanine", "CHEMICAL", 236, 243], ["Aspartate Aminotransferase", "SIMPLE_CHEMICAL", 204, 230], ["ALT Alanine Aminotransferase", "SIMPLE_CHEMICAL", 232, 260], ["p", "TEST", 143, 144], ["Interquartile Range", "TEST", 156, 175], ["LSR", "TEST", 177, 180], ["Liver", "TEST", 181, 186], ["Spleen", "TEST", 187, 193], ["Ratio", "TEST", 194, 199], ["AST", "TEST", 200, 203], ["Aspartate", "TEST", 204, 213], ["Aminotransferase", "TEST", 214, 230], ["ALT", "TEST", 232, 235], ["Alanine", "TEST", 236, 243], ["Aminotransferase", "TEST", 244, 260], ["WBC", "TEST", 262, 265], ["White Blood Cell", "TEST", 266, 282], ["PNI Prognostic Nutritional IndexMedian (IQR) Median (IQR) Median (IQR)Anthropometrics and body parameters", "TREATMENT", 284, 389], ["Liver", "ANATOMY", 181, 186], ["Spleen", "ANATOMY", 187, 193]]], ["It remains to be shown the pathophysiological characteristics of patients who have a contagious duration of up to 37 days.", [["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73]]], ["Hence, the importance of assessing the inflammatory state, through circulating cytokines, has already been highlighted in patients suffering from acute respiratory distress syndrome.", [["respiratory", "ANATOMY", 152, 163], ["acute respiratory distress syndrome", "DISEASE", 146, 181], ["patients", "ORGANISM", 122, 130], ["circulating cytokines", "PROTEIN", 67, 88], ["patients", "SPECIES", 122, 130], ["the inflammatory state", "PROBLEM", 35, 57], ["acute respiratory distress syndrome", "PROBLEM", 146, 181], ["inflammatory", "OBSERVATION", 39, 51], ["acute", "OBSERVATION_MODIFIER", 146, 151], ["respiratory distress", "OBSERVATION", 152, 172], ["syndrome", "OBSERVATION", 173, 181]]], ["Indeed, it was possible to identify two distinct phenotypes, with two different mortality risks.", [["two distinct phenotypes", "PROBLEM", 36, 59], ["distinct", "OBSERVATION_MODIFIER", 40, 48], ["phenotypes", "OBSERVATION", 49, 59]]], ["This is fundamental for indicating the patient future prognosis [31] .", [["patient", "ORGANISM", 39, 46], ["patient", "SPECIES", 39, 46]]], ["In obese, lipid metabolism is already altered [13, 32] and a COVID-19 infection leads to an overexpression of the genes involved with a further increase in the production of pro-inflammatory cytokines and a reduced capability responding to infection.Median (IQR) Median (IQR) Median (IQR)In our study, \"lean\" patients-according FM%, showed a significative reduction in C-protein reactive, direct bilirubin and fibrinogen and an important increase of lymphocytes at day 10th of ICU.", [["lymphocytes", "ANATOMY", 450, 461], ["infection", "DISEASE", 70, 79], ["infection", "DISEASE", 240, 249], ["bilirubin", "CHEMICAL", 396, 405], ["bilirubin", "CHEMICAL", 396, 405], ["lipid", "SIMPLE_CHEMICAL", 10, 15], ["COVID-19", "GENE_OR_GENE_PRODUCT", 61, 69], ["patients", "ORGANISM", 309, 317], ["C-protein", "GENE_OR_GENE_PRODUCT", 369, 378], ["bilirubin", "GENE_OR_GENE_PRODUCT", 396, 405], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 410, 420], ["lymphocytes", "CELL", 450, 461], ["pro-inflammatory cytokines", "PROTEIN", 174, 200], ["C-protein", "PROTEIN", 369, 378], ["bilirubin", "PROTEIN", 396, 405], ["fibrinogen", "PROTEIN", 410, 420], ["lymphocytes", "CELL_TYPE", 450, 461], ["patients", "SPECIES", 309, 317], ["lipid metabolism", "TEST", 10, 26], ["a COVID-19 infection", "PROBLEM", 59, 79], ["pro-inflammatory cytokines", "PROBLEM", 174, 200], ["a reduced capability", "PROBLEM", 205, 225], ["infection", "PROBLEM", 240, 249], ["Median (IQR) Median (IQR)", "TREATMENT", 250, 275], ["our study", "TEST", 291, 300], ["a significative reduction in C-protein reactive", "PROBLEM", 340, 387], ["direct bilirubin", "TEST", 389, 405], ["fibrinogen", "TEST", 410, 420], ["an important increase of lymphocytes", "PROBLEM", 425, 461], ["obese", "OBSERVATION", 3, 8], ["lipid metabolism", "OBSERVATION", 10, 26], ["infection", "OBSERVATION", 70, 79], ["increase", "OBSERVATION_MODIFIER", 144, 152], ["pro-inflammatory cytokines", "OBSERVATION", 174, 200], ["reduced", "OBSERVATION_MODIFIER", 207, 214], ["capability", "OBSERVATION_MODIFIER", 215, 225], ["infection", "OBSERVATION", 240, 249], ["important", "OBSERVATION_MODIFIER", 428, 437], ["increase", "OBSERVATION_MODIFIER", 438, 446]]], ["Increased FM% is associated with a reduced ICU treatment response.", [["FM", "MULTI-TISSUE_STRUCTURE", 10, 12], ["Increased FM", "PROBLEM", 0, 12], ["a reduced ICU treatment", "TREATMENT", 33, 56]]], ["Actually, our data showed that \"obese\" do not show the same improvement, based on biochemical-clinical parameters, respect to \"lean\" after the first 10th ICU days.Median (IQR) Median (IQR) Median (IQR)According to presented data, adipose tissue quantity acts on therapeutic goal achievement.", [["adipose tissue", "ANATOMY", 230, 244], ["adipose tissue", "TISSUE", 230, 244], ["our data", "TEST", 10, 18], ["Median (IQR) Median (IQR) Median (IQR)", "TREATMENT", 163, 201]]], ["Increased adipose tissue leads to a lipid metabolism modification with increased storage of fat in liver and onset of steatosis in \"obese\".", [["adipose tissue", "ANATOMY", 10, 24], ["fat", "ANATOMY", 92, 95], ["liver", "ANATOMY", 99, 104], ["steatosis", "DISEASE", 118, 127], ["adipose tissue", "TISSUE", 10, 24], ["lipid", "SIMPLE_CHEMICAL", 36, 41], ["fat", "TISSUE", 92, 95], ["liver", "ORGAN", 99, 104], ["Increased adipose tissue", "PROBLEM", 0, 24], ["a lipid metabolism modification", "TREATMENT", 34, 65], ["increased storage of fat in liver", "PROBLEM", 71, 104], ["steatosis", "PROBLEM", 118, 127], ["adipose tissue", "OBSERVATION", 10, 24], ["lipid metabolism modification", "OBSERVATION", 36, 65], ["increased", "OBSERVATION_MODIFIER", 71, 80], ["fat", "OBSERVATION", 92, 95], ["liver", "ANATOMY", 99, 104], ["steatosis", "OBSERVATION", 118, 127], ["obese", "OBSERVATION", 132, 137]]], ["Consequently, these patients suffer for high production of pro-inflammatory cytokines [33, 34] and conduct to unfavorable condition, requiring defined protocols to counter malnutrition resulting [35] .Median (IQR) Median (IQR) Median (IQR)Additionally, these patients are at higher risk for infection also because of COVID-19 use angiotensin converting enzyme 2 (ACE2) receptors to enter the host cell [36] .", [["cell", "ANATOMY", 397, 401], ["malnutrition", "DISEASE", 172, 184], ["infection", "DISEASE", 291, 300], ["angiotensin", "CHEMICAL", 330, 341], ["patients", "ORGANISM", 20, 28], ["patients", "ORGANISM", 259, 267], ["COVID-19", "GENE_OR_GENE_PRODUCT", 317, 325], ["angiotensin converting enzyme 2", "GENE_OR_GENE_PRODUCT", 330, 361], ["ACE2", "GENE_OR_GENE_PRODUCT", 363, 367], ["cell", "CELL", 397, 401], ["pro-inflammatory cytokines", "PROTEIN", 59, 85], ["COVID", "PROTEIN", 317, 322], ["angiotensin converting enzyme 2 (ACE2) receptors", "PROTEIN", 330, 378], ["patients", "SPECIES", 20, 28], ["patients", "SPECIES", 259, 267], ["high production of pro-inflammatory cytokines", "PROBLEM", 40, 85], ["unfavorable condition", "PROBLEM", 110, 131], ["malnutrition", "PROBLEM", 172, 184], ["Median (IQR) Median (IQR) Median (IQR)", "TREATMENT", 201, 239], ["infection", "PROBLEM", 291, 300], ["COVID", "TEST", 317, 322], ["angiotensin converting enzyme 2 (ACE2) receptors", "TREATMENT", 330, 378], ["infection", "OBSERVATION", 291, 300], ["host cell", "OBSERVATION", 392, 401]]], ["The ACE2 is expressed in different tissues: kidney, lung, heart and adipose tissue [36] .", [["tissues", "ANATOMY", 35, 42], ["kidney", "ANATOMY", 44, 50], ["lung", "ANATOMY", 52, 56], ["heart", "ANATOMY", 58, 63], ["adipose tissue", "ANATOMY", 68, 82], ["ACE2", "GENE_OR_GENE_PRODUCT", 4, 8], ["tissues", "TISSUE", 35, 42], ["kidney", "ORGAN", 44, 50], ["lung", "ORGAN", 52, 56], ["heart", "ORGAN", 58, 63], ["adipose tissue", "TISSUE", 68, 82], ["ACE2", "PROTEIN", 4, 8], ["different tissues", "OBSERVATION", 25, 42], ["kidney", "ANATOMY", 44, 50], ["lung", "ANATOMY", 52, 56], ["heart", "ANATOMY", 58, 63], ["adipose tissue", "ANATOMY", 68, 82]]], ["COVID-19 infection leads to an upregulation of the genes associated with lipid metabolism, involved in the regulation of inflammation [37] .Median (IQR) Median (IQR) Median (IQR)Thus, obese have a higher expression of ACE2 and are therefore more susceptible to this infection [38] .", [["COVID-19", "CHEMICAL", 0, 8], ["infection", "DISEASE", 9, 18], ["inflammation", "DISEASE", 121, 133], ["infection", "DISEASE", 266, 275], ["COVID-19", "GENE_OR_GENE_PRODUCT", 0, 8], ["lipid", "SIMPLE_CHEMICAL", 73, 78], ["ACE2", "GENE_OR_GENE_PRODUCT", 218, 222], ["ACE2", "PROTEIN", 218, 222], ["COVID", "TEST", 0, 5], ["infection", "PROBLEM", 9, 18], ["lipid metabolism", "PROBLEM", 73, 89], ["inflammation", "PROBLEM", 121, 133], ["Median (IQR) Median (IQR)", "TREATMENT", 140, 165], ["obese", "PROBLEM", 184, 189], ["a higher expression of ACE2", "PROBLEM", 195, 222], ["this infection", "PROBLEM", 261, 275], ["infection", "OBSERVATION", 9, 18], ["lipid metabolism", "OBSERVATION", 73, 89], ["inflammation", "OBSERVATION", 121, 133], ["infection", "OBSERVATION", 266, 275]]], ["The complex picture is characterized by increased predisposition to infection and reduced ability to respond to it.", [["infection", "DISEASE", 68, 77], ["The complex picture", "PROBLEM", 0, 19], ["increased predisposition to infection", "PROBLEM", 40, 77], ["reduced ability", "PROBLEM", 82, 97], ["complex", "OBSERVATION_MODIFIER", 4, 11], ["picture", "OBSERVATION", 12, 19], ["increased", "OBSERVATION_MODIFIER", 40, 49], ["infection", "OBSERVATION", 68, 77], ["reduced", "OBSERVATION_MODIFIER", 82, 89]]], ["In addition, these patients already present organ damage that induces worse response to treatments.Median (IQR) Median (IQR) Median (IQR)According to the results, the main aim is a proper nutritional medical therapy, which takes into account the amount of fat, as a risk factor for complications in COVID-19.", [["organ", "ANATOMY", 44, 49], ["fat", "ANATOMY", 256, 259], ["organ damage", "DISEASE", 44, 56], ["patients", "ORGANISM", 19, 27], ["organ", "ORGAN", 44, 49], ["fat", "TISSUE", 256, 259], ["patients", "SPECIES", 19, 27], ["organ damage", "PROBLEM", 44, 56], ["treatments", "TREATMENT", 88, 98], ["Median (IQR) Median (IQR) Median (IQR)", "TREATMENT", 99, 137], ["a proper nutritional medical therapy", "TREATMENT", 179, 215], ["complications", "PROBLEM", 282, 295], ["COVID", "TEST", 299, 304], ["organ", "ANATOMY", 44, 49], ["damage", "OBSERVATION", 50, 56], ["amount", "OBSERVATION_MODIFIER", 246, 252], ["fat", "ANATOMY", 256, 259]]], ["Therefore, the therapeutic approach must be customized on the body composition.", [["body", "ANATOMY", 62, 66], ["body", "ORGANISM_SUBDIVISION", 62, 66], ["the therapeutic approach", "TREATMENT", 11, 35], ["the body composition", "TREATMENT", 58, 78]]], ["In addition, the loss of body protein content is a negative prognosis factor and it has been a constant observation in ICU.Median (IQR) Median (IQR) Median (IQR)A further aim, in the not-affected, affected and discharged COVID-19 patients, is the saving and recovery of lean body mass, following an appropriate protein prescription.Median (IQR) Median (IQR) Median (IQR)In pre-COVID-19 patients, a personalized and balanced Italian Mediterranean Reference Diet characterized by anti-inflammatory and antioxidant properties [39] , should be adopted as obesity preventive and therapeutic tool.", [["body", "ANATOMY", 25, 29], ["lean body", "ANATOMY", 270, 279], ["body", "ORGANISM_SUBDIVISION", 25, 29], ["patients", "ORGANISM", 230, 238], ["lean", "TISSUE", 270, 274], ["body", "ORGANISM_SUBDIVISION", 275, 279], ["patients", "ORGANISM", 386, 394], ["patients", "SPECIES", 230, 238], ["patients", "SPECIES", 386, 394], ["the loss of body protein content", "PROBLEM", 13, 45], ["Median (IQR) Median (IQR)", "TREATMENT", 123, 148], ["lean body mass", "PROBLEM", 270, 284], ["an appropriate protein prescription", "TREATMENT", 296, 331], ["Median (IQR) Median (IQR) Median (IQR)", "TREATMENT", 332, 370], ["anti-inflammatory and antioxidant properties", "TREATMENT", 478, 522], ["loss", "OBSERVATION_MODIFIER", 17, 21], ["protein content", "OBSERVATION", 30, 45], ["negative prognosis", "OBSERVATION_MODIFIER", 51, 69], ["mass", "OBSERVATION", 280, 284]]], ["The protein intake required is based on lean mass content (2 g/kg of lean mass/day), a parameter that can be directly measured or calculated with prediction equations, accessible to all users [15] .Median (IQR) Median (IQR) Median (IQR)In COVID-19 patients, a macronutrient balance calculated according to the clinical condition, a correct calorie intake based on the metabolic condition and all micronutrients must be guaranteed.", [["lean", "ORGANISM_SUBDIVISION", 40, 44], ["patients", "ORGANISM", 248, 256], ["patients", "SPECIES", 248, 256], ["lean mass content", "PROBLEM", 40, 57], ["Median (IQR) Median (IQR) Median (IQR)", "TREATMENT", 198, 236], ["a macronutrient balance", "TREATMENT", 258, 281], ["a correct calorie intake", "TREATMENT", 330, 354]]], ["In detail, respiratory failure requires hyperlipidic nutritional medical therapy, to counter hypercapnia and promoting metabolic flexibility [35, 40] .", [["respiratory", "ANATOMY", 11, 22], ["respiratory failure", "DISEASE", 11, 30], ["hypercapnia", "DISEASE", 93, 104], ["respiratory failure", "PROBLEM", 11, 30], ["hyperlipidic nutritional medical therapy", "TREATMENT", 40, 80], ["hypercapnia", "PROBLEM", 93, 104], ["respiratory failure", "OBSERVATION", 11, 30], ["metabolic flexibility", "OBSERVATION", 119, 140]]], ["The calorie prescription must be adjusted daily, following the catabolic and anabolic phases of hospitalization.", [["The calorie prescription", "TREATMENT", 0, 24]]], ["Similarly, the protein prescription must be modulated according to the metabolic phase.", [["the protein prescription", "TREATMENT", 11, 35]]], ["In the anabolic phase, the protein administrated should not be counted in the daily energy expenditure and the protein intake must be 1.3 g/kg of body weight/day [40] .Median (IQR) Median (IQR) Median (IQR)In post-COVID-19 patients, keeping in mind that the fragility deriving from bedrest and inadequate nutrition, due to the ventilatory support, a specific nutritional and motor rehabilitation must be provided [40] .", [["body", "ANATOMY", 146, 150], ["bedrest", "DISEASE", 282, 289], ["body", "ORGANISM_SUBDIVISION", 146, 150], ["patients", "ORGANISM", 223, 231], ["patients", "SPECIES", 223, 231], ["the protein", "TREATMENT", 23, 34], ["Median (IQR) Median (IQR) Median (IQR)", "TREATMENT", 168, 206], ["the fragility", "PROBLEM", 254, 267], ["bedrest", "TREATMENT", 282, 289], ["inadequate nutrition", "TREATMENT", 294, 314], ["the ventilatory support", "TREATMENT", 323, 346], ["motor rehabilitation", "TREATMENT", 375, 395], ["anabolic phase", "OBSERVATION_MODIFIER", 7, 21]]], ["For patients with comorbidity, nutrition support to anabolic and recovery stress represent a complex passage.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["comorbidity", "PROBLEM", 18, 29], ["nutrition support", "TREATMENT", 31, 48]]], ["Diet therapy, personalized based on the body composition [35] , must be hyperproteic, 2-2.5 g/kg of lean mass/day, complete with all amino acids and enriched with branched amino acids, to promote anabolism.", [["body", "ANATOMY", 40, 44], ["amino acids", "CHEMICAL", 133, 144], ["amino acids", "CHEMICAL", 172, 183], ["amino acids", "CHEMICAL", 133, 144], ["amino acids", "CHEMICAL", 172, 183], ["body", "ORGANISM_SUBDIVISION", 40, 44], ["lean", "ORGANISM_SUBDIVISION", 100, 104], ["amino acids", "AMINO_ACID", 133, 144], ["amino acids", "AMINO_ACID", 172, 183], ["Diet therapy", "TREATMENT", 0, 12], ["lean mass", "PROBLEM", 100, 109], ["all amino acids", "TREATMENT", 129, 144], ["branched amino acids", "TREATMENT", 163, 183]]], ["The meals consistency must be progressively personalized according to the subject ability to feed.Median (IQR) Median (IQR) Median (IQR)Our data, even if the sample size required by statistical tests is respected, nevertheless presents a limited number of patients.", [["patients", "ORGANISM", 256, 264], ["patients", "SPECIES", 256, 264], ["Median (IQR) Median (IQR)", "TREATMENT", 98, 123], ["Our data", "TEST", 136, 144], ["the sample size", "TEST", 154, 169], ["statistical tests", "TEST", 182, 199]]], ["At the same time, it is a strength, which has allowed an estimate of body composition, since other methods such as bioimpedance and anthroplicometry are difficult to apply in ICU.Median (IQR) Median (IQR) Median (IQR)It is hoped that from the COVID-19 lesson, the Public Institutions will promote the prevention and treatment of obesity and sarcopenia, through healthy nutrition and a correct lifestyle.Median (IQR) Median (IQR) Median (IQR)The comorbidities costs and the obstacle in the clinical treatment of an obese patient, in addition to the known health-care costs [41] , has been paid with human lives.", [["body", "ANATOMY", 69, 73], ["obesity", "DISEASE", 329, 336], ["sarcopenia", "DISEASE", 341, 351], ["body", "ORGANISM_SUBDIVISION", 69, 73], ["patient", "ORGANISM", 520, 527], ["human", "ORGANISM", 598, 603], ["patient", "SPECIES", 520, 527], ["human", "SPECIES", 598, 603], ["human", "SPECIES", 598, 603], ["bioimpedance and anthroplicometry", "TREATMENT", 115, 148], ["Median (IQR) Median (IQR) Median (IQR)", "TREATMENT", 179, 217], ["obesity", "PROBLEM", 329, 336], ["sarcopenia", "PROBLEM", 341, 351], ["Median (IQR) Median (IQR) Median (IQR)", "TREATMENT", 403, 441], ["The comorbidities costs", "PROBLEM", 441, 464], ["obesity", "OBSERVATION", 329, 336], ["sarcopenia", "OBSERVATION", 341, 351], ["obese", "OBSERVATION", 514, 519]]]], "4d905684c5956528931bacbccaf538cb64d71bb1": [["INTRODUCTIONA salient feature of SARS-CoV-2, the virus that causes COVID-19, is its ability to rapidly spread, leading it to affect over 100 countries in a matter of weeks.", [["SARS", "DISEASE", 33, 37], ["SARS-CoV-2", "ORGANISM", 33, 43], ["SARS-CoV", "SPECIES", 33, 41], ["SARS", "PROBLEM", 33, 37], ["CoV", "TEST", 38, 41], ["the virus", "PROBLEM", 45, 54], ["COVID", "TEST", 67, 72], ["SARS", "OBSERVATION", 33, 37]]], ["It is increasingly clear that asymptomatic and pre-symptomatic infection play an important role in the ongoing spread of COVID-19 [1] .", [["infection", "DISEASE", 63, 72], ["COVID-19", "CHEMICAL", 121, 129], ["asymptomatic", "PROBLEM", 30, 42], ["pre-symptomatic infection", "PROBLEM", 47, 72], ["increasingly", "OBSERVATION_MODIFIER", 6, 18], ["clear", "OBSERVATION", 19, 24]]], ["Peak infectiousness likely occurs on or before symptom onset [2, 3] , with a significant proportion of secondary infections arising from the index case during the pre-symptomatic stage [4, 5] , highlighting the urgent need for non-invasive screening tools to identify people who may be asymptomatic or pre-symptomatic.", [["infections", "DISEASE", 113, 123], ["people", "ORGANISM", 268, 274], ["people", "SPECIES", 268, 274], ["Peak infectiousness", "PROBLEM", 0, 19], ["secondary infections", "PROBLEM", 103, 123], ["non-invasive screening tools", "TEST", 227, 255], ["asymptomatic", "PROBLEM", 286, 298], ["pre-symptomatic", "PROBLEM", 302, 317], ["infectiousness", "OBSERVATION", 5, 19], ["significant", "OBSERVATION_MODIFIER", 77, 88], ["secondary", "OBSERVATION_MODIFIER", 103, 112], ["infections", "OBSERVATION", 113, 123]]], ["This is especially true for healthcare workers (HCW) treating COVID-19 patients.", [["COVID", "DISEASE", 62, 67], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79]]], ["HCW are at high risk for nosocomial infection themselves and may unknowingly spread infection through contact with hospital staff and patients [6] [7] [8] .INTRODUCTIONReduced olfactory sensitivity, or anosmia, has been identified as a common manifestation of COVID-19.", [["olfactory", "ANATOMY", 176, 185], ["infection", "DISEASE", 36, 45], ["infection", "DISEASE", 84, 93], ["anosmia", "DISEASE", 202, 209], ["patients", "ORGANISM", 134, 142], ["olfactory", "ORGAN", 176, 185], ["patients", "SPECIES", 134, 142], ["nosocomial infection themselves", "PROBLEM", 25, 56], ["olfactory sensitivity", "TEST", 176, 197], ["anosmia", "PROBLEM", 202, 209], ["COVID", "TEST", 260, 265], ["infection", "OBSERVATION", 36, 45]]], ["Olfactory loss has been identified by self-report in 15-85% of COVID-19 patients in Korea [9] , Italy [8, [10] [11] [12] , Spain [13] , Canada [14, 15] , the UK [16] , and Iran [17] .", [["Olfactory", "ANATOMY", 0, 9], ["Olfactory loss", "DISEASE", 0, 14], ["Olfactory", "ORGAN", 0, 9], ["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["Olfactory loss", "PROBLEM", 0, 14], ["COVID", "TEST", 63, 68], ["loss", "OBSERVATION", 10, 14]]], ["Remarkably, the correlation between the risk of COVID-19 and selfreported olfactory loss has been reported to be as high as r=0.87 [17] .", [["olfactory", "ANATOMY", 74, 83], ["olfactory loss", "DISEASE", 74, 88], ["olfactory", "ORGAN", 74, 83], ["COVID", "TEST", 48, 53], ["selfreported olfactory loss", "PROBLEM", 61, 88]]], ["Among patients with COVID-19 assessed for smell loss, 41% and 98% had impaired tests of olfaction on two different tests of olfactory function [18, 19] .", [["olfactory", "ANATOMY", 124, 133], ["smell loss", "DISEASE", 42, 52], ["patients", "ORGANISM", 6, 14], ["olfactory", "ORGAN", 124, 133], ["patients", "SPECIES", 6, 14], ["COVID", "TEST", 20, 25], ["smell loss", "PROBLEM", 42, 52], ["impaired tests of olfaction", "PROBLEM", 70, 97]]], ["Smell loss is also being evaluated for its diagnostic value in COVID-19 case identification [20] .", [["Smell loss", "DISEASE", 0, 10], ["Smell loss", "PROBLEM", 0, 10]]], ["One epidemiological study reported that average odor intensity ratings of household items predicted prevalence of COVID-19 in a Swedish population, with large differences in smell intensity ratings in individuals with and without COVID-19 symptoms [21] .", [["One epidemiological study", "TEST", 0, 25], ["COVID", "TEST", 114, 119], ["large differences in smell intensity ratings", "PROBLEM", 153, 197], ["COVID", "TEST", 230, 235], ["symptoms", "PROBLEM", 239, 247], ["large", "OBSERVATION_MODIFIER", 153, 158], ["differences", "OBSERVATION_MODIFIER", 159, 170]]], ["Furthermore, individuals progressing from asymptomatic to reporting some COVID-19 symptoms had a large .", [["some COVID-19 symptoms", "PROBLEM", 68, 90], ["large", "OBSERVATION_MODIFIER", 97, 102]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint drop in odor intensity ratings.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["preprint drop in odor intensity ratings", "PROBLEM", 197, 236], ["med", "ANATOMY", 99, 102], ["odor intensity", "OBSERVATION", 214, 228]]], ["Another study reported loss of taste, smell, and chemesthesis following a COVID-19 diagnosis using a self-report questionnaire [22] .", [["loss of taste, smell", "DISEASE", 23, 43], ["taste", "ORGANISM_SUBDIVISION", 31, 36], ["Another study", "TEST", 0, 13], ["loss of taste", "PROBLEM", 23, 36], ["smell", "PROBLEM", 38, 43]]], ["This compelling evidence highlights the potential importance of tracking smell sensitivity to identify SARS-CoV-2 infection.", [["infection", "DISEASE", 114, 123], ["smell", "ORGANISM_SUBDIVISION", 73, 78], ["SARS-CoV-2", "ORGANISM", 103, 113], ["SARS-CoV", "SPECIES", 103, 111], ["tracking smell sensitivity", "TEST", 64, 90], ["SARS", "PROBLEM", 103, 107], ["CoV-2 infection", "PROBLEM", 108, 123], ["infection", "OBSERVATION", 114, 123]]], ["However, smell loss has not yet been prospectively evaluated in asymptomatic or pre-symptomatic individuals undergoing regular, frequent SARS-CoV-2 testing.", [["smell loss", "DISEASE", 9, 19], ["smell loss", "PROBLEM", 9, 19], ["CoV-2 testing", "TEST", 142, 155], ["smell loss", "OBSERVATION", 9, 19]]], ["Given the extreme infectiousness of the SARS-CoV-2 virus, it is critical to determine the onset and trajectory of smell loss, with respect to the time of infection, and whether smell loss predicts symptom type and/or severity.INTRODUCTIONTesting for objective smell loss using standard laboratory or clinical techniques is not feasible for widespread testing, and as self-report surveys are not sufficiently reliable, an accessible at-home smell sensitivity screen is of paramount importance.INTRODUCTIONSmell-tracker at-home self-monitoring for the first sign of diminished smell function would enable rapid testing and/or self-quarantine, thus protecting the community from exposure and preventing further spread prior to a formal diagnosis.INTRODUCTIONThe aim of this study was to determine if tracking smell sensitivity and loss using an at-home assessment could identify HCW who are infected with SARS-CoV-2.", [["SARS", "DISEASE", 40, 44], ["smell loss", "DISEASE", 114, 124], ["infection", "DISEASE", 154, 163], ["smell loss", "DISEASE", 177, 187], ["smell loss", "DISEASE", 260, 270], ["SARS", "DISEASE", 902, 906], ["SARS-CoV-2 virus", "ORGANISM", 40, 56], ["smell", "ORGANISM_SUBDIVISION", 114, 119], ["SARS-CoV-2", "ORGANISM", 902, 912], ["CoV-2 virus", "SPECIES", 45, 56], ["SARS-CoV-2 virus", "SPECIES", 40, 56], ["SARS-CoV", "SPECIES", 902, 910], ["the extreme infectiousness", "PROBLEM", 6, 32], ["the SARS-CoV-2 virus", "PROBLEM", 36, 56], ["smell loss", "PROBLEM", 114, 124], ["infection", "PROBLEM", 154, 163], ["smell loss", "PROBLEM", 177, 187], ["symptom type and/or severity", "PROBLEM", 197, 225], ["objective smell loss", "PROBLEM", 250, 270], ["clinical techniques", "TEST", 300, 319], ["widespread testing", "TEST", 340, 358], ["home smell sensitivity screen", "TEST", 435, 464], ["diminished smell function", "PROBLEM", 564, 589], ["rapid testing", "TEST", 603, 616], ["this study", "TEST", 766, 776], ["tracking smell sensitivity", "PROBLEM", 797, 823], ["loss", "PROBLEM", 828, 832], ["an at-home assessment", "TEST", 839, 860], ["infection", "OBSERVATION", 154, 163]]], ["High risk HCW undergoing routine (every 3 days) viral screening for SARS-CoV-2 infection completed a novel at-home brief smell sensitivity screen, the Yale Jiffy (Supplemental Table 1 ), to track ratings of odor intensity perception using two household olfactory stimuli.", [["SARS-CoV-2 infection", "DISEASE", 68, 88], ["SARS-CoV-2", "ORGANISM", 68, 78], ["CoV-2", "SPECIES", 73, 78], ["SARS-CoV-2", "SPECIES", 68, 78], ["viral screening", "TEST", 48, 63], ["SARS", "PROBLEM", 68, 72], ["CoV", "PROBLEM", 73, 76], ["2 infection", "PROBLEM", 77, 88]]], ["HCW also self-reported smell loss and changes across this time, along with symptoms commonly used to screen for COVID-19.METHODS. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintMETHODSThe copyright holder for this this version posted September 10, 2020. possible moderate to high risk exposure to COVID-19, or work in a COVID-19 unit, and e) SARS-CoV-2 negative at study entry.", [["smell loss", "DISEASE", 23, 33], ["CC", "CHEMICAL", 130, 132], ["COVID-19", "CHEMICAL", 455, 463], ["smell loss", "PROBLEM", 23, 33], ["symptoms", "PROBLEM", 75, 83], ["COVID", "TEST", 112, 117], ["CC", "TEST", 130, 132], ["moderate to high risk exposure", "PROBLEM", 421, 451], ["COVID", "TEST", 455, 460], ["a COVID", "TEST", 476, 483], ["SARS", "TEST", 500, 504], ["CoV", "TEST", 505, 508], ["med", "ANATOMY", 229, 232], ["moderate", "OBSERVATION_MODIFIER", 421, 429]]], ["For this analysis of smell alterations and COVID-19, we excluded subjects without at least one SARS-CoV-2 PCR result and those who had not completed at least one daily symptom questionnaire or Yale Jiffy.", [["smell alterations", "DISEASE", 21, 38], ["smell", "ORGANISM_SUBDIVISION", 21, 26], ["COVID-19", "DNA", 43, 51], ["this analysis", "TEST", 4, 17], ["smell alterations", "PROBLEM", 21, 38], ["COVID", "TEST", 43, 48]]], ["All reported data were collected between March 31 and July 7, 2020.Viral testingSARS-CoV-2 real-time quantitative polymerase chain reaction (RT-qPCR) testing was performed on self-collected nasopharyngeal and saliva specimens every three days.", [["nasopharyngeal", "ANATOMY", 190, 204], ["saliva specimens", "ANATOMY", 209, 225], ["nasopharyngeal", "CANCER", 190, 204], ["saliva specimens", "ORGANISM_SUBSTANCE", 209, 225], ["Viral testingSARS", "TEST", 67, 84], ["CoV", "TEST", 85, 88], ["quantitative polymerase chain reaction", "PROBLEM", 101, 139], ["RT-qPCR) testing", "TEST", 141, 157], ["nasopharyngeal", "ANATOMY", 190, 204]]], ["Specimens were processed and tested on the same day as collection following previously described protocols [23, 24] .", [["Specimens", "ANATOMY", 0, 9], ["Specimens", "TEST", 0, 9]]], ["Two HCW reported positive results from a CLIA-certified lab outside of the study protocol.Yale Jiffy.", [["the study protocol", "TEST", 71, 89]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintYale JiffyThe copyright holder for this this version posted September 10, 2020. .", [["CC", "CHEMICAL", 0, 2], ["Yale Jiffy", "SPECIES", 205, 215], ["CC", "TEST", 0, 2], ["med", "ANATOMY", 99, 102]]], ["The Yale Jiffy is an online survey developed to screen for smell loss that can be conducted in under two minutes using readily available household items.", [["smell loss", "DISEASE", 59, 69], ["smell loss", "PROBLEM", 59, 69]]], ["The questionnaire includes two sections using self-ratings of: 1) ability to smell, and 2) strength of smell in response to olfactory and trigeminal stimuli.", [["sections", "ANATOMY", 31, 39], ["olfactory", "ANATOMY", 124, 133], ["trigeminal", "ANATOMY", 138, 148], ["olfactory", "TISSUE", 124, 133], ["trigeminal stimuli", "TEST", 138, 156], ["trigeminal stimuli", "ANATOMY", 138, 156]]], ["Peanut butter (or jam/jelly) was used as the olfactory stimulus as it has minimal or no trigeminal component, allowing for isolation of effects on the olfactory system.", [["olfactory", "ANATOMY", 45, 54], ["trigeminal", "ANATOMY", 88, 98], ["olfactory system", "ANATOMY", 151, 167], ["Peanut", "ORGANISM", 0, 6], ["butter", "ORGANISM_SUBDIVISION", 7, 13], ["olfactory system", "MULTI-TISSUE_STRUCTURE", 151, 167], ["Peanut", "SPECIES", 0, 6], ["Peanut", "SPECIES", 0, 6], ["Peanut butter", "TREATMENT", 0, 13], ["trigeminal component", "PROBLEM", 88, 108], ["minimal", "OBSERVATION_MODIFIER", 74, 81], ["no", "UNCERTAINTY", 85, 87], ["trigeminal", "ANATOMY", 88, 98]]], ["We also included a stimulus with a trigeminal component as a control stimulus (i.e., vinegar).Yale JiffyFirst, participants were asked to rate their ability to smell on a categorical scale Responses were collected using Qualtrics, a secure HIPAA-compliant webbased survey platform, and retention was encouraged using daily e-mail reminders.Daily Symptom QuestionnaireAs part of the IMPACT study, HCW completed an online daily symptom questionnaire.", [["trigeminal", "ANATOMY", 35, 45], ["vinegar", "ORGANISM_SUBDIVISION", 85, 92], ["participants", "ORGANISM", 111, 123], ["participants", "SPECIES", 111, 123], ["a stimulus", "TEST", 17, 27], ["a trigeminal component", "TREATMENT", 33, 55], ["the IMPACT study", "TEST", 378, 394], ["trigeminal", "ANATOMY", 35, 45]]], ["HCW were given a list of symptoms and prompted to indicate whether .", [["symptoms", "PROBLEM", 25, 33]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintDaily Symptom QuestionnaireThe copyright holder for this this version posted September 10, 2020. . they had developed such symptoms in the past 24 hours.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["such symptoms", "PROBLEM", 323, 336], ["med", "ANATOMY", 99, 102]]], ["Listed symptoms included objective fever (>100.4\u00b0F), subjective fever, cough, shortness of breath, stuffy nose, sore throat, chills, sweating, malaise, fatigue, muscle pain, anorexia, nausea, vomiting, diarrhea, abdominal pain, and dizziness.", [["muscle", "ANATOMY", 161, 167], ["abdominal", "ANATOMY", 212, 221], ["fever", "DISEASE", 35, 40], ["fever", "DISEASE", 64, 69], ["cough", "DISEASE", 71, 76], ["shortness of breath", "DISEASE", 78, 97], ["sore throat", "DISEASE", 112, 123], ["chills", "DISEASE", 125, 131], ["sweating", "DISEASE", 133, 141], ["fatigue", "DISEASE", 152, 159], ["muscle pain", "DISEASE", 161, 172], ["anorexia", "DISEASE", 174, 182], ["nausea", "DISEASE", 184, 190], ["vomiting", "DISEASE", 192, 200], ["diarrhea", "DISEASE", 202, 210], ["abdominal pain", "DISEASE", 212, 226], ["dizziness", "DISEASE", 232, 241], ["nose", "ORGANISM_SUBDIVISION", 106, 110], ["muscle", "ORGAN", 161, 167], ["abdominal", "ORGANISM_SUBDIVISION", 212, 221], ["Listed symptoms", "PROBLEM", 0, 15], ["objective fever", "PROBLEM", 25, 40], ["subjective fever", "PROBLEM", 53, 69], ["cough", "PROBLEM", 71, 76], ["shortness of breath", "PROBLEM", 78, 97], ["stuffy nose", "PROBLEM", 99, 110], ["sore throat", "PROBLEM", 112, 123], ["chills", "PROBLEM", 125, 131], ["sweating", "PROBLEM", 133, 141], ["malaise", "PROBLEM", 143, 150], ["fatigue", "PROBLEM", 152, 159], ["muscle pain", "PROBLEM", 161, 172], ["anorexia", "PROBLEM", 174, 182], ["nausea", "PROBLEM", 184, 190], ["vomiting", "PROBLEM", 192, 200], ["diarrhea", "PROBLEM", 202, 210], ["abdominal pain", "PROBLEM", 212, 226], ["dizziness", "PROBLEM", 232, 241], ["sore throat", "ANATOMY", 112, 123], ["chills", "OBSERVATION", 125, 131], ["muscle", "ANATOMY", 161, 167], ["anorexia", "OBSERVATION", 174, 182], ["abdominal", "ANATOMY", 212, 221], ["pain", "OBSERVATION", 222, 226], ["dizziness", "OBSERVATION", 232, 241]]], ["In addition, we included screening questions for parosmia -changes in odor quality perception [26] -and for hypogeusia -reduced ability to taste [27] .", [["screening questions", "TEST", 25, 44], ["parosmia", "PROBLEM", 49, 57], ["hypogeusia", "PROBLEM", 108, 118]]], ["Participants completed four parosmia screening questions (Supplemental Table 2 ), indicating how often they were bothered by common complaints caused by smell distortions, with responses ranging from \"always\" (1 point) to \"never\" (4 points).", [["smell distortions", "DISEASE", 153, 170], ["Participants", "SPECIES", 0, 12], ["smell distortions", "PROBLEM", 153, 170]]], ["Parosmia was defined as a cumulative score less than or equal to 14 (out of 16) .", [["a cumulative score", "TEST", 24, 42]]], ["HCW responded to four hypogeusia screening questions for saltiness, sourness, sweetness, and bitterness, by indicating that they could detect these tastes \"Easily\" (3 points), \"Somewhat\" (2 points), or \"Not at all\" (1 point).", [["saltiness", "DISEASE", 57, 66], ["saltiness", "PROBLEM", 57, 66], ["bitterness", "PROBLEM", 93, 103]]], ["Hypogeusia was defined as any total score less than the maximum of 12 points.Statistical AnalysesDescriptive statistics were used to characterize the study population.", [["Hypogeusia", "DISEASE", 0, 10], ["Hypogeusia", "PROBLEM", 0, 10], ["the study population", "TEST", 146, 166]]], ["The Fisher's exact and Wilcoxon rank-sum tests were used to compare COVID-19-positive and negative HCW.", [["COVID-19", "GENE_OR_GENE_PRODUCT", 68, 76], ["The Fisher's exact", "TEST", 0, 18], ["Wilcoxon rank", "TEST", 23, 36], ["sum tests", "TEST", 37, 46], ["COVID", "TEST", 68, 73]]], ["Multivariable logistic regression models were developed to calculate adjusted odds ratios for the associations between smell symptoms and COVID-19 diagnosis.", [["smell symptoms", "DISEASE", 119, 133], ["Multivariable logistic regression models", "PROBLEM", 0, 40], ["smell symptoms", "PROBLEM", 119, 133], ["COVID", "TEST", 138, 143]]], ["Each model included one symptom as the predictor and additionally adjusted for age, sex, body mass index (BMI), ethnicity, and number of symptom surveys completed.Statistical Analyses.", [["body", "ANATOMY", 89, 93], ["body", "ORGANISM_SUBDIVISION", 89, 93], ["body mass index", "PROBLEM", 89, 104], ["symptom surveys", "TEST", 137, 152]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintStatistical AnalysesThe copyright holder for this this version posted September 10, 2020. . https://doi.org/10.1101/2020.09.07.20188813 doi: medRxiv preprint To further examine the strength of association between symptoms of smell loss and a diagnosis of COVID-19, we compared HCW reporting smell loss to a subset of HCW never reporting smell loss who were well-matched on age, sex, ethnicity, and the number of daily symptom surveys completed.", [["CC", "CHEMICAL", 0, 2], ["smell loss", "DISEASE", 430, 440], ["smell loss", "DISEASE", 496, 506], ["smell loss", "DISEASE", 542, 552], ["CC", "TEST", 0, 2], ["medRxiv", "TREATMENT", 346, 353], ["symptoms", "PROBLEM", 418, 426], ["smell loss", "PROBLEM", 430, 440], ["COVID", "TEST", 460, 465], ["smell loss", "PROBLEM", 496, 506], ["smell loss", "PROBLEM", 542, 552], ["med", "ANATOMY", 99, 102], ["smell loss", "OBSERVATION", 430, 440]]], ["We used the R package 'MatchIt' for this analysis, specifying a control to case ratio of 2:1 and employing optimal matching, which minimizes the overall differences between cases and controls.", [["the R package 'MatchIt'", "TREATMENT", 8, 31], ["this analysis", "TEST", 36, 49]]], ["To estimate the strength of association between smell loss and a diagnosis of COVID-19, we conducted conditional logistic regression using the matched dataset and the R package 'survival.'Statistical AnalysesWe compared results of three matched logistic regression analyses among those reporting smell loss on either survey (Yale Jiffy or daily symptom questionnaire), on the Yale Jiffy only, and on the daily symptom questionnaire only.", [["smell loss", "DISEASE", 48, 58], ["smell loss", "DISEASE", 296, 306], ["smell loss", "PROBLEM", 48, 58], ["COVID", "TEST", 78, 83], ["the matched dataset", "TREATMENT", 139, 158], ["the R package 'survival", "TREATMENT", 163, 186], ["smell loss", "PROBLEM", 296, 306]]], ["Sensitivity analyses tested whether inclusion of covariates was needed to adjust for residual confounding after matching, determined by a change in the point estimate of >10%.Statistical AnalysesFinally, we summarized responses to the Yale Jiffy and daily symptom questionnaires and used Fisher's exact and Wilcoxon rank-sum tests to compare responses between COVID-19-positive and COVID-19-negative HCW.", [["COVID-19", "GENE_OR_GENE_PRODUCT", 360, 368], ["COVID-19", "SIMPLE_CHEMICAL", 382, 390], ["HCW", "ORGANISM", 400, 403], ["Sensitivity analyses", "TEST", 0, 20], ["residual confounding", "PROBLEM", 85, 105], ["Fisher's exact", "TEST", 288, 302], ["Wilcoxon rank", "TEST", 307, 320], ["sum tests", "TEST", 321, 330], ["COVID", "TEST", 360, 365], ["COVID", "TEST", 382, 387]]], ["We also examined longitudinal responses among HCW who completed the questionnaires multiple times.Statistical AnalysesAll analyses were conducted with a two-sided statistical significance level of P < .05 using R statistical software (version 3.4.2).Participant characteristics.", [["All analyses", "TEST", 118, 130], ["P", "TEST", 197, 198]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintParticipant characteristicsThe copyright holder for this this version posted September 10, 2020. . https://doi.org/10.1101/2020.09.07.20188813 doi: medRxiv preprint 588 HCW were recruited and consented in the IMPACT study between March 31 and July 7, 2020, of whom 473 (80%) were eligible for the smell sub-study (Figure 1) .Participant characteristicsWithin the sub-study population, 373 (79%) participants were female; the mean (SD) age was 37.5 (11.2) years; 375 (79%) were white non-Hispanic/Latino; 261 (55%) were registered nurses (RNs) and 98 (21%) were medical doctors (MDs) ( Table 1) .Participant characteristicsCompared to HCW included in this analysis, IMPACT HCW ineligible for the sub-study were more likely to be Black, Asian, or other ethnicity (P < .001) and have higher BMI (P = 0.004) (Supplemental table 3) .Participant characteristicsHCW included in the sub-study completed the daily symptom questionnaire Table 1) .", [["CC", "CHEMICAL", 0, 2], ["participants", "ORGANISM", 600, 612], ["Participant", "SPECIES", 530, 541], ["participants", "SPECIES", 600, 612], ["Participant", "SPECIES", 1033, 1044], ["CC", "TEST", 0, 2], ["the smell sub-study", "TEST", 498, 517], ["white non-Hispanic", "TEST", 682, 700], ["this analysis", "TEST", 855, 868], ["IMPACT HCW", "TREATMENT", 870, 880], ["the sub-study", "TEST", 896, 909], ["higher BMI", "PROBLEM", 986, 996], ["med", "ANATOMY", 99, 102]]], ["Nine of the 17 (53%) COVID-positive HCW completed the Yale Jiffy at least once, but most began rating the household items only after they reported categorical smell loss.", [["smell loss", "DISEASE", 159, 169], ["COVID", "CANCER", 21, 26], ["COVID", "TEST", 21, 26], ["categorical smell loss", "PROBLEM", 147, 169], ["smell loss", "OBSERVATION", 159, 169]]], ["Therefore, the number of individuals with a positive diagnosis and pre-post ratings was too small to analyze for smell loss.", [["smell loss", "DISEASE", 113, 123], ["pre-post ratings", "TEST", 67, 83], ["smell loss", "PROBLEM", 113, 123]]], ["COVID-.", [["COVID", "PROTEIN", 0, 5]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintParticipant characteristicsThe copyright holder for this this version posted September 10, 2020. . https://doi.org/10.1101/2020.09.07.20188813 doi: medRxiv preprint positive HCW were more likely to report categorical smell loss on the Jiffy, with 5/9 (56%) COVID-positive HCW versus 43/304 (14%) COVID-negative HCW reporting smell loss (OR=7.6, 95% CI: 2.0-29.4) ( Table 1) .", [["CC", "CHEMICAL", 0, 2], ["smell loss", "DISEASE", 422, 432], ["smell loss", "DISEASE", 530, 540], ["COVID", "GENE_OR_GENE_PRODUCT", 462, 467], ["CC", "TEST", 0, 2], ["categorical smell loss", "PROBLEM", 410, 432], ["COVID", "TEST", 462, 467], ["COVID", "TEST", 501, 506], ["smell loss", "PROBLEM", 530, 540], ["CI", "TEST", 554, 556], ["med", "ANATOMY", 99, 102]]], ["The five COVID-positive HCW who reported categorical smell loss via the Jiffy had a mean (SD) reduction in smell of 5.8 Table 1) .", [["smell loss", "DISEASE", 53, 63], ["categorical smell loss", "PROBLEM", 41, 63], ["a mean (SD) reduction in smell", "PROBLEM", 82, 112], ["smell loss", "OBSERVATION", 53, 63]]], ["Six of those seven also reported smell loss.Participant characteristicsRelative to Day 0 (defined as the day of test positivity), the median timing of reported smell loss was Day -2 (IQR, Day -16 to Day +2) among COVID-positive HCW reporting smell loss, with 6/9 (67%) reporting smell loss before test positivity (Figure 3) .Participant characteristicsSubjects recovered their sense of smell a median of nine days (IQR, 4, 16.5) after first .", [["smell loss", "DISEASE", 33, 43], ["smell loss", "DISEASE", 160, 170], ["smell loss", "DISEASE", 242, 252], ["smell loss", "DISEASE", 279, 289], ["HCW", "ORGANISM", 228, 231], ["Subjects", "ORGANISM", 352, 360], ["smell loss", "PROBLEM", 33, 43], ["test positivity", "TEST", 112, 127], ["smell loss", "PROBLEM", 160, 170], ["smell loss", "PROBLEM", 242, 252], ["smell loss", "PROBLEM", 279, 289], ["test positivity", "TEST", 297, 312], ["smell loss", "OBSERVATION", 33, 43], ["smell loss", "OBSERVATION", 242, 252]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review) preprintThe copyright holder for this this version posted September 10, 2020. . https://doi.org/10.1101/2020.09.07.20188813 doi: medRxiv preprint reporting smell loss.", [["CC", "CHEMICAL", 0, 2], ["smell loss", "DISEASE", 352, 362], ["CC", "TEST", 0, 2], ["smell loss", "PROBLEM", 352, 362], ["med", "ANATOMY", 99, 102], ["smell loss", "OBSERVATION", 352, 362]]], ["Of those who reported smell loss, 3/9 (33%) reported parosmia or smell loss as their first symptom.DISCUSSIONIn this prospective study of a high-risk HCW population, we assessed smell loss alongside routine viral testing, finding that HCW who acquired SARS-CoV-2 infection over the course of the study had significantly increased odds of reporting smell loss compared to COVID-negative HCW.", [["smell loss", "DISEASE", 22, 32], ["parosmia", "DISEASE", 53, 61], ["smell loss", "DISEASE", 65, 75], ["smell loss", "DISEASE", 178, 188], ["SARS-CoV-2 infection", "DISEASE", 252, 272], ["smell loss", "DISEASE", 348, 358], ["SARS-CoV-2", "ORGANISM", 252, 262], ["smell", "ORGANISM_SUBDIVISION", 348, 353], ["CoV-", "SPECIES", 257, 261], ["smell loss", "PROBLEM", 22, 32], ["parosmia", "PROBLEM", 53, 61], ["smell loss", "PROBLEM", 65, 75], ["their first symptom", "PROBLEM", 79, 98], ["this prospective study", "TEST", 112, 134], ["smell loss", "PROBLEM", 178, 188], ["routine viral testing", "TEST", 199, 220], ["SARS", "PROBLEM", 252, 256], ["CoV-2 infection", "PROBLEM", 257, 272], ["the study", "TEST", 292, 301], ["smell loss", "PROBLEM", 348, 358], ["COVID", "TEST", 371, 376], ["smell loss", "OBSERVATION", 22, 32], ["smell loss", "OBSERVATION", 65, 75], ["infection", "OBSERVATION", 263, 272], ["smell loss", "OBSERVATION", 348, 358]]], ["This finding was consistent across bivariate (OR=3.7), regression-adjusted (OR=4.5), and matched (OR=6.0) analyses.", [["regression", "TEST", 55, 65]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintDISCUSSIONThe copyright holder for this this version posted September 10, 2020. . https://doi.org/10.1101/2020.09.07.20188813 doi: medRxiv preprint COVID-positive HCW reported significantly more severe smell loss compared to COVID-negative HCW.", [["CC", "CHEMICAL", 0, 2], ["smell loss", "DISEASE", 407, 417], ["CC", "TEST", 0, 2], ["significantly more severe smell loss", "PROBLEM", 381, 417], ["COVID", "TEST", 430, 435], ["med", "ANATOMY", 99, 102]]], ["Overall, our findings add to the accumulating evidence demonstrating the efficacy and feasibility of using prospective, self-administered, athome assessments of smell sensitivity to track changes over time in a group of individuals at high risk for SARS-CoV-2 infection.DISCUSSIONOur findings are consistent with recent research demonstrating robust associations between smell perturbations and SARS-CoV-2 infection.", [["SARS-CoV-2 infection", "DISEASE", 249, 269], ["SARS-CoV-2 infection", "DISEASE", 395, 415], ["SARS-CoV-2", "ORGANISM", 249, 259], ["SARS-CoV-2", "ORGANISM", 395, 405], ["SARS-CoV-2", "SPECIES", 249, 259], ["SARS-CoV-2", "SPECIES", 395, 405], ["athome assessments", "TEST", 139, 157], ["smell sensitivity", "PROBLEM", 161, 178], ["SARS", "PROBLEM", 249, 253], ["CoV", "PROBLEM", 254, 257], ["2 infection", "PROBLEM", 258, 269], ["smell perturbations", "PROBLEM", 371, 390], ["SARS", "PROBLEM", 395, 399], ["CoV-2 infection", "PROBLEM", 400, 415], ["infection", "OBSERVATION", 260, 269], ["consistent with", "UNCERTAINTY", 297, 312], ["infection", "OBSERVATION", 406, 415]]], ["Specifically, smell and taste impairments are reported prior to (20%) or during (13%) hospitalization [10] , typically lasting 4-17 days [28] , and provide better predictive ability than fever or cough [29] , two of the more commonly used symptoms to screen for COVID-19.", [["taste impairments", "DISEASE", 24, 41], ["fever", "DISEASE", 187, 192], ["cough", "DISEASE", 196, 201], ["COVID-19", "CHEMICAL", 262, 270], ["smell", "PROBLEM", 14, 19], ["taste impairments", "PROBLEM", 24, 41], ["fever", "PROBLEM", 187, 192], ["cough", "PROBLEM", 196, 201], ["symptoms", "PROBLEM", 239, 247], ["COVID", "TEST", 262, 267], ["smell", "OBSERVATION", 14, 19]]], ["Indeed, a large cross-sectional study found that sudden self-reported smell loss was the best predictive indicator of COVID-19 infection [30] .", [["smell loss", "DISEASE", 70, 80], ["infection", "DISEASE", 127, 136], ["COVID-19", "GENE_OR_GENE_PRODUCT", 118, 126], ["a large cross-sectional study", "TEST", 8, 37], ["smell loss", "PROBLEM", 70, 80], ["COVID-19 infection", "PROBLEM", 118, 136], ["large", "OBSERVATION_MODIFIER", 10, 15]]], ["Our study extends these findings by uniquely assessing for prospective smell loss alongside viral screening in a high-risk group, all of whom were COVID-19 negative at study entry.", [["smell loss", "DISEASE", 71, 81], ["Our study", "TEST", 0, 9], ["prospective smell loss", "PROBLEM", 59, 81], ["viral screening", "TEST", 92, 107], ["COVID", "TEST", 147, 152]]], ["Moreover, distortion in smell was a better predictor of COVID-19 than many other physical symptoms.", [["distortion in smell", "PROBLEM", 10, 29], ["COVID", "TEST", 56, 61], ["many other physical symptoms", "PROBLEM", 70, 98], ["distortion", "OBSERVATION_MODIFIER", 10, 20]]], ["Cough, headache, and dyspnea were also significantly associated with increased odds of COVID-19 diagnosis in this study.", [["Cough", "DISEASE", 0, 5], ["headache", "DISEASE", 7, 15], ["dyspnea", "DISEASE", 21, 28], ["Cough", "PROBLEM", 0, 5], ["headache", "PROBLEM", 7, 15], ["dyspnea", "PROBLEM", 21, 28], ["COVID", "TEST", 87, 92], ["this study", "TEST", 109, 119], ["headache", "OBSERVATION", 7, 15]]], ["However, these symptoms are commonly experienced in other respiratory infections and not specific symptoms for COVID-19, and therefore less useful than loss of smell for monitoring for COVID-19 among asymptomatic individuals.DISCUSSIONInterestingly, we found an association between reduction in smell ability and neurological symptoms in COVID-19.", [["respiratory", "ANATOMY", 58, 69], ["neurological", "ANATOMY", 313, 325], ["respiratory infections", "DISEASE", 58, 80], ["reduction in smell ability", "DISEASE", 282, 308], ["neurological symptoms", "DISEASE", 313, 334], ["these symptoms", "PROBLEM", 9, 23], ["other respiratory infections", "PROBLEM", 52, 80], ["specific symptoms", "PROBLEM", 89, 106], ["COVID", "TEST", 111, 116], ["loss of smell", "PROBLEM", 152, 165], ["COVID", "TEST", 185, 190], ["reduction in smell ability", "PROBLEM", 282, 308], ["neurological symptoms", "PROBLEM", 313, 334], ["COVID", "TEST", 338, 343], ["respiratory", "ANATOMY", 58, 69], ["infections", "OBSERVATION", 70, 80]]], ["While the exact pathophysiology underlying COVID-19 related smell loss remains incompletely understood, the association between .", [["smell loss", "DISEASE", 60, 70], ["COVID-19", "GENE_OR_GENE_PRODUCT", 43, 51], ["COVID", "TEST", 43, 48], ["smell loss", "PROBLEM", 60, 70]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintDISCUSSIONThe copyright holder for this this version posted September 10, 2020. . https://doi.org/10.1101/2020.09.07.20188813 doi: medRxiv preprint smell loss and other neurological symptoms suggests a potential common mechanism underlying these symptoms.", [["neurological", "ANATOMY", 374, 386], ["CC", "CHEMICAL", 0, 2], ["smell loss", "DISEASE", 353, 363], ["neurological symptoms", "DISEASE", 374, 395], ["CC", "TEST", 0, 2], ["medRxiv preprint smell loss", "PROBLEM", 336, 363], ["other neurological symptoms", "PROBLEM", 368, 395], ["these symptoms", "PROBLEM", 445, 459], ["med", "ANATOMY", 99, 102]]], ["A growing body of evidence has demonstrated the potential for SARS-CoV-2 to infect neurons [31, 32] , and our results lend support to the hypothesis that smell loss may be related to central nervous system infection by SARS-CoV-2, consistent with studies reporting MRI abnormalities in the olfactory bulb in a subset of patients with COVID-19 related anosmia [33, 34] .DISCUSSIONOur study has several limitations.", [["neurons", "ANATOMY", 83, 90], ["central nervous system", "ANATOMY", 183, 205], ["olfactory bulb", "ANATOMY", 290, 304], ["smell loss", "DISEASE", 154, 164], ["central nervous system infection", "DISEASE", 183, 215], ["anosmia", "DISEASE", 351, 358], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 62, 72], ["neurons", "CELL", 83, 90], ["central nervous system", "ANATOMICAL_SYSTEM", 183, 205], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 219, 229], ["olfactory bulb", "MULTI-TISSUE_STRUCTURE", 290, 304], ["patients", "ORGANISM", 320, 328], ["patients", "SPECIES", 320, 328], ["SARS-CoV", "SPECIES", 62, 70], ["SARS-CoV", "SPECIES", 219, 227], ["SARS", "PROBLEM", 62, 66], ["CoV", "TEST", 67, 70], ["smell loss", "PROBLEM", 154, 164], ["central nervous system infection", "PROBLEM", 183, 215], ["CoV", "TEST", 224, 227], ["MRI abnormalities in the olfactory bulb", "PROBLEM", 265, 304], ["COVID", "TEST", 334, 339], ["anosmia", "PROBLEM", 351, 358], ["DISCUSSIONOur study", "TEST", 369, 388], ["may be related to", "UNCERTAINTY", 165, 182], ["central", "ANATOMY_MODIFIER", 183, 190], ["nervous system", "ANATOMY", 191, 205], ["infection", "OBSERVATION", 206, 215], ["consistent with", "UNCERTAINTY", 231, 246], ["olfactory bulb", "ANATOMY", 290, 304]]], ["Smell sensitivity and loss using the Yale Jiffy were evaluated using both categorical responses and a VAS [35] .", [["Smell sensitivity", "PROBLEM", 0, 17]]], ["Indeed, those indicating severe loss reported an average of an 8.3cm decrease on the 10cm scale, compared to a 2.2cm reduction in those indicating slight loss, suggesting categorical responses are sufficient for identifying asymptomatic carriers.", [["severe loss", "PROBLEM", 25, 36], ["an 8.3cm decrease on the 10cm scale", "PROBLEM", 60, 95], ["a 2.2cm reduction", "TREATMENT", 109, 126], ["slight loss", "PROBLEM", 147, 158], ["asymptomatic carriers", "PROBLEM", 224, 245], ["severe", "OBSERVATION_MODIFIER", 25, 31], ["loss", "OBSERVATION", 32, 36], ["average", "OBSERVATION_MODIFIER", 49, 56], ["8.3cm", "OBSERVATION_MODIFIER", 63, 68], ["decrease", "OBSERVATION_MODIFIER", 69, 77], ["10cm scale", "OBSERVATION_MODIFIER", 85, 95], ["2.2cm", "OBSERVATION_MODIFIER", 111, 116], ["reduction", "OBSERVATION_MODIFIER", 117, 126], ["slight", "OBSERVATION_MODIFIER", 147, 153], ["loss", "OBSERVATION", 154, 158], ["suggesting", "UNCERTAINTY", 160, 170], ["categorical responses", "OBSERVATION", 171, 192]]], ["However, because many participants already had smell loss the first time they completed the VAS, we were not able to detect any changes.", [["smell loss", "DISEASE", 47, 57], ["participants", "ORGANISM", 22, 34], ["participants", "SPECIES", 22, 34], ["smell loss", "PROBLEM", 47, 57]]], ["Consistent daily ratings of a household item could prove useful for further evaluating the magnitude of loss but would require further instructions and possibly practice using the scale.", [["loss", "PROBLEM", 104, 108], ["the scale", "TREATMENT", 176, 185]]], ["Adopting the generalized labeled magnitude scale (gLMS), a specialized line scale with semantic labels at empirically derived intervals, may also improve outcomes, as this scale is less subject to floor and ceiling effects [36] .DISCUSSIONHowever, it requires some training and practice.", [["a specialized line scale", "TREATMENT", 57, 81], ["some training", "TREATMENT", 260, 273]]], ["Additionally, the low number of positive cases limited statistical power.DISCUSSIONIn our study, self-reported changes in smell perception were predictive of SARS-CoV-2 infection in a healthcare worker population.", [["SARS-CoV-2 infection", "DISEASE", 158, 178], ["SARS-CoV", "SPECIES", 158, 166], ["our study", "TEST", 86, 95], ["changes in smell perception", "PROBLEM", 111, 138], ["SARS", "PROBLEM", 158, 162], ["CoV", "PROBLEM", 163, 166], ["2 infection", "PROBLEM", 167, 178], ["low number", "OBSERVATION_MODIFIER", 18, 28], ["positive", "OBSERVATION_MODIFIER", 32, 40], ["infection", "OBSERVATION", 169, 178]]], ["At-home smell assessments should be considered for non-invasive screening of groups that are at high risk for COVID-19.DISCUSSION. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintDISCUSSIONThe copyright holder for this this version posted September 10, 2020. .", [["CC", "CHEMICAL", 131, 133], ["home smell assessments", "TEST", 3, 25], ["non-invasive screening", "TEST", 51, 73], ["COVID", "TEST", 110, 115], ["CC", "TEST", 131, 133], ["med", "ANATOMY", 230, 233]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["med", "ANATOMY", 99, 102]]], ["Boxes with a \"YJ\" specifically indicate a Yale Jiffy response.DISCUSSION. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintDISCUSSIONThe copyright holder for this this version posted September 10, 2020. . https://doi.org/10.1101/2020.09.07.20188813 doi: medRxiv preprint", [["CC", "CHEMICAL", 74, 76], ["CC", "TEST", 74, 76], ["medRxiv", "TREATMENT", 410, 417], ["med", "ANATOMY", 173, 176]]]], "aea4ba522133c19b4b39dcfb8bb0882575490ccd": [["IntroductionCountries around the world are confronted with a rising count of patients that die from COVID-19.", [["COVID-19", "CHEMICAL", 100, 108], ["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["IntroductionCountries", "TREATMENT", 0, 21], ["a rising count", "TEST", 59, 73], ["COVID", "TEST", 100, 105]]], ["Up to this date, there is no scientific evidence that proves that a COVID-19 corpse is still infectious.", [["a COVID", "TEST", 66, 73], ["infectious", "PROBLEM", 93, 103], ["no", "UNCERTAINTY", 26, 28], ["infectious", "OBSERVATION", 93, 103]]], ["Different guidelines are being followed worldwide on how to deal with a COVID-19 positive corpse.", [["a COVID", "TEST", 70, 77]]], ["The aim of this review is to compare different guidelines and literature on best practice for handling a COVID-19 positive corpse.ResultsThe guidelines vary greatly in the use of PPE's and other safety measures especially during autopsy.", [["a COVID", "TEST", 103, 110], ["PPE's", "TREATMENT", 179, 184], ["other safety measures", "TREATMENT", 189, 210]]], ["There is great variation in the use of disinfectant and its concentration.", [["great variation", "PROBLEM", 9, 24], ["disinfectant", "TREATMENT", 39, 51], ["great", "OBSERVATION_MODIFIER", 9, 14], ["variation", "OBSERVATION_MODIFIER", 15, 24]]], ["More scientific evidence is needed to substantiate the handling of COVID-19 positive corpses to make an educated decision on how to safely handle a COVID-19 positive corpse.IntroductionOn December 31 st 2019, a cluster of patients presenting with pneumonia was detected in Wuhan, China.", [["pneumonia", "DISEASE", 247, 256], ["patients", "ORGANISM", 222, 230], ["patients", "SPECIES", 222, 230], ["COVID", "TEST", 67, 72], ["a COVID", "TEST", 146, 153], ["pneumonia", "PROBLEM", 247, 256], ["pneumonia", "OBSERVATION", 247, 256]]], ["On January 9 th 2020, the WHO (World Health Organization) reported that this outbreak was caused by a new coronavirus later named COVID-19.", [["coronavirus", "DISEASE", 106, 117], ["coronavirus", "ORGANISM", 106, 117], ["a new coronavirus", "PROBLEM", 100, 117]]], ["The COVID-19 (SARS-CoV-2) is very similar to SARS (SARS-CoV-1).", [["SARS", "DISEASE", 45, 49], ["SARS", "DISEASE", 51, 55], ["COVID-19", "GENE_OR_GENE_PRODUCT", 4, 12], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 14, 24], ["SARS-CoV-1", "SPECIES", 51, 61], ["The COVID", "TEST", 0, 9], ["SARS-CoV", "TEST", 14, 22], ["SARS", "TEST", 51, 55], ["CoV", "TEST", 56, 59]]], ["The virus has been detected in bodily fluids like sputum, feces and eye fluid.", [["bodily fluids", "ANATOMY", 31, 44], ["sputum", "ANATOMY", 50, 56], ["feces", "ANATOMY", 58, 63], ["eye fluid", "ANATOMY", 68, 77], ["sputum", "ORGANISM_SUBSTANCE", 50, 56], ["feces", "ORGANISM_SUBSTANCE", 58, 63], ["eye", "ORGAN", 68, 71], ["fluid", "ORGANISM_SUBSTANCE", 72, 77], ["The virus", "PROBLEM", 0, 9], ["bodily fluids", "TEST", 31, 44], ["sputum, feces and eye fluid", "TEST", 50, 77], ["virus", "OBSERVATION", 4, 9], ["sputum", "OBSERVATION", 50, 56], ["eye", "ANATOMY", 68, 71], ["fluid", "OBSERVATION", 72, 77]]], ["1,2 The most important transmission route of the virus is through sputum droplets.", [["sputum droplets", "ANATOMY", 66, 81], ["1,2", "CHEMICAL", 0, 3], ["the virus", "PROBLEM", 45, 54], ["sputum droplets", "PROBLEM", 66, 81], ["virus", "OBSERVATION", 49, 54]]], ["It is unclear if fecal-oral is a transmission route.", [["oral", "ANATOMY", 23, 27], ["fecal", "ORGANISM_SUBSTANCE", 17, 22], ["oral", "ORGANISM_SUBDIVISION", 23, 27]]], ["2 By these transmission routes the virus spreads in the environment and can be detected outside the host.", [["the virus", "PROBLEM", 31, 40], ["virus", "OBSERVATION", 35, 40]]], ["COVID-19 has been detected on surfaces after 5 days, with a temperature between 22-25 degrees Celsius and a humidity of 40-50%.", [["COVID-19", "CHEMICAL", 0, 8], ["COVID-19", "DNA", 0, 8], ["COVID", "TEST", 0, 5], ["a temperature", "TEST", 58, 71], ["a humidity", "TEST", 106, 116]]], ["3 The virus has been detected on plastic after 72 hours, stainless steel after 48 hours and copper after 8 hours.", [["copper", "CHEMICAL", 92, 98], ["copper", "CHEMICAL", 92, 98], ["copper", "SIMPLE_CHEMICAL", 92, 98], ["The virus", "PROBLEM", 2, 11], ["stainless steel", "TREATMENT", 57, 72], ["virus", "OBSERVATION", 6, 11]]], ["3 A recent article on a ship carrying COVID-19 positive patients, states that viral material could still be detected after 17 days.", [["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["viral material", "PROBLEM", 78, 92]]], ["4 DNA-techniques indicated the presence of COVID-19 in Dutch sewage water.", [["COVID-19", "CHEMICAL", 43, 51], ["DNA", "CELLULAR_COMPONENT", 2, 5], ["COVID-19", "DNA", 43, 51], ["COVID", "TEST", 43, 48]]], ["The Dutch authority on infectious diseases (Rijksinstituut voor Volksgezondheid en Milieu = RIVM) stated that the virus ended up in the sewage water through bodily fluids.", [["infectious diseases", "DISEASE", 23, 42], ["infectious diseases", "PROBLEM", 23, 42], ["Rijksinstituut voor Volksgezondheid en Milieu = RIVM", "TREATMENT", 44, 96], ["the virus", "PROBLEM", 110, 119], ["virus", "OBSERVATION", 114, 119]]], ["5 Little is known about the behavior of the COVID-19 virus after the human host has died.", [["COVID-19 virus", "ORGANISM", 44, 58], ["human", "ORGANISM", 69, 74], ["human", "SPECIES", 69, 74], ["COVID-19 virus", "SPECIES", 44, 58], ["human", "SPECIES", 69, 74]]], ["It is known that SARS can be detected in the lungs and small intestine until 90-175 hours post mortal.", [["lungs", "ANATOMY", 45, 50], ["small intestine", "ANATOMY", 55, 70], ["SARS", "DISEASE", 17, 21], ["lungs", "ORGAN", 45, 50], ["small intestine", "ORGAN", 55, 70], ["SARS", "PROBLEM", 17, 21], ["SARS", "OBSERVATION", 17, 21], ["lungs", "ANATOMY", 45, 50], ["small", "OBSERVATION_MODIFIER", 55, 60], ["intestine", "ANATOMY", 61, 70]]], ["It is unclear if the virus was still infective.", [["the virus", "PROBLEM", 17, 26], ["infective", "PROBLEM", 37, 46], ["unclear if", "UNCERTAINTY", 6, 16], ["virus", "OBSERVATION", 21, 26], ["infective", "OBSERVATION", 37, 46]]], ["6 How long COVID-19 can be detected in bodily fluids is unknown.", [["bodily fluids", "ANATOMY", 39, 52], ["COVID-19", "CHEMICAL", 11, 19], ["COVID-19", "CHEMICAL", 11, 19], ["long COVID-19", "DNA", 6, 19]]], ["Our research group has tested COVID-19 post mortem (through a nasopharynx and oropharynx swab) and the virus could still be detected 27 hours after death.", [["nasopharynx", "ANATOMY", 62, 73], ["oropharynx swab", "ANATOMY", 78, 93], ["death", "DISEASE", 148, 153], ["nasopharynx", "ORGAN", 62, 73], ["oropharynx swab", "ORGAN", 78, 93], ["COVID", "TEST", 30, 35], ["a nasopharynx and oropharynx swab", "TEST", 60, 93], ["the virus", "PROBLEM", 99, 108], ["death", "PROBLEM", 148, 153], ["nasopharynx", "ANATOMY", 62, 73], ["oropharynx", "ANATOMY", 78, 88]]], ["If the bodily fluids pose an infection risk when the virus can be detected, is unknown.", [["bodily fluids", "ANATOMY", 7, 20], ["infection", "DISEASE", 29, 38], ["the bodily fluids", "TREATMENT", 3, 20], ["an infection risk", "PROBLEM", 26, 43], ["the virus", "PROBLEM", 49, 58], ["infection", "OBSERVATION", 29, 38]]], ["The RIVM states a corpse can be infectious for some hours till a day after death, but does not refer to a scientific study.", [["death", "DISEASE", 75, 80], ["a scientific study", "TEST", 104, 122]]], ["7 Countries around the world are confronted with a rising count of patients that die with/from COVID-19.", [["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["COVID", "TEST", 95, 100]]], ["Different guidelines are being followed worldwide on how to deal with a COVID-19 positive corpse to keep transmission risk as low as possible.", [["a COVID", "TEST", 70, 77]]], ["The aim of this review is to compare different guidelines and literature on best practice for handling a COVID-19 positive corpse.Material and methodsFor this literary review government guidelines on the handling of COVID-19 positive corpses were used.", [["a COVID", "TEST", 103, 110], ["COVID", "TEST", 216, 221]]], ["Search criteria on google included \"COVID-19\" AND \"guideline\" AND (\"post mortal\" OR \"corpse\" OR \"dead body\" OR \"funeral workers\" OR \"funeral service\".", [["body", "ANATOMY", 102, 106], ["body", "ORGANISM_SUBDIVISION", 102, 106]]], ["17 Guidelines on SARS and general infectious diseases from included countries were also reviewed when available.", [["SARS", "DISEASE", 17, 21], ["infectious diseases", "DISEASE", 34, 53], ["SARS", "PROBLEM", 17, 21], ["general infectious diseases", "PROBLEM", 26, 53], ["infectious", "OBSERVATION", 34, 44]]], ["Recent published literature on the handling of COVID-19 positive corpses was also used, 18, 19, 20 as well as reports from the WHO.", [["COVID", "TEST", 47, 52]]], ["The use of Personal Protection Equipment (PPE) was reviewed, as well as special measures to be taken with the corpse itself and cleaning and disinfecting the environment.Material and methods-- Table 1 -Results Table 1 shows the sources each guideline is based on.", [["Personal Protection Equipment (PPE)", "TREATMENT", 11, 46], ["special measures", "TREATMENT", 72, 88]]], ["A review of the guidelines results in the following overview.COVID-19 transmissionMuch is still unknown about the transmission of COVID-19.", [["COVID-19", "CHEMICAL", 130, 138], ["COVID-19", "DNA", 130, 138], ["COVID", "TEST", 61, 66], ["COVID", "TEST", 130, 135]]], ["The WHO states that a person who has contracted COVID-19 could be symptomatic for 14 days in mild cases to several weeks in severe cases.", [["COVID-19", "CHEMICAL", 48, 56], ["COVID-19", "CHEMICAL", 48, 56], ["person", "SPECIES", 22, 28], ["symptomatic", "PROBLEM", 66, 77], ["severe cases", "PROBLEM", 124, 136]]], ["The Netherlands state that a corpse could be infectious for several hours to days.", [["infectious", "PROBLEM", 45, 55], ["infectious", "OBSERVATION", 45, 55]]], ["None of the other reviewed literature state anything about how long bodily fluids stay infectious in the corpse, nor anything about post mortal transmission risk of COVID-19.Handling of the corpse (without autopsy)The use of PPE's while handling the corpse has been outlined in table 2.", [["corpse", "ANATOMY", 190, 196], ["COVID", "TEST", 165, 170], ["PPE's", "TREATMENT", 225, 230]]], ["Contact with bodily fluids should be minimized.", [["bodily fluids", "TREATMENT", 13, 26]]], ["The consensus appears to be that the body of the deceased should be transported as soon as possible to the morgue.", [["body", "ANATOMY", 37, 41], ["body", "ORGANISM_SUBDIVISION", 37, 41], ["appears to be", "UNCERTAINTY", 14, 27]]], ["Transport between place of death and morgue is advised to be in a leak-proof body bag to limit the contact with bodily fluids.", [["body", "ANATOMY", 77, 81], ["death", "DISEASE", 27, 32], ["body", "ORGANISM_SUBDIVISION", 77, 81], ["a leak-proof body bag", "TREATMENT", 64, 85], ["bodily fluids", "TREATMENT", 112, 125], ["leak", "OBSERVATION", 66, 70]]], ["China, India and Germany state that wound openings should be cleaned, disinfected and covered with a waterproof band aid.", [["wound", "ANATOMY", 36, 41], ["wound", "PATHOLOGICAL_FORMATION", 36, 41], ["wound openings", "PROBLEM", 36, 50], ["a waterproof band aid", "TREATMENT", 99, 120], ["wound openings", "OBSERVATION", 36, 50]]], ["These three countries further state that the body orifices (mouth, nose and anus) should be plugged.", [["body orifices", "ANATOMY", 45, 58], ["mouth", "ANATOMY", 60, 65], ["nose", "ANATOMY", 67, 71], ["anus", "ANATOMY", 76, 80], ["body orifices", "MULTI-TISSUE_STRUCTURE", 45, 58], ["mouth", "ORGANISM_SUBDIVISION", 60, 65], ["nose", "ORGANISM_SUBDIVISION", 67, 71], ["anus", "ORGAN", 76, 80], ["the body orifices (mouth, nose and anus", "PROBLEM", 41, 80], ["body", "ANATOMY", 45, 49], ["orifices", "ANATOMY_MODIFIER", 50, 58], ["mouth", "ANATOMY", 60, 65], ["nose", "ANATOMY", 67, 71], ["anus", "ANATOMY", 76, 80], ["plugged", "OBSERVATION", 92, 99]]], ["In China, India and Germany the skin of the corpse should be disinfected.", [["skin", "ANATOMY", 32, 36], ["skin", "ORGAN", 32, 36], ["corpse", "ORGANISM", 44, 50], ["skin", "ANATOMY", 32, 36], ["disinfected", "OBSERVATION", 61, 72]]], ["Body bags are required in China, USA, UK, Australia, India and by the WHO.", [["Body bags", "ANATOMY", 0, 9], ["Body bags", "TREATMENT", 0, 9]]], ["These body bags then have to be disinfected in China, USA and India.", [["body", "ANATOMY", 6, 10], ["These body bags", "TREATMENT", 0, 15], ["disinfected", "OBSERVATION", 32, 43]]], ["In China and India, the body bags have to be covered by a sheet.", [["body", "ANATOMY", 24, 28], ["body", "ORGANISM_SUBDIVISION", 24, 28], ["bags", "ORGANISM_SUBSTANCE", 29, 33], ["the body bags", "TREATMENT", 20, 33]]], ["In Germany, the corpse has to be wrapped in a double sheet doused in disinfectant, put in a double-layer (leak-proof) body bag with chlorine that is then placed in a coffin which has to be closed immediately.", [["body", "ANATOMY", 118, 122], ["chlorine", "CHEMICAL", 132, 140], ["chlorine", "CHEMICAL", 132, 140], ["chlorine", "SIMPLE_CHEMICAL", 132, 140], ["a double sheet doused in disinfectant", "TREATMENT", 44, 81], ["a double-layer (leak-proof) body bag", "TREATMENT", 90, 126], ["chlorine", "TREATMENT", 132, 140], ["chlorine", "OBSERVATION", 132, 140]]], ["In Germany and India, the vehicle that has transported either a body bag or coffin should be disinfected after transport.", [["body", "ANATOMY", 64, 68], ["body", "ORGANISM_SUBDIVISION", 64, 68], ["a body bag", "TREATMENT", 62, 72]]], ["India states that a COVID-19 positive corpse should be stored separately from COVID-19 negative corpses, including separate ventilation.", [["a COVID", "TEST", 18, 25], ["COVID", "TEST", 78, 83], ["separate ventilation", "TREATMENT", 115, 135]]], ["The body bag when disinfected can be handled with just the use of gloves and proper hand hygiene.", [["body", "ANATOMY", 4, 8], ["hand", "ANATOMY", 84, 88], ["body", "ORGANISM_SUBDIVISION", 4, 8], ["hand", "ORGANISM_SUBDIVISION", 84, 88], ["The body bag", "TREATMENT", 0, 12], ["gloves", "TREATMENT", 66, 72], ["body bag", "OBSERVATION", 4, 12], ["disinfected", "OBSERVATION", 18, 29]]], ["Contact with the body bag should be minimalized.Handling of the corpse (without autopsy)-- Table 2 -Handling of the corpse during autopsyThe use of PPE's during autopsy has been outlined in table 2.", [["body", "ANATOMY", 17, 21], ["body", "ORGANISM_SUBDIVISION", 17, 21], ["PPE", "GENE_OR_GENE_PRODUCT", 148, 151], ["the body bag", "TREATMENT", 13, 25], ["autopsy", "TEST", 130, 137], ["PPE's", "TREATMENT", 148, 153], ["autopsy", "TEST", 161, 168]]], ["In addition to extensive PPE's and limited personnel, a cut-proof layer between double gloves is advised by Germany and India.", [["extensive PPE's", "TREATMENT", 15, 30], ["a cut-proof layer between double gloves", "TREATMENT", 54, 93]]], ["The UK, India and Germany state that an autopsy should be performed in a negative pressure room with whole ventilation or down-drafts at the workstations.", [["an autopsy", "TEST", 37, 47], ["whole ventilation", "TREATMENT", 101, 118]]], ["Germany further states that autopsy rooms should be in a separate building from patient care with standalone sewage and ventilation and that showers should be available for personnel.", [["patient", "ORGANISM", 80, 87], ["patient", "SPECIES", 80, 87], ["standalone sewage", "TREATMENT", 98, 115], ["ventilation", "TREATMENT", 120, 131]]], ["The USA, UK and Germany advise a whole-body suit with vented respirators while being in the autopsy room.", [["body", "ORGANISM_SUBDIVISION", 39, 43], ["a whole-body suit", "TREATMENT", 31, 48], ["vented respirators", "TREATMENT", 54, 72]]], ["While performing the autopsy, UK, India and Germany state it is preferred that only one body cavity should be opened at a time.", [["body cavity", "ANATOMY", 88, 99], ["body cavity", "ORGAN", 88, 99]]], ["Emphasis has been put on minimalizing the chance of cutting or puncture injuries.", [["puncture injuries", "DISEASE", 63, 80], ["puncture injuries", "PROBLEM", 63, 80]]], ["Most guidelines state that Aerosol Generating Procedures (AGP) or splashing procedures (use of high flow water, dropping organs in water) should be avoided or minimalized.", [["organs", "ANATOMY", 121, 127], ["organs", "ORGAN", 121, 127], ["Aerosol Generating Procedures (AGP)", "TREATMENT", 27, 62], ["splashing procedures", "TREATMENT", 66, 86], ["high flow water", "TREATMENT", 95, 110]]], ["An oscillator saw should be either avoided or used with suction extraction.Cleaning the morgueThe reviewed literature shows different cleaning and disinfectant protocols.", [["An oscillator", "TREATMENT", 0, 13], ["suction extraction", "TREATMENT", 56, 74], ["different cleaning", "TREATMENT", 124, 142], ["disinfectant protocols", "TREATMENT", 147, 169]]], ["Table 3 shows an overview of used disinfections and its concentration.", [["disinfections", "TREATMENT", 34, 47]]], ["Bleach/chlorine (in different solutions) and alcohol 70% is most frequently used.", [["Bleach/chlorine", "CHEMICAL", 0, 15], ["alcohol", "CHEMICAL", 45, 52], ["chlorine", "CHEMICAL", 7, 15], ["alcohol", "CHEMICAL", 45, 52], ["chlorine", "SIMPLE_CHEMICAL", 7, 15], ["alcohol", "SIMPLE_CHEMICAL", 45, 52], ["Bleach/chlorine (in different solutions", "TREATMENT", 0, 39], ["alcohol", "TREATMENT", 45, 52]]], ["Different concentrations of disinfectants are used.", [["Different concentrations of disinfectants", "PROBLEM", 0, 41], ["concentrations", "OBSERVATION_MODIFIER", 10, 24], ["disinfectants", "OBSERVATION", 28, 41]]], ["The surroundings where the deceased has come in contact with, need to be cleaned of visible bodily fluids and disinfected with chlorine or alcohol 70%.", [["chlorine", "CHEMICAL", 127, 135], ["alcohol", "CHEMICAL", 139, 146], ["chlorine", "CHEMICAL", 127, 135], ["alcohol", "CHEMICAL", 139, 146], ["chlorine", "SIMPLE_CHEMICAL", 127, 135], ["alcohol", "SIMPLE_CHEMICAL", 139, 146], ["chlorine", "TREATMENT", 127, 135]]], ["Germany states that the circulated air in the autopsy room should be sterilized with UV-light for one hour and filtered through a Fan Filter Unit (FFU) for two hours.", [["UV", "TREATMENT", 85, 87], ["a Fan Filter Unit", "TREATMENT", 128, 145], ["air", "OBSERVATION", 35, 38]]], ["Germany also states that body excretions should not be washed down the drain into normal sewage water, but has to be put for 1,5 hours in 40mg/l of chlorine.", [["body", "ANATOMY", 25, 29], ["chlorine", "CHEMICAL", 148, 156], ["chlorine", "CHEMICAL", 148, 156], ["body", "ORGANISM_SUBDIVISION", 25, 29], ["chlorine", "SIMPLE_CHEMICAL", 148, 156], ["body excretions", "PROBLEM", 25, 40], ["the drain", "TREATMENT", 67, 76], ["chlorine", "TREATMENT", 148, 156], ["drain", "OBSERVATION", 71, 76], ["sewage water", "OBSERVATION_MODIFIER", 89, 101]]], ["The mix should then be washed down the drain with more chlorine until the sewage water contains a concentration of 10 mg/l chlorine.Cleaning the morgue-- Table 3 -Funeral servicesThe use of PPE's by funeral workers has been outlined in table 2.", [["chlorine", "CHEMICAL", 55, 63], ["chlorine", "CHEMICAL", 123, 131], ["chlorine", "CHEMICAL", 55, 63], ["chlorine", "CHEMICAL", 123, 131], ["chlorine", "SIMPLE_CHEMICAL", 55, 63], ["chlorine", "SIMPLE_CHEMICAL", 123, 131], ["the drain", "TREATMENT", 35, 44], ["more chlorine", "TREATMENT", 50, 63], ["the sewage water", "TREATMENT", 70, 86], ["a concentration", "TREATMENT", 96, 111], ["PPE's", "TREATMENT", 190, 195], ["drain", "OBSERVATION", 39, 44]]], ["In the Netherlands only thanatopraxis is allowed, in the UK and Australia embalming is allowed when using proper additional protection equipment.", [["proper additional protection equipment", "TREATMENT", 106, 144]]], ["Family of the deceased is allowed to have physical contact with the deceased with proper hand hygiene in the Netherlands.", [["hand", "ANATOMY", 89, 93], ["hand", "ORGANISM_SUBDIVISION", 89, 93]]], ["Other countries advise limited (with the use of PPE's) to no physical contact with the deceased.", [["PPE's", "TREATMENT", 48, 53]]], ["In China, it is advised to cremate corpses positive for COVID-19.", [["COVID", "TEST", 56, 61]]], ["Germany states that the body has to be buried at least 2 meters below the surface.Discussion and conclusionThroughout the world many guidelines on the handling of deceased due to COVID-19 exist.", [["body", "ANATOMY", 24, 28], ["surface", "ANATOMY", 74, 81], ["body", "ORGANISM_SUBDIVISION", 24, 28], ["surface", "CELLULAR_COMPONENT", 74, 81], ["COVID", "TEST", 179, 184], ["body", "ANATOMY", 24, 28], ["buried", "OBSERVATION", 39, 45], ["surface", "OBSERVATION_MODIFIER", 74, 81]]], ["Some guidelines concentrate on corpses that have been tested positive for COVID-19 before death, others also include corpses of people suspected to have COVID-19.", [["death", "DISEASE", 90, 95], ["people", "ORGANISM", 128, 134], ["people", "SPECIES", 128, 134], ["COVID", "TEST", 74, 79], ["death", "PROBLEM", 90, 95], ["COVID", "TEST", 153, 158]]], ["Since not everyone suspected of COVID-19 infection is tested before death, a suspected positive COVID-19 corpse should be handled the same as a positive COVID-19 corpse.", [["infection", "DISEASE", 41, 50], ["death", "DISEASE", 68, 73], ["COVID-19", "ORGANISM", 32, 40], ["COVID-19 infection", "PROBLEM", 32, 50], ["a suspected positive COVID", "PROBLEM", 75, 101], ["infection", "OBSERVATION", 41, 50]]], ["No extra precautions are necessary and the relatives can say goodbye to the deceased in the way they want, because there is no risk of contamination since the corpse is not breathing.", [["extra precautions", "TREATMENT", 3, 20], ["contamination", "PROBLEM", 135, 148], ["extra", "OBSERVATION_MODIFIER", 3, 8], ["precautions", "OBSERVATION", 9, 20], ["no risk of", "UNCERTAINTY", 124, 134], ["contamination", "OBSERVATION", 135, 148]]], ["All possible precautions should be taken and the corpse should be touched as little as possible and the surroundings should be decontaminated, because the risk of contamination is enormous.", [["precautions", "TREATMENT", 13, 24], ["contamination", "PROBLEM", 163, 176], ["contamination", "OBSERVATION", 163, 176]]], ["Scientific evidence about post-mortem handling lacks to a great extent.", [["great extent", "OBSERVATION_MODIFIER", 58, 70]]], ["The WHO does not mention the post-mortem contamination as a major knowledge gap.", [["the post-mortem contamination", "PROBLEM", 25, 54]]], ["However, the WHO does advice to conduct pathogenesis studies using biopsy/post-mortem specimens.", [["specimens", "ANATOMY", 86, 95], ["pathogenesis studies", "TEST", 40, 60], ["biopsy", "TEST", 67, 73], ["post-mortem specimens", "TEST", 74, 95]]], ["Until this moment no such a study has been published.", [["a study", "TEST", 26, 33]]], ["Up to this date, there is no scientific evidence that proves that a COVID-19 corpse is still infectious.", [["a COVID", "TEST", 66, 73], ["infectious", "PROBLEM", 93, 103], ["no", "UNCERTAINTY", 26, 28], ["infectious", "OBSERVATION", 93, 103]]], ["The guidelines vary greatly in the use of PPE's and other safety measures especially during autopsy.", [["PPE's", "TREATMENT", 42, 47], ["other safety measures", "TREATMENT", 52, 73]]], ["There is great variation in the use of disinfectant and its concentration.", [["great variation", "PROBLEM", 9, 24], ["disinfectant", "TREATMENT", 39, 51], ["great", "OBSERVATION_MODIFIER", 9, 14], ["variation", "OBSERVATION_MODIFIER", 15, 24]]], ["Also recommended funeral services and contact with relatives vary greatly.Discussion and conclusionSome COVID-19 guidelines are based on SARS/MERS guidelines, while others are a complete new set of guidelines specific to COVID-19.", [["conclusionSome COVID", "TREATMENT", 89, 109], ["COVID", "TEST", 221, 226]]], ["The United Kingdom is the only country that classifies COVID-19 in Hazard Group 3, the same group as SARS and MERS.", [["SARS", "DISEASE", 101, 105]]], ["Other countries imply COVID-19 is similar to SARS, but the guidelines don/t .", [["SARS", "DISEASE", 45, 49], ["COVID", "TEST", 22, 27]]], ["It is still unclear if COVID-19 (SARS-CoV2) has the same infectious properties in a corpse as SARS (SARS-CoV1).", [["SARS", "DISEASE", 94, 98], ["SARS", "DISEASE", 100, 104], ["COVID-19", "GENE_OR_GENE_PRODUCT", 23, 31], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 33, 42], ["COVID", "TEST", 23, 28], ["infectious", "OBSERVATION", 57, 67]]], ["In fact, too little is scientifically known of COVID-19 to propose an educated guideline at this moment.", [["COVID", "TEST", 47, 52], ["too little", "OBSERVATION_MODIFIER", 9, 19]]], ["In conclusion, there is very limited scientific evidence on which the guidelines in this research are based.", [["very", "OBSERVATION_MODIFIER", 24, 28]]], ["15 Europe + CHP -COVID-19 9 China + + + + DGHS -COVID-19 17 India + + + + RIVM -COVID-19 7 Netherlands + --Parekh UN -Covid-19 20 India + + Separate ventilation in storage unit from non COVID-19 positive corpses WHO -SARS 21 + + + + CDC -SARS 11 USA + + + HSE -Infectious diseases 12 UK + + + 15 Europe + Advise next of kin: no/least as possible physical contact with PPE.", [["SARS", "DISEASE", 217, 221], ["SARS", "DISEASE", 238, 242], ["Infectious diseases", "DISEASE", 261, 280], ["-COVID", "TEST", 16, 22], ["China", "TEST", 28, 33], ["DGHS", "TEST", 42, 46], ["-COVID", "TEST", 47, 53], ["India", "TEST", 60, 65], ["RIVM", "TEST", 74, 78], ["-COVID", "TEST", 79, 85], ["Netherlands", "TEST", 91, 102], ["UN", "TEST", 114, 116], ["Covid", "TEST", 118, 123], ["COVID", "TEST", 186, 191], ["SARS", "TEST", 217, 221], ["CDC", "TEST", 233, 236], ["SARS", "TEST", 238, 242], ["USA", "TEST", 246, 249], ["HSE", "TEST", 256, 259], ["Infectious diseases", "PROBLEM", 261, 280], ["Infectious", "OBSERVATION", 261, 271]]], ["CHP -COVID-19 9 China + -+ + NSW -COVID-19 16 Australia + + + Advise next of kin: no/least as possible physical contact.", [["CHP", "TEST", 0, 3], ["-COVID", "TEST", 4, 10], ["COVID", "TEST", 34, 39]]], ["DGHS -COVID-19 17 India + + No contact with next of kin.", [["DGHS", "TEST", 0, 4], ["COVID", "TEST", 6, 11]]], ["RIVM -COVID-19 7 Netherlands + -Parekh UN -Covid-19 20 India + WHO -SARS 21 + + + * Standard PPE: gloves, disposable gown, hand hygiene", [["hand", "ANATOMY", 123, 127], ["SARS", "DISEASE", 68, 72], ["hand", "ORGANISM_SUBDIVISION", 123, 127], ["RIVM", "TEST", 0, 4], ["COVID", "TEST", 6, 11], ["UN", "TEST", 39, 41], ["Covid", "TEST", 43, 48], ["SARS", "TEST", 68, 72], ["gloves", "TREATMENT", 98, 104]]]], "d772cf651ac48e97d8eb399468d16205a2ab4a69": [["Since then, the disease has spread around the world reaching the pandemic stage, according to the WHO [1] , on 11 March.", [["the disease", "PROBLEM", 12, 23], ["disease", "OBSERVATION", 16, 23], ["spread", "OBSERVATION_MODIFIER", 28, 34]]], ["The infection fatality ratio (IFR), defined as the number of deaths divided by the number of infected cases, is an important quantity that informs us on the expected number of casualties at the end of an epidemic, when a given proportion of the population has been infected.", [["infection", "DISEASE", 4, 13], ["deaths", "DISEASE", 61, 67], ["The infection fatality ratio", "PROBLEM", 0, 28], ["infected", "PROBLEM", 265, 273], ["infection", "OBSERVATION", 4, 13], ["infected", "OBSERVATION", 93, 101], ["infected", "OBSERVATION", 265, 273]]], ["Although the data on the number of deaths from COVID-19 are probably accurate, the actual number of infected people in the population is not known.", [["deaths", "DISEASE", 35, 41], ["people", "ORGANISM", 109, 115], ["people", "SPECIES", 109, 115], ["COVID", "TEST", 47, 52], ["infected", "OBSERVATION", 100, 108], ["not known", "UNCERTAINTY", 137, 146]]], ["Thus, due to the relatively low number of screening tests that have been carried out in France (about five in 10,000 people in France to be compared with 50 in 10,000 in South Korea up to 15 March 2020; sources: Sant\u00e9 Publique France and Korean Center for Disease Control) the direct computation of the IFR is not possible.", [["IFR", "PROTEIN", 303, 306], ["people", "SPECIES", 117, 123], ["screening tests", "TEST", 42, 57], ["Disease Control", "TREATMENT", 256, 271], ["the IFR", "TEST", 299, 306], ["not possible", "UNCERTAINTY", 310, 322]]], ["Based on the PCR-confirmed cases in international residents repatriated from China on January 2020, Verity et al. [2] obtained an estimate of the infection fatality ratio (IFR) of 0.66% in China, and, adjusting for non-uniform attack rates by age, an IFR of 0.9% was obtained in the UK [3] .", [["infection", "DISEASE", 146, 155], ["the PCR", "TEST", 9, 16], ["the infection fatality ratio", "TEST", 142, 170], ["IFR", "TEST", 172, 175], ["non-uniform attack rates", "PROBLEM", 215, 239], ["an IFR", "TEST", 248, 254], ["infection", "OBSERVATION", 146, 155]]], ["Using data from the quarantined Diamond Princess cruise ship in Japan and correcting for delays between confirmation and death, Russel et al. [4] obtained an IFR of 1.3%.IntroductionUsing the early data (up to 17 March) available in France, our objectives are: (1) to compute the IFR in France, (2) to estimate the number of people infected with COVID-19 in France, and (3) to compute a basic reproduction number R 0 .DataWe obtained the number of positive cases and deaths in France, day by day from Johns Hopkins University Center for Systems Science and Engineering [5] .", [["death", "DISEASE", 121, 126], ["deaths", "DISEASE", 467, 473], ["people", "ORGANISM", 325, 331], ["people", "SPECIES", 325, 331], ["an IFR", "TEST", 155, 161], ["COVID", "TEST", 346, 351]]], ["The data on the number of tests carried out was obtained from Sant\u00e9 Publique France [6] .", [["tests", "TEST", 26, 31]]], ["As some data (positive cases, deaths, number of tests) are not fully reliable (example: 0 new cases detected in France on 12 March 2020), we smoothed the data with a moving average over 5 days.", [["deaths", "DISEASE", 30, 36], ["tests", "TEST", 48, 53]]], ["Official data on the number of deaths by COVID-19 in France only take into account hospitalised people.", [["deaths", "DISEASE", 31, 37], ["people", "ORGANISM", 96, 102], ["people", "SPECIES", 96, 102]]], ["About 728,000 people in France live in nursing homes (EHPAD, source: DREES [7] ).", [["people", "ORGANISM", 14, 20], ["people", "SPECIES", 14, 20]]], ["Recent data in the Grand Est region (source: Agence R\u00e9gionale de Sant\u00e9 Grand Est [8] ), report a total of 570 deaths in these nursing homes, which have to be added to the official count (1015 deaths on 31 March).Mechanistic-Statistical ModelThe mechanistic-statistical formalism, which is becoming standard in ecology [9] [10] [11] allows the analyst to couple a mechanistic model that describes a latent variable, here an ordinary differential equation model (ODE) of the SIR type, and uncertain, non-exhaustive data.", [["deaths", "DISEASE", 110, 116], ["deaths", "DISEASE", 192, 198]]], ["To bridge the gap between the mechanistic model and the data, the approach uses a probabilistic model describing the data collection process.", [["the approach", "TREATMENT", 62, 74]]], ["A statistical method is then used for the estimation of the parameters of the mechanistic model.Mechanistic-Statistical ModelMechanistic model.", [["A statistical method", "TREATMENT", 0, 20], ["ModelMechanistic model", "OBSERVATION", 120, 142]]], ["The dynamics of the epidemic are described by the following SIR compartmental model:Mechanistic-Statistical Modelwith S the susceptible population, I the infected population, R the recovered population (immune individuals) and N = S + I + R the total population, supposed to be constant.", [["the infected population", "PROBLEM", 150, 173], ["immune individuals", "TEST", 203, 221], ["infected", "OBSERVATION_MODIFIER", 154, 162], ["supposed to be", "UNCERTAINTY", 263, 277], ["constant", "OBSERVATION_MODIFIER", 278, 286]]], ["The parameter \u03b1 is the infection rate (to be estimated) and 1/\u03b2 is the mean time until an infected becomes recovered.", [["infection", "DISEASE", 23, 32], ["the infection rate", "PROBLEM", 19, 37], ["infection", "OBSERVATION", 23, 32], ["infected", "OBSERVATION", 90, 98]]], ["Based on the results in [12] , the median period of viral shedding is 20 days, but the infectiousness tends to decay before the end of this period: the results in [13] show that infectiousness starts from 2.5 days before symptom onset and declines within 7 days of illness onset.", [["illness", "DISEASE", 265, 272], ["viral shedding", "PROBLEM", 52, 66], ["the infectiousness", "PROBLEM", 83, 101], ["infectiousness", "PROBLEM", 178, 192], ["illness onset", "PROBLEM", 265, 278], ["viral", "OBSERVATION", 52, 57], ["20 days", "OBSERVATION_MODIFIER", 70, 77]]], ["The initial conditions are S(t 0 ) = N \u2212 1, I(t 0 ) = 1 and R(t 0 ) = 0, where N = 67 \u00b7 10 6 corresponds to the population size.", [["The initial conditions", "TEST", 0, 22], ["S", "TEST", 27, 28], ["size", "OBSERVATION_MODIFIER", 123, 127]]], ["The SIR model is started at some time t = t 0 , which will be estimated and should approach the date of introduction of the virus in France (this point is shortly discussed at the end of this paper).", [["the virus", "PROBLEM", 120, 129]]], ["The ODE system (1) is solved thanks to a standard numerical algorithm, using Matlab \u00ae ode45 solver.Mechanistic-Statistical ModelNext we denote by D(t) the number of deaths due to the epidemic.", [["deaths", "DISEASE", 165, 171], ["the epidemic", "PROBLEM", 179, 191]]], ["The dynamics of D(t) depends on I(t) trough the differential equation:Mechanistic-Statistical Modelwith \u03b3(t) the mortality rate of the infecteds.Mechanistic-Statistical ModelObservation model.", [["the infecteds", "PROBLEM", 131, 144]]], ["We suppose that the number of cases tested positive on day t, denoted by\u03b4 t , follow independent binomial laws, conditionally on the number of tests n t carried out on day t, and on p t the probability of being tested positive in this sample:Mechanistic-Statistical ModelThe tested population consists of a fraction of the infected cases and a fraction of the susceptibles:Mechanistic-Statistical Modelwith \u03ba t := \u03c4 2 (t)/\u03c4 1 (t), the relative probability of undergoing a screening test for an individual of type S vs. an individual of type I (probability of being tested conditionally on being S/probability of being tested conditionally on being I).", [["by\u03b4 t", "DNA", 70, 75], ["a screening test", "TEST", 470, 486], ["fraction", "OBSERVATION_MODIFIER", 307, 315], ["infected cases", "OBSERVATION", 323, 337], ["type I", "OBSERVATION_MODIFIER", 536, 542]]], ["The coefficient \u03c3 corresponds to the sensitivity of the test.", [["the test", "TEST", 52, 60]]], ["In most cases, RT-PCR tests have been used and existing data indicate that the sensitivity of this test using pharyngeal and nasal swabs is about 63-72% [14] .", [["pharyngeal", "ANATOMY", 110, 120], ["nasal swabs", "ANATOMY", 125, 136], ["pharyngeal", "ORGAN", 110, 120], ["nasal swabs", "MULTI-TISSUE_STRUCTURE", 125, 136], ["RT-PCR tests", "TEST", 15, 27], ["this test", "TEST", 94, 103], ["pharyngeal and nasal swabs", "TEST", 110, 136], ["pharyngeal", "ANATOMY", 110, 120], ["nasal", "ANATOMY", 125, 130]]], ["We take here \u03c3 = 0.7 (70% sensitivity).Statistical InferenceThe unknown parameters are \u03b1, t 0 and \u03ba.", [["\u03b1", "GENE_OR_GENE_PRODUCT", 87, 88]]], ["Using the observation model (3) , and assuming that the increments\u03b4 t are independent conditionally on the underlying SIR process and that the number of tests n t is known, we get:Statistical Inferencewith t i the date of the first observation and t f the date of the last observation.", [["\u03b4 t", "DNA", 66, 69]]], ["In this expression L(\u03b1, t 0 , \u03ba) depends on \u03b1, t 0 , \u03ba through p t .", [["\u03b1, t 0", "DNA", 44, 50], ["p t", "DNA", 63, 66]]], ["The maximum likelihood estimator (MLE, i.e., the parameters that maximise L), is computed using the BFGS constrained minimisation algorithm, applied to \u2212 ln(L), via the Matlab \u00ae function fmincon.", [["the BFGS constrained minimisation algorithm", "TREATMENT", 96, 139], ["maximum", "OBSERVATION_MODIFIER", 4, 11], ["likelihood", "OBSERVATION_MODIFIER", 12, 22], ["estimator", "OBSERVATION_MODIFIER", 23, 32], ["ln", "ANATOMY", 154, 156]]], ["In order to find a global maximum of L, we apply this method starting from random initial values for \u03b1, t 0 , \u03ba drawn uniformly in the following intervals: \u03b1 \u2208 (0, 1), t 0 \u2208 (1, 31), (1-31 January) and \u03ba \u2208 (0, 1).", [["this method", "TREATMENT", 49, 60], ["\u2208", "TEST", 204, 205]]], ["The minimisation algorithm is applied to 10,000 random initial values of the parameters.Statistical InferenceThe posterior distribution of the parameters (\u03b1, t 0 , \u03ba) is computed with a Bayesian method, using uniform prior distributions in the intervals given above (a more informative prior distribution has also been tested, see Appendix A).", [["The minimisation algorithm", "TEST", 0, 26], ["the parameters", "TEST", 139, 153], ["posterior", "ANATOMY_MODIFIER", 113, 122]]], ["This posterior distribution corresponds to the distribution of the parameters conditionally on the observations:Statistical Inferencewhere \u03c0(\u03b1, t 0 , \u03ba) corresponds to the prior distribution of the parameters (therefore uniform) and C is a normalisation constant independent of the parameters.", [["posterior", "ANATOMY_MODIFIER", 5, 14], ["distribution", "OBSERVATION_MODIFIER", 47, 59], ["uniform", "OBSERVATION_MODIFIER", 220, 227], ["normalisation", "OBSERVATION", 240, 253]]], ["The numerical computation of the posterior distribution is performed with a Metropolis-Hastings (MCMC) algorithm, using four independent chains, each of which with 10 6 iterations, starting from random values close to the MLE (only the second half of the iterations are used to generate the posterior).", [["a Metropolis-Hastings (MCMC) algorithm", "TREATMENT", 74, 112], ["posterior", "ANATOMY_MODIFIER", 33, 42], ["posterior", "ANATOMY_MODIFIER", 291, 300]]], ["The Matlab \u00ae codes are available as Supplementary Materials.", [["Matlab \u00ae codes", "DNA", 4, 18]]], ["The data\u03b4 t used to compute the MLE and the posterior distribution are those corresponding to the period from 29 February to 17 March.ResultsModel fit.", [["data\u03b4 t", "DNA", 4, 11], ["The data\u03b4 t", "TEST", 0, 11], ["posterior", "ANATOMY_MODIFIER", 44, 53], ["Model fit", "OBSERVATION", 141, 150]]], ["To assess model fit, we compared the observations, i.e., the cumulated number of cases \u03a3 t := \u03a3 s=1,...,t\u03b4s , with the expectation of the observation model associated with the MLE (expectation of a binomial).", [["cases", "TEST", 81, 86], ["s", "TEST", 96, 97], ["t\u03b4s", "TEST", 104, 107], ["the MLE", "PROBLEM", 172, 179]]], ["Infection fatality ratio and actual number of infected cases.", [["Infection fatality ratio", "PROBLEM", 0, 24], ["infected cases", "PROBLEM", 46, 60], ["infected", "OBSERVATION", 46, 54]]], ["Using the posterior distribution of the model parameters (the pairwise distributions are presented in Appendix A, see Figure A1 ), we computed the daily distribution of the actual number of infected peoples.", [["posterior", "ANATOMY_MODIFIER", 10, 19], ["model parameters", "OBSERVATION", 40, 56], ["Appendix", "ANATOMY", 102, 110], ["infected", "OBSERVATION", 190, 198]]], ["The IFR corresponds to the fraction of the infected who die, that is:ResultsWe thus obtain, on 17 March an IFR of 0.5% (95%-CI: 0.3-0.8), and the distribution of the IFR is relatively stable over time (see Figure A3 in the Appendix A).ResultsAdditionally, the distribution of the cumulated number of infected cases (I(t) + R(t)) across time is presented in Figure 2 .", [["IFR", "PROTEIN", 4, 7], ["an IFR", "TEST", 104, 110], ["CI", "TEST", 124, 126], ["the IFR", "TEST", 162, 169], ["infected", "OBSERVATION", 43, 51], ["relatively", "OBSERVATION_MODIFIER", 173, 183], ["stable", "OBSERVATION_MODIFIER", 184, 190], ["Appendix", "ANATOMY", 223, 231], ["distribution", "OBSERVATION_MODIFIER", 260, 272], ["infected", "OBSERVATION", 300, 308]]], ["The average estimated ratio between the actual number of individuals that have been infected and observed cases (I(t) + R(t))/\u03a3 t is eight (95%-CI: 5-12) over the considered period.ResultsTaking into account the data in the nursing homes.", [["The average estimated ratio", "TEST", 0, 27], ["CI", "TEST", 144, 146], ["infected", "OBSERVATION", 84, 92]]], ["The above computation of the IFR is based on the official counting of deaths by COVID-19 in France, which does not take into account the number of deaths in nursing homes.", [["deaths", "DISEASE", 70, 76], ["deaths", "DISEASE", 147, 153]]], ["Based on the local data in Grand Est region, we infer that the IFR that we computed has been underestimated by a factor about (1015 + 570)/1015 \u2248 1.6, leading to an adjusted IFR of 0.8% (95%-CI: 0.45-1.25).", [["IFR", "PROTEIN", 63, 66], ["the IFR", "TEST", 59, 66], ["an adjusted IFR", "TEST", 162, 177], ["CI", "TEST", 191, 193]]], ["Basic reproduction number.", [["reproduction", "OBSERVATION_MODIFIER", 6, 18], ["number", "OBSERVATION_MODIFIER", 19, 25]]], ["When R 0 > 1, the infected compartment I increases as long as R 0 S > N = S + I + R. We computed the marginal posterior distribution of the basic reproduction number R 0 .", [["infected", "OBSERVATION", 18, 26], ["increases", "OBSERVATION_MODIFIER", 41, 50], ["marginal", "OBSERVATION_MODIFIER", 101, 109], ["posterior", "OBSERVATION_MODIFIER", 110, 119], ["distribution", "OBSERVATION_MODIFIER", 120, 132]]], ["This leads to a mean value of R 0 of 3.2 (95%-CI: 3.1-3.3).", [["a mean value", "TEST", 14, 26], ["CI", "TEST", 46, 48]]], ["The full distribution is available in the Appendix A ( Figure A4 ).", [["full", "OBSERVATION_MODIFIER", 4, 8], ["distribution", "OBSERVATION_MODIFIER", 9, 21], ["Appendix", "ANATOMY", 42, 50]]], ["Sensitivity of the results with respect to the fixed model parameters.", [["the fixed model parameters", "TEST", 43, 69]]], ["We computed the MLE with a larger infectious period (1/\u03b2) of 20 days estimated by [12] .", [["larger", "OBSERVATION_MODIFIER", 27, 33], ["infectious", "OBSERVATION", 34, 44]]], ["This leads to a much larger basic reproductive number R 0 = 4.8 and a factor \u00d715 between the reported cases and the actual number of cases.", [["a factor \u00d7", "TEST", 68, 78], ["much", "OBSERVATION_MODIFIER", 16, 20], ["larger", "OBSERVATION_MODIFIER", 21, 27], ["basic", "OBSERVATION_MODIFIER", 28, 33], ["reproductive", "OBSERVATION_MODIFIER", 34, 46], ["number", "OBSERVATION_MODIFIER", 47, 53]]], ["However, the value of the IFR remains unchanged (0.5%).", [["the value", "TEST", 9, 18], ["the IFR", "TEST", 22, 29], ["unchanged", "OBSERVATION_MODIFIER", 38, 47]]], ["Computations of the MLE with a window width of 3 days (and \u03b2 = 1/10) led to the same results as those presented above, namely a R 0 = 3.2 and an IFR of 0.5%.DiscussionOn the IFR and the number of infected cases.", [["an IFR", "TEST", 142, 148], ["infected", "OBSERVATION", 196, 204]]], ["The actual number of infected individuals in France is probably much higher than the observations (we find here a factor \u00d78), which leads at a lower mortality rate than that calculated on the basis of the observed cases: we found here an IFR of 0.5% based on hospital death counting data, to be compared with a case fatality rate (CFR, number of deaths over number of diagnosed cases) of 2% on 17 March.", [["death", "DISEASE", 268, 273], ["deaths", "DISEASE", 346, 352], ["infected individuals", "PROBLEM", 21, 41], ["an IFR", "TEST", 235, 241], ["number", "OBSERVATION_MODIFIER", 11, 17], ["infected", "OBSERVATION_MODIFIER", 21, 29], ["individuals", "OBSERVATION", 30, 41], ["probably", "UNCERTAINTY", 55, 63], ["much", "OBSERVATION_MODIFIER", 64, 68], ["higher", "OBSERVATION_MODIFIER", 69, 75]]], ["Adjusting for the number of deaths in the nursing homes, we obtained an IFR of 0.8%.", [["deaths", "DISEASE", 28, 34], ["an IFR", "TEST", 69, 75]]], ["These values for the IFR are consistent with the findings in [2] (0.66% in China) and [3] (0.9% in the UK).", [["These values", "TEST", 0, 12], ["the IFR", "TEST", 17, 24], ["consistent with", "UNCERTAINTY", 29, 44]]], ["The value of 1.3% estimated on the Diamond Princess cruise ship [4] falls above the top end of our 95% CI.", [["The value", "TEST", 0, 9]]], ["This reflects the age distribution on the ship, which was skewed towards older individuals (mean age: 58 years), among whom the IFR is higher [3, 4] .DiscussionThe objective of our study was to estimate the IFR based on early data, before large scale surveys become available.", [["the IFR", "TEST", 124, 131], ["our study", "TEST", 177, 186], ["early data", "TEST", 220, 230], ["large scale surveys", "TEST", 239, 258], ["higher", "OBSERVATION_MODIFIER", 135, 141]]], ["By late April, new data and preliminary studies are available and can be compared to our results.", [["preliminary studies", "TEST", 28, 47]]], ["An antibody study in New York released on 24 April 2020 shows about 14 percent tested positive, corresponding to 2.7 million cases, to be compared with the 271,000 confirmed cases and a statewide total of 15,500 deaths.", [["deaths", "DISEASE", 212, 218], ["An antibody study", "TEST", 0, 17]]], ["This corresponds to an IFR of 0.6%.", [["an IFR", "TEST", 20, 26]]], ["In France, another preliminary study conducted by Pasteur Institute [16] , and based on a joint estimate from French data up to 14 April (hospital death counting data) and from the Diamond Princess cruise ship data finds an IFR of 0.5% thus confirming our result.", [["death", "DISEASE", 147, 152], ["another preliminary study", "TEST", 11, 36], ["an IFR", "TEST", 221, 227], ["joint", "ANATOMY", 90, 95]]], ["By 28 April, the number of deaths from COVID-19 in Lombardy (Italy) is 13,575 (source: Ministero della Salute), for a population of 10 million people, showing that the IFR is at least 0.14%.", [["deaths", "DISEASE", 27, 33], ["COVID-19", "CHEMICAL", 39, 47], ["people", "ORGANISM", 143, 149], ["people", "SPECIES", 143, 149], ["COVID", "TEST", 39, 44], ["the IFR", "TEST", 164, 171]]], ["On the other hand, in South Korea where the number of detected cases rapidly reached a plateau, suggesting a small proportion of undetected cases, the ratio between the number of deaths and the number of positive cases is 244/10,752 \u2248 2.3% (source: Johns Hopkins University Center for Systems Science and Engineering [5] ), which can be considered as an upper bound for the IFR, though overestimated.DiscussionIf the virus led to contaminate 80% of the French population [3] , the total number of deaths to deplore in the absence of variation in the mortality rate (increase induced for example by the saturation of hospital structures, or decrease linked to better patient care) would be 336,000 (95%-CI: 192,000-537,000), excluding the number of deaths in the nursing homes.", [["deaths", "DISEASE", 179, 185], ["deaths", "DISEASE", 497, 503], ["deaths", "DISEASE", 748, 754], ["patient", "ORGANISM", 666, 673], ["patient", "SPECIES", 666, 673], ["an upper bound", "PROBLEM", 351, 365], ["the IFR", "TEST", 370, 377], ["the virus", "PROBLEM", 413, 422], ["CI", "TEST", 702, 704], ["small", "OBSERVATION_MODIFIER", 109, 114]]], ["This estimate could be corroborated or invalidated when 80% of the population will be infected, eventually over several years, assuming that an infected individual is definitively immunised.", [["an infected individual", "PROBLEM", 141, 163], ["infected", "OBSERVATION", 86, 94], ["infected", "OBSERVATION", 144, 152]]], ["It has to be noted that measures of confinement or social distancing can decrease both the percentage of infected individuals in the population and the degree of saturation of hospital structures.DiscussionOn the value of R 0 .", [["infected individuals", "PROBLEM", 105, 125], ["percentage", "OBSERVATION_MODIFIER", 91, 101], ["infected", "OBSERVATION", 105, 113], ["degree", "OBSERVATION_MODIFIER", 152, 158], ["saturation", "OBSERVATION_MODIFIER", 162, 172]]], ["The estimated distribution in France is high compared to recent estimates (2.0-2.6, see [3] ) but consistent with the findings in [17] (2.24-3.58).", [["recent estimates", "TEST", 57, 73], ["estimated", "OBSERVATION_MODIFIER", 4, 13], ["distribution", "OBSERVATION_MODIFIER", 14, 26], ["France", "OBSERVATION_MODIFIER", 30, 36], ["high", "OBSERVATION_MODIFIER", 40, 44], ["consistent with", "UNCERTAINTY", 98, 113]]], ["A direct estimate, by a non-mechanistic method, of the parameters (\u03c1, t 0 ) of a model of the form\u03b4 t = e \u03c1 (t\u2212t 0 ) gives t 0 = 36 (5 February) and \u03c1 = 0.22.", [["the parameters", "TEST", 51, 65], ["\u03c1", "TEST", 149, 150]]], ["With the SIR model, I (t) \u2248 I (\u03b1 \u2212 \u03b2) for small times (S \u2248 N), which leads to a growth rate equal to \u03c1 \u2248 \u03b1 \u2212 \u03b2, and a value of \u03b1 \u2248 0.32, that is to say R 0 = 3.2, which is consistent with our distribution of R 0 .", [["\u03b2", "PROTEIN", 35, 36], ["\u03c1", "PROTEIN", 101, 102], ["\u03b1", "PROTEIN", 105, 106], ["\u03b2", "PROTEIN", 109, 110], ["a growth rate", "TEST", 78, 91], ["a value", "TEST", 116, 123]]], ["The uncertainty on the actual number of infected and therefore the IFR are very high.", [["infected", "PROBLEM", 40, 48], ["the IFR", "TEST", 63, 70], ["infected", "OBSERVATION", 40, 48], ["very", "OBSERVATION_MODIFIER", 75, 79], ["high", "OBSERVATION", 80, 84]]], ["We deliberately chose a parsimonious model with a few parameters to avoid identifiability issues.", [["identifiability issues", "PROBLEM", 74, 96]]], ["In particular, we assumed a mean duration of the infectious period (1/\u03b2) of 10 days.", [["infectious", "OBSERVATION", 49, 59]]], ["A much larger infectious period of 20 days (corresponding to the median period of viral shedding found in [12] ) would lead to a much larger basic reproduction number R 0 = 4.8 (but still within the range 1.4-6.49 described in [18] ) and a factor \u00d715 between the reported cases and the actual number of cases.", [["viral shedding", "PROBLEM", 82, 96], ["a factor \u00d7", "TEST", 238, 248], ["larger", "OBSERVATION_MODIFIER", 7, 13], ["infectious", "OBSERVATION_MODIFIER", 14, 24]]], ["However, our main result on the IFR would remain unchanged (0.5%).", [["the IFR", "TEST", 28, 35], ["main", "OBSERVATION_MODIFIER", 13, 17], ["unchanged", "OBSERVATION_MODIFIER", 49, 58]]], ["We also assessed the sensitivity of the inference with respect to the prior knowledge, by proposing a set of more informative uniform prior distributions than the set specified in the main text.", [["main text", "OBSERVATION", 184, 193]]], ["Overall, this prior modification does not significantly influence the posterior distributions; see Appendix A. On the hypotheses underlying the model.", [["posterior", "ANATOMY_MODIFIER", 70, 79], ["Appendix", "ANATOMY", 99, 107]]], ["This limit led us to use a particularly parsimonious model in order to avoid problems of identifiability for the parameters.", [["a particularly parsimonious model", "TREATMENT", 25, 58]]], ["For instance, the date of the introduction t 0 must be seen as an efficient date of introduction for a dynamics where a single introduction would be decisive for the outbreak and the other (anterior and posterior) introductions would have an insignificant effect on the dynamics.DiscussionA more complex epidemiological model of the COVID-19 epidemic in China has been proposed in [19] , with an infectious class divided into several compartments (asymptomatic individuals, unobserved symptomatic infectious and observed symptomatic infectious).", [["anterior", "MULTI-TISSUE_STRUCTURE", 190, 198], ["COVID-19", "ORGANISM", 333, 341], ["the introduction t 0", "TREATMENT", 26, 46], ["the outbreak", "PROBLEM", 162, 174], ["anterior and posterior) introductions", "TREATMENT", 190, 227], ["the COVID", "TEST", 329, 338], ["an infectious class", "PROBLEM", 393, 412], ["asymptomatic individuals", "PROBLEM", 448, 472], ["symptomatic infectious", "PROBLEM", 485, 507], ["symptomatic infectious)", "PROBLEM", 521, 544], ["insignificant", "OBSERVATION_MODIFIER", 242, 255], ["effect", "OBSERVATION", 256, 262], ["infectious", "OBSERVATION", 396, 406]]], ["The authors use this model in [20] to make forecasts on the cumulative number of cases in China, while taking into account management strategies.", [["management strategies", "TREATMENT", 123, 144]]], ["In these two studies the authors emphasise the importance of being able to estimate the fraction of infectious cases that are not observed in order to forecast the dynamics of the epidemic.", [["infectious cases", "PROBLEM", 100, 116], ["infectious", "OBSERVATION", 100, 110]]], ["Our study, though based on a simpler SIR model, shows that this fraction can be estimated based on early data.", [["Our study", "TEST", 0, 9], ["this fraction", "PROBLEM", 59, 72]]], ["Acknowledgments: We thank Laurent Desvillettes for his suggestion about the computation of a lower bound for the IFR based on data from the Lombardy province in Italy.", [["a lower bound", "PROBLEM", 91, 104], ["the IFR", "TEST", 109, 116]]], ["We also thank the anonymous reviewers for their suggestions and comments.Conflicts of Interest:The authors declare no conflict of interest.AbbreviationsThe following abbreviations are used in this manuscript: The joint posterior distributions of the three pairs of parameters (\u03b1, \u03ba), (t 0 , \u03b1) and (t 0 , \u03ba) are depicted in Figure A1 . \u2022AbbreviationsTo check the robustness of our results with respect to the choice of the prior distribution, we also considered the case of a more informative prior.", [["joint posterior", "MULTI-TISSUE_STRUCTURE", 213, 228], ["joint", "ANATOMY", 213, 218], ["posterior", "ANATOMY_MODIFIER", 219, 228]]], ["Namely, we assumed the following uniform prior distributions:Abbreviations\u2022 \u03b1 \u2208 (0.14, 0.65), corresponding to \u03b2 \u00d7 R 0 with \u03b2 = 1/10 and R 0 values ranging between 1.4 and 6.49 (the range described in [18] ); \u2022 t 0 \u2208 (20, 31) corresponding to an introduction during late January; \u2022 \u03ba \u2208 (0, 10 \u22122 ), corresponding to a small probability of being tested for the susceptible cases, compared to the infected cases.AbbreviationsWe obtained the posterior distributions shown in Figure A2 , based on two independent chains with 10 6 iterations (only the second half of the iterations are used to generate the posterior).AbbreviationsOverall, these distributions are relatively similar to those displayed on Figure A1 and obtained with the prior distributions defined in the main text. \u2022AbbreviationsThe dynamics of the estimated distribution of the IFR are depicted in Figure A3 . \u2022AbbreviationsThe marginal posterior distribution of R 0 is depicted in Figure A4 .", [["\u03b2", "PROTEIN", 111, 112], ["IFR", "PROTEIN", 842, 845], ["Abbreviations", "TEST", 61, 74], ["\u03b2", "TEST", 124, 125], ["the susceptible cases", "PROBLEM", 356, 377], ["small", "OBSERVATION_MODIFIER", 318, 323], ["infected", "OBSERVATION", 395, 403], ["posterior", "ANATOMY_MODIFIER", 439, 448], ["posterior", "ANATOMY_MODIFIER", 602, 611], ["distributions", "OBSERVATION_MODIFIER", 641, 654], ["main text", "ANATOMY", 767, 776], ["marginal", "OBSERVATION_MODIFIER", 892, 900], ["posterior", "OBSERVATION_MODIFIER", 901, 910], ["distribution", "OBSERVATION_MODIFIER", 911, 923], ["R", "ANATOMY_MODIFIER", 927, 928]]]]}